{"columns":["record_id","prospero_ids","osf_ids","doi","pmid","pmcid","title","year","journal","first_author","n_references","n_cited_inventory_records","n_cited_randomized_trials","registration","registry_ids"],"rows":[["R0000007",null,null,"10.1055/a-2923-3830","42600634",null,"Effects of Glucagon-Like Peptide-1 Receptor Agonists as Weight Loss Drugs on Pancreatitis and Pancreatic Cancer: A Meta-Analysis.","2026","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","Zhong X","0","0","0","none found",null],["R0000008","CRD42024505558",null,"10.7326/annals-25-05519","42673585",null,"Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.","2026","Annals of internal medicine","Moiz A","0","0","0","PROSPERO","PROSPERO:CRD42024505558"],["R0000014",null,null,"10.1016/j.jcjd.2026.04.001","41967797",null,"Preferred Glucagon-like Peptide-1 Receptor Agonists in Adults With Type 2 Diabetes and Established Cardiovascular Disease or High Cardiovascular Risk: A Network Meta-analysis of Randomized Trials.","2026","Canadian journal of diabetes","Abomohsen M","31","20","11","none found",null],["R0000025",null,null,"10.1002/osp4.70181","42564827","PMC13445785","Role of Oral Glucagon-Like Peptide-1 Receptor Agonists in Weight Management for Individuals With Overweight or Obesity Without Diabetes: A Network Meta-Analysis of Randomized Controlled Trials.","2026","Obesity science & practice","Kamrul-Hasan ABM","41","26","14","none found",null],["R0000049",null,null,"10.1111/obr.70120","41792979","PMC13371786","Association of Glucagon-Like Peptide-1 Receptor Agonists and Suicidality: A Systematic Review.","2026","Obesity reviews : an official journal of the International Association for the Study of Obesity","Au HCT","33","24","7","none found",null],["R0000059",null,null,"10.1016/j.pmedr.2026.103548","42381894","PMC13316655","Glucagon-like peptide-1 receptor agonist use and risk of gynecologic cancers: a meta-analysis of multinational real-world cohort studies.","2026","Preventive medicine reports","Li R","32","20","0","none found",null],["R0000076",null,null,"10.1007/s12020-026-04701-9","42536323","PMC13427886","Hypertensive disorders of pregnancy and GLP-1 receptor agonist timing: a systematic review and meta-analysis.","2026","Endocrine","Pisani D","30","18","2","none found",null],["R0000081","CRD420261321430",null,"10.1111/dom.71106","42449480","PMC13538776","Effects of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta-Analysis.","2026","Diabetes, obesity & metabolism","Kanbay M","62","53","38","PROSPERO","PROSPERO:CRD420261321430"],["R0000086",null,null,"10.1371/journal.pone.0354497","42594084","PMC13472420","Gastroparesis induced by glucagon-like peptide-1 receptor agonists: A systematic review of clinical features, diagnosis, management, and outcomes.","2026","PloS one","Olubodun T","32","24","2","none found",null],["R0000118",null,null,"10.1016/j.ajog.2026.04.037","42061782",null,"Neonatal and obstetric outcomes following periconceptional exposure to glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis.","2026","American journal of obstetrics and gynecology","Hakim J","57","24","3","none found",null],["R0000121",null,null,"10.3390/nu18111662","42280306","PMC13258732","GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists in Children and Adolescents with Obesity: Clinical Outcomes and the Impact of Nutritional and Behavioral Co-Interventions-A Systematic Review.","2026","Nutrients","Myśliwczyk D","30","23","16","none found",null],["R0000132",null,null,"10.1007/s12015-025-11002-7","41129073","PMC12795975","The Influence of GLP-1 Agonists on Human Mesenchymal Stem Cells: A Systematic Review.","2026","Stem cell reviews and reports","Weber L","58","51","3","none found",null],["R0000151",null,null,"10.1186/s40001-026-03933-9","41582189","PMC12918571","Effect of glucagon-like peptide-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: a systematic review and pairwise and network meta-analysis of randomized controlled trials.","2026","European journal of medical research","Zhang Y","52","34","18","none found",null],["R0000165",null,null,"10.1007/s00586-026-10205-x","42471496",null,"Can glucagon-like peptide-1 receptor agonists affect outcomes after spine surgery? A systematic review and meta-analysis.","2026","European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society","Muthu S","31","25","4","none found",null],["R0000171",null,null,"10.1186/s12933-026-03113-3","41761267","PMC13049956","Comparative efficacy of tirzepatide and glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis.","2026","Cardiovascular diabetology","Shokravi A","35","31","21","none found",null],["R0000172",null,null,"10.32388/i85yu1",null,null,"The GLP-1 Nutritional Paradox: A Global Meta-Analysis of Sarcopenic Risks and Micronutrient Gaps in the Post-Obesity Era","2026","Qeios","Hungund S",null,"0","0","none found",null],["R0000174",null,null,"10.1016/j.diabres.2025.112954","42618994",null,"Efficacy and safety of different once-weekly glucagon-like peptide-1 receptor agonists-A systematic review and Bayesian network meta-analysis.","2025","Diabetes research and clinical practice","Xu Y","0","0","0","none found",null],["R0000178",null,null,"10.1016/j.cjco.2026.02.008","42327438","PMC13282519","Glucagon-Like Peptide-1 Receptor Agonists Improve Cardiovascular Outcomes in Heart Failure with Preserved Ejection Fraction, Independent of Diabetes: A Systematic Review and Meta-Analysis.","2026","CJC open","Shokravi A","36","26","10","none found",null],["R0000181",null,null,"10.3390/jcm15124781","42355949","PMC13300848","Glucagon-like Peptide-1 Receptor Agonists and Alcohol Use Outcomes: A Systematic Review of Clinical Evidence.","2026","Journal of clinical medicine","Altami IK","19","18","7","none found",null],["R0000193",null,null,"10.21203/rs.3.rs-10216709/v1",null,null,"Risk of Diabetic Ketoacidosis with Glucagon-Like Peptide-1 Receptor Agonists: A Systematic Review and Meta-analysis","2026","Research Square","Alkhushaym N",null,"0","0","none found",null],["R0000198","CRD420251007882",null,"10.1186/s12886-026-05036-9","42380920","PMC13591686","Assessing the risk of diabetic retinopathy progression with GLP-1 receptor agonists: a systematic review and meta-analysis.","2026","BMC ophthalmology","Yang Q","47","35","12","PROSPERO","PROSPERO:CRD420251007882"],["R0000202","CRD42024566217",null,"10.1002/hup.70041","41914576",null,"Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Psychological Well-Being and Depressive Symptoms: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","2026","Human psychopharmacology","Hung TH","78","30","18","PROSPERO","PROSPERO:CRD42024566217"],["R0000205",null,null,"10.7717/peerj.21713","42729958","PMC13564392","Weight regain following discontinuation of glucagon-like peptide-1 receptor agonists in adults who are overweight or obese: a systematic review and meta-analysis.","2026","PeerJ","Qi H","45","36","22","none found",null],["R0000206",null,null,"10.1111/dom.70884","42209204",null,"Comparative Effects of Individual Glucagon-Like Peptide-1 Receptor Agonist-Based Medications on Direct Measurement of Body Composition Among Adults With Overweight or Obesity With or Without Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials.","2026","Diabetes, obesity & metabolism","Wachiraphansakul N","78","53","40","none found",null],["R0000216",null,"osf.io/x58ne","10.1016/j.abrep.2026.100671","41696398","PMC12906085","Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov.","2026","Addictive behaviors reports","Patil S","49","36","22","OSF",null],["R0000227",null,null,"10.1093/ajhp/zxag121","42033237",null,"Cardiovascular outcomes of glucagon-like peptide-1 receptor agonists: A systematic review.","2026","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","Bihelek N","32","25","15","none found",null],["R0000231","CRD420261297384",null,"10.1177/00368504261444578","41998799","PMC13100445","GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling.","2026","Science progress","Gupta AK","44","30","6","PROSPERO","PROSPERO:CRD420261297384"],["R0000232",null,null,"10.1016/j.aed.2026.03.003","42221413","PMC13221932","Incretin-Based Therapy and Thyroid Cancer Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","2026","AACE endocrinology and diabetes","Eisa N","31","24","15","none found",null],["R0000236",null,null,"10.1002/ejhf.70085","41216984",null,"Glucagon-like peptide-1 receptor agonists reduce atrial fibrillation among patients with heart failure with preserved and mildly reduced ejection fraction - a meta-analysis of randomized controlled trials.","2025","European journal of heart failure","Ravikulan R","20","8","6","none found",null],["R0000240",null,null,"10.3389/fendo.2026.1849318","42661791","PMC13518207","Glucagon-like peptide-1 receptor agonists and the risk of Parkinson's disease in patients with type 2 diabetes: a systematic review and meta-analysis of large-scale real-world data.","2026","Frontiers in endocrinology","Chen Y","33","20","2","none found",null],["R0000255","CRD420251183938",null,"10.1016/j.jcjo.2026.05.010","42242290",null,"Age-related macular degeneration associated with glucagon-like peptide-1 receptor agonist use: a systematic review.","2026","Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","Al-Burak SA","39","20","4","PROSPERO","PROSPERO:CRD420251183938"],["R0000256",null,null,"10.1093/alcalc/agaf069","41273789",null,"GLP-1 receptor agonists and alcohol use disorder: a systematic review.","2025","Alcohol and alcoholism (Oxford, Oxfordshire)","Patel S","0","0","0","none found",null],["R0000261",null,null,"10.14740/gr2108","42137745","PMC13171266","Evaluating Glucagon-Like Peptide-1 Receptor Agonist Safety Before Upper Endoscopy: A Systematic Review and Meta-Analysis.","2026","Gastroenterology research","Ahmed Z","32","26","2","none found",null],["R0000267",null,null,"10.1007/s00586-026-10258-y","42570103",null,"Impact of glucagon-like peptide-1 receptor agonists on outcomes following anterior cervical discectomy and fusion: a systematic review and meta-analysis.","2026","European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society","Duru DO","20","5","0","none found",null],["R0000288",null,null,"10.7759/cureus.109953","42382865","PMC13315952","Incretin-Based Therapies in Obesity-Related Heart Failure With Preserved Ejection Fraction (HFpEF): A Systematic Review of Emerging Cardiometabolic Disease Modification Beyond Glycemic Control.","2026","Cureus","Hemdev V","19","13","9","none found",null],["R0000290",null,null,"10.3390/jcm15135126","42452586","PMC13362826","Effects of GLP-1 Receptor Agonists on Psoriasis: An \"Agent-Specific\" Systematic Review of the Literature.","2026","Journal of clinical medicine","Marani A","42","34","8","none found",null],["R0000296",null,null,"10.7759/cureus.115703","42829595","PMC13633565","Impact of Glucagon-Like Peptide-1 Receptor Agonists on Mental Health: A Systematic Review of Psychiatric Safety and Antidepressant Potential.","2026","Cureus","Quadir A","0","0","0","none found",null],["R0000299",null,null,"10.1111/dom.70878","42150748","PMC13341386","Association Between Glucagon-Like Peptide-1 Receptor Agonists and Suicidality: A Systematic Review.","2026","Diabetes, obesity & metabolism","Chan TH","75","54","3","none found",null],["R0000305",null,null,"10.1111/dom.70188","41334580","PMC12673429","Glucagon-like peptide-1 receptor agonist treatment reduces body weight and improves glycaemic outcomes in patients with concurrent overweight/obesity and type 1 diabetes: A systematic review and meta-analysis.","2026","Diabetes, obesity & metabolism","Purcell AR","34","24","22","none found",null],["R0000313","CRD420251177261",null,"10.1016/j.schres.2026.06.025","42497473",null,"Effects of glucagon-like peptide-1 receptor agonists on metabolic outcomes in antipsychotic-treated patients with schizophrenia: A systematic review and meta-analysis.","2026","Schizophrenia research","Sobral MVS","31","16","9","PROSPERO","PROSPERO:CRD420251177261"],["R0000326",null,null,"10.1111/anae.16601","40230298","PMC12171790","Association between glucagon-like peptide-1 receptor agonist use and peri-operative pulmonary aspiration: a systematic review and meta-analysis.","2025","Anaesthesia","Elkin J","66","49","4","none found",null],["R0000340",null,null,"10.1212/wnl.0000000000214864","42060879",null,"Glucagon-like Peptide-1 Receptor Agonists and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy: Systematic Review and Meta-Analysis.","2026","Neurology","Dhivagaran T","32","19","4","none found",null],["R0000345","CRD420261360837",null,"10.3390/nu18111781","42280424","PMC13259188","GLP-1RA- and Incretin-Based Therapies Within Lifestyle Interventions for Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis.","2026","Nutrients","Bruna-Mejias A","39","36","34","PROSPERO","PROSPERO:CRD420261360837"],["R0000357",null,null,"10.3390/jcdd13020103","41745350","PMC12942127","Effect of GLP-1 Receptor Agonists in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.","2026","Journal of cardiovascular development and disease","Behers BJ","32","20","9","none found",null],["R0000358",null,null,"10.1007/s00586-026-10293-9","42635669",null,"GLP-1 receptor agonists and outcomes after cervical spine fusion: a systematic review, meta-analysis, and evidence map of real-world evidence.","2026","European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society","Yu X","52","27","8","none found",null],["R0000361",null,null,"10.1017/neu.2025.4","39950609","PMC13130299","Association of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and neurogenesis: a systematic review.","2025","Acta neuropsychiatrica","Au HCT","52","30","0","none found",null],["R0000368",null,null,"10.1016/j.gie.2026.03.005","42601135",null,"Glucagon-like peptide-1 receptor agonists and bowel preparation: methodological and clinical considerations for meta-analysis.","2026","Gastrointestinal endoscopy","Yang N","0","0","0","none found",null],["R0000376",null,null,"10.1016/j.xnsj.2026.100938","42740823","PMC13572007","Do glucagon-like peptide-1 receptor agonists influence cervical fusion outcomes? A systematic review and meta-analysis.","2026","North American Spine Society journal","Alves MLM","25","15","3","none found",null],["R0000388",null,null,"10.1016/j.phrs.2026.108333","42401410",null,"GLP-1 receptor agonist therapy in children and adolescents with obesity: A network meta-analysis of differential cardiometabolic efficacy and safety profiles.","2026","Pharmacological research","Li Y","59","39","20","none found",null],["R0000393",null,null,"10.1007/s12020-025-04494-3","41489846",null,"Exploring the rates of Gastrointestinal adverse effects among five GLP-1 receptor agonists: A systematic review and Meta-Analysis of randomized controlled trials.","2026","Endocrine","Joy B","76","76","71","none found",null],["R0000397",null,null,"10.1093/eurjpc/zwaf560","40899050",null,"Effect of incretin-based therapies on blood pressure: a systematic review and meta-analysis.","2026","European journal of preventive cardiology","Basile C","33","21","6","none found",null],["R0000405",null,null,"10.1007/s12012-026-10119-6","42455418","PMC13372915","Incretin-Based Therapies in Doxorubicin-Induced Cardiotoxicity: A Systematic Review of GLP-1 and Dual GIP/GLP-1 Agonists.","2026","Cardiovascular toxicology","Khatami S","77","32","7","none found",null],["R0000409",null,null,"10.1016/j.neubiorev.2026.106990","42762879",null,"Central nervous system effects of GLP-1 receptor agonists: A systematic review of human neuroimaging studies.","2026","Neuroscience and biobehavioral reviews","Brucar LR","0","0","0","none found",null],["R0000413",null,null,"10.1177/15578518261442833","41973746",null,"Visual and Neurological Outcomes Following Glucagon-Like Peptide-1 Receptor Agonist Therapy and Bariatric Surgery in Idiopathic Intracranial Hypertension: A Network Meta-Analysis.","2026","Metabolic syndrome and related disorders","Phutinart S","47","22","2","none found",null],["R0000415","CRD420261385854",null,"10.1016/j.msard.2026.107388","42470876",null,"GLP-1 receptor agonists in multiple sclerosis: a systematic review of preclinical and clinical evidence.","2026","Multiple sclerosis and related disorders","Sajjad M","24","12","0","PROSPERO","PROSPERO:CRD420261385854"],["R0000423",null,null,"10.1016/j.diabres.2026.113333","42155605",null,"Glucagon-like peptide-1 receptor agonists and hair loss: A systematic review and meta-analysis.","2026","Diabetes research and clinical practice","Cheng PL","31","20","7","none found",null],["R0000426","CRD420251061447",null,"10.1177/21925682251415347","41483457","PMC12764418","Glucagon-Like Peptide-1 Receptor Agonist Use Does Not Impact Spine Surgery Outcomes: A Systematic Review and Meta-Analysis.","2026","Global spine journal","Ibrahim S","34","24","1","PROSPERO","PROSPERO:CRD420251061447"],["R0000427",null,null,"10.1016/j.diabres.2026.113400","42365860",null,"GLP-1 receptor agonists in pediatric obesity and diabetes: a systematic review of efficacy, metabolic effects, and safety.","2026","Diabetes research and clinical practice","Soliman AT","32","12","8","none found",null],["R0000442",null,null,"10.7759/cureus.110952","42465136","PMC13374084","Urological Complications of Morbid Obesity and the Role of Bariatric Surgery and Glucagon-Like Peptide-1 Receptor Agonists in Their Management: A Systematic Review.","2026","Cureus","Khalil W","36","7","3","none found",null],["R0000444",null,null,"10.1038/s41598-026-61582-8","42420519",null,"Pregnancy outcomes following maternal GLP-1 receptor agonist exposure: a systematic review and meta-analysis.","2026","Scientific reports","Uysal N","0","0","0","none found",null],["R0000473",null,null,"10.1016/j.arth.2025.11.036","41276236",null,"Glucagon-Like Peptide-1 Receptor Agonists, Readmission, and Postoperative Complications in Arthroplasty: A Systematic Review and Meta-Analysis.","2026","The Journal of arthroplasty","Chan YC","48","16","2","none found",null],["R0000476",null,null,"10.1016/j.survophthal.2026.08.007","42612754",null,"Glucagon-like peptide-1 receptor agonists and risk of diabetic retinopathy in type 2 diabetes: A systematic review and network meta-analysis of randomized clinical trials.","2026","Survey of ophthalmology","Ortiz-Seller A","0","0","0","none found",null],["R0000483",null,null,"10.1136/bmjdrc-2026-006225","42618306","PMC13504861","Glucagon-like peptide-1 receptor agonists for primary cardiovascular disease prevention in type 2 diabetes, a systematic review.","2026","BMJ open diabetes research & care","Grenet G","59","35","17","none found",null],["R0000488",null,null,"10.1002/oby.70169","41936548",null,"Weight Loss With GLP-1 Agonists in Nondiabetic Adults: Systematic Review and Network Meta-Analysis.","2026","Obesity (Silver Spring, Md.)","Lim M","52","28","14","none found",null],["R0000496",null,null,"10.1002/brb3.71344","41880197","PMC13109035","Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists in Parkinson Disease: A Systematic Review and Meta-Analysis.","2026","Brain and behavior","Raza H","31","17","5","none found",null],["R0000497",null,null,"10.7326/annals-25-05519-ps","42673597",null,"Summary for Patients: An Updated Systematic Review on Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes.","2026","Annals of internal medicine",null,"0","0","0","none found",null],["R0000511",null,null,"10.1007/s00266-026-05820-4","42162206",null,"Effects of GLP-1 Receptor Agonists on Skin Quality: A Comprehensive Literature Review.","2026","Aesthetic plastic surgery","Barone M","23","10","3","none found",null],["R0000529",null,null,"10.1097/aog.0000000000006363","42391628","PMC13489104","Glucagon-Like Peptide-1 Receptor Agonists and Risk of Adverse Maternal Pregnancy Outcomes: A Systematic Review and Meta-analysis.","2026","Obstetrics and gynecology","Hattler E","61","24","3","none found",null],["R0000536",null,null,"10.1177/02698811261478625","42746999",null,"Adjunctive GLP-1 receptor agonists for cardiometabolic risk in antipsychotic-treated patients: A GRADE-assessed meta-analysis of randomized trials.","2026","Journal of psychopharmacology (Oxford, England)","Moubarak ES","0","0","0","none found",null],["R0000538",null,null,"10.3390/medicina62081536","42654433","PMC13515371","Is There a Better Day of the Week to Administer Semaglutide or Tirzepatide? A Systematic Literature Review.","2026","Medicina (Kaunas, Lithuania)","La Vignera S","10","8","7","none found",null],["R0000539",null,null,"10.1111/dom.16581","40613325",null,"Cost-effectiveness analysis of four glucagon-like peptide-1 or glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists for the treatment of adult patients with overweight and obesity in China.","2025","Diabetes, obesity & metabolism","Fu W","50","22","17","none found",null],["R0000540",null,null,"10.3390/ijms27146447","42511792","PMC13411477","Relationship Between GLP-1-Based Therapies and Periodontal Health: A Systematic Review of Current Evidence and Future Perspectives.","2026","International journal of molecular sciences","Nijakowski K","39","26","0","none found",null],["R0000543",null,null,"10.1093/ehjqcco/qcag079","42142362",null,"Cardiovascular and renal outcomes of GLP-1 receptor agonists in type 2 diabetes mellitus: a systematic review and meta-analysis.","2026","European heart journal. Quality of care & clinical outcomes","Ahmed M","59","47","23","none found",null],["R0000544",null,null,"10.7759/cureus.113777","42677221","PMC13528408","Incretin-Based Therapies Versus Bariatric and Metabolic Surgery for Obesity and Type 2 Diabetes Mellitus: A Head-to-Head Systematic Review of Glycaemic, Cardiovascular, Hepatic, Weight, and Quality-of-Life Outcomes.","2026","Cureus","Alsayed O","20","11","5","none found",null],["R0000545","CRD420251181076",null,"10.1111/dom.70779","42037117","PMC13244000","Dietary Strategies and Nutritional Management in Patients Receiving GLP-1 and Dual GIP/GLP-1 Receptor Agonists as Adjuncts to Lifestyle Interventions: A Systematic Review of Randomised Clinical Trials.","2026","Diabetes, obesity & metabolism","de Paulo RS","56","31","18","PROSPERO","PROSPERO:CRD420251181076"],["R0000548",null,null,"10.1002/dmrr.70194","42319968","PMC13282017","The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Co-Transporter-2 Inhibitors on Lean Body Mass in Humans: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.","2026","Diabetes/metabolism research and reviews","Jobanputra R","75","32","24","none found",null],["R0000559",null,null,"10.7759/cureus.92454","41111833","PMC12530271","Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review.","2025","Cureus","Alsuwailem OA","25","16","3","none found",null],["R0000560","CRD420251153352",null,"10.1093/ckj/sfag105","42017027","PMC13092978","Clinical outcomes of glucagon-like peptide-1 receptor agonist therapy in kidney transplant recipients: a systematic review and meta-analysis.","2026","Clinical kidney journal","Kanbay M","56","50","5","PROSPERO","PROSPERO:CRD420251153352"],["R0000562",null,null,"10.1186/s12933-026-03283-0","42410649","PMC13617921","Glucagon-like peptide-1 receptor agonists and major limb events in adults with type 2 diabetes and peripheral artery disease: a systematic review and meta-analysis of RCTs and cohort studies.","2026","Cardiovascular diabetology","Caruso P","45","27","4","none found",null],["R0000575","CRD420261414637",null,"10.14444/8954","42754392",null,"Do Preoperative Glucagon-Like Peptide-1 Receptor Agonists Influence Lumbar Fusion Outcomes? A Systematic Review and Meta-Analysis.","2026","International journal of spine surgery","Alves MLM","0","0","0","PROSPERO","PROSPERO:CRD420261414637"],["R0000576",null,null,"10.1111/obr.13929","40186344",null,"Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis.","2025","Obesity reviews : an official journal of the International Association for the Study of Obesity","Berg S","44","18","10","none found",null],["R0000577",null,null,"10.1177/00912174261479866","42628005",null,"Decreased Risk of Mental Illness Worsening: Comment on \"Glucagon-like Peptide-1 Receptor Agonists in Individuals With Severe Mental Illness: A Systematic Review and Meta-Analysis of Randomized Controlled Trials\".","2026","International journal of psychiatry in medicine","Wajid MA","5","4","1","none found",null],["R0000591",null,null,"10.1080/0886022x.2026.2620155","41644273","PMC12879500","Cardiorenal protective effects of glucagon-like peptide-1 receptor agonists in chronic kidney disease: a systematic review and meta-analysis.","2026","Renal failure","Wang Y","47","25","8","none found",null],["R0000595","CRD420261337353",null,"10.3390/ijms27125618","42353331","PMC13299499","Therapeutic Effects of Glucagon-like Peptide-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: A Systematic Review.","2026","International journal of molecular sciences","Mahoon D","49","24","11","PROSPERO","PROSPERO:CRD420261337353"],["R0000599",null,null,"10.1111/dom.70572","41725443",null,"Comparative effectiveness of continuous positive airway pressure and glucagon-like peptide-1 receptor agonists in obstructive sleep apnea: A network meta-analysis of randomised trials.","2026","Diabetes, obesity & metabolism","Chiappa GR","37","10","7","none found",null],["R0000603","CRD420251034652",null,"10.1097/xce.0000000000000360","42376130","PMC13313748","Effect of glucagon-like peptide-1 receptor agonists on major adverse cardiovascular events in adults with type 2 diabetes and established atherosclerotic cardiovascular disease: systematic review and meta-analysis of randomised trials.","2026","Cardiovascular endocrinology & metabolism","Montenegro-Avila A","19","15","8","PROSPERO","PROSPERO:CRD420251034652"],["R0000604",null,null,"10.3390/cells15151319","42587729","PMC13464801","Metabolic Reversal of Functional Hypogonadism? GLP-1 Receptor Agonists and Male Reproductive Endocrinology-A Systematic Review.","2026","Cells","Zafrani Z","27","11","5","none found",null],["R0000616",null,null,"10.1017/neu.2026.10060","41684077","PMC13130272","The effect of GLP-1 receptor agonists on autophagy: insights gathered from research evaluating neurodegenerative disorders with these agents.","2026","Acta neuropsychiatrica","Sioufi MC","72","25","1","none found",null],["R0000621",null,null,"10.1177/00912174261480243","42633966",null,"Response to Letter to the Editor: Decreased Risk of Mental Illness Worsening: Comment on \"Glucagon-like Peptide-1 Receptor Agonists in Individuals With Severe Mental Illness: A Systematic Review and Meta-Analysis of Randomized Controlled Trials\".","2026","International journal of psychiatry in medicine","Srisurapanont M","6","5","4","none found",null],["R0000626",null,null,"10.1101/2025.07.05.25330933",null,null,"Differential effects of glucagon-like peptide-1 receptor agonist classes on blood pressure: a systematic review and network meta-analysis of randomised controlled trials with meta-regression","2025","medRxiv","Chou OHI",null,"0","0","none found",null],["R0000633",null,null,"10.3390/ph18050735","40430553","PMC12115298","Risk of Hearing Loss in Patients Treated with Exendin-4 Derivatives: A Network Meta-Analysis of Glucagon-like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors.","2025","Pharmaceuticals (Basel, Switzerland)","Chen JJ","174","99","89","none found",null],["R0000641",null,null,"10.1111/cob.70012","40265328","PMC12289403","Effect of glucagon-like peptide 1 receptor agonists on systolic blood pressure in patients with obesity, with or without diabetes: A systematic review and network meta-analysis.","2025","Clinical obesity","Ali A","49","41","36","none found",null],["R0000649",null,null,"10.1530/ec-26-0280","42447044","PMC13386145","Periconceptional use of GLP-1 receptor agonists and the risk of major congenital malformations: a systematic review and meta-analysis.","2026","Endocrine connections","Liu X","53","30","6","none found",null],["R0000652",null,null,"10.1210/clinem/dgaf336","40489581",null,"Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis.","2025","The Journal of clinical endocrinology and metabolism","Wang Y","92","50","26","none found",null],["R0000661",null,null,"10.1093/jsxmed/qdaf381","41498523",null,"Effects of glucagon-like peptide-1 receptor agonists on male reproductive hormones, semen parameters, and metabolic outcomes: a systematic review.","2026","The journal of sexual medicine","Deameh MG","19","17","6","none found",null],["R0000662",null,null,"10.1002/edm2.70113","40988099","PMC12457091","Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.","2025","Endocrinology, diabetes & metabolism","Wen J","20","12","1","none found",null],["R0000664",null,null,null,null,"PMC13145756","ABSTRACT NUMBER: ESOC2026A1557 EFFICACY AND SAFETY OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ON STROKE RISK AND CEREBROVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A NETWORK META-ANALYSIS","2026","European stroke journal",null,"0","0","0","none found",null],["R0000676","CRD420251251321",null,"10.1007/s00592-026-02730-4","42334596",null,"Adjunctive use of glucagon-like peptide-1 receptor agonists after bariatric surgery: updated systematic review and meta-analysis of randomized controlled trials.","2026","Acta diabetologica","Arora S","28","16","7","PROSPERO","PROSPERO:CRD420251251321"],["R0000686",null,null,"10.3389/fonc.2026.1859759","42523690","PMC13407199","Cancer outcomes and biological mechanisms among patients with type 2 diabetes mellitus using glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis.","2026","Frontiers in oncology","Eze ED","35","33","1","none found",null],["R0000687",null,null,"10.1002/edm2.70102","41721616","PMC12928090","Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists Following Bariatric Surgery: A Systematic Review and Meta-Analysis.","2026","Endocrinology, diabetes & metabolism","Bilal AR","40","21","8","none found",null],["R0000710",null,null,"10.1016/j.pan.2026.04.005","41991368",null,"Glucagon-like Peptide-1 receptor agonists are not associated with increased risk of pancreatic cancer: A systematic review and meta-analysis.","2026","Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]","Lauri G","83","67","47","none found",null],["R0000725","CRD420251024082",null,"10.1007/s40265-026-02365-3","42730869","PMC13615104","GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-Analysis.","2026","Drugs","Beaudart C","102","84","45","PROSPERO","PROSPERO:CRD420251024082"],["R0000729","CRD420261299499",null,"10.3389/fendo.2026.1874720","42312204","PMC13268877","Glucagon-like peptide-1 receptor agonists and advanced liver outcomes in type 2 diabetes: a systematic review and exploratory meta-analysis.","2026","Frontiers in endocrinology","Hu JH","40","23","5","PROSPERO","PROSPERO:CRD420261299499"],["R0000737",null,null,"10.1016/j.jaip.2026.05.010","42167405",null,"Glucagon-Like Peptide-1 Receptor Agonists in Asthma and Obesity-Associated Asthma: A Systematic Review of Clinical Outcomes and Translational Mechanisms.","2026","The journal of allergy and clinical immunology. In practice","Saadat S","78","21","0","none found",null],["R0000741",null,null,"10.1001/jamainternmed.2025.8222","41770554","PMC12954602","Heterogeneity of Treatment Effects of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss in Adults: A Systematic Review and Meta-Analysis.","2026","JAMA internal medicine","Alexander GC","74","57","36","none found",null],["R0000744",null,null,"10.3390/ijms27093882","42123472","PMC13164057","Metabolic Benefits vs. Cardiovascular Uncertainty: A Critical Review of GLP-1 Receptor Agonists in Type 1 Diabetes.","2026","International journal of molecular sciences","Wójcik-Sosnowska E","34","17","1","none found",null],["R0000759",null,null,"10.12688/f1000research.186847.1",null,null,"Comparison of Mazdutide and Dulaglutide for Type 2 Diabetes: a GRADE assessed systematic review and meta-analysis of randomized controlled trials","2026","F1000Res","Hassan A",null,"0","0","none found",null],["R0000763",null,null,"10.1111/dom.70382","41395692","PMC12890775","Injection-site and dermatologic reactions associated with glucagon-like peptide-1 receptor agonists: Insights from meta-analysis of randomised controlled trials and real-world evidence.","2026","Diabetes, obesity & metabolism","Taj S","71","62","38","none found",null],["R0000770",null,null,"10.1016/j.ajp.2026.104870","41619567",null,"Molecular evidence associating GLP-1 receptor agonists and brain-derived neurotrophic factors in neurodegenerative and psychiatric disorders: A systematic review.","2026","Asian journal of psychiatry","Xu T","40","22","0","none found",null],["R0000777",null,null,"10.1007/s10072-026-08929-1","41995965","PMC13090280","Efficacy of GLP-1 receptor agonists in Parkinson's disease: a systematic review and exploratory network meta-analysis of randomized controlled trials.","2026","Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","Ali M","15","11","5","none found",null],["R0000798",null,null,"10.1177/21532176251413898","41715277","PMC13191177","The Effect of GLP-1 Receptor Agonists on Alanine Aminotransferase and Other Metabolic Parameters in Youths with Obesity: A Systematic Review and Meta-Analysis.","2026","Childhood obesity (Print)","Hertzer LA","20","15","7","none found",null],["R0000819",null,null,"10.1007/s00592-026-02666-9","41706180","PMC13468739","The combination of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors: a narrative review of existing meta-analysis.","2026","Acta diabetologica","Avogaro A","24","17","4","none found",null],["R0000820",null,null,"10.3310/skht8119","40580049","PMC12336958","The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review.","2026","Health technology assessment (Winchester, England)","Nunns M","76","71","24","none found",null],["R0000821","CRD42023461665",null,"10.1007/s12630-026-03114-6","42087044","PMC13249630","Glucagon-like peptide-1 receptor agonists and gastric emptying time: a systematic review and meta-analysis of prospective studies.","2026","Canadian journal of anaesthesia = Journal canadien d'anesthesie","Chen A","28","19","8","PROSPERO","PROSPERO:CRD42023461665"],["R0000825",null,null,"10.1186/s13098-026-02179-z","42121292","PMC13343907","Glucagon-like peptide-1 receptor agonists improve hepatic histology and metabolic parameters in type 2 diabetes with MASLD: a meta-analysis of randomized controlled trials.","2026","Diabetology & metabolic syndrome","Zou M","35","24","12","none found",null],["R0000829",null,null,"10.1038/s41366-025-01859-6","40804463","PMC12532569","Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis.","2025","International journal of obesity (2005)","Ismaiel A","56","52","36","none found",null],["R0000831","CRD420261287573",null,"10.1007/s12072-026-11132-1","42509395",null,"GLP-1 receptor agonists in metabolic dysfunction-associated steatohepatitis: a systematic review and meta-analysis of randomized controlled trials.","2026","Hepatology international","Sun SP","42","34","28","PROSPERO","PROSPERO:CRD420261287573"],["R0000840",null,null,"10.2337/dc25-1238","41498755",null,"Association Between GLP-1 Receptor Agonists and Ischemic Optic Neuropathy: A Meta-analysis.","2026","Diabetes care","Nogueira A","9","7","0","none found",null],["R0000852","CRD420251074381",null,"10.1002/oby.70098","41640092","PMC13535706","Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists Use in Elderly People With Obesity-A Meta-Analysis.","2026","Obesity (Silver Spring, Md.)","Rego de Figueiredo I","15","12","5","PROSPERO","PROSPERO:CRD420251074381"],["R0000859",null,null,"10.1007/s11325-026-03681-4","42029967","PMC13109165","Efficacy of GLP-1 Receptor agonists in treating Obstructive sleep apnea: A systematic review and meta-analysis of cardiometabolic and respiratory outcomes.","2026","Sleep & breathing = Schlaf & Atmung","Dandamudi M","26","8","5","none found",null],["R0000863",null,null,"10.7759/cureus.114350","42725235","PMC13561143","Neuropsychiatric Effects of Glucagon-Like Peptide-1 Receptor Agonists in Schizophrenia-Spectrum Disorders: A Systematic Review.","2026","Cureus","Alsanosi ZY","17","6","6","none found",null],["R0000875",null,null,"10.1016/j.diabres.2026.113158","41722869",null,"Glucagon-like peptide-1 receptor agonists and the risk of obesity-related cancers: a systematic review and meta-analysis.","2026","Diabetes research and clinical practice","Ateiwi YA","65","34","1","none found",null],["R0000876",null,null,"10.1097/md.0000000000046173","41366934","PMC12688971","Assessing the shadows: A meta-analysis of GLP-1 agonists and suicidal ideation.","2025","Medicine","Alansari AO","33","26","4","none found",null],["R0000877",null,null,"10.3389/fcvm.2026.1868320","42723815","PMC13557988","Association of glucagon-like peptide-1 receptor agonists with atrial fibrillation recurrence after catheter ablation: a systematic review and meta-analysis.","2026","Frontiers in cardiovascular medicine","He D","51","29","2","none found",null],["R0000878",null,null,"10.1016/j.dsx.2025.103238","40388845",null,"Glucagon-Like Peptide-1 receptor agonists, dual GIP/GLP-1 receptor agonist tirzepatide and suicidal ideation and behavior: A systematic review of clinical studies and pharmacovigilance reports.","2025","Diabetes & metabolic syndrome","Di Stefano R","52","29","5","none found",null],["R0000882",null,null,"10.1186/s12888-026-08016-x","41904417","PMC13151306","Glucagon-like peptide-1 receptor agonists and risk of depression: a systematic review and meta-analysis.","2026","BMC psychiatry","Bi Z","54","35","7","none found",null],["R0000885",null,null,"10.7759/cureus.113641","42668799","PMC13525620","Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, and Atrial Fibrillation: An Umbrella Review With Methodological Appraisal of Overlapping Meta-Analyses.","2026","Cureus","Ramzy D","14","9","0","none found",null],["R0000895",null,null,"10.1177/00912174261422822","41618880",null,"Glucagon-like peptide-1 receptor agonists in individuals with severe mental illness: A systematic review and meta-analysis of randomized controlled trials.","2026","International journal of psychiatry in medicine","Srisurapanont M","41","16","10","none found",null],["R0000904",null,null,"10.20944/preprints202407.2397.v1",null,null,"Efficacy and Safety of GLP-1RAs including Tirzepatide, in the Management of Obesity in Nondiabetic Patients: A Systematic Review","2024","Preprints.org","Ndubuisi J",null,"0","0","none found",null],["R0000907","CRD42024592825",null,"10.1111/dom.70635","41804851",null,"Relative Efficacy of Next-Generation Incretin Therapies for Cardio-Renal Protection in Type 2 Diabetes: Evidence From a Network Meta-Analysis.","2026","Diabetes, obesity & metabolism","Pham TP","61","25","17","PROSPERO","PROSPERO:CRD42024592825"],["R0000911",null,null,"10.1002/cam4.71434","41388641","PMC12701129","Glucagon-Like Peptide-1 Receptor Agonists and Hepatocellular Carcinoma Prevention: A Meta-Analysis and Clinical Decision Framework.","2025","Cancer medicine","Dalbeni A","30","19","5","none found",null],["R0000916",null,null,"10.1016/j.jns.2026.125953","42176522",null,"Comment on \"Efficacy of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension: A systematic review and meta-analysis\".","2026","Journal of the neurological sciences","M A","5","1","0","none found",null],["R0000919",null,null,"10.1007/s00228-026-04015-9","41811375",null,"Economic evaluation of sodium-glucose transporter 2 inhibitors compared with glucagon-like peptide 1 receptor agonist for the treatment of type 2 diabetes: a systematic review.","2026","European journal of clinical pharmacology","Wang L","36","21","4","none found",null],["R0000921","CRD420251118829",null,"10.1177/02698811261456190","42312633",null,"Effects of glucagon-like peptide-1 receptor agonists on anthropometric and adiposity measures in patients with antipsychotic-induced weight gain: A systematic review and meta-analysis.","2026","Journal of psychopharmacology (Oxford, England)","Lee S","48","21","15","PROSPERO","PROSPERO:CRD420251118829"],["R0000923",null,null,"10.1177/10732748261483767","42677883","PMC13535051","Associations Between Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) and Cancer Risk: A Systematic Review and Meta-Analysis.","2026","Cancer control : journal of the Moffitt Cancer Center","Lalani I","109","76","12","none found",null],["R0000935",null,null,"10.5946/ce.2025.137","41943648","PMC13058711","Impact of glucagon-like peptide-1 receptor agonists on colonoscopy outcomes: a systematic review and meta-analysis.","2026","Clinical endoscopy","Abdulraheem A","35","20","4","none found",null],["R0000936",null,null,"10.1016/j.metop.2026.100484","42434480","PMC13351396","Direct effects of glucagon-like Peptide-1 receptor agonists on mitochondrial function in human-derived in vitro models: A systematic review and meta-analysis.","2026","Metabolism open","Greenblatt ZL","38","23","1","none found",null],["R0000937",null,null,"10.1111/febs.70656","42625391",null,"Effects of GLP-1 agonists on the gut microbiota in type 2 diabetes mellitus: a systematic review.","2026","The FEBS journal","Santos Dantas R","0","0","0","none found",null],["R0000939","CRD420261354941",null,"10.1111/dom.71051","42410309","PMC13449074","Cardiovascular Outcomes With Tirzepatide Versus GLP-1 Receptor Agonists in Overweight or Obesity: A Systematic Review and Meta-Analysis.","2026","Diabetes, obesity & metabolism","Silva JPMRJ","32","21","14","PROSPERO","PROSPERO:CRD420261354941"],["R0000943",null,null,"10.1007/s40200-026-02000-8","42422116","PMC13341986","Efficacy and safety of GLP-1RA on cardio-metabolic outcomes in overweight or obese Chinese adults: a systematic review and meta-analysis.","2026","Journal of diabetes and metabolic disorders","Bilal AR","0","0","0","none found",null],["R0000950","CRD42024615851",null,"10.1002/phar.70135","41947645",null,"Incretin-Based Therapies for the Treatment of Binge Eating-A Systematic Review.","2026","Pharmacotherapy","White RT","36","15","7","PROSPERO","PROSPERO:CRD42024615851"],["R0000953",null,null,"10.1111/dom.71325","42723273",null,"Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists as Adjuncts to Insulin Therapy in Type 1 Diabetes Mellitus: An Overlap-Informed Umbrella Review.","2026","Diabetes, obesity & metabolism","Lee O","40","26","0","none found",null],["R0000956",null,null,"10.1007/s00592-026-02700-w","42089955",null,"Comment on \"The combination of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors: a narrative review of existing meta-analysis\".","2026","Acta diabetologica","Cao B","5","4","1","none found",null],["R0000959",null,null,"10.1038/s41366-026-02141-z","42399550","PMC13649565","The impact of glucagon-like peptide-1 receptor agonists on objective physical activity in adults: a systematic review and exploratory meta-analysis.","2026","International journal of obesity (2005)","Kim H","56","32","18","none found",null],["R0000962",null,null,"10.4103/jfmpc.jfmpc_1811_25","42257115","PMC13241106","Indications, efficacy, and safety of glucagon-like peptide-1 receptor agonists in respiratory diseases: A systematic review.","2026","Journal of family medicine and primary care","Esmaeel MN","20","18","6","none found",null],["R0000966","CRD420261360886",null,"10.1136/bmjopen-2026-121200","42642087","PMC13536143","Efficacy and safety of glucagon-like peptide-1 receptor agonists for diabetic cardiomyopathy: a protocol for systematic review and meta-analysis.","2026","BMJ open","Tang B","28","11","5","PROSPERO","PROSPERO:CRD420261360886"],["R0000969",null,null,"10.1177/20451253251396304","41445693","PMC12722685","Effects of glucagon-like peptide-1 receptor agonists on psychiatric disorders: a systematic review.","2025","Therapeutic advances in psychopharmacology","Lee S","38","29","13","none found",null],["R0000976",null,null,"10.7759/cureus.111723","42529614","PMC13418259","Comparative Cardiovascular Outcomes and Safety Profiles of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Trials.","2026","Cureus","Mohamed Abdalla SA","28","17","11","none found",null],["R0000992",null,null,"10.1016/j.artd.2026.102043","42182892","PMC13197706","Glucagon-Like Peptide-1 Receptor Agonists in Hip and Knee Arthroplasty: A Comprehensive Systematic Review and Meta-Analysis of Perioperative and Postoperative Outcomes.","2026","Arthroplasty today","Wajda B","45","31","3","none found",null],["R0001004",null,null,"10.1186/s43044-026-00767-y","42479368","PMC13388624","A systematic review and meta-analyses of glucagon-like peptide-1 receptor agonists in acute myocardial infarction.","2026","The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology","Bhullar JK","40","25","10","none found",null],["R0001018",null,null,null,null,"PMC12739814","Glucagon‐like peptide‐1 receptor agonists for neurological disorders: a systematic review and meta‐analysis","2025","Alzheimer's & dementia : the journal of the Alzheimer's Association","Manolopoulos A","0","0","0","none found",null],["R0001019","CRD42024570728",null,"10.1016/j.eclinm.2026.104007","42666688","PMC13523834","The effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on binge eating in patients with obesity: a systematic review and meta-analysis.","2026","EClinicalMedicine","Emptage I","64","38","23","PROSPERO","PROSPERO:CRD42024570728"],["R0001021",null,null,"10.1016/j.psyneuen.2026.107844","41931929",null,"The effect of GLP-1 receptor agonists on anxiety: A systematic review.","2026","Psychoneuroendocrinology","Yi YT","56","24","2","none found",null],["R0001028",null,null,"10.3389/fmed.2026.1783429","42292219","PMC13253451","Efficacy and safety of GLP-1 receptor agonists in patients with metabolic-associated fatty liver diseases: an umbrella review.","2026","Frontiers in medicine","Wu H","62","40","1","none found",null],["R0001032","CRD420251045294",null,"10.1186/s13722-025-00637-z","41350683","PMC12805745","The effects of glucagon-like peptide-1 receptor agonists (GLP1-RAs) on alcohol-related outcomes: a systematic review and meta-analysis.","2025","Addiction science & clinical practice","Sinha B","24","15","4","PROSPERO","PROSPERO:CRD420251045294"],["R0001038",null,null,null,null,"PMC12794896","Assessing the efficacy of large language models in data extraction for a meta-analysis on the role of glucagon-like peptide-1 receptor agonists in heart failure","2026","European heart journal. Digital health",null,"0","0","0","none found",null],["R0001058","CRD420251009075",null,"10.1016/j.eclinm.2025.103645","41324012","PMC12663662","Effects of glucagon-like peptide-1 receptor agonists on alcohol consumption: a systematic review and meta-analysis.","2025","EClinicalMedicine","Eshraghi R","37","25","6","PROSPERO","PROSPERO:CRD420251009075"],["R0001068",null,null,"10.1111/cob.70112","42733128","PMC13572569","Weight Reduction Heterogenicity and Mediators of GLP-1RAs and Dual Agonists for Individuals With Obesity: A Meta-Analysis.","2026","Clinical obesity","Lu D","50","42","38","none found",null],["R0001070",null,null,"10.1097/hc9.0000000000000871","41543478",null,"Effect of glucagon-like peptide-1 receptor agonists on histologic MASH: A meta-analysis of randomized controlled trials.","2026","Hepatology communications","Siranart N","14","6","6","none found",null],["R0001071",null,null,"10.7759/cureus.96162","41367446","PMC12683079","Cardiorenal Safety Markers With Injectable Glucagon-Like Peptide-1 (GLP-1) Agonists in Type 2 Diabetes: A Network Meta-Analysis.","2025","Cureus","Rai A","39","35","19","none found",null],["R0001072",null,null,"10.1186/s12886-025-04559-x","41501669","PMC12781364","GLP-1 receptor agonists in eye disease: a comprehensive review of current research and future potential.","2026","BMC ophthalmology","Luo Y","129","73","13","none found",null],["R0001086",null,null,"10.1038/s41598-025-09807-0","40619508","PMC12230154","Efficacy and safety of GLP-1 agonists in the treatment of T2DM: A systematic review and network meta-analysis.","2025","Scientific reports","Ren X","91","74","63","none found",null],["R0001087",null,null,"10.1111/dom.15381","38016705",null,"A comment on tirzepatide versus glucagon-like peptide-1 receptor agonists and heart rate with regard to 'Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis'.","2024","Diabetes, obesity & metabolism","Goldenberg RM","8","6","4","none found",null],["R0001092","CRD42024586000",null,"10.1186/s12967-025-06461-y","40281607","PMC12032824","Impact of monotherapy and combination therapy with glucagon-like peptide-1 receptor agonists on exosomal and non-exosomal MicroRNA signatures in type 2 diabetes mellitus: a systematic review.","2025","Journal of translational medicine","Yu H","67","25","1","PROSPERO","PROSPERO:CRD42024586000"],["R0001105",null,null,"10.1016/j.jns.2026.125877","41955853",null,"Comment on \"efficacy of glucagon-like Peptide-1 receptor agonists in idiopathic intracranial hypertension: A systematic review and meta-analysis\".","2026","Journal of the neurological sciences","Srinivasan N","0","0","0","none found",null],["R0001107","CRD420261320374",null,"10.1007/s13300-026-01911-2","42678648","PMC13620032","Effect of Combination Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists on Myocardial Infarction and Stroke in Type 2 Diabetes: A Systematic Review and Meta-Analysis.","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","Ghafoury R","57","22","7","PROSPERO","PROSPERO:CRD420261320374"],["R0001122","CRD420251053598",null,"10.1007/s12325-026-03559-7","41874854","PMC13156165","Evidence-Based Positioning of Sodium-Glucose Co-transporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Management of Chronic Kidney Disease with Type 2 Diabetes and Overweight or Obesity: A Systematic Literature Review.","2026","Advances in therapy","Handelsman Y","55","43","12","PROSPERO","PROSPERO:CRD420251053598"],["R0001125",null,null,"10.1016/j.arth.2025.09.054","41072556",null,"The Impact of Glucagon-Like Peptide-1 Receptor Agonist Use on Clinical Outcomes After Total Hip and Knee Arthroplasty: A Systematic Review and Meta-Analysis of 346,899 Patients.","2026","The Journal of arthroplasty","Lee S","49","17","3","none found",null],["R0001126",null,null,"10.1097/xce.0000000000000344","40978810","PMC12445413","Glucagon-like peptide-1 receptor agonists and obesity paradox in heart failure with preserved ejection fraction: a systematic review.","2025","Cardiovascular endocrinology & metabolism","Hullon D","53","25","17","none found",null],["R0001128",null,null,"10.7759/cureus.110621","42292722","PMC13254196","Glucagon-Like Peptide-1 Receptor Agonists Across the Heart Failure Spectrum: A Systematic Review and Meta-Analysis.","2026","Cureus","Muller Ferreira V","33","20","14","none found",null],["R0001142",null,null,"10.1016/j.arth.2025.12.010","41881605",null,"Reply to the Letter to the Editor on \"The Association Between Glucagon-like Peptide-1 Receptor Agonists and Postoperative Complications after Arthroplasty: A Systematic Review and Meta-Analysis\".","2026","The Journal of arthroplasty","Chan YC","0","0","0","none found",null],["R0001145",null,null,"10.1016/j.jns.2026.125867","41826174",null,"Comment on \"Efficacy of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension: A systematic review and meta-analysis\".","2026","Journal of the neurological sciences","Zhang M","0","0","0","none found",null],["R0001147","CRD420251032222",null,"10.1016/j.jacc.2025.08.027","40892610",null,"Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients.","2025","Journal of the American College of Cardiology","Galli M","44","34","23","PROSPERO","PROSPERO:CRD420251032222"],["R0001151",null,null,"10.1177/10926429261469272","42452903",null,"Comparative Outcomes of Metabolic and Bariatric Surgery Versus GLP-1 Receptor Agonists: An Updated Systematic Review and Meta-Analysis of 14,548 Patients.","2026","Journal of laparoendoscopic & advanced surgical techniques. Part A","Rivero-Moreno Y","37","17","4","none found",null],["R0001152",null,null,"10.1111/head.70131","42619634",null,"Glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension: A systematic review and meta-analysis.","2026","Headache","Falcão L","0","0","0","none found",null],["R0001159","CRD420251176164",null,"10.1016/j.jcjo.2026.05.004","42242293",null,"Diabetic macular edema and GLP-1 receptor agonist use: a systematic review and meta-analysis.","2026","Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","Al-Burak SA","45","26","3","PROSPERO","PROSPERO:CRD420251176164"],["R0001161","CRD420261352699",null,"10.1111/dom.71337","42733137",null,"Effects of Renin-Angiotensin Inhibitors, Sodium-Glucose Cotransporter 2 Inhibitors, Mineralocorticoid Receptor Antagonists and Glucagon-Like Peptide 1 Receptor Agonists on Kidney Outcomes in Patients With Type 1 Diabetes: A Systematic Review and Meta-Analysis.","2026","Diabetes, obesity & metabolism","Perry F","0","0","0","PROSPERO","PROSPERO:CRD420261352699"],["R0001168",null,null,"10.1111/eci.70000","39937048","PMC12066890","Effects of glucagon-like PEPTIDE-1 receptor agonists on incidence of hepatocellular carcinoma and liver decompensation in patients with diabetes: A systematic review and META-analysis.","2025","European journal of clinical investigation","Pasta A","16","11","1","none found",null],["R0001170",null,null,"10.3389/fpsyt.2026.1857078","42553449","PMC13433608","GLP-1 receptor agonists and psychiatric outcomes: a bibliometric analysis of research trends, thematic evolution, and collaboration networks.","2026","Frontiers in psychiatry","Roca Mora MM","17","16","5","none found",null],["R0001172","CRD420261305938",null,"10.64898/2026.09.18.26363449",null,null,"GLP-1 Receptor Agonists, Stroke, and Cognitive Outcomes: Systematic Review and Meta-Regression","2026","medRxiv","Danielli M",null,"0","0","PROSPERO","PROSPERO:CRD420261305938"],["R0001174",null,null,"10.1093/eurjpc/zwaf730","41253686",null,"The role of glucagon-like peptide-1 receptor agonists in cancer therapy-related cardiovascular disease: a meta-analysis.","2026","European journal of preventive cardiology","Farmakis D","11","7","2","none found",null],["R0001175",null,null,"10.1016/j.jns.2026.125866","41833129",null,"Response to \"Comment on 'efficacy of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension: A systematic review and meta-analysis'\".","2026","Journal of the neurological sciences","Ahmed W","0","0","0","none found",null],["R0001177",null,null,"10.1016/j.jns.2026.125876","41916123",null,"Response to comment by Srinivasan et al. on \"Efficacy of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension: A systematic review and meta-analysis\".","2026","Journal of the neurological sciences","Ahmed W","0","0","0","none found",null],["R0001189",null,null,"10.1016/j.soard.2025.12.009","41946634",null,"Comment on: Cardiovascular outcomes and mortality of bariatric surgery versus glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis.","2026","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","Zheng X","0","0","0","none found",null],["R0001209",null,null,"10.20524/aog.2026.1067","42434158","PMC13352199","Effect of GLP-1 receptor agonists on upper gastrointestinal endoscopy outcomes: a systematic review and meta-analysis.","2026","Annals of gastroenterology","Malandris K","42","38","5","none found",null],["R0001210","CRD420251237987",null,"10.1007/s00417-026-07430-x","42541561",null,"Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: a systematic review of diabetic retinopathy outcomes.","2026","Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie","Francisco C","35","28","5","PROSPERO","PROSPERO:CRD420251237987"],["R0001218",null,null,"10.1017/neu.2025.10038","40899147","PMC13130282","Glucagon-like peptide-1 receptor agonists for the treatment of opioid use disorders: a systematic review.","2025","Acta neuropsychiatrica","Au HCT","34","24","1","none found",null],["R0001222",null,null,"10.1016/j.disamonth.2026.102150","42215399",null,"GLP-1 receptor agonists for weight management and potential thromboembolic risk reduction in high risk population with cancer, diabetes, cardiovascular disease: A systematic review.","2026","Disease-a-month : DM","Parekh RS","0","0","0","none found",null],["R0001231",null,null,"10.1007/s10072-026-09084-3","42105060","PMC13157460","Efficacy and safety of GLP-1 receptor agonists in Parkinson's disease: a systematic review and meta-analysis of randomized clinical trials.","2026","Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","Mendonça MF","31","17","4","none found",null],["R0001233",null,null,"10.1111/pace.70262","42033283","PMC13456437","Effect of GLP-1 Receptor Agonists on Post-Ablation Atrial Fibrillation Recurrence: A Meta‑Analysis.","2026","Pacing and clinical electrophysiology : PACE","Shubietah A","35","15","4","none found",null],["R0001249","CRD420251162316",null,"10.1007/s11739-026-04384-0","42141180",null,"Effects of glucagon-like peptide-1 receptor agonists and dual glucagon-like peptide-1 receptor agonists/glucose-dependent insulinotropic polypeptide on liver stiffness and steatosis evaluated through Fibroscan®: a systematic review and meta-analysis.","2026","Internal and emergency medicine","Berardicurti A","42","15","7","PROSPERO","PROSPERO:CRD420251162316"],["R0001251","CRD420251008703",null,"10.1177/17562864251408269","41631108","PMC12861370","Efficacy and safety of glucagon-like peptide-1 receptor agonists in Parkinson's disease: a systematic review and meta-analysis of randomized placebo-controlled clinical trials.","2026","Therapeutic advances in neurological disorders","Stefanou MI","44","26","5","PROSPERO","PROSPERO:CRD420251008703"],["R0001263",null,null,"10.1007/s11695-025-08137-4","40782272",null,"Preoperative Glucagon-Like Peptide-1 Receptor Agonists and Bariatric Surgery Outcomes: A Systematic Review.","2025","Obesity surgery","Esparham A","28","24","1","none found",null],["R0001275",null,null,"10.3389/fcvm.2025.1633114","41112222","PMC12533278","Efficacy and safety of GLP-1 receptor agonists in the treatment of obese patients with chronic heart failure: a meta-analysis.","2025","Frontiers in cardiovascular medicine","Jia A","42","33","12","none found",null],["R0001278",null,null,"10.1016/j.arth.2025.11.050","41881604",null,"Letter Regarding \"The Association Between Glucagon-Like Peptide-1 Receptor Agonists and Postoperative Complications After Arthroplasty: A Systematic Review and Meta-Analysis (Chan et al., J Arthroplasty, 2025)\".","2026","The Journal of arthroplasty","Guevel B","0","0","0","none found",null],["R0001279",null,null,"10.1016/j.amjcard.2026.02.030","41759565",null,"CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment.","2026","The American journal of cardiology","Gadelmawla AF","55","21","6","none found",null],["R0001285",null,null,"10.2147/dmso.s570273","41836360","PMC12982893","A Systematic Review and Meta-Analysis of Efficacy and Safety of Liraglutide in Patients with Type 2 Diabetes Mellitus.","2026","Diabetes, metabolic syndrome and obesity : targets and therapy","Joshi S","60","36","29","none found",null],["R0001288",null,null,"10.1007/s13300-026-01847-7","41762380","PMC13103177","Efficacy and Safety of Once-Weekly IcoSema Versus Once-Daily IDegLira in People with Type 2 Diabetes: Systematic Literature Review and Network Meta-analysis.","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","Kandalam S","27","21","10","none found",null],["R0001292","CRD42023480167",null,"10.1111/1753-0407.70063","40040445","PMC11880690","Sex Differences in the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta-Analysis.","2025","Journal of diabetes","Yang Y","48","32","21","PROSPERO","PROSPERO:CRD42023480167"],["R0001294",null,null,"10.1101/2024.07.18.24310630",null,null,"Efficacy of a fixed-ratio combination of glucagon-like peptide-1 receptor agonist and basal insulin therapy for the treatment of type 2 diabetes: a protocol for systematic review and meta-analysis of randomized clinical trials","2024","medRxiv","Ramalan MA",null,"0","0","none found",null],["R0001302",null,null,"10.3390/ijms27094137","42123715","PMC13164542","Differential Acute Kidney Injury Profiles of GLP-1RAs and SGLT2is: A Network Meta-Analysis.","2026","International journal of molecular sciences","Liang CS","245","114","88","none found",null],["R0001309",null,null,"10.1002/edm2.70311","42700367","PMC13546078","Comparative Cardiovascular Outcomes of GLP-1 Receptor Agonists Versus Bariatric Surgery: A Systematic Review and Network Meta-Analysis.","2026","Endocrinology, diabetes & metabolism","Shirmohammadi E","65","24","13","none found",null],["R0001316",null,null,"10.1177/03000605261458641","42424036","PMC13351244","Effect of glucagon-like peptide-1 receptor agonists on body weight and urinary albumin-to-creatinine ratio in patients with and without type 2 diabetes: A systematic review and meta-analysis.","2026","The Journal of international medical research","Huang R","32","26","9","none found",null],["R0001351","CRD42024571356",null,"10.3389/fphar.2025.1702448","41552827","PMC12808432","The potential role of GLP-1 receptor agonists in substance use disorders - a systematic review.","2025","Frontiers in pharmacology","Völker KM","46","44","8","PROSPERO","PROSPERO:CRD42024571356"],["R0001359",null,null,"10.1007/s12020-026-04559-x","41697556",null,"GLP-1 receptor agonists and smoking cessation: therapeutic promise beyond glycemia.","2026","Endocrine","Bhaduri G","31","16","5","none found",null],["R0001360",null,"osf.io/u7wdy","10.3389/fnins.2026.1894856","42591537","PMC13462061","Research hotspots and trends of GLP-1 receptor agonists in the treatment of Parkinson's disease: a bibliometric analysis.","2026","Frontiers in neuroscience","Yu T","52","38","6","OSF",null],["R0001366",null,null,"10.1002/phar.70137","41947629",null,"SGLT2 Inhibitors and GLP-1 Receptor Agonists After Acute Kidney Injury: A Systematic Review With Meta-Analysis.","2026","Pharmacotherapy","Barreto EF","0","0","0","none found",null],["R0001372",null,null,"10.1016/j.obpill.2026.100272","42095067","PMC13141732","Pharmacological interventions for obesity in patients with inflammatory bowel disease: A systematic review of GLP-1 receptor agonist efficacy and safety.","2026","Obesity pillars","Jan A","22","13","3","none found",null],["R0001373","CRD42024609736",null,"10.1002/bcp.70492","41703425",null,"Comparative efficacy of GLP-1 RA, tirzepatide and SGLT-2 inhibitors in metabolic liver disease: A network meta-analysis.","2026","British journal of clinical pharmacology","Belančić A","1","1","0","PROSPERO","PROSPERO:CRD42024609736"],["R0001380",null,null,"10.1111/dom.71035","42348164","PMC13449011","Cardiovascular Efficacy of GLP-1 Receptor Agonists by Kidney Function: An Updated Meta-Analysis of Randomized Trials Including the SOUL Trial.","2026","Diabetes, obesity & metabolism","Hasebe M","54","27","14","none found",null],["R0001392",null,null,"10.1016/j.eprac.2025.06.005","40553959",null,"Comparative Effectiveness of Glucagon-like Peptide-1- Receptor Agonists in Patients With Heart Failure With Preserved or Minimally Reduced Ejection Fraction: A Comprehensive Bayesian Network Meta-Analysis and Network Meta-Regression.","2025","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Khalil I","36","14","10","none found",null],["R0001393",null,null,"10.1111/1753-0407.70151","40887719","PMC12399406","Impact of GLP-1 Receptor Agonists on Suicide Behavior: A Meta-Analysis Based on Randomized Controlled Trials.","2025","Journal of diabetes","Chen J","49","34","23","none found",null],["R0001394",null,null,"10.3390/healthcare13222958","41302345","PMC12652309","Evaluating Suicidal Risk in GLP-1RA Therapy: An Umbrella Review of Meta-Analytic Evidence.","2025","Healthcare (Basel, Switzerland)","Ștefănescu C","28","19","4","none found",null],["R0001397",null,null,"10.5662/wjm.v15.i4.105478","40900863","PMC12400322","Safety and efficacy of glucagon-like peptide-1 receptor agonists in individuals with type 2 diabetes mellitus fasting during Ramadan: a systematic review and meta-analysis.","2025","World journal of methodology","Kamrul-Hasan ABM","31","18","4","none found",null],["R0001398","CRD420251080120",null,"10.3389/fphar.2026.1808359","42311413","PMC13269103","Ocular disorders during treatment with GLP-1 receptor agonists: a systematic review and meta-analysis of observational studies.","2026","Frontiers in pharmacology","Anatriello A","76","58","4","PROSPERO","PROSPERO:CRD420251080120"],["R0001401",null,null,"10.1111/cob.70105","42584177","PMC13464048","Burden and Risk of Depression in Patients Receiving Semaglutide: A Systematic Review and Meta-Analysis.","2026","Clinical obesity","Bhaduri G","16","10","1","none found",null],["R0001415",null,null,"10.1002/phar.70142","41947610",null,"Beyond Monotherapy: The Superior Efficacy of Combined GLP-1 Receptor Agonist and SGLT2 Inhibitors on Renal Biomarkers: A Systematic Review and Meta-Analysis.","2026","Pharmacotherapy","AbdelMagid AM","0","0","0","none found",null],["R0001420","CRD42024608365",null,"10.7326/annals-25-02237","41359966",null,"Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists : A Systematic Review and Meta-analysis.","2026","Annals of internal medicine","Ko A","80","64","49","PROSPERO","PROSPERO:CRD42024608365"],["R0001429",null,null,"10.1016/j.jhepr.2025.101708","41810433","PMC12969438","Efficacy and safety of GLP-1 receptor agonists in MASH with fibrosis: A systematic review and meta-analysis.","2026","JHEP reports : innovation in hepatology","Dos Santos Borges R","60","30","11","none found",null],["R0001453",null,null,"10.2174/011570159x439787260312090015","42163663",null,"The Efficacy of Glucagon-like Peptide-1 Receptor Agonists on Different Cognitive Domains: A Meta-analysis of Randomized Controlled Trials.","2026","Current neuropharmacology","Xu H","0","0","0","none found",null],["R0001467",null,null,"10.1016/j.medj.2026.101267","42810337",null,"GLP-1 receptor agonist exposure in the periconceptional period and adverse obstetric outcomes: A systematic review and meta-analysis.","2026","Med (New York, N.Y.)","D'Antonio F","0","0","0","none found",null],["R0001487",null,null,"10.1002/edm2.70275","42487237","PMC13392217","Metabolic and Glycemic Effects of Orforglipron, a GLP-1 Receptor Agonist, in Adults With or Without Diabetes: A Network Meta-Analysis of Randomised Clinical Trials.","2026","Endocrinology, diabetes & metabolism","Hageen AW","52","26","10","none found",null],["R0001488",null,null,"10.14336/ad.2025.1165","41400575",null,"Glucagon Like Peptide-1 Receptor Agonists for Sarcopenia and Muscle Wasting Disorders: A Systematic Review of Efficacy and Mechanisms.","2025","Aging and disease","Maihemuti A","0","0","0","none found",null],["R0001492",null,null,"10.1016/j.jns.2025.125711","41468715",null,"Efficacy of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension: A systematic review and meta-analysis.","2026","Journal of the neurological sciences","Ahmed W","50","10","2","none found",null],["R0001493",null,null,"10.1111/dom.70749","41969171","PMC13243948","Estimated Glomerular Filtration Rate Change and Heart Failure Events With GLP-1 Receptor Agonists: A Meta-Analysis and Meta-Regression of Randomised Controlled Trials.","2026","Diabetes, obesity & metabolism","Hasebe M","50","30","19","none found",null],["R0001515",null,null,"10.1111/dom.70699","41885132",null,"Safety of GLP-1 and Dual GLP-1/GIP Receptor Agonists in Preconception, Pregnancy, and Lactation: A Systematic Review of Maternal, Fetal, and Neonatal Outcomes.","2026","Diabetes, obesity & metabolism","Ozbek L","55","39","5","none found",null],["R0001517",null,null,"10.1038/s41398-026-04253-6","42420255","PMC13631319","Glucagon-like peptide-1 receptor agonists for weight management in mental illness: a network meta-analysis.","2026","Translational psychiatry","Kishi T","53","19","11","none found",null],["R0001519",null,null,"10.1186/s13741-026-00662-9","41723539","PMC13032261","Perioperative anesthesia management of GLP-1 receptor agonists: a systematic review of potential risks.","2026","Perioperative medicine (London, England)","Merhavy ZI","30","24","2","none found",null],["R0001526","CRD42025641616",null,"10.1007/s12029-025-01330-9","41075111",null,"Do Incretin-Based Therapies Influence the Risk of Cholangiocarcinoma in Type 2 Diabetes Patients? Insights from a Systematic Review and Meta-Analysis.","2025","Journal of gastrointestinal cancer","Yonatan ER","18","12","0","PROSPERO","PROSPERO:CRD42025641616"],["R0001529",null,null,"10.1002/14651858.cd015952","40237224","PMC12001318","Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors combination therapy for adults with type 2 diabetes mellitus: a network meta-analysis.","2025","The Cochrane database of systematic reviews","Osman AA","74","14","4","none found",null],["R0001530","CRD420261279841",null,"10.1136/bmjmed-2026-003026","42688617","PMC13536023","Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.","2026","BMJ medicine","Chen D","34","15","6","PROSPERO","PROSPERO:CRD420261279841"],["R0001532",null,null,"10.1002/dmrr.70134","41668634",null,"Association Between GLP-1 Receptor Agonists and the Risk of Colon Cancer in Adults With Type 2 Diabetes or Obesity: A Systematic Review and Network Meta-Analysis.","2026","Diabetes/metabolism research and reviews","Guo M","57","16","7","none found",null],["R0001543",null,null,"10.1016/j.diabres.2026.113270","42105869",null,"Safety of GLP-1 receptor agonists in type 1 diabetes: a systematic review and meta-analysis.","2026","Diabetes research and clinical practice","Kateel R","44","30","22","none found",null],["R0001545",null,null,"10.1136/gutjnl-2024-334591","40015951",null,"Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies.","2025","Gut","Celsa C","36","20","6","none found",null],["R0001548","CRD420251029748",null,"10.1016/j.mcn.2026.104091","42014236",null,"The effects of GLP-1 receptor agonists on Alzheimer's pathophysiology: A systematic review.","2026","Molecular and cellular neurosciences","Corcoran E","76","53","6","PROSPERO","PROSPERO:CRD420251029748"],["R0001549",null,null,"10.1007/s13300-025-01728-5","40214900","PMC12085526","Efficacy and Safety of Tirzepatide Compared with GLP-1 RAs in Patients with Type 2 Diabetes Treated with Basal Insulin: A Network Meta-analysis.","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","Osumili B","215","203","195","none found",null],["R0001567",null,null,"10.1016/j.disamonth.2026.102151","42285803",null,"GLP-1 agonist and neuroprotection in Stroke and Parkinson's disease: A systematic review.","2026","Disease-a-month : DM","Parekh DS","0","0","0","none found",null],["R0001577","CRD420251034203",null,"10.1007/s00592-026-02697-2","42101662",null,"The effect of GLP-1 receptor agonists on osteoarthritis risk in individuals with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized controlled trials.","2026","Acta diabetologica","Zhou L","92","77","60","PROSPERO","PROSPERO:CRD420251034203"],["R0001580",null,null,"10.1016/j.metabol.2024.156113","39719170",null,"Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis.","2025","Metabolism: clinical and experimental","Karakasis P","74","37","24","none found",null],["R0001582",null,null,"10.7759/cureus.89514","40918811","PMC12413470","Cardiovascular Benefits of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Type 2 Diabetes Mellitus With Atherosclerotic Cardiovascular Disease: A Systematic Review of Randomized Controlled Trials.","2025","Cureus","Ahmad M","23","18","12","none found",null],["R0001588",null,null,"10.1080/01616412.2026.2640121","41776834",null,"Potential therapeutic role of GLP-1 receptor agonists in Idiopathic intracranial hypertension: a systematic review and meta-analysis.","2026","Neurological research","Song J","0","0","0","none found",null],["R0001589",null,null,"10.1016/j.soard.2025.11.024","41506923",null,"Cardiovascular outcomes and mortality of bariatric surgery versus glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis.","2026","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","Cordova F","27","15","4","none found",null],["R0001592",null,null,"10.3233/adr-230181","38746639","PMC11091751","Clinical Evidence for GLP-1 Receptor Agonists in Alzheimer's Disease: A Systematic Review.","2024","Journal of Alzheimer's disease reports","Liang Y","19","13","5","none found",null],["R0001605",null,null,"10.1177/1759720x261428147","41782908","PMC12953953","The association between glucagon-like peptide-1 receptor agonists and reported musculoskeletal adverse events: a systematic review and meta-analysis of randomized controlled trials.","2026","Therapeutic advances in musculoskeletal disease","Cao M","40","27","3","none found",null],["R0001609",null,null,"10.1097/mjt.0000000000002069","41656069",null,"Outcomes With Glucagon-Like Peptide-1 Receptor Agonists in Idiopathic Intracranial Hypertension: A Systematic Review and Meta-Analysis.","2026","American journal of therapeutics","Sayed MS","15","9","1","none found",null],["R0001612",null,null,"10.1111/liv.70256","40736113","PMC12309150","Glucagon-Like Peptide-1 Receptor Agonists Improve MASH and Liver Fibrosis: A Meta-Analysis of Randomised Controlled Trials.","2025","Liver international : official journal of the International Association for the Study of the Liver","Mantovani A","46","28","16","none found",null],["R0001616","CRD420251112823",null,"10.1111/dom.70298","41255131","PMC12803684","Efficacy and safety of glucagon-like peptide 1 receptor agonists across all health outcomes in type 2 diabetes: An umbrella review and evidence map of randomised controlled trials.","2026","Diabetes, obesity & metabolism","Yeo D","72","52","5","PROSPERO","PROSPERO:CRD420251112823"],["R0001627",null,"osf.io/3rv6d","10.3389/fphar.2026.1736380","41743116","PMC12929497","Reassessing cancer risk with GLP-1 receptor agonists: a comprehensive meta-analysis of gastrointestinal malignancies.","2026","Frontiers in pharmacology","Wali AF","63","63","61","OSF",null],["R0001628",null,null,"10.1007/s42000-025-00704-9","40760325","PMC12678461","Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus: a systematic review and meta-analysis.","2025","Hormones (Athens, Greece)","Rebelos E","52","33","26","none found",null],["R0001637",null,null,"10.1007/s13300-026-01843-x","41697522","PMC13000097","Evaluating the Effects of Glucagon-Like Peptide 1 Receptor Agonists as a Secondary Prevention in Peripheral Arterial Disease: A Meta-Analysis.","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","Elliott B","28","15","6","none found",null],["R0001653",null,null,"10.7759/cureus.100947","41658748","PMC12875684","Long-Term Cardiovascular Outcomes of Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Obesity: A Systematic Review and Meta-Analysis.","2026","Cureus","Tom-Ayegunle K","24","20","13","none found",null],["R0001656",null,null,"10.7759/cureus.96279","41362522","PMC12681965","Impact of Glucagon-Like Peptide-1 Receptor Agonists on Hip Arthroplasty Outcomes: A Systematic Review and Meta-Analysis.","2025","Cureus","Zaffar H","41","18","5","none found",null],["R0001657",null,null,"10.1111/dom.71094","42426564",null,"Efficacy and Safety of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Ventricular Arrhythmias and Cardiovascular Events: A Disease-Stratified Network Meta-Analysis.","2026","Diabetes, obesity & metabolism","Sun WT","58","16","11","none found",null],["R0001664",null,null,"10.1111/wrr.70085","40888511","PMC12400791","Exploring the Role of GLP-1 Agents in Managing Diabetic Foot Ulcers: A Narrative and Systematic Review.","2025","Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society","Gruzmark FS","138","57","22","none found",null],["R0001666",null,null,"10.7326/annals-25-04736-vs","41359969",null,"Annals Video Summary - Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists: A Systematic Review and Meta-analysis.","2026","Annals of internal medicine",null,"0","0","0","none found",null],["R0001677",null,null,"10.1186/s10194-025-02148-3","41057780","PMC12502165","Use of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension : a systematic review.","2025","The journal of headache and pain","Ognard J","51","23","4","none found",null],["R0001681",null,null,"10.22541/au.176719154.49976277/v1",null,null,"The impact of Glucagon-like peptide-1 receptor agonists (GLP-1RAs) on anesthetic risk in patients undergoing surgery or esophagogastroduodenoscopy: A systematic review and meta-Analysis","2025","Authorea Preprints","Chen X",null,"0","0","none found",null],["R0001696",null,null,"10.31083/rcm45797","41659090","PMC12873659","Association Between Glucagon-Like Peptide-1 Receptor Agonists and Major Adverse Cardiovascular Outcomes Based on Race and Sex Among Patients With and Without Diabetes Mellitus: A Meta-Analysis of Nine Randomized Controlled Trials.","2026","Reviews in cardiovascular medicine","Jaiswal V","12","12","9","none found",null],["R0001697",null,null,"10.1007/s11695-026-08551-2","41826529",null,"Metabolic Bariatric Surgery versus GLP-1 Receptor Agonists for Obesity Management: A Systematic Review and Meta-Analysis.","2026","Obesity surgery","Delgado LM","29","13","1","none found",null],["R0001698",null,null,"10.1002/edm2.70222","42116665","PMC13161550","The Gastrointestinal Safety of Orforglipron, a GLP-1 Receptor Agonist, in Adults With or Without Type 2 Diabetes: A Network Meta-Analysis of Randomized Controlled Trials.","2026","Endocrinology, diabetes & metabolism","Hageen AW","43","30","9","none found",null],["R0001700",null,null,"10.1053/j.jfas.2026.07.011","42508720",null,"\"Examining the impact of perioperative glucagon-like-peptide-1 use within foot and ankle surgery: A systematic review of comparative studies\".","2026","The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons","Anaspure OS","48","30","2","none found",null],["R0001707",null,null,"10.1186/s40842-026-00295-3","42063138","PMC13134098","The long-term cardiovascular safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in high-risk cardiovascular populations: a systematic review and meta-analysis.","2026","Cardiovascular diabetology. Endocrinology reports","Peter K","25","22","11","none found",null],["R0001721","CRD420251230032",null,"10.7759/cureus.106038","42051839","PMC13120833","THR-β Agonists vs Incretin Therapies for Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Biopsy-Anchored Systematic Review With Grading of Recommendations Assessment, Development and Evaluation (GRADE) Certainty.","2026","Cureus","Alzaki AA","37","10","9","PROSPERO","PROSPERO:CRD420251230032"],["R0001726",null,null,"10.1186/s40842-025-00248-2","41354946","PMC12683810","Effectiveness of SGLT2 inhibitors, incretin-based therapies, and finerenone on cardiorenal outcomes: a meta-analysis and network meta-analysis.","2025","Cardiovascular diabetology. Endocrinology reports","Shokravi A","69","32","18","none found",null],["R0001733",null,null,"10.21203/rs.3.rs-10332369/v1",null,null,"Combined Use of Glp-1 Receptor Agonists and Sglt2 Inhibitors in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Observational Cohort Studies","2026","Research Square","ÇİFTÇİOĞLU M",null,"0","0","none found",null],["R0001747",null,null,null,"41658349","PMC12879061","Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in MASH Resolution and Fibrosis Reduction: A Meta-Analysis.","2025","Gastroenterology & hepatology",null,"6","6","6","none found",null],["R0001748",null,null,"10.1192/bjo.2026.12001","42179170","PMC13202607","The safety and efficacy of semaglutide in people with schizophrenia spectrum disorders: systematic review and meta-analysis of randomised controlled trials.","2026","BJPsych open","Trott M","35","12","8","none found",null],["R0001752",null,null,"10.3390/brainsci16090926","42793351","PMC13604221","Neuropsychiatric Outcomes Associated with GLP-1 Receptor Agonists in Adults with Overweight or Obesity: A Systematic Review.","2026","Brain sciences","Lubo C","33","21","5","none found",null],["R0001753","CRD420251155026",null,"10.1007/s00417-026-07291-4","42201355",null,"Semaglutide and risk of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) in type 2 diabetes mellitus: A systematic review and meta-analysis.","2026","Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie","Lampsas S","30","18","2","PROSPERO","PROSPERO:CRD420251155026"],["R0001757",null,null,"10.1016/j.jtha.2025.06.020","40602613",null,"Glucagon-like peptide 1 receptor agonists and risk of venous thromboembolism: a systematic review and meta-analysis of randomized controlled trials.","2025","Journal of thrombosis and haemostasis : JTH","Chiang CH","62","36","29","none found",null],["R0001763","CRD42024603661",null,"10.1016/j.ejphar.2025.177966","40680981",null,"The efficacy and safety of glucagon-like peptide-1 receptor agonists in non-diabetic adults with overweight/obesity: An umbrella review of systematic reviews and meta-analyses.","2025","European journal of pharmacology","Zamanian N","78","26","9","PROSPERO","PROSPERO:CRD42024603661"],["R0001781",null,null,"10.1089/dia.2024.0533","39911047",null,"Quantitative Comparison of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Adults: A Systematic Review and Model-Based Meta-Analysis.","2025","Diabetes technology & therapeutics","Zhang S","40","26","6","none found",null],["R0001786",null,null,"10.7759/cureus.105269","41988613","PMC13077518","Systematic Review Evaluating the Effects of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use on the Postoperative Outcomes of Patients Undergoing Arthroplasty Procedures.","2026","Cureus","Tabor H","39","25","5","none found",null],["R0001789",null,null,"10.64898/2026.03.19.26348844",null,null,"GLP-1 receptor agonists and the risk of acute pancreatitis: a living systematic review and meta-analysis","2026","medRxiv","Bakker L",null,"0","0","none found",null],["R0001799",null,null,"10.3389/fendo.2025.1646956","41450584","PMC12727569","The efficacy and safety of danuglipron and orforglipron in patients with type 2 diabetes and obesity: a systematic review and meta-analysis.","2025","Frontiers in endocrinology","Zhou J","33","20","10","none found",null],["R0001812",null,null,"10.7759/cureus.106972","42137703","PMC13170771","Risk of Depression With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Compared to Other Antidiabetic Medications in Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis.","2026","Cureus","Ferrer Zavala GM","37","16","0","none found",null],["R0001818","CRD420251107996",null,"10.1177/15209156261420209","41640116",null,"Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Sodium-Glucose Cotransporter-2 Inhibitors as Adjunctive Therapy to Automated Insulin Delivery System in Type 1 Diabetes: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.","2026","Diabetes technology & therapeutics","Zhou Y","0","0","0","PROSPERO","PROSPERO:CRD420251107996"],["R0001824","CRD420251009368",null,"10.1186/s13643-026-03153-6","41808133","PMC13088735","The use of GLP-1 receptor agonists and co-agonists in adults without diabetes: a systematic review and network meta-analysis protocol.","2026","Systematic reviews","Moiz A","44","20","7","PROSPERO","PROSPERO:CRD420251009368"],["R0001825",null,null,"10.64898/2026.01.31.702984","41676468","PMC12889473","Do GLP-1 Receptor Agonists Alter Brain Responses to Reward-Related Cues? A Systematic Review.","2026","bioRxiv : the preprint server for biology","Dang V",null,"0","0","none found",null],["R0001833",null,null,"10.3389/fendo.2026.1777907","41798193","PMC12960479","Glucagon-like peptide-1 agonists in children with obesity and type 2 diabetes. an umbrella review.","2026","Frontiers in endocrinology","Mirghani H","46","29","5","none found",null],["R0001838",null,null,"10.1186/s42836-026-00375-w","41872949","PMC13007374","Glucagon-like peptide-1 receptor agonists in total joint arthroplasty: a comprehensive systematic review of what orthopaedic surgeons should know.","2026","Arthroplasty (London, England)","Abdelaziz O","32","22","3","none found",null],["R0001841",null,null,"10.1007/s12020-026-04752-y","42616235",null,"Combined use of SGLT2 inhibitor and GLP-1 receptor agonist versus either monotherapy for cardiorenal Outcomes: an exploratory network meta-analysis of 16 randomized trials.","2026","Endocrine","Banerjee M","27","8","2","none found",null],["R0001862",null,null,"10.1101/2024.11.10.24317070",null,null,"Association Between Glucagon-like Peptide-1 Receptor Agonist Use and Perioperative Aspiration: A Systematic Review and Meta-Analysis","2024","medRxiv","Elkin J",null,"0","0","none found",null],["R0001863",null,null,"10.1016/j.semerg.2025.102628","41223488",null,"Glucagon-like peptide-1 receptor agonists for improving quality of life and mortality in adults with heart failure with preserved ejection fraction: A systematic review and meta-analysis of efficacy and safety.","2025","Semergen","Ahmad B","36","19","8","none found",null],["R0001871","CRD420261299756",null,"10.3389/fendo.2026.1902802","42591121","PMC13461399","Cardiovascular outcomes of SGLT2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes and a history of myocardial infarction: a systematic review and network meta-analysis of randomized controlled trials.","2026","Frontiers in endocrinology","Ren Y","39","17","6","PROSPERO","PROSPERO:CRD420261299756"],["R0001881",null,null,"10.7759/cureus.108216","42245865","PMC13231299","Peri-Procedural Fasting and Gastric Ultrasound Strategies in Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Users: A Systematic Review With Qualitative Synthesis.","2026","Cureus","Abdallah OW","25","22","2","none found",null],["R0001882","CRD420250631751",null,"10.1016/j.eclinm.2026.103796","41938838","PMC13043475","Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression.","2026","EClinicalMedicine","Budini B","28","24","15","PROSPERO","PROSPERO:CRD420250631751"],["R0001884",null,null,"10.14309/ajg.0000000000003362","39933910",null,"Effect of Glucagon-Like Peptide-1 Receptor Agonists on Bowel Preparation for Colonoscopy: A Systematic Review and Meta-Analysis.","2025","The American journal of gastroenterology","Beran A","15","5","0","none found",null],["R0001909",null,null,"10.1016/j.obpill.2026.100281","42318161","PMC13272577","Effects of lifestyle and glucagon-like Peptide-1 receptor agonist-based therapies on waist circumference: A systematic review and meta-analysis.","2026","Obesity pillars","Ghosal S","50","20","18","none found",null],["R0001919",null,null,"10.1002/edm2.70059","40509955","PMC12163345","Incidence of Glaucoma in Type 2 Diabetes Patients Treated With GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis.","2025","Endocrinology, diabetes & metabolism","Asif M","38","27","4","none found",null],["R0001922",null,null,"10.1111/1753-0407.70192","41664890","PMC12887578","Who Wins the Battle Against Obesity? A Network Meta-Analysis Comparing Tirzepatide and Semaglutide.","2026","Journal of diabetes","Bernardi JC","42","32","28","none found",null],["R0001929","CRD42024532845",null,"10.1038/s41366-025-01790-w","40269110",null,"Metabolic outcomes and safety of GLP-1 receptor agonists in children and adolescents with obesity: A systematic review and meta-analysis.","2025","International journal of obesity (2005)","Sedenho-Prado LG","28","19","9","PROSPERO","PROSPERO:CRD42024532845"],["R0001931",null,null,"10.1111/dom.70121","40926380","PMC12587236","Cardiovascular risk reduction with glucagon-like peptide-1 receptor agonists is proportional to HbA1c lowering in type 2 diabetes: An updated meta-regression analysis incorporating FLOW and SOUL trials.","2025","Diabetes, obesity & metabolism","Hasebe M","51","33","19","none found",null],["R0001942",null,null,"10.3350/cmh.2024.0558","39038961","PMC11540406","Incretin-based therapy in the management of metabolic dysfunction-associated steatotic liver disease (MASLD): one piece of the puzzle: Editorial on \"Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis\".","2024","Clinical and molecular hepatology","Ren TY","18","11","8","none found",null],["R0001948",null,null,"10.1002/dmrr.70114","41398448",null,"Effectiveness of GLP-1 RAs in Restoring Normoglycemia in Patients With Prediabetes: An Updated Systematic Review and Meta-Analysis.","2026","Diabetes/metabolism research and reviews","Tsironikos GI","34","9","6","none found",null],["R0001951",null,null,"10.1111/dom.70198","41126551","PMC12673456","Psychiatric effects of GLP-1 receptor agonists: A systematic review of emerging evidence.","2026","Diabetes, obesity & metabolism","Sa B","33","31","5","none found",null],["R0001971",null,null,"10.64898/2026.02.10.26345946",null,null,"Glucagon-Like Peptide-1 Receptor Agonists Across the Heart Failure Spectrum: A Systematic Review and Meta-Analysis","2026","medRxiv","Ferreira VM",null,"0","0","none found",null],["R0001974",null,null,"10.1016/j.diabres.2025.112914","40976497",null,"Association of SGLT2 inhibitors and GLP-1 receptor agonists with the risk of Parkinson's disease in patients with type 2 diabetes: A propensity score-matched cohort study with meta-analysis.","2025","Diabetes research and clinical practice","Yeh JA","46","9","3","none found",null],["R0001979","CRD42025628850",null,"10.1111/apt.70485","41319219","PMC12690230","Systematic Review: Efficacy, Safety and Metabolic Outcomes of GLP-1 Receptor Agonists in Inflammatory Bowel Disease.","2026","Alimentary pharmacology & therapeutics","Maracle B","39","27","4","PROSPERO","PROSPERO:CRD42025628850"],["R0001981",null,null,"10.7759/cureus.102018","41728423","PMC12923295","Comparative Efficacy and Safety of Different Orforglipron Doses in Patients With Type 2 Diabetes Mellitus and Obesity: A Systematic Review and Network Meta-Analysis.","2026","Cureus","Tantoush M","37","26","13","none found",null],["R0001995",null,null,"10.1016/j.jad.2026.121452","41713610",null,"Causal association between glucagon-like peptide-1 receptor agonists and mental disorders: insight from genetic and real-world evidence.","2026","Journal of affective disorders","Ouyang C","41","20","2","none found",null],["R0001996",null,null,"10.3390/ph17070828","39065679","PMC11279917","Comparative Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity or Overweight: A Systematic Review and Network Meta-Analysis.","2024","Pharmaceuticals (Basel, Switzerland)","Liu L","55","35","16","none found",null],["R0001999",null,null,"10.1111/dom.16228","39910752",null,"Comparison of the efficacy and safety of GLP-1 receptor agonists on cardiovascular events and risk factors: A review and network meta-analysis.","2025","Diabetes, obesity & metabolism","An X","62","43","21","none found",null],["R0002000",null,null,"10.1007/s10072-025-08602-z","41524953",null,"The effect of GLP-1 receptor agonists on cognition in nondiabetic patients with mild cognitive impairment or alzheimer's disease: a meta-analysis of randomized controlled trials.","2026","Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","O'Mara A","21","10","7","none found",null],["R0002008","CRD420251025534",null,"10.1016/j.clinthera.2026.02.010","41862354",null,"Effect of Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) on Neuropsychiatric Outcomes: A Systematic Review and Meta-Analysis.","2026","Clinical therapeutics","Choudhury I","97","78","25","PROSPERO","PROSPERO:CRD420251025534"],["R0002019",null,null,"10.1016/j.soard.2026.07.012","42660781",null,"The comparative effectiveness of bariatric operations versus GLP-1 RAs: a systematic review and meta-analysis.","2026","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","Campbell C","0","0","0","none found",null],["R0002030",null,null,"10.7759/cureus.93282","41020015","PMC12466318","Use of Glucagon-Like Peptide-1 (GLP-1) Agonists in Modulating Preexisting Dermatologic Disease: A Systematic Review.","2025","Cureus","Tassavor B","75","39","6","none found",null],["R0002031",null,null,"10.1016/j.jdiacomp.2026.109271","41619622",null,"Effects of GLP-1 receptor agonists on vascular dementia: a systematic review and meta-analysis.","2026","Journal of diabetes and its complications","Stefanou MI","50","18","7","none found",null],["R0002033",null,null,"10.1002/eat.70145","42223191",null,"Eating Disorders in the GLP-1 Era: A Spotlight on Emerging Clinical Risks, Research Gaps, and Practice Priorities.","2026","The International journal of eating disorders","Škudar S","14","11","3","none found",null],["R0002035",null,null,"10.1111/dom.70458","41565576","PMC12992182","GLP-1 receptor agonists and cardiovascular outcomes in Asian, Black or African American, and White populations: An updated meta-analysis including the SOUL trial.","2026","Diabetes, obesity & metabolism","Hasebe M","43","19","9","none found",null],["R0002036","CRD420251090801",null,"10.2147/dmso.s565093","41710713","PMC12912157","Impact of Glucagon-Like Peptide-1 Receptor Agonists on Liver-Related Outcomes, Laboratory and Physiologic Parameters in Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Meta-Analysis.","2026","Diabetes, metabolic syndrome and obesity : targets and therapy","Wang MJ","44","38","28","PROSPERO","PROSPERO:CRD420251090801"],["R0002041",null,null,"10.1155/jobe/3897161","41211586","PMC12591819","Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Obesity Management in Adults With and Without Type 2 Diabetes: A Systematic Review.","2025","Journal of obesity","Velji-Ibrahim J","48","39","28","none found",null],["R0002047",null,null,"10.7759/cureus.69008","39385875","PMC11463578","Semaglutide Versus Other Glucagon-Like Peptide-1 Agonists for Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis.","2024","Cureus","Wen J","30","22","12","none found",null],["R0002050",null,null,"10.1007/s11695-025-07733-8","39948306",null,"Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Suboptimal Initial Clinical Response and Weight Gain Recurrence After Bariatric Surgery: a Systematic Review and Meta-analysis.","2025","Obesity surgery","Nie Y","61","33","11","none found",null],["R0002057",null,null,"10.1111/dom.70322","41365841","PMC12803668","GLP-1 receptor agonists for treating obesity without diabetes: A systematic review and meta-analysis of economic evaluations.","2026","Diabetes, obesity & metabolism","Dhippayom T","36","21","0","none found",null],["R0002058",null,null,"10.7759/cureus.106751","42116999","PMC13157524","Effectiveness of GLP-1 Receptor Agonists in Patients With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.","2026","Cureus","Buragohain S","26","19","16","none found",null],["R0002065",null,null,"10.3389/fendo.2026.1854779","42483679","PMC13385192","Investigation into the efficacy and safety profile of oral small-molecule GLP-1 receptor agonists in type 2 diabetes and obesity: a systematic review and meta-analysis.","2026","Frontiers in endocrinology","Li L","41","41","27","none found",null],["R0002075",null,null,"10.1186/s12902-026-02246-6","41928191","PMC13169775","Glucagon-like peptide-1 receptor agonists reduce major adverse cardiovascular events and worsening heart failure in patients with heart failure: an umbrella meta-analysis.","2026","BMC endocrine disorders","Sun C","52","27","3","none found",null],["R0002077","CRD42023438624",null,"10.1016/j.bja.2025.04.001","40379536","PMC12597468","Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement.","2025","British journal of anaesthesia","Oprea AD","164","137","50","PROSPERO","PROSPERO:CRD42023438624"],["R0002087",null,null,"10.2337/dc25-1929","41587563",null,"GLP-1 Receptor Agonists and Risk of Optic Nerve or Vision-Threatening Events in Patients With Type 2 Diabetes or Cardiometabolic Diseases: A Meta-analysis of Randomized Controlled Trials.","2026","Diabetes care","Li HY","40","34","21","none found",null],["R0002096","CRD42024567890; CRD420251037959",null,"10.3389/fendo.2025.1695075","41234238","PMC12605505","Comparative effects of SGLT2 inhibitors and incretin-based therapies on dementia risk in type 2 diabetes: a systematic review and meta-analysis.","2025","Frontiers in endocrinology","Song K","62","16","3","PROSPERO","PROSPERO:CRD42024567890; PROSPERO:CRD420251037959"],["R0002099",null,null,"10.23736/s0026-4806.25.09709-5","40932602",null,"Glucagon-like peptide-1 receptor agonists and its possible nephroprotective role: a systematic review.","2025","Minerva medica","Perencin A","0","0","0","none found",null],["R0002112",null,null,"10.1038/s41467-025-67701-9","41501059","PMC12847739","Comprehensive evaluation of GLP-1 receptor agonists: an umbrella review of clinical outcomes across multiple diseases.","2026","Nature communications","Kong F","60","41","10","none found",null],["R0002113",null,null,"10.2106/jbjs.25.00879","41921052","PMC13127733","No Mid-Term Benefits of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Following Total Joint Arthroplasty: A Systematic Review.","2026","The Journal of bone and joint surgery. American volume","Leggieri F","44","29","3","none found",null],["R0002132",null,null,"10.1186/s13098-025-02006-x","41508124","PMC12825243","Repurposing GLP-1 receptor agonists for alcohol use disorder: a systematic review and meta-analysis.","2026","Diabetology & metabolic syndrome","Nasrollahizadeh A","46","25","8","none found",null],["R0002140","CRD42024507993",null,"10.1136/bmj-2026-372161","42419792",null,"Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.","2026","BMJ (Clinical research ed.)","Nong K","49","10","5","PROSPERO","PROSPERO:CRD42024507993"],["R0002144",null,null,"10.20944/preprints202508.0031.v1",null,null,"Ocular Effects of GLP-1 Receptor Agonists: A Systematic Review of Current Evidence and Safety Concerns","2025","Preprints.org","Albanese GM",null,"0","0","none found",null],["R0002146",null,null,"10.1210/jendso/bvaf150","41230025","PMC12602866","GLP-1R Agonists for Weight Loss in Psychiatric Disorders: A Systematic Review and Meta-analysis.","2025","Journal of the Endocrine Society","Müller Alves K","63","39","13","none found",null],["R0002150",null,null,"10.1093/sleep/zsae280","39626095",null,"Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea: a meta-analysis.","2025","Sleep","Li M","36","15","7","none found",null],["R0002155",null,null,"10.1186/s12902-024-01775-2","39551761","PMC11571652","Risk of Hepatocellular Carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis.","2024","BMC endocrine disorders","Shabil M","31","18","2","none found",null],["R0002162",null,null,"10.56305/001c.132255","40191699","PMC11966775","Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Receptor Agonists: A Scoping Review.","2025","Journal of Brown hospital medicine","Luna Ceron E","63","53","21","none found",null],["R0002167","CRD42024599675",null,"10.1093/nutrit/nuaf115","40700548",null,"Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Obese or Diabetic Patients With Obstructive Sleep Apnea Syndrome: A Meta-Analysis.","2026","Nutrition reviews","Xu S","29","8","4","PROSPERO","PROSPERO:CRD42024599675"],["R0002170",null,null,null,null,"PMC12100276","Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists improve indices of atrial cardiomyopathy: a systematic review and meta-analysis","2025","Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology",null,"0","0","0","none found",null],["R0002173",null,null,"10.21203/rs.3.rs-9197869/v1",null,null,"Effects of Glucagon-Like Peptide-1 Receptor Agonists on Perioperative Outcomes in Hip and Knee Arthroplasty: A Systematic Review and Meta-Analysis","2026","Research Square","Brady A",null,"0","0","none found",null],["R0002195",null,null,"10.17925/ee.2025.21.2.5","41246119","PMC12616672","Dual GIP/GLP1-RA, GCGR/GLP-1 RA and GLP1-RA for the Treatment of Metabolic Dysfunction-associated Steatotic Liver Disease with Type 2 Diabetes: A Systematic Review and Meta-analysis.","2025","TouchREVIEWS in endocrinology","Gunawan B","42","33","16","none found",null],["R0002200",null,null,"10.22541/au.176402391.10613553/v1",null,null,"Efficacy and Safety of Tirzepatide  for the Management of Obesity: A Systematic Review and Meta-analysis of Randomized  Controlled Trials (RCTs)            ","2025","Authorea Preprints","Ghose K",null,"0","0","none found",null],["R0002203",null,null,"10.3390/ph19081236","42653733","PMC13516247","Oral vs. Subcutaneous Semaglutide for Obesity Treatment: A Systematic Review of Efficacy, Safety, and Patient-Oriented Outcomes.","2026","Pharmaceuticals (Basel, Switzerland)","La Vignera S","23","18","11","none found",null],["R0002206","CRD420251152746",null,"10.3389/fphar.2026.1846714","42394981","PMC13322860","Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus: a network meta-analysis based on clinical trials.","2026","Frontiers in pharmacology","Wu X","29","14","6","PROSPERO","PROSPERO:CRD420251152746"],["R0002213","CRD420251016726",null,"10.1080/17446651.2026.2656247","41968780",null,"Comparison of pharmacotherapies for obesity with sleeve gastrectomy: a network meta-analysis and systematic review.","2026","Expert review of endocrinology & metabolism","Omeh Z","0","0","0","PROSPERO","PROSPERO:CRD420251016726"],["R0002214","CRD42023413199",null,"10.1007/s40261-023-01319-x","37938535",null,"Glucagon-Like Peptide-1 Receptor Agonist and Risk of Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials.","2023","Clinical drug investigation","Jiao X","57","45","31","PROSPERO","PROSPERO:CRD42023413199"],["R0002221",null,null,"10.1111/dom.15312","37828829",null,"Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes mellitus.","2024","Diabetes, obesity & metabolism","Tsukamoto S","60","44","32","none found",null],["R0002222",null,null,"10.1016/j.jaad.2025.06.077","40706684",null,"Glucagon-like peptide-1 receptor agonists in the adjunctive treatment of patients with hidradenitis suppurativa: A systematic review.","2025","Journal of the American Academy of Dermatology","Sánchez-Feliciano A","5","0","0","none found",null],["R0002223","CRD420251079970",null,"10.1007/s40265-026-02380-4","42791433",null,"GLP-1 Receptor Agonists in Heart Failure: A Systematic Review and Meta-analysis with Phenotype-Specific Effects and Dual Analytical Frameworks.","2026","Drugs","Yuan Y","38","26","13","PROSPERO","PROSPERO:CRD420251079970"],["R0002232","CRD42024605727",null,"10.1503/cmaj.250369","42442791","PMC13374707","Cardiovascular and renal outcomes of combined SGLT2 inhibitors and GLP-1 receptor agonists versus monotherapy in patients with type 2 diabetes mellitus: a network meta-analysis.","2026","CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne","Chuang MH","40","26","11","PROSPERO","PROSPERO:CRD42024605727"],["R0002235","CRD420251178714",null,"10.1111/dom.71397","42811398",null,"Contemporary Initial Glucose-Lowering Strategies for Type 2 Diabetes: A Systematic Review and Bayesian Network Meta-Analysis.","2026","Diabetes, obesity & metabolism","Cavalcante Lima Chagas G","0","0","0","PROSPERO","PROSPERO:CRD420251178714"],["R0002238",null,null,"10.1016/j.ijcha.2025.101638","40165866","PMC11957674","Efficacy of glucagon-like peptide-1 receptor agonists for prevention of stroke among patients with and without diabetes: A meta-analysis with the SELECT and FLOW trails.","2025","International journal of cardiology. Heart & vasculature","Gera A","38","25","11","none found",null],["R0002244","CRD420251143171",null,"10.3390/pharmaceutics18010069","41599176","PMC12844791","Liraglutide and Exenatide in Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Cognitive Outcomes.","2026","Pharmaceutics","Santos P","26","15","6","PROSPERO","PROSPERO:CRD420251143171"],["R0002254",null,null,"10.1097/brs.0000000000005466","40719010",null,"Are GLP-1 Receptor Agonists Safe in Spine Surgery: A Systematic Review.","2025","Spine","Younus I","0","0","0","none found",null],["R0002268",null,null,"10.1097/crd.0000000000001465","42693519",null,"Safety and Glycemic Efficacy of Perioperative Liraglutide in Cardiac Surgery: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","2026","Cardiology in review","Gamal I","23","11","7","none found",null],["R0002273",null,null,"10.1186/s13098-026-02226-9","42365335","PMC13573484","Comparative cardiovascular efficacy of antidiabetic therapies in type 2 diabetes: a systematic review and network meta-analysis of randomized trials.","2026","Diabetology & metabolic syndrome","Mohammadi D","181","56","45","none found",null],["R0002276",null,null,"10.1161/jaha.124.039446","40314346","PMC12184242","Glucagon-Like Peptide-1 Receptor Agonists and Risk of Venous Thromboembolism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","2025","Journal of the American Heart Association","Liu Y","68","49","38","none found",null],["R0002277",null,null,"10.3389/fendo.2023.1244432","37701904","PMC10493284","Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review.","2023","Frontiers in endocrinology","Xie Z","60","45","41","none found",null],["R0002286",null,null,"10.1111/jdi.70293","41902544","PMC13238613","Comparative efficacy and safety of three fixed-ratio combination products in type 2 diabetes: A network meta-analysis.","2026","Journal of diabetes investigation","Wang X","36","20","15","none found",null],["R0002307","CRD420261277032",null,"10.1007/s12272-026-01615-y","42098470","PMC13222307","Evaluating the clinical effects of GLP-1 receptor agonists for Alzheimer's and Parkinson's diseases using minimal clinically important difference: systematic review and meta-analysis.","2026","Archives of pharmacal research","Elghanam Y","66","31","13","PROSPERO","PROSPERO:CRD420261277032"],["R0002317",null,null,"10.1007/s11914-025-00937-y","41026248",null,"Headline: Fracture Risk in Type 2 Diabetes: Systematic Review of Cardiovascular Outcome Trials with Glucagon Like Peptide Receptor Agonists.","2025","Current osteoporosis reports","Mahalingasivam AA","33","21","4","none found",null],["R0002328",null,null,"10.1016/j.arth.2025.07.015","40675511",null,"Impact of Glucagon-Like Peptide-1 Receptor Agonists on Postoperative Outcomes in Arthroplasty: A Systematic Review.","2025","The Journal of arthroplasty","Lee V","34","11","1","none found",null],["R0002331",null,null,"10.1111/dom.70013","40757429",null,"Glucagon-like peptide-1 receptor agonists and the risk of nonarteritic anterior ischaemic optic neuropathy: A systematic review and meta-analysis of observational studies.","2025","Diabetes, obesity & metabolism","Goldenberg RM","19","10","1","none found",null],["R0002336",null,null,"10.3390/ijms27020759","41596408","PMC12841515","A Systematic Review on GLP-1 Receptor Agonists in Reproductive Health: Integrating IVF Data, Ovarian Physiology and Molecular Mechanisms.","2026","International journal of molecular sciences","Voros C","50","29","4","none found",null],["R0002346",null,"osf.io/sz87j","10.1007/s13300-026-01854-8","41848820","PMC13103125","Renal Outcomes of GLP-1 Receptor Agonists and Tirzepatide Across CKD Stages and Metabolic Phenotypes (Type 2 Diabetes and/or Overweight/Obesity): A Scoping Review.","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","Rico-Fontalvo J","42","36","22","OSF",null],["R0002347",null,null,"10.1007/s40519-025-01770-z","40877612","PMC12394290","The role of glucagon-like peptide-1 receptor agonists in weight regain treatment or prevention after bariatric surgery: a systematic review and meta-analysis.","2025","Eating and weight disorders : EWD","Mousavi A","77","62","17","none found",null],["R0002354",null,null,"10.1007/s00464-025-11962-4","40634731",null,"Impact of GLP-1 receptor agonists on upper gastrointestinal endoscopy: an updated systematic review and meta-analysis.","2025","Surgical endoscopy","Abdulraheem A","40","28","8","none found",null],["R0002356",null,null,"10.1016/j.soard.2026.02.019","41887957",null,"Efficacy of preoperative GLP-1 receptor agonists on the perioperative outcomes of bariatric surgery: a systematic review and meta-analysis.","2026","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","Liu C","40","24","3","none found",null],["R0002376","CRD42022342241",null,"10.1097/md.0000000000034122","37417602","PMC10328610","Comparative efficacy and safety of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes: A network meta-analysis.","2023","Medicine","Chen H","20","16","8","PROSPERO","PROSPERO:CRD42022342241"],["R0002388","CRD420251110220",null,"10.1007/s40257-026-01049-8","42295612",null,"A Systematic Review of the Clinical Impact of GLP-1 Receptor Agonists in Hidradenitis Suppurativa.","2026","American journal of clinical dermatology","Visan MA","39","26","1","PROSPERO","PROSPERO:CRD420251110220"],["R0002389","CRD42024592308",null,"10.3389/fphar.2025.1613610","41050409","PMC12491879","Comparative gastrointestinal adverse effects of GLP-1 receptor agonists and multi-target analogs in type 2 diabetes: a Bayesian network meta-analysis.","2025","Frontiers in pharmacology","Xie X","73","68","49","PROSPERO","PROSPERO:CRD42024592308"],["R0002390",null,null,"10.1159/000543149","39746343","PMC11844710","Cardiovascular and Kidney Outcomes of Glucagon-Like Peptide 1 Receptor Agonist Therapy in Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Systematic Review and Meta-Analysis.","2025","Cardiorenal medicine","Felix N","25","20","12","none found",null],["R0002391",null,null,"10.2215/cjn.0000000584","39480988","PMC11835157","The Impact of Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes: A Meta-Analysis of Randomized Placebo-Controlled Trials.","2025","Clinical journal of the American Society of Nephrology : CJASN","Mendonça L","28","24","13","none found",null],["R0002413","CRD420251168485",null,"10.1186/s12872-025-05455-4","41454299","PMC12849425","SGLT2 inhibitors versus GLP-1 receptor agonists for major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.","2025","BMC cardiovascular disorders","Ahmed AAO","24","13","6","PROSPERO","PROSPERO:CRD420251168485"],["R0002423","CRD420251090801",null,"10.1186/s13643-025-03011-x","41373001","PMC12817519","Effects of glucagon-like peptide-1 receptor agonists on patients with metabolic dysfunction-associated steatohepatitis: protocol for a systematic review and sequential meta-analysis.","2025","Systematic reviews","Wang MJ","34","19","13","PROSPERO","PROSPERO:CRD420251090801"],["R0002425",null,null,"10.2337/dc24-1533","39977628","PMC12081317","Comparative Efficacy of Glucagon-Like Peptide 1 Receptor Agonists for Cardiovascular Outcomes in Asian Versus White Populations: Systematic Review and Meta-analysis of Randomized Trials of Populations With or Without Type 2 Diabetes and/or Overweight or Obesity.","2025","Diabetes care","Lee MMY","20","16","12","none found",null],["R0002427","CRD42023491646",null,"10.7326/annals-24-03764","42296503",null,"Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.","2026","Annals of internal medicine","Damen JAA","51","23","3","PROSPERO","PROSPERO:CRD42023491646"],["R0002451",null,null,"10.2337/dca24-0034","39190488",null,"Regional Heterogeneity of the Results of Glucagon-Like Peptide 1 Receptor Agonist Trials in Type 2 Diabetes: A Reanalysis of Individual Participant Data.","2024","Diabetes care","Jullien A","19","3","0","none found",null],["R0002456","CRD42024558287",null,"10.1186/s12967-025-06302-y","40181368","PMC11967144","Glucagon-like Peptide-1 receptor agonists for obstructive sleep apnea in patients with obesity and type 2 diabetes mellitus: a systematic review and meta-analysis.","2025","Journal of translational medicine","Yang R","75","26","8","PROSPERO","PROSPERO:CRD42024558287"],["R0002460",null,null,"10.1016/j.diabres.2026.113429","42425328",null,"Meta-analysis of sodium glucose transport 2 inhibitors versus other glucose-lowering agents on the progression of diabetic retinopathy and diabetic macular edema.","2026","Diabetes research and clinical practice","Akande R","31","9","1","none found",null],["R0002462","CRD420261456447",null,"10.1111/dom.71400","42811393",null,"Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis.","2026","Diabetes, obesity & metabolism","Amjad MM","0","0","0","PROSPERO","PROSPERO:CRD420261456447"],["R0002469",null,null,"10.1016/j.dld.2025.03.004","40121157",null,"The impact of glucagon-like peptide-1 receptor agonists on the quality indicators of colonoscopy - a systematic review and meta-analysis.","2025","Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver","Chiu YT","36","12","2","none found",null],["R0002475",null,null,"10.1210/clinem/dgae176","38488042",null,"Effect of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) on Weight Loss Following Bariatric Treatment.","2024","The Journal of clinical endocrinology and metabolism","Kramer CK","32","20","9","none found",null],["R0002485",null,null,"10.7759/cureus.96218","41211260","PMC12591504","Cardiometabolic Benefits and Risks of Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitor and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review.","2025","Cureus","Tantawy D","27","17","10","none found",null],["R0002487",null,null,"10.1053/j.gastro.2025.06.003","40499738",null,"Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis.","2025","Gastroenterology","Chiang CH","92","70","56","none found",null],["R0002490",null,null,"10.1016/j.jpsychires.2025.02.008","39956093",null,"The effect of glucagon-like Peptide-1 receptor agonists on measures of suicidality: A systematic review.","2025","Journal of psychiatric research","Valentino K","34","23","3","none found",null],["R0002502",null,null,"10.21203/rs.3.rs-9317100/v1",null,null,"Comparative Effectiveness of Metformin versus GLP-1 Receptor Agonists in Treating Antipsychotic-Induced Metabolic Disturbances: A Systematic Review and Network Meta-Analysis","2026","Research Square","Chen Y",null,"0","0","none found",null],["R0002503","CRD42024556732",null,"10.1016/j.gie.2024.12.019","39694296",null,"Glucagon-like peptide-1 receptor agonist use and the risk of residual gastric contents and aspiration in patients undergoing GI endoscopy: a systematic review and a meta-analysis.","2025","Gastrointestinal endoscopy","Baig MU","41","16","2","PROSPERO","PROSPERO:CRD42024556732"],["R0002521","CRD420251029748",null,"10.21203/rs.3.rs-7631508/v1",null,null,"The Effects of GLP-1 Receptor Agonists on Alzheimer's Pathophysiology: A Systematic Review","2025","Research Square","Corcoran E",null,"0","0","PROSPERO","PROSPERO:CRD420251029748"],["R0002525",null,null,"10.1002/pds.70087","39805811","PMC11730806","Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Among Type 2 Diabetes Patients: Replication and Reliability Assessment Across a Research Network.","2025","Pharmacoepidemiology and drug safety","Conover MM","27","1","1","none found",null],["R0002528",null,null,"10.1186/s12894-025-02005-0","41291666","PMC12752444","Effect of GLP-1 agonists on testosterone levels: a systematic review and meta-analysis.","2025","BMC urology","Orra SH","15","8","3","none found",null],["R0002535",null,null,"10.1186/s13098-025-01633-8","40165263","PMC11959866","The effect of beinaglutide as an glucagon-like peptide-1 receptor agonists on cardiometabolic factors: a systematic review and meta-analysis.","2025","Diabetology & metabolic syndrome","Xu Y","30","8","1","none found",null],["R0002538",null,null,"10.1186/s12933-025-02900-8","41029853","PMC12487346","Cardiovascular and renal outcomes of dual combination therapies with glucagon-like peptide-1 receptor agonists and sodium-glucose transport protein 2 inhibitors: a systematic review and meta-analysis.","2025","Cardiovascular diabetology","Shokravi A","51","30","9","none found",null],["R0002539",null,null,"10.1097/tp.0000000000005496","40702593",null,"SGLT2 Inhibitors and GLP-1 Receptor Agonists in Kidney Transplantation: A Systematic Review and Meta-Analysis.","2026","Transplantation","Lee SA","56","17","4","none found",null],["R0002540",null,null,"10.23876/j.krcp.24.271","40905039","PMC12611633","Safety and efficacy of glucagon-like peptide 1 receptor agonists in solid organ transplant recipients with diabetes mellitus: a systematic review and meta-analysis.","2025","Kidney research and clinical practice","Usman M","48","34","8","none found",null],["R0002542",null,null,"10.1007/s40200-026-01969-6","42299230","PMC13264643","Cardiovascular outcomes of glucagon-like peptide-1 receptor agonists in patients without obesity: a systematic review and meta-analysis of randomized controlled trials.","2026","Journal of diabetes and metabolic disorders","Waqas SA","0","0","0","none found",null],["R0002555",null,null,"10.3389/fcdhc.2025.1694808","41451292","PMC12727544","Effectiveness of GLP-1 RAs and SGLT2 inhibitors in preventing T2DM in high-risk patients: an updated systematic review and meta-analysis.","2025","Frontiers in clinical diabetes and healthcare","Tsironikos GI","37","24","13","none found",null],["R0002560",null,null,"10.1186/s12876-025-04211-4","40847331","PMC12372225","Association between GLP-1 receptor agonists as a class and colorectal cancer risk: a meta-analysis of retrospective cohort studies.","2025","BMC gastroenterology","Zhong Y","43","26","0","none found",null],["R0002567",null,null,"10.1016/j.dsx.2026.103466","42508090",null,"Nutritional intake changes during GLP-1 receptor agonist therapy: A systematic review and meta-analysis.","2026","Diabetes & metabolic syndrome","Quan AT","21","16","11","none found",null],["R0002571","CRD42023473875",null,"10.1002/ctm2.70829","42711998","PMC13554713","Evidence-based ranking of diabetes prevention in prediabetes: A comprehensive network meta-analysis of 378 randomised controlled trials.","2026","Clinical and translational medicine","Maria B","30","5","0","PROSPERO","PROSPERO:CRD42023473875"],["R0002574",null,null,"10.1111/dom.16512","40497333",null,"Incretin-based therapies for individuals with obesity and heart failure with mildly reduced or preserved ejection fraction: A systematic review and meta-analysis of randomized controlled trials.","2025","Diabetes, obesity & metabolism","Costa TA","17","10","6","none found",null],["R0002577",null,null,"10.1016/j.drugalcdep.2025.112840","40845737",null,"Impact of glucagon-like peptide-1 receptor agonists on alcohol consumption and liver-related outcomes: A systematic review and meta-analysis.","2025","Drug and alcohol dependence","de Faria Moraes B","49","27","9","none found",null],["R0002582","CRD42024585971",null,"10.1080/14740338.2025.2465870","39964295",null,"Evaluating bowel obstruction and ileus events in patients on GLP-1 receptor agonists: a systematic review and meta-analysis.","2026","Expert opinion on drug safety","Alfehaid L","47","27","9","PROSPERO","PROSPERO:CRD42024585971"],["R0002587",null,null,"10.1007/s11695-026-08508-5","41697578","PMC13038674","Efficacy of Metabolic and Bariatric Surgery Compared with GLP-1 Receptor Agonist Treatment in Preventing Mortality and Major Adverse Cardiac Events Among Individuals with Obesity and Type 2 Diabetes: A Systematic Review and Meta-analysis.","2026","Obesity surgery","Chadwick J","44","21","6","none found",null],["R0002593",null,null,"10.1007/s11606-025-09950-4","41249646","PMC12960891","Effects of Glucagon-Like Peptide-1 Receptor Agonists After Treatment Withdrawal: A Systematic Review and Meta-Analysis.","2026","Journal of general internal medicine","Zhou L","28","16","5","none found",null],["R0002597",null,null,"10.1111/obr.13543","36579723",null,"Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials.","2023","Obesity reviews : an official journal of the International Association for the Study of Obesity","Alkhezi OS","39","12","5","none found",null],["R0002598",null,null,"10.1007/s10072-026-09238-3","42432163",null,"Glucagon-like peptide-1 agonists in Parkinson's disease: a meta-analysis.","2026","Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","Abdallah AK","29","14","5","none found",null],["R0002602",null,null,"10.1111/dom.16504","40468864",null,"Risk of thyroid cancer related to glucagon-like peptide-1 receptor agonists: A systematic review with meta-analysis of harms of randomized controlled trials.","2025","Diabetes, obesity & metabolism","Duchemin L","15","7","0","none found",null],["R0002607",null,null,"10.1186/s13098-025-01927-x","40859274","PMC12382109","Economic evaluation of liraglutide vs dulaglutide or oral semaglutide in patients with type 2 diabetes mellitus: a systematic review.","2025","Diabetology & metabolic syndrome","Wang L","36","19","3","none found",null],["R0002614",null,null,"10.1007/s11154-023-09807-3","37231200","PMC10404567","Effects of GLP-1 receptor agonists on neurological complications of diabetes.","2023","Reviews in endocrine & metabolic disorders","García-Casares N","62","37","26","none found",null],["R0002623",null,null,"10.1111/obr.70043","41287923","PMC13008604","GLP-1 Receptor Agonists for the Prevention of New-Onset Heart Failure: A Systematic Review and Meta-Analysis of Placebo-Controlled Randomized Clinical Trials.","2026","Obesity reviews : an official journal of the International Association for the Study of Obesity","Neves JS","39","24","14","none found",null],["R0002624",null,null,null,null,"PMC12545469","SAT-147 The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Erectile Dysfunction and Testosterone Levels: A Systematic Review and Meta-Analysis","2025","Journal of the Endocrine Society",null,"0","0","0","none found",null],["R0002628",null,null,"10.1111/dom.15777","39044306",null,"Glucagon-like peptide-1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity-a systematic review and network meta-analysis.","2024","Diabetes, obesity & metabolism","Shamim MA","80","43","24","none found",null],["R0002650",null,null,null,null,"PMC12543558","SUN-665 Meta-Analysis of Psychiatric and Quality of Life Outcomes in Patients With Obesity and Diabetes Treated With Glucagon-Like Peptide 1 Receptor Agonists","2025","Journal of the Endocrine Society",null,"0","0","0","none found",null],["R0002661","CRD42024565567",null,"10.1016/j.endien.2025.501562","40413013",null,"Effect of glucagon-like peptide-1 receptor agonists on the risk of major adverse limb events in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized clinical trials.","2025","Endocrinologia, diabetes y nutricion","Garagoli F","38","22","13","PROSPERO","PROSPERO:CRD42024565567"],["R0002664",null,null,"10.2174/0109298673349221251203101854","42099143",null,"Efficacy of SGLT2i and GLP-1RA in Acute Myocardial Infarction: A Meta-Analysis of Randomized Controlled Trials.","2026","Current medicinal chemistry","Zhao H","0","0","0","none found",null],["R0002668",null,null,"10.1111/dom.70613","41757397","PMC13071187","Dose-Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting.","2026","Diabetes, obesity & metabolism","Nauck MA","47","47","36","none found",null],["R0002672",null,null,"10.1007/s00210-026-05809-5","42608559",null,"Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials.","2026","Naunyn-Schmiedeberg's archives of pharmacology","Khan BW","27","20","10","none found",null],["R0002677",null,null,"10.7759/cureus.96071","41356998","PMC12676983","Assessing the Oncological Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Systematic Review and Meta-Analysis.","2025","Cureus","Jaradat JH","51","41","12","none found",null],["R0002683",null,null,"10.1186/s13098-025-01878-3","40830891","PMC12366118","Understanding the risk of diabetic retinopathy from glucagon-like peptide-1 receptor agonists: a Mendelian randomization study and systematic review of European populations.","2025","Diabetology & metabolic syndrome","Shen B","72","33","4","none found",null],["R0002684",null,null,null,null,"PMC12545136","SUN-114 Comparative Analysis of Glucagon-Like Peptide-1 Receptor Agonists, Metformin, and Inositol in Managing Polycystic Ovary Syndrome: A Network Meta-Analysis","2025","Journal of the Endocrine Society",null,"0","0","0","none found",null],["R0002692",null,null,"10.1111/dom.15529","38505997",null,"Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression.","2024","Diabetes, obesity & metabolism","Rivera FB","98","85","68","none found",null],["R0002703",null,null,"10.2337/dc25-0896","40834250",null,"Comment on Lee et al. Comparative Efficacy of Glucagon-Like Peptide 1 Receptor Agonists for Cardiovascular Outcomes in Asian Versus White Populations: Systematic Review and Meta-analysis of Randomized Trials of Populations With or Without Type 2 Diabetes and/or Overweight or Obesity. Diabetes Care 2025;48:489-493.","2025","Diabetes care","Chang YT","4","1","0","none found",null],["R0002709",null,null,"10.1016/j.diabres.2025.111999","39828025",null,"Comparison of the effectiveness and safety of GLP-1 receptor agonists for type 2 diabetes mellitus patients with overweight/obesity: A systematic review and network meta-analysis.","2025","Diabetes research and clinical practice","Wen Z","33","17","3","none found",null],["R0002714","CRD420251231137",null,"10.3389/fendo.2026.1942151","42745769","PMC13574646","Incremental effects of SGLT2 inhibitors, GLP-1 receptor agonists, and pioglitazone in type 2 diabetes and MASLD across Asian study settings: a systematic review and meta-analysis.","2026","Frontiers in endocrinology","Zheng H","56","17","5","PROSPERO","PROSPERO:CRD420251231137"],["R0002717",null,null,"10.1093/ecco-jcc/jjaf193","41212197",null,"Can GLP-1 agonists be used safely in inflammatory bowel disease? A meta-analysis.","2025","Journal of Crohn's & colitis","Siranart N","16","8","4","none found",null],["R0002719","CRD42024582164",null,"10.2147/dmso.s580095","41907103","PMC13023393","Cardiovascular Outcomes and Safety of GLP-1 Receptor Agonists in Elderly Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.","2026","Diabetes, metabolic syndrome and obesity : targets and therapy","Gao W","32","26","7","PROSPERO","PROSPERO:CRD42024582164"],["R0002729",null,null,"10.2337/dci25-0060","40834256",null,"Response to Comment on Lee et al. Comparative Efficacy of Glucagon-Like Peptide 1 Receptor Agonists for Cardiovascular Outcomes in Asian Versus White Populations: Systematic Review and Meta-analysis of Randomized Trials of Populations With or Without Type 2 Diabetes and/or Overweight or Obesity. Diabetes Care 2025;48:489-493.","2025","Diabetes care","Lee MMY","3","3","1","none found",null],["R0002732",null,null,"10.1111/dom.16424","40342232",null,"Glucagon-like peptide-1 receptor agonists lower risk of cardiovascular and non-cardiovascular mortality: A meta-analysis of eleven cardiovascular outcome trials.","2025","Diabetes, obesity & metabolism","Kang YM","9","4","1","none found",null],["R0002735",null,null,"10.3390/medicina60030357","38541083","PMC10972401","A Review and Meta-Analysis of the Safety and Efficacy of Using Glucagon-like Peptide-1 Receptor Agonists.","2024","Medicina (Kaunas, Lithuania)","Hu EH","65","49","24","none found",null],["R0002737","CRD42024535096",null,"10.1093/ejendo/lvag033","41701618",null,"GLP-1 receptor agonist treatment in women with polycystic ovary syndrome-a systematic review and meta-analysis.","2026","European journal of endocrinology","Forslund M","60","24","14","PROSPERO","PROSPERO:CRD42024535096"],["R0002747",null,null,"10.1007/s11695-026-08500-z","41644868",null,"Comparing Cardiovascular Outcomes of GLP-1 Receptor Agonists Versus Metabolic Bariatric Surgery: A Systematic Review and Meta-Analysis.","2026","Obesity surgery","Shekouh D","41","18","8","none found",null],["R0002748","CRD420261282728",null,"10.3390/ijms27062619","41898482","PMC13026302","Gastric Neoplasm Risk with DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT2 Inhibitors: Network Meta-Analysis of Randomized Trials.","2026","International journal of molecular sciences","Hung CM","85","28","12","PROSPERO","PROSPERO:CRD420261282728"],["R0002757","CRD420251157476",null,"10.3389/fendo.2025.1734549","41625236","PMC12852008","Inflammatory biomarker response to GLP-1 receptor agonists versus other glucose-lowering medications in patients with type 2 diabetes: a systematic review and meta-analysis.","2025","Frontiers in endocrinology","Alrasheed T","54","50","37","PROSPERO","PROSPERO:CRD420251157476"],["R0002768","CRD420261305875",null,"10.1186/s40842-026-00311-6","42316363","PMC13281493","Pulmonary adverse events associated with GLP-1 receptor agonists: a systematic review of respiratory safety signals.","2026","Cardiovascular diabetology. Endocrinology reports","Ahuja A","17","14","5","PROSPERO","PROSPERO:CRD420261305875"],["R0002775",null,null,"10.1111/imj.16126","37189293",null,"Weight loss with subcutaneous semaglutide versus other glucagon-like peptide 1 receptor agonists in type 2 diabetes: a systematic review.","2023","Internal medicine journal","Stretton B","35","21","13","none found",null],["R0002780","CRD420251088042",null,"10.1016/j.metabol.2025.156433","41207615",null,"GLP-1RAs and tirzepatide may reduce heart failure risk in obese but not in non-obese patients with cardiovascular or renal disease: A systematic review and meta-analysis.","2026","Metabolism: clinical and experimental","Zhang J","68","49","19","PROSPERO","PROSPERO:CRD420251088042"],["R0002786",null,null,"10.1016/j.diabres.2026.113271","42009258",null,"GLP-1-based therapies and limb outcomes in PAD: a systematic review and meta-analysis of real-world studies.","2026","Diabetes research and clinical practice","Boccatonda A","29","20","9","none found",null],["R0002790",null,null,"10.1111/dom.70503","41588709","PMC12992183","Comparative effectiveness of pharmacotherapy for heart failure with preserved ejection fraction: A systematic review and network meta-analysis.","2026","Diabetes, obesity & metabolism","Chen SH","55","8","1","none found",null],["R0002803",null,null,"10.1002/oby.70256","42399213","PMC13535703","Wernicke's Encephalopathy Following Semaglutide Treatment for Obesity: A Systematic PRISMA Review of Case-Based Evidence.","2026","Obesity (Silver Spring, Md.)","Bidesie J","19","8","4","none found",null],["R0002807",null,null,"10.1017/neu.2025.6","39969054","PMC13130248","A systematic review on the role of glucagon-like peptide-1 receptor agonists on alcohol-related behaviors: potential therapeutic strategy for alcohol use disorder.","2025","Acta neuropsychiatrica","Zheng YJ","38","31","3","none found",null],["R0002808",null,null,"10.1016/j.jacadv.2024.101386","39583870","PMC11585747","Enrollment of Females in Randomized Trials for Glucagon-Like Peptide 1 Receptor Agonists: A Systematic Review.","2024","JACC. Advances","Rivera FB","52","10","3","none found",null],["R0002812","CRD42024546896",null,"10.1111/dom.70692","41852258",null,"Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Psychiatric Disorders: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.","2026","Diabetes, obesity & metabolism","Han S","45","29","4","PROSPERO","PROSPERO:CRD42024546896"],["R0002813",null,null,"10.1093/ecco-jcc/jjaf181","41071055","PMC12668684","Glucagon-like peptide 1 receptor agonists and the clinical outcomes of inflammatory bowel disease: a systematic review and meta-analysis.","2025","Journal of Crohn's & colitis","Bayoumy AB","41","25","0","none found",null],["R0002815",null,null,"10.20944/preprints202609.1706.v1",null,null,"<span data-teams=\"true\">Efficacy and Safety of Oral Small-Molecule (Non-Peptide) GLP-1 Receptor Agonists in Type 2 Diabetes and Obesity: A Systematic Review of the Complete Orforglipron and Danuglipron Clinical Development Programs","2026","Preprints.org","Labate AM",null,"0","0","none found",null],["R0002820",null,null,"10.1016/j.jad.2025.119509","40447157",null,"Association of glucagon-like peptide-1 receptor agonists and seven common mental disorders: A drug target and mediation Mendelian randomization.","2025","Journal of affective disorders","Zhang Z","69","28","5","none found",null],["R0002831",null,null,"10.1016/j.clnu.2025.10.006","41187492",null,"Glucagon-like peptide-1 receptor agonists and sarcopenia-related markers in diabetes: A systematic review and meta-analysis.","2025","Clinical nutrition (Edinburgh, Scotland)","Chen W","62","28","7","none found",null],["R0002841","CRD42024505558",null,"10.7326/annals-24-01590","39761578",null,"Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials.","2025","Annals of internal medicine","Moiz A","75","64","36","PROSPERO","PROSPERO:CRD42024505558"],["R0002844",null,null,"10.7759/cureus.107195","42153045","PMC13180454","Association Between Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Atrial Fibrillation Adverse Events: A Systematic Review and Meta-Analysis of Randomized Trials.","2026","Cureus","Aiwuyo HO","22","11","7","none found",null],["R0002846",null,null,"10.1016/j.gie.2024.10.011","39401599",null,"Effects of glucagon-like peptide-1 receptor agonists on endoscopy outcomes: systematic review and meta-analysis.","2025","Gastrointestinal endoscopy","Singh S","39","21","0","none found",null],["R0002861","CRD420251243172",null,"10.1016/j.jhlto.2026.100565","42088447","PMC13137046","Effects of GLP-1 receptor agonists on cardiometabolic outcomes in heart transplant recipients: A systematic review and meta-analysis of observational studies.","2026","JHLT open","Dalal N","34","22","12","PROSPERO","PROSPERO:CRD420251243172"],["R0002875",null,null,"10.1016/j.gie.2025.08.027","40846241",null,"Bowel preparation quality in patients using glucagon-like peptide-1 agonists: a systematic review and meta-analysis.","2026","Gastrointestinal endoscopy","Ahmed Z","15","7","0","none found",null],["R0002879","CRD420251063158",null,"10.1186/s12876-025-04496-5","41275083","PMC12752087","Efficacy of GLP-1 receptor agonists on obesity and metabolic profile in patients with inflammatory bowel disease: a systematic review and meta-analysis.","2025","BMC gastroenterology","Shirmard FO","54","29","1","PROSPERO","PROSPERO:CRD420251063158"],["R0002880",null,null,"10.1016/j.disamonth.2026.102113","41991422",null,"Approved weight loss drugs for obesity with a thorough emphasis on GLP-1 agonist medications: A systematic review.","2026","Disease-a-month : DM","Gunasekaran P","101","70","11","none found",null],["R0002883",null,null,"10.4274/jcrpe.galenos.2024.2024-1-5","38828884","PMC11590762","Efficacy of Glucagon-like Peptide-1 Receptor Agonists in Overweight/Obese and/or T2DM Adolescents: A Meta-analysis Based on Randomized Controlled Trials.","2024","Journal of clinical research in pediatric endocrinology","Dai M","50","30","17","none found",null],["R0002884","CRD42023405356",null,"10.1002/dmrr.70066","40698871","PMC12285216","Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists Versus Other Glucose-Lowering Agents in People With Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Data.","2025","Diabetes/metabolism research and reviews","Fishkin A","59","43","13","PROSPERO","PROSPERO:CRD42023405356"],["R0002890","CRD420250631751",null,"10.1101/2025.06.09.25328726",null,null,"Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression","2025","medRxiv","Budini B",null,"0","0","PROSPERO","PROSPERO:CRD420250631751"],["R0002896",null,null,"10.1007/s00415-025-13301-y","40760123",null,"Clinical efficacy of GLP-1 receptor agonists in the treatment of Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials.","2025","Journal of neurology","Zhang Y","50","18","6","none found",null],["R0002901",null,null,"10.26355/eurrev_202404_36023","38708466",null,"Network meta-analysis of the risk of dyspepsia and anorexia in patients with type 2 diabetes mellitus induced by glucagon-like peptide 1 receptor agonist hypoglycemic drugs.","2024","European review for medical and pharmacological sciences","Jiao BL","0","0","0","none found",null],["R0002902",null,"osf.io/7vxn5","10.1186/s12933-025-02840-3","40652242","PMC12255114","Glucagon-like peptide-1 receptor agonist in myocardial infarction and atherosclerotic cardiovascular disease risk reduction: a comprehensive meta-analysis of number needed to treat, efficacy and safety.","2025","Cardiovascular diabetology","Tang ASP","103","49","25","OSF",null],["R0002911",null,null,"10.1111/andr.70238","42011503",null,"Emerging Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Male Sexual Hormones and Behaviors: Systematic Review and Meta-Analysis.","2026","Andrology","Corona G","92","21","5","none found",null],["R0002924","CRD420251074882",null,"10.1093/eschf/xvag091","41883191","PMC13064920","Glucagon-like peptide-1 receptor agonists for prevention of heart failure events in type 2 diabetes and/or obesity.","2026","ESC heart failure","Raveendra K","47","32","17","PROSPERO","PROSPERO:CRD420251074882"],["R0002929",null,null,"10.1111/eci.14292","39058274",null,"Glucagon-like peptide-1 receptor agonist semaglutide reduces atrial fibrillation incidence: A systematic review and meta-analysis.","2024","European journal of clinical investigation","Saglietto A","40","18","10","none found",null],["R0002932",null,null,"10.1111/dme.70346","42036870",null,"Interventions for binge eating disorder in adults with type 2 diabetes: A systematic review.","2026","Diabetic medicine : a journal of the British Diabetic Association","Nybo PF","28","1","1","none found",null],["R0002939",null,null,"10.1016/j.euroneuro.2025.08.002","40925272",null,"Repurposing glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of depression: A systematic review of preclinical, observational and clinical investigations.","2025","European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology","Li S","68","39","1","none found",null],["R0002940",null,null,"10.1111/obr.13916","40181228","PMC12137041","How do glucagon-like Peptide-1 receptor agonists affect measures of muscle mass in individuals with, and without, type 2 diabetes: A systematic review and meta-analysis.","2025","Obesity reviews : an official journal of the International Association for the Study of Obesity","Anyiam O","98","60","28","none found",null],["R0002945","CRD420251130232",null,"10.7189/jogh.16.04187","42626880","PMC13494846","Comparative neuroprotective effects of antidiabetic medications on Parkinson's disease risk: a Bayesian network meta-analysis.","2026","Journal of global health","Lee SH","43","6","0","PROSPERO","PROSPERO:CRD420251130232"],["R0002950",null,null,"10.7759/cureus.111363","42495484","PMC13394370","Efficacy and Safety of Once-Weekly Semaglutide Versus Basal Insulin and Other GLP-1 Receptor Agonists in Adults With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs: A Systematic Review and Pairwise Meta-Analysis.","2026","Cureus","Aljulajil FA","17","11","6","none found",null],["R0002955",null,null,"10.1111/dom.70907","42162578","PMC13341395","The Effects of Combined Antihypertensive and Antidiabetic Therapies on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis.","2026","Diabetes, obesity & metabolism","Hsieh WC","49","9","7","none found",null],["R0002975",null,null,"10.2147/dmso.s539822","41019499","PMC12476180","Long-Term Efficacy Trajectories of GLP-1 Receptor Agonists: A Systematic Review and Network Meta-Analysis.","2025","Diabetes, metabolic syndrome and obesity : targets and therapy","Li Z","34","25","7","none found",null],["R0002979",null,null,"10.1111/1753-0407.70082","40207414","PMC11982705","Efficacy of GLP-1 Receptor Agonist-Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta-Analysis of Randomized Controlled Trials.","2025","Journal of diabetes","Yin Y","60","46","30","none found",null],["R0002981",null,null,"10.1002/edm2.70045","40184508","PMC11970626","Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Direct Comparative Studies.","2025","Endocrinology, diabetes & metabolism","Wen J","20","15","10","none found",null],["R0002985",null,null,"10.3390/ijms26062741","40141382","PMC11942543","Impact of Glucagon-like Peptide-1 Receptor Agonists on Mental Illness: Evidence from a Mendelian Randomization Study.","2025","International journal of molecular sciences","Xiang L","85","33","3","none found",null],["R0002991",null,null,"10.1016/j.metabol.2025.156463","41349790",null,"Effect of GLP-1 receptor agonists and co-agonists on atrial fibrillation risk in overweight or obesity: systematic review and meta-analysis of randomized controlled trials.","2026","Metabolism: clinical and experimental","Karakasis P","76","54","33","none found",null],["R0002995","CRD42024518348",null,"10.3389/fendo.2025.1486655","40933374","PMC12417164","Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors vs glucagon-like peptide 1 receptor agonists in elderly patients with type 2 diabetes mellitus: a meta-analysis.","2025","Frontiers in endocrinology","Wang Y","76","34","10","PROSPERO","PROSPERO:CRD42024518348"],["R0002998","CRD420251058602",null,"10.1111/head.70005","41246926",null,"Effect of GLP-1 receptor agonists on idiopathic intracranial hypertension: A systematic review.","2026","Headache","de Oliveira HM","36","18","5","PROSPERO","PROSPERO:CRD420251058602"],["R0003024",null,null,"10.1097/yic.0000000000000595","40577093",null,"Glucagon-like peptide-1 receptor agonist semaglutide through the lens of psychiatry: a systematic review of potential benefits and risks.","2026","International clinical psychopharmacology","Carminati M","112","58","12","none found",null],["R0003026",null,null,"10.1002/oby.24360","40685589",null,"Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA.","2025","Obesity (Silver Spring, Md.)","Sinha B","27","23","20","none found",null],["R0003035",null,null,"10.1093/ehjcvp/pvae093","39923808","PMC11905764","Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in atherosclerotic cardiovascular disease phenotypes: a systematic review and meta-analysis.","2025","European heart journal. Cardiovascular pharmacotherapy","Lin YM","56","21","11","none found",null],["R0003040",null,null,"10.2196/86960","41802231","PMC13010075","AI-Enabled Personalization of Semaglutide Therapy in Type 2 Diabetes: Systematic Review With an Integration Framework.","2026","JMIR AI","Barakat G","37","18","1","none found",null],["R0003048","CRD42024613545",null,"10.3389/fendo.2025.1548346","40134805","PMC11932899","Improvement of irritable bowel syndrome with glucagon like peptide-1 receptor agonists: a systematic review and meta-analysis.","2025","Frontiers in endocrinology","Mostafa MEA","64","26","3","PROSPERO","PROSPERO:CRD42024613545"],["R0003049",null,null,"10.1302/0301-620x.108b8.bjj-2025-1486.r2","42538001",null,"Glucagon-like peptide-1 receptor agonists are associated with improved 90-day outcomes after total hip and knee arthroplasty : a systematic review and meta-analysis.","2026","The bone & joint journal","Rudran B","0","0","0","none found",null],["R0003051",null,null,"10.1016/j.arth.2025.06.083","40617546",null,"The Association Between Glucagon-Like Peptide-1 Receptor Agonists and Postoperative Complications After Arthroplasty: A Systematic Review and Meta-Analysis.","2025","The Journal of arthroplasty","Chan YC","46","14","2","none found",null],["R0003064","CRD420261320840",null,"10.1007/s40256-026-00812-w","42429894",null,"Combination Therapy of GLP-1 RA and SGLT2i in Patients with Established Heart Failure: A Systematic Review and Meta-Analysis of Observational Studies.","2026","American journal of cardiovascular drugs : drugs, devices, and other interventions","Tristan CD","32","19","6","PROSPERO","PROSPERO:CRD420261320840"],["R0003075",null,null,"10.1111/dom.70123","40932012","PMC12587241","Sex differences in the efficacy of GLP-1 receptor agonists: A systematic review and meta-analysis of cardiovascular and renal outcome trials.","2025","Diabetes, obesity & metabolism","Siddiqui HF","51","37","17","none found",null],["R0003079",null,null,"10.2337/dc25-0241","40156846",null,"Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials.","2025","Diabetes care","Lee MMY","0","0","0","none found",null],["R0003089","CRD420251170531",null,"10.3389/fneur.2026.1858507","42490867","PMC13375474","GLP-1 receptor agonists in Parkinson's disease: a meta-analysis revealing motor benefit and highlighting mood improvement.","2026","Frontiers in neurology","Chen Y","34","22","8","PROSPERO","PROSPERO:CRD420251170531"],["R0003092",null,null,"10.3350/cmh.2024.0801","39314134","PMC11540347","Reply to correspondence on \"Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis\".","2024","Clinical and molecular hepatology","Ren TY","15","6","2","none found",null],["R0003102",null,null,"10.21203/rs.3.rs-10121806/v1",null,null,"Treatment Strategies for Weight Loss Insufficiency and Weight Regain After Sleeve Gastrectomy: A Network Meta-Analysis and Systematic Review","2026","Research Square","Min Y",null,"0","0","none found",null],["R0003103","CRD42024515966",null,"10.1177/17562864241281903","39345822","PMC11437580","Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis.","2024","Therapeutic advances in neurological disorders","Stefanou MI","49","36","19","PROSPERO","PROSPERO:CRD42024515966"],["R0003105",null,null,"10.1111/dom.70102","40937512",null,"Efficacy of GLP-1 receptor agonists in patients with obesity and heart failure with preserved ejection fraction: A systematic review and meta-analysis of randomised controlled trials.","2025","Diabetes, obesity & metabolism","Talavera A","26","15","10","none found",null],["R0003108","CRD42024543945",null,"10.3389/fendo.2025.1532587","40182628","PMC11966957","A meta-analysis on the risk of esophageal cancer in type 2 diabetes patients treated with GLP-1 receptor agonists.","2025","Frontiers in endocrinology","Wu Q","20","17","5","PROSPERO","PROSPERO:CRD42024543945"],["R0003109",null,null,"10.1111/dom.70506","41605813",null,"Efficacy and safety of GLP-1 receptor agonists and SGLT2 inhibitors as adjuncts to insulin in type 1 diabetes: Systematic review and meta-analysis.","2026","Diabetes, obesity & metabolism","Abdel-Rahman SM","122","52","32","none found",null],["R0003116","CRD42025636991",null,"10.1186/s12916-026-04705-2","41715123","PMC13020221","Efficacy and safety of anti-prediabetic drugs in patients with prediabetes: a Bayesian network meta-analysis.","2026","BMC medicine","Wu Y","89","13","8","PROSPERO","PROSPERO:CRD42025636991"],["R0003129",null,"osf.io/jvmz6","10.1016/j.autrev.2025.103936","41077375",null,"Impact of GLP-1 analogues on immune-mediated inflammatory diseases: A systematic review.","2026","Autoimmunity reviews","Birda CL","73","27","4","OSF",null],["R0003134",null,null,"10.1007/s40200-025-01801-7","41522206","PMC12783420","GLP-1 receptor agonists in kidney transplant recipients with type 2 diabetes mellitus: a systematic review and meta-analysis on mortality and major adverse kidney events.","2026","Journal of diabetes and metabolic disorders","Aliyeva T","39","27","8","none found",null],["R0003139",null,null,"10.1007/s00423-025-03831-4","41071360","PMC12513976","GLP-1 receptor agonists as an adjunct to bariatric surgery for weight loss and metabolic outcome improvement: a systematic review and meta-analysis.","2025","Langenbeck's archives of surgery","Tan YW","42","33","9","none found",null],["R0003154",null,null,"10.7759/cureus.116039","42724505","PMC13559776","Cardiorenal Protection in Type 2 Diabetes: A Systematic Review Comparing Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors.","2026","Cureus","Branigan P","52","38","10","none found",null],["R0003161",null,null,"10.1016/j.amjcard.2025.09.039","41022246",null,"GLP-1 Receptor Agonists and Cardiovascular Outcomes in Adults With Diabetes and Peripheral Artery Disease: An Updated Systematic Review and Meta-Analysis.","2026","The American journal of cardiology","Shuja SH","26","17","5","none found",null],["R0003162","CRD420261335458",null,"10.1159/000553070","42621629","PMC13489628","GLP-1 Receptor Agonists and Alopecia: A Systematic Review and Meta-Analysis of Incidence, Risk, Subtypes, and Mechanisms.","2026","Skin appendage disorders","Viquez Burboa GU","0","0","0","PROSPERO","PROSPERO:CRD420261335458"],["R0003164",null,null,"10.21203/rs.3.rs-7859743/v1",null,null,"GLP-1 Receptor Agonists in Kidney Transplant Recipients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis on Mortality and Major Adverse Kidney Events","2025","Research Square","Aliyeva T",null,"0","0","none found",null],["R0003173",null,null,"10.1111/dom.70676","41873009",null,"Weight Loss Outcomes Between GLP-1 Receptor Agonists and Bariatric Surgery in Adults With Obesity: A Systematic Review, Meta-Analysis and Meta-Regression.","2026","Diabetes, obesity & metabolism","Tahir M","42","12","1","none found",null],["R0003187",null,null,null,null,"PMC11453410","8007 The Effect of Glucagon-Like Peptide-1 Receptor Agonists in Reducing Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Bayesian Network Meta-Analysis","2024","Journal of the Endocrine Society",null,"0","0","0","none found",null],["R0003188","CRD420251146144",null,"10.3389/fendo.2026.1750615","41987895","PMC13076170","Efficacy and safety of novel antidiabetic drugs in patients with type 2 diabetes and chronic kidney disease: a network meta-analysis.","2026","Frontiers in endocrinology","Zhu X","56","19","8","PROSPERO","PROSPERO:CRD420251146144"],["R0003195","CRD420250656321",null,"10.3389/fphar.2025.1627691","41158135","PMC12554640","Emerging therapeutic potential of glucagon-like Peptide-1 receptor agonists in knee osteoarthritis: a systematic review.","2025","Frontiers in pharmacology","Li Y","54","19","3","PROSPERO","PROSPERO:CRD420250656321"],["R0003196",null,null,"10.1177/17455057241234530","38444070","PMC10916466","A systematic review of GLP-1 on anthropometrics, metabolic and endocrine parameters in patients with PCOS.","2024","Women's health (London, England)","Bader S","28","16","9","none found",null],["R0003200",null,null,"10.3350/cmh.2024.0705","39188227","PMC11540367","Correspondence to editorial on \"Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis\".","2024","Clinical and molecular hepatology","Kim H","15","5","2","none found",null],["R0003206",null,null,"10.1186/s12902-026-02538-x","42750018","PMC13579720","Efficacy and safety of orforglipron 12 mg versus orforglipron 36 mg maintenance dose among patients with obesity with or without diabetes: a systematic review and comprehensive meta-analysis.","2026","BMC endocrine disorders","Hegaz MG","57","36","21","none found",null],["R0003207",null,null,"10.2337/dc26-0336","41973508",null,"Hepatic Events Prevention by Antihyperglycemic Therapies and Intervention Comparisons in Type 2 Diabetes: The HEPATIC-T2DM Network Meta-analysis.","2026","Diabetes care","Passos PRC","0","0","0","none found",null],["R0003208","CRD420251034071",null,"10.3390/jcm14248734","41464636","PMC12733705","The Effect of Semaglutide on Pancreatic β-Cell Function in Adults with Type 2 Diabetes: A Systematic Review and Meta-Analysis.","2025","Journal of clinical medicine","Abusedera O","43","34","22","PROSPERO","PROSPERO:CRD420251034071"],["R0003212",null,null,"10.1016/j.metabol.2024.156038","39305981",null,"Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.","2024","Metabolism: clinical and experimental","Xie Z","62","48","34","none found",null],["R0003216",null,null,"10.1017/rsm.2026.10098","42230565",null,"Model-based network meta-analysis: Joint estimation of dose-response and time-course relationships.","2026","Research synthesis methods","Strathe A","25","9","7","none found",null],["R0003220",null,null,"10.1097/hjh.0000000000003903","39445607",null,"Effects of glucagon-like peptide-1 receptor agonists on blood pressure in overweight or obese patients: a meta-analysis of randomized controlled trials.","2025","Journal of hypertension","Wong HJ","75","50","32","none found",null],["R0003228",null,null,"10.3892/br.2026.2165","42339050","PMC13284603","Semaglutide and major adverse cardiovascular events in patients with and without DM: A systematic review and meta-analysis.","2026","Biomedical reports","Li Y","30","28","17","none found",null],["R0003245","CRD42023396138",null,"10.1186/s13098-023-01118-6","37491292","PMC10369734","The relationship between the use of GLP-1 receptor agonists and the incidence of respiratory illness: a meta-analysis of randomized controlled trials.","2023","Diabetology & metabolic syndrome","Yu M","56","44","32","PROSPERO","PROSPERO:CRD42023396138"],["R0003256",null,null,"10.1016/j.ejphar.2025.177885","40615102",null,"The effects of GLP-1 receptor agonists on body composition in patients with type 2 diabetes, overweight or obesity: A meta-analysis of randomized controlled trials.","2025","European journal of pharmacology","Lu J","70","52","37","none found",null],["R0003259","CRD420251111692",null,"10.1016/j.xnsj.2025.100835","41551027","PMC12811479","Do GLP-1 agonists affect perioperative risk in spine surgery? A systematic review and meta-analysis.","2026","North American Spine Society journal","Ononogbu-Uche FC","60","41","5","PROSPERO","PROSPERO:CRD420251111692"],["R0003265",null,null,"10.1186/s12902-025-01948-7","40336001","PMC12056997","Influence of glucagon-like peptide-1 receptor agonists on renal parameters: a meta-analysis of randomized controlled trials.","2025","BMC endocrine disorders","Li W","69","49","31","none found",null],["R0003270",null,null,"10.1111/cob.12642","38273176",null,"The role of glucagon-like peptide 1 receptor agonists for weight control in individuals with acquired hypothalamic obesity-A systematic review.","2024","Clinical obesity","Ng VWW","40","17","5","none found",null],["R0003277","CRD420251158592",null,"10.3389/fmed.2025.1721311","41567683","PMC12815760","Novel antidiabetic agents and the risk of respiratory diseases: a systematic review and meta-analysis of 27 randomized controlled trials.","2025","Frontiers in medicine","Yu Z","57","20","13","PROSPERO","PROSPERO:CRD420251158592"],["R0003285",null,"osf.io/zyhws","10.3389/fendo.2026.1833904","42490840","PMC13375489","Comparative analysis of glucagon-like peptide-1 receptor agonists, metformin, and inositol in improving anthropometric and metabolic outcomes in women with polycystic ovary syndrome: a network meta-analysis.","2026","Frontiers in endocrinology","Omarion A","32","17","12","OSF",null],["R0003297",null,null,"10.1002/edm2.70187","41787737","PMC12963462","Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials.","2026","Endocrinology, diabetes & metabolism","Abulehia A","38","34","13","none found",null],["R0003324",null,null,"10.1161/strokeaha.125.053075","41263069",null,"GLP-1 Receptor Agonists as Treatment of Nondiabetic Ischemic Stroke: A Systematic Review and Meta-Analysis.","2026","Stroke","Michaelsen MK","96","54","8","none found",null],["R0003329",null,null,"10.7759/cureus.77089","39917155","PMC11801804","Efficacy and Safety of Efpeglenatide in Patients With Type 2 Diabetes and Obesity: A Systematic Review.","2025","Cureus","Narayan N","25","22","13","none found",null],["R0003356",null,null,"10.1186/s13098-026-02218-9","42363271","PMC13563702","Efficacy and safety of orforglipron in obesity with type 2 diabetes mellitus: a GRADE-assessed meta-analysis of randomized controlled trials.","2026","Diabetology & metabolic syndrome","Emara A","33","18","9","none found",null],["R0003358",null,null,"10.1080/03007995.2024.2442027","39666879",null,"Glucagon-like peptide 1 receptor agonists modestly reduced low-density lipoprotein cholesterol and total cholesterol levels independent of weight reduction: a meta-analysis and meta-regression of placebo controlled randomized controlled trials.","2025","Current medical research and opinion","Rivera FB","72","62","45","none found",null],["R0003362",null,null,"10.1016/j.cardfail.2025.01.022","39993464",null,"Efficacy of GLP-1 Receptor Agonists in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.","2025","Journal of cardiac failure","Waqas SA","8","7","6","none found",null],["R0003366",null,null,"10.1002/dmrr.70037","39945396","PMC11823376","Association of GLP-1 Receptor Agonists With Risk of Suicidal Ideation and Behaviour: A Systematic Review and Meta-Analysis.","2025","Diabetes/metabolism research and reviews","Bushi G","24","21","3","none found",null],["R0003372",null,null,"10.3390/diagnostics15060770","40150111","PMC11941505","Evidence Report on the Safety of Gastrointestinal Endoscopy in Patients on Glucagon-like Peptide-1 Receptor Agonists: A Systematic Review and Meta-Analysis.","2025","Diagnostics (Basel, Switzerland)","Tarar ZI","39","27","2","none found",null],["R0003375",null,null,"10.3390/healthcare14101319","42194410","PMC13206233","Long-Acting Lipid-Lowering Injectables and Behavioral Moral Hazard: A Systematic Review of Adherence, Lifestyle Measurement, and Structural Evidence Gaps.","2026","Healthcare (Basel, Switzerland)","Cumpăt CM","14","1","1","none found",null],["R0003380",null,null,"10.5662/wjm.119385","42626264","PMC13491145","Glucagon-like receptor-1 agonists and impotence: A meta-analysis.","2026","World journal of methodology","Mirghani HO","36","15","3","none found",null],["R0003382",null,null,null,null,"PMC13145916","ABSTRACT NUMBER: ESOC2026A2308 GLP-1 OR DUAL GIP/GLP-1 RECEPTOR AGONIST IN ACUTE ISCHAEMIC STROKE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF PRE-CLINICAL STUDIES","2026","European stroke journal",null,"0","0","0","none found",null],["R0003383",null,null,"10.2147/dmso.s575790","41328392","PMC12665223","Optimising GLP-1RA Efficacy: A Meta-Analysis of Baseline Age and HbA1c as Predictors of MACE Reduction in T2DM.","2025","Diabetes, metabolic syndrome and obesity : targets and therapy","Ghosal S","25","17","11","none found",null],["R0003387",null,null,"10.1001/jamapsychiatry.2025.0091","40105856","PMC11923776","Suicide and Self-Harm Events With GLP-1 Receptor Agonists in Adults With Diabetes or Obesity: A Systematic Review and Meta-Analysis.","2025","JAMA psychiatry","Ebrahimi P","65","54","41","none found",null],["R0003388",null,null,"10.1002/dmrr.3843","39311048",null,"Effects of Glucagon-Like Peptide-1 Receptor Agonist on Bone Mineral Density and Bone Turnover Markers: A Meta-Analysis.","2024","Diabetes/metabolism research and reviews","Kim HJ","63","16","7","none found",null],["R0003391",null,null,"10.1002/brb3.70661","40635383","PMC12241715","Efficacy and Safety of Glucagon-Like Peptide-1 Agonists for Psychiatric Symptoms: A Systematic Review.","2025","Brain and behavior","Meshkat S","55","39","15","none found",null],["R0003398",null,null,"10.1111/jnc.16242","39453834",null,"Effect of the glucagon-like peptide-1 receptor agonists on diabetic peripheral neuropathy: A meta-analysis.","2025","Journal of neurochemistry","Fan S","53","28","9","none found",null],["R0003402",null,null,"10.1186/s12902-026-02248-4","41913139","PMC13159308","Efficacy and safety of GLP-1 receptor agonists for adolescents and children with obesity: a meta-analysis of randomized controlled trials.","2026","BMC endocrine disorders","Chen Q","37","23","17","none found",null],["R0003412",null,null,"10.1017/s1092852924000531","39582175",null,"A systematic review on the efficacy of GLP-1 receptor agonists in mitigating psychotropic drug-related weight gain.","2024","CNS spectrums","Menon T","31","16","8","none found",null],["R0003417","CRD420251270326",null,"10.1007/s40256-026-00809-5","42387250",null,"GLP-1 Receptor Agonists and Cardiovascular Outcomes in Patients with Type 2 Diabetes Across Myocardial Infarction-Defined Populations: A Systematic Review and Meta-Analysis.","2026","American journal of cardiovascular drugs : drugs, devices, and other interventions","Batista PG","30","21","5","PROSPERO","PROSPERO:CRD420251270326"],["R0003424","CRD42024522782; CRD42024522787",null,"10.1016/j.ocarto.2025.100567","39995585","PMC11849622","Effect of glucagon-like peptide-1 receptor agonists in osteoarthritis: A systematic review of pre-clinical and human studies.","2025","Osteoarthritis and cartilage open","Cheng J","34","14","5","PROSPERO","PROSPERO:CRD42024522782; PROSPERO:CRD42024522787"],["R0003429","CRD420251147337",null,"10.3389/fcvm.2025.1731127","41472878","PMC12745249","Effects of subcutaneous or oral semaglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.","2025","Frontiers in cardiovascular medicine","Tan S","28","23","8","PROSPERO","PROSPERO:CRD420251147337"],["R0003435","CRD420261435182",null,"10.7759/cureus.115758","42830876","PMC13634180","Comparative Efficacy and Safety of Liraglutide Versus Metformin in Women With Polyendocrine Metabolic Ovarian Syndrome (PMOS): A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","2026","Cureus","Banerjee I","0","0","0","PROSPERO","PROSPERO:CRD420261435182"],["R0003451",null,null,"10.1016/j.jcjd.2023.03.002","36963632",null,"Comparison of Efficacy and Safety of Commercially Available Fixed-Ratio Combinations of Insulin Degludec/Liraglutide and Insulin Glargine/Lixisenatide: A Network Meta-analysis.","2023","Canadian journal of diabetes","Visolyi GÁ","47","27","12","none found",null],["R0003458","CRD420251002447",null,"10.1038/s41366-026-02088-1","42034831","PMC13461353","GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis.","2026","International journal of obesity (2005)","Sawicka-Gutaj N","69","57","15","PROSPERO","PROSPERO:CRD420251002447"],["R0003463",null,null,"10.1002/jcsm.13677","39815782","PMC11735953","The Effects of Glucagon-Like Peptide-1 Receptor Agonists on Mitochondrial Function Within Skeletal Muscle: A Systematic Review.","2025","Journal of cachexia, sarcopenia and muscle","Old VJ","72","43","20","none found",null],["R0003472",null,null,"10.1111/dom.70957","42304171","PMC13449080","Comparative Effects of Antidiabetic Drugs on Body Composition: A Systematic Review and Network Meta-Analysis.","2026","Diabetes, obesity & metabolism","Rakhsha SS","100","38","23","none found",null],["R0003473",null,null,"10.3390/jcm14134619","40648992","PMC12251260","Efficacy and Safety of GLP-1 Receptor Agonists and SGLT-2 Inhibitors in the Treatment of Diabetes Mellitus and Obesity in Liver Transplant Recipients: A Systematic Review.","2025","Journal of clinical medicine","Garlatti Costa E","42","22","5","none found",null],["R0003475",null,null,"10.1002/dmrr.70111","41331723",null,"Effect of Glucagon-Like Peptide-1 Receptor Agonists on Cardiometabolic Risk Factors in Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.","2026","Diabetes/metabolism research and reviews","Chen Y","78","28","16","none found",null],["R0003478",null,null,"10.1016/j.dsx.2024.103069","38963997",null,"Glucagon-like peptide-1 receptor agonist and new-onset diabetes in overweight/obese individuals with prediabetes: A systematic review and meta-analysis of randomized trials.","2024","Diabetes & metabolic syndrome","Yanto TA","40","22","12","none found",null],["R0003479",null,null,"10.1016/j.cgh.2024.07.021","39142543",null,"Effects of Glucagon-Like Peptide-1 Receptor Agonists on Upper Gastrointestinal Endoscopy: A Meta-Analysis.","2025","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","Facciorusso A","24","15","1","none found",null],["R0003482","CRD420261306111",null,"10.1159/000551686","41979993",null,"Cardiovascular Outcomes in Diabetic Patients Treated with Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonist: A Systematic Review and Meta-Analysis.","2026","Cardiology","Marino G","46","23","14","PROSPERO","PROSPERO:CRD420261306111"],["R0003484","CRD42022342845",null,"10.1136/bmj-2023-076410","38286487","PMC10823535","Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.","2024","BMJ (Clinical research ed.)","Yao H","41","22","8","PROSPERO","PROSPERO:CRD42022342845"],["R0003485",null,null,"10.1038/s41598-025-99622-4","40360648","PMC12075827","Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials.","2025","Scientific reports","Lin S","45","25","13","none found",null],["R0003486",null,null,"10.1111/andr.70022","40105090","PMC12569732","Effects of glucagon-like peptide 1 receptor agonists on testicular dysfunction: A systematic review and meta-analysis.","2025","Andrology","Salvio G","44","21","6","none found",null],["R0003489",null,null,"10.1155/2024/3212795","38529046","PMC10963118","Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Intima-Media Thickness: Systematic Review and Meta-Analysis.","2024","Journal of diabetes research","Akbari A","68","38","6","none found",null],["R0003494",null,null,"10.1016/j.amjcard.2026.06.015","42342009",null,"Semaglutide for the Silent Phenotype: A Translational Signal in Obesity-Driven HFpEF.","2026","The American journal of cardiology","Ceravolo R","40","9","9","none found",null],["R0003497",null,null,"10.1016/j.cpcardiol.2025.103194","41173128",null,"Efficacy of GLP-1 receptor agonists in obese patients with heart failure with preserved ejection fraction: A systematic review and meta-analysis of randomized trials and propensity score-matched cohorts.","2026","Current problems in cardiology","Caldeira Gaelzer G","47","12","9","none found",null],["R0003499",null,null,"10.3389/fmed.2026.1913929","42666665","PMC13522774","Mapping GLP-1 receptor agonist research across the MASLD-MASH-HCC continuum: a bibliometric and translational analysis.","2026","Frontiers in medicine","Xie Y","66","30","9","none found",null],["R0003501","CRD42024531982",null,"10.1016/j.eclinm.2024.102920","39764544","PMC11701477","Association between glucagon-like peptide-1 receptor agonists use and change in alcohol consumption: a systematic review.","2024","EClinicalMedicine","Subhani M","34","22","9","PROSPERO","PROSPERO:CRD42024531982"],["R0003505",null,null,"10.3389/fpubh.2023.1201818","37744474","PMC10513082","Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model.","2023","Frontiers in public health","Yuan S","50","18","11","none found",null],["R0003508",null,null,null,null,"PMC12047309","SAT-631 Glucagon-Like Peptide-1 Receptor Agonist Liraglutide for the Treatment of Weight Regain After Bariatric Surgery: A Systematic Review and Meta-Analysis","2024","Journal of the Endocrine Society",null,"0","0","0","none found",null],["R0003528",null,null,"10.1093/eurjpc/zwag077","41662383",null,"Impact of Semaglutide on Limb Events: A Meta-Analysis of Randomized Controlled Trials.","2026","European journal of preventive cardiology","Cesaro A","52","34","22","none found",null],["R0003529",null,null,"10.1111/dom.15809","39044308",null,"Medication adherence to sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists: A meta-analysis.","2024","Diabetes, obesity & metabolism","Johnson CE","33","16","2","none found",null],["R0003535","CRD42023393020",null,"10.1186/s13098-024-01337-5","38659064","PMC11044464","The efficacy and safety of GLP-1 receptor agonists in youth with type 2 diabetes: a meta-analysis.","2024","Diabetology & metabolic syndrome","Yugar LBT","28","13","5","PROSPERO","PROSPERO:CRD42023393020"],["R0003550",null,null,"10.3126/nje.v16i1.92323","42211533","PMC13215652","Comparative Efficacy and Safety of Tirzepatide versus Semaglutide: A Systematic Review and Meta-Analysis with Cardiometabolic Implications.","2026","Nepal journal of epidemiology","Baba AH","23","19","7","none found",null],["R0003562","CRD420251015882",null,"10.3389/fmed.2025.1621958","40917833","PMC12408605","The role of GLP-1 receptor agonists in IBD-related surgery and IBD-related complications of inflammatory bowel disease among patients with metabolic comorbidities: a systematic review and meta-analysis.","2025","Frontiers in medicine","Yang M","30","12","0","PROSPERO","PROSPERO:CRD420251015882"],["R0003586",null,null,"10.3389/fmed.2026.1764664","42100257","PMC13143735","Tirzepatide vs. semaglutide for obesity, glycemic control, and cardiovascular outcomes: a narrative review of clinical trials.","2026","Frontiers in medicine","Harbi MH","29","24","18","none found",null],["R0003588",null,null,"10.1111/dom.71006","42324178","PMC13449088","Effects of Incretin-Based Therapies, Diet and Exercise Interventions, and Bariatric Surgery on Fat-Free Mass in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis.","2026","Diabetes, obesity & metabolism","Busk-Cirera L","65","24","10","none found",null],["R0003595",null,null,"10.1186/s12991-024-00527-9","39529123","PMC11552190","Glucagon-like peptide-1 receptor agonists (GLP-1RAs) as treatment for nicotine cessation in psychiatric populations: a systematic review.","2024","Annals of general psychiatry","Lee S","28","14","2","none found",null],["R0003600",null,null,"10.1177/17562864251372747","40951542","PMC12426393","GLP-1 receptor agonists in Parkinson's disease progression: a meta-analysis with trial sequential analysis of randomized controlled trials.","2025","Therapeutic advances in neurological disorders","Tsai WW","31","21","8","none found",null],["R0003606","CRD42025650082",null,"10.1111/ene.70358","40937960","PMC12426903","Efficacy and Safety of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension: A Systematic Review and Meta-Analysis.","2025","European journal of neurology","Stefanou MI","42","14","1","PROSPERO","PROSPERO:CRD42025650082"],["R0003610",null,null,"10.17925/ee.2026.22.1.8","42272996","PMC13249221","Efficacy and Safety of Oral Semaglutide in the Management of Diabetes and Obesity: A Comprehensive Meta-analysis of Real-world Evidence.","2026","TouchREVIEWS in endocrinology","Jena S","77","70","7","none found",null],["R0003613",null,null,"10.1111/dom.16398","40212008","PMC12146062","Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo-controlled clinical trials.","2025","Diabetes, obesity & metabolism","Kang YM","44","42","24","none found",null],["R0003616",null,null,"10.1016/j.jpag.2026.01.001","41506442",null,"Nonhormonal Pharmacological Interventions in Adolescent Polycystic Ovary Syndrome (PCOS): A Systematic Review.","2026","Journal of pediatric and adolescent gynecology","Sibal R","36","1","0","none found",null],["R0003623",null,null,"10.1016/j.sleep.2025.02.010","39978242",null,"Efficacy and safety of GLP-1 receptor agonists in the management of obstructive sleep apnea in individuals without diabetes: A systematic review and meta-analysis of randomized, placebo-controlled trials.","2025","Sleep medicine","Kow CS","19","4","2","none found",null],["R0003625",null,null,"10.1111/dom.16366","40230207",null,"The effect of GLP-1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: A systematic review and meta-analysis.","2025","Diabetes, obesity & metabolism","Ren Y","140","47","26","none found",null],["R0003633",null,null,"10.1016/j.jhepr.2025.101661","41503569","PMC12771308","Impact of SGLT2i and GLP-1RA on liver-related events in patients with MASLD and type 2 diabetes: A network meta-analysis.","2026","JHEP reports : innovation in hepatology","Li L","49","23","8","none found",null],["R0003641",null,null,"10.1001/jamanetworkopen.2026.4722","41915388","PMC13040404","GLP-1 Receptor Agonists and Noncardiometabolic Outcomes: An Umbrella Review of Meta-Analyses.","2026","JAMA network open","Yang K","89","75","4","none found",null],["R0003646","CRD42024516313",null,"10.3389/fcdhc.2025.1579961","40937349","PMC12420244","GLP-1 receptor agonists and pancreatic beta cell apoptosis in diabetes mellitus: a systematic review and meta-analysis of preclinical studies.","2025","Frontiers in clinical diabetes and healthcare","Rea N","39","26","3","PROSPERO","PROSPERO:CRD42024516313"],["R0003662",null,null,"10.7759/cureus.92175","41084648","PMC12515520","Insulin Versus Established GLP-1 Receptor Agonists, DPP-4 Inhibitors, and SGLT-2 Inhibitors for Uncontrolled Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","2025","Cureus","Ahmed A","38","17","11","none found",null],["R0003668",null,null,"10.1111/dom.16476","40390279",null,"Effects of GLP-1 receptor agonists on incidence and outcomes of ischemic stroke and myocardial infarction: A systematic review and meta-analysis.","2025","Diabetes, obesity & metabolism","Alammari N","46","30","12","none found",null],["R0003677",null,null,"10.1016/j.physbeh.2024.114622","38945189",null,"Glucagon-like peptide 1 agonist and effects on reward behaviour: A systematic review.","2024","Physiology & behavior","Badulescu S","85","34","12","none found",null],["R0003686",null,null,"10.1111/dom.15382","38018310",null,"Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials.","2024","Diabetes, obesity & metabolism","Silverii GA","64","34","16","none found",null],["R0003691",null,null,"10.1111/dom.70010","40798873",null,"Comparative analysis on renal and cardiovascular outcomes of antidiabetic treatment in chronic kidney disease patients-A systematic review and network meta-analysis.","2025","Diabetes, obesity & metabolism","Bramlage P","55","18","5","none found",null],["R0003694",null,null,"10.7759/cureus.66280","39238716","PMC11376316","The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Adolescents Without Diabetes Mellitus: A Systematic Review and Meta-Analysis.","2024","Cureus","Katole NT","27","20","9","none found",null],["R0003702",null,null,"10.1016/j.eprac.2024.11.017","39701283",null,"Comparison of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter Protein-2 Inhibitors on Treating Metabolic Dysfunction-Associated Steatotic Liver Disease or Metabolic Dysfunction-Associated Steatohepatitis: Systematic Review and Network Meta-Analysis of Randomised Controlled Trials.","2025","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Xu R","87","34","18","none found",null],["R0003713",null,null,"10.1093/ehjcvp/pvaf037","40886073","PMC12450594","Clinical features modifying the cardiovascular benefits of GLP-1 receptor agonists: a systematic review and meta-analysis.","2025","European heart journal. Cardiovascular pharmacotherapy","Kalayci A","36","21","11","none found",null],["R0003717",null,null,"10.1111/dom.15979","39344842",null,"Effects of glucagon-like peptide-1 receptor agonists on glycated haemoglobin and continuous glucose monitoring metrics as adjunctive therapy to insulin in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.","2024","Diabetes, obesity & metabolism","Karakasis P","40","23","12","none found",null],["R0003723","CRD42023473528",null,"10.1186/s13098-025-01877-4","40770817","PMC12326795","Dionysus or apollo, skeletal muscle mass changes in type 2 diabetes with sarcopenia receiving GLP-1 receptor agonist: systematic review and meta-analysis.","2025","Diabetology & metabolic syndrome","Wang Y","59","19","5","PROSPERO","PROSPERO:CRD42023473528"],["R0003732",null,null,"10.1177/23969873241234238","38400569","PMC11418422","Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis.","2024","European stroke journal","Stefanou MI","51","40","18","none found",null],["R0003740",null,null,"10.1007/s12325-026-03523-5","41820778","PMC13156185","Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials.","2026","Advances in therapy","Ciudin A","19","12","8","none found",null],["R0003756",null,null,"10.1093/jncics/pkag014","41703670","PMC12972670","Diet, nutrition, and hormone therapy for prostate cancer: a systematic review with implications for future interventions.","2026","JNCI cancer spectrum","Pahulu I","57","7","2","none found",null],["R0003757",null,null,"10.1111/ceo.14445","39327045",null,"Impact of glucagon-like peptide-1 receptor agonists on diabetic retinopathy: A meta-analysis of clinical studies emphasising retinal changes as a primary outcome.","2025","Clinical & experimental ophthalmology","Kapoor I","31","20","3","none found",null],["R0003770",null,null,"10.1111/dom.16136","39726212",null,"Anti-diabetic effects of GLP-1 receptor agonists on obese and overweight patients across diabetes status, administration routes, treatment duration and baseline characteristics: A systematic review.","2025","Diabetes, obesity & metabolism","Wong HJ","45","20","1","none found",null],["R0003772",null,null,"10.1016/j.ijcard.2025.133604","40623630",null,"GLP-1RA versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: An updated meta-analysis of randomized controlled trials.","2025","International journal of cardiology","Duhan S","15","6","6","none found",null],["R0003773",null,null,"10.1007/s10072-025-08411-4","40835782",null,"From diabetes to dopamine: Evaluating the disease-modifying potential of GLP-1 receptor agonists in Parkinson's disease. A systematic review and meta-analysis of placebo-controlled trials.","2025","Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","Badran AS","23","12","5","none found",null],["R0003794",null,null,"10.1111/dom.70084","40936218",null,"Comparative efficacy and safety of Glucagon-like pepetide-1 receptor agonists with metformin in Asian versus non-Asian patients with type 2 diabetes: A systematic review and meta-analysis.","2025","Diabetes, obesity & metabolism","Li W","38","13","7","none found",null],["R0003803",null,null,"10.1002/clc.24314","38953365","PMC11217813","Glucagon-Like Peptide-1 Receptor Agonists and Major Adverse Cardiovascular Events in Patients With and Without Diabetes: A Meta-Analysis of Randomized-Controlled Trials.","2024","Clinical cardiology","Hosseinpour A","39","34","25","none found",null],["R0003822",null,null,"10.1002/edm2.70248","42207966","PMC13239642","Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials.","2026","Endocrinology, diabetes & metabolism","Hamarsheh S","18","6","5","none found",null],["R0003830",null,null,"10.1007/s40256-024-00695-9","39616304",null,"Role of Incretin Mimetics in Cardiovascular Outcomes and Other Classical Cardiovascular Risk Factors beyond Obesity and Diabetes Mellitus in Nondiabetic Adults with Obesity: a Meta-analysis of Randomized Controlled Trials.","2025","American journal of cardiovascular drugs : drugs, devices, and other interventions","Kamarullah W","45","32","12","none found",null],["R0003842",null,null,"10.2337/dc24-1678","39841962",null,"Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference for Patients With Obesity or Overweight: A Systematic Review, Meta-analysis, and Meta-regression of 47 Randomized Controlled Trials.","2025","Diabetes care","Wong HJ","40","20","2","none found",null],["R0003845",null,null,"10.21203/rs.3.rs-9176897/v1",null,null,"Safety and efficacy of semaglutide for non-alcoholic fatty liver disease: A meta-analysis of clinical outcomes","2026","Research Square","Faheem MSB",null,"0","0","none found",null],["R0003862","CRD420251149266",null,"10.1016/j.urolonc.2026.05.024","42314323",null,"Antidiabetic medications and the risk of bladder cancer in patients with diabetes mellitus: A systematic review and meta-analysis.","2026","Urologic oncology","Lei D","0","0","0","PROSPERO","PROSPERO:CRD420251149266"],["R0003865",null,null,"10.1177/10225536251391959","41233973",null,"Impact of glucagon-like peptide-1 receptor agonists on postoperative complications after total joint arthroplasty: A systematic review and meta-analysis.","2025","Journal of orthopaedic surgery (Hong Kong)","Mashayekhi Y","55","35","7","none found",null],["R0003878","CRD42024542379",null,"10.1177/20420188261437346","41969412","PMC13069171","Antidiabetic drug and chronic respiratory disease in type 2 diabetes: a network meta-analysis and Mendelian randomization analysis.","2026","Therapeutic advances in endocrinology and metabolism","Patel I","77","13","1","PROSPERO","PROSPERO:CRD42024542379"],["R0003897",null,null,"10.1371/journal.pmed.1005064","42166479","PMC13221145","Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies.","2026","PLoS medicine","Chrzanowski J","73","55","10","none found",null],["R0003910",null,null,"10.1097/md.0000000000049986","42536519","PMC13433015","Effectiveness & safety of semaglutide in weight reduction in obese nondiabetic patients: A systematic review and meta-analysis.","2026","Medicine","Naz F","24","17","5","none found",null],["R0003914",null,null,"10.1016/j.cardfail.2026.06.025","42401228",null,"Time to Benefit of Incretin-Based Therapies in Adiposity-Related Heart Failure With Mildly Reduced or Preserved Ejection Fraction: a Systematic Review and Meta-Analysis.","2026","Journal of cardiac failure","Spiazzi BF","33","10","7","none found",null],["R0003916",null,null,"10.2147/dmso.s439587","37954886","PMC10638946","Evaluating Glycemic Control Efficacy and Safety of the Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron in Type 2 Diabetes Patients: A Systemic Review and Meta-Analysis.","2023","Diabetes, metabolic syndrome and obesity : targets and therapy","Fatima H","30","24","11","none found",null],["R0003929","CRD42024532383",null,"10.1007/s00125-025-06565-6","41117973","PMC12686040","Effectiveness and safety of combining SGLT2 inhibitors and GLP-1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of cohort studies.","2026","Diabetologia","Colombijn JMT","51","31","5","PROSPERO","PROSPERO:CRD42024532383"],["R0003932",null,null,"10.26355/eurrev_202403_35731","38567590",null,"Is polyethylene glycol loxenatide 100 μg the preferred glucagon-like peptide-1 receptor agonist for type 2 diabetes mellitus? A meta-analysis and trial sequential analysis.","2024","European review for medical and pharmacological sciences","Liu P","0","0","0","none found",null],["R0003937",null,null,"10.7759/cureus.71684","39552962","PMC11568484","Comparative Effectiveness of Bariatric Metabolic Surgery Versus Glucagon-Like Peptide-1 Receptor Agonists on Cardiovascular Outcomes and Mortality: A Meta-Analysis.","2024","Cureus","Saeed L","30","18","4","none found",null],["R0003944",null,null,null,"42488294","PMC13389273","Outcomes of Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1A) and Patients Undergoing Total Hip Arthroplasty (THA): A Systematic Review and Meta-Analysis.","2026","The Iowa orthopaedic journal","Puga TB","21","11","1","none found",null],["R0003951",null,null,"10.1093/postmj/qgae148","39487697",null,"Effects of new hypoglycemic drugs on patients with heart failure: a systematic review and network meta-analysis.","2025","Postgraduate medical journal","Song R","82","29","21","none found",null],["R0003952",null,null,"10.1007/s11255-024-04266-4","39495435",null,"Effect of GLP-1 receptor agonists on prostate cancer risk reduction: a systematic review and meta-analysis.","2025","International urology and nephrology","Sharma N","19","11","0","none found",null],["R0003954",null,null,"10.1016/j.rmed.2025.108197","40480531",null,"Glucagon-like peptide 1 (GLP-1) receptor agonists and asthma and COPD exacerbations in adults with diabetes: A systematic review.","2025","Respiratory medicine","Cooper DH","47","17","1","none found",null],["R0003961",null,null,"10.1016/j.eprac.2026.09.007","42810621",null,"SGLT2 Inhibitors and Nephrolithiasis Risk in Adults With Type 2 Diabetes: A Systematic Review and Meta-analysis.","2026","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Abreu M","0","0","0","none found",null],["R0003964",null,null,"10.5144/0256-4947.2025.129","40189856","PMC12542916","Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese individuals without diabetes: a systematic review and meta analysis.","2025","Annals of Saudi medicine","Safwan M","40","37","18","none found",null],["R0003967","CRD42023448720",null,"10.3389/fendo.2024.1410883","39464183","PMC11502341","Risk of bone fracture by using dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus: a network meta-analysis of population-based cohort studies.","2024","Frontiers in endocrinology","Mostafa MEA","67","20","5","PROSPERO","PROSPERO:CRD42023448720"],["R0003969",null,null,"10.1111/jgh.16752","39322970",null,"Influence of glucagon-like peptide-1 receptor agonists on hepatic events in type 2 diabetes: a systematic review and meta-analysis.","2025","Journal of gastroenterology and hepatology","Passos PRC","64","27","3","none found",null],["R0003976",null,null,"10.1111/dom.70411","41504379","PMC12890774","Sex differences in trial representation and the cardiovascular effectiveness of newer glucose-lowering agents in patients with and without type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials.","2026","Diabetes, obesity & metabolism","Zawadka M","89","30","18","none found",null],["R0003978",null,null,"10.1097/hep.0000000000001695","41609749",null,"Impact of newer antihyperglycemic agents on hepatic complications: A systematic review and meta-analysis of data from 5.3 million patients with type 2 diabetes mellitus.","2026","Hepatology (Baltimore, Md.)","Yang J","65","27","1","none found",null],["R0003985",null,null,"10.1111/dom.14202","32991041","PMC7756611","Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonists in people with type 2 diabetes mellitus: A network meta-analysis.","2021","Diabetes, obesity & metabolism","Rayner CK","56","46","29","none found",null],["R0004004",null,null,"10.64898/2026.07.22.26358702",null,null,"GLP-1 Receptor Agonists vs SGLT2 Inhibitors for Alzheimer’s Disease Risk in Type 2 Diabetes: A Systematic Review and Meta-Analysis","2026","medRxiv","Silva LL",null,"0","0","none found",null],["R0004007",null,null,"10.7759/cureus.80321","40206909","PMC11979670","Comparative Effectiveness of Semaglutide, Liraglutide, Orlistat, and Phentermine for Weight Loss in Obese Individuals: A Systematic Review.","2025","Cureus","Patel JP","41","12","8","none found",null],["R0004015","CRD42022359346",null,"10.3389/fendo.2023.1149328","37484944","PMC10359616","GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis.","2023","Frontiers in endocrinology","Zhang Z","100","93","70","PROSPERO","PROSPERO:CRD42022359346"],["R0004027",null,null,"10.1016/j.diabres.2025.112088","40057043",null,"SGLT2 inhibitors and nephrolithiasis risk in patients with type 2 diabetes: A cohort study and meta-analysis.","2025","Diabetes research and clinical practice","Yeh JA","37","6","1","none found",null],["R0004031",null,null,"10.1111/ddg.15431","38824670",null,"Efficacy of glucagon-like peptide-1 receptor agonists for psoriasis: An updated systematic review and meta-analysis.","2024","Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG","Ku SC","11","9","2","none found",null],["R0004052","CRD42025640318",null,"10.3389/fendo.2025.1681965","41133230","PMC12540095","Comparative effectiveness of GLP-1 receptor agonists and dual agonists in the treatment of patients with metabolic dysfunction associated steatohepatitis: a systematic review and meta-analysis.","2025","Frontiers in endocrinology","Li M","63","24","8","PROSPERO","PROSPERO:CRD42025640318"],["R0004054","CRD42024553048",null,"10.3389/fcvm.2024.1453297","39323759","PMC11422096","Comparison of glucagon-like peptide-1 receptor agonists vs. placebo on any cardiovascular events in overweight or obese non-diabetic patients: a systematic review and meta-analysis.","2024","Frontiers in cardiovascular medicine","Kelkar R","30","24","17","PROSPERO","PROSPERO:CRD42024553048"],["R0004056",null,null,"10.3389/fendo.2021.609110","33897616","PMC8063104","Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.","2021","Frontiers in endocrinology","Wong C","57","22","7","none found",null],["R0004062",null,null,"10.1016/j.smrv.2025.102119","40633481",null,"Efficacy of incretin-based therapies in obesity-related obstructive sleep apnea: a systematic review and meta-analysis of randomized controlled trials.","2025","Sleep medicine reviews","Bardóczi A","53","15","10","none found",null],["R0004076",null,null,"10.7759/cureus.75304","39776746","PMC11704649","Comparative Efficacy of Semaglutide Versus Liraglutide or Efinopegdutide on Weight Loss in Obese Patients: A Systematic Review and Meta-Analysis.","2024","Cureus","Wen J","33","25","8","none found",null],["R0004079",null,null,"10.1016/j.eprac.2025.11.017","41419174",null,"Antidiabetic Medications and Bladder Cancer Risk in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","2026","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Rao Y","55","13","12","none found",null],["R0004086",null,null,"10.1186/s12891-025-09022-y","40751153","PMC12315457","Differential effects of GLP-1 receptor agonists on diabetic osteopathy in type 2 diabetes: a patient-stratified network meta-analysis.","2025","BMC musculoskeletal disorders","Alalwani YJ","43","36","23","none found",null],["R0004087",null,null,"10.1111/dom.15219","37529870",null,"Effects of once-weekly glucagon-like peptide-1 receptor agonists on type 2 diabetes mellitus complicated with coronary artery disease: Potential role of the renin-angiotensin system.","2023","Diabetes, obesity & metabolism","Kan M","70","37","13","none found",null],["R0004104","CRD420251146788",null,"10.1007/s13300-025-01817-5","41201574","PMC12847540","Risk-Benefit Trade-offs of GLP-1RAs and SGLT-2is in Type 2 Diabetes Mellitus (T2D): Systematic Review, Meta-Analysis, and Net Benefit Modeling.","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","Ghosal S","44","25","14","PROSPERO","PROSPERO:CRD420251146788"],["R0004114",null,null,null,null,"PMC12047111","MON-301 Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Children and Adolescents: A Meta-Analysis of Randomized Controlled Trials","2024","Journal of the Endocrine Society",null,"0","0","0","none found",null],["R0004118",null,null,"10.14740/cr1523","37559715","PMC10409547","The Impact of Glucagon-Like Peptide-1 Receptor Agonist on the Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis and Systematic Review.","2023","Cardiology research","Rahman A","49","31","11","none found",null],["R0004120",null,null,"10.7759/cureus.40448","37456411","PMC10349654","Role of Glucagon-Like Peptide-1 Receptor Agonists on the Weight Loss of Individuals With Type 2 Diabetes: A Systematic Review.","2023","Cureus","Irfan H","12","8","3","none found",null],["R0004150","CRD420261335230",null,"10.1002/edm2.70225","42007544","PMC13093900","Tirzepatide as Adjunct to Insulin in Adults With Type 1 Diabetes and Overweight or Obesity: A Systematic Review of Randomized and Real-World Evidence.","2026","Endocrinology, diabetes & metabolism","Acucella GA","22","15","8","PROSPERO","PROSPERO:CRD420261335230"],["R0004157",null,null,"10.1016/j.jacl.2024.03.011","38906751",null,"Sex, racial, ethnic, and geographical disparities in major adverse cardiovascular outcome of glucagon-like peptide-1 receptor agonists among patients with and without diabetes mellitus: A meta-analysis of placebo-controlled randomized controlled trials.","2024","Journal of clinical lipidology","Rivera FB","0","0","0","none found",null],["R0004161",null,null,"10.2147/dmso.s616418","42763732","PMC13589532","Efficacy and Safety of CagriSema for Metabolic Outcomes: Systematic Review and Pairwise Meta-Analysis of Randomized Controlled Trials.","2026","Diabetes, metabolic syndrome and obesity : targets and therapy","Shao C","32","25","18","none found",null],["R0004171",null,null,"10.1111/jgh.70084","41025363",null,"Efficacy of Incretin-Based Therapies in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.","2025","Journal of gastroenterology and hepatology","Liu L","77","42","28","none found",null],["R0004188","CRD420251107346",null,"10.1016/j.ophtha.2026.02.013","41692115",null,"Semaglutide and the Risk of Nonarteritic Ischemic Optic Neuropathy: A Systematic Review and Certainty of Evidence Meta-Analysis.","2026","Ophthalmology","Abdelaal A","37","18","1","PROSPERO","PROSPERO:CRD420251107346"],["R0004204",null,null,"10.1016/j.survophthal.2023.07.002","37454782",null,"GLP-1 receptor agonists and diabetic retinopathy: A meta-analysis of randomized clinical trials.","2023","Survey of ophthalmology","Kapoor I","120","13","3","none found",null],["R0004206",null,null,"10.1097/jw9.0000000000000143","38586157","PMC10997314","A meta-analysis of the incidence of acne vulgaris in patients treated with GLP-1 agonists.","2024","International journal of women's dermatology","Ogunremi OO","21","9","0","none found",null],["R0004219",null,null,"10.3390/ijms26136143","40649920","PMC12249713","New Perspectives in Modulating the Entero-Insular Axis in Pediatric Obesity.","2025","International journal of molecular sciences","Dira LM","99","22","11","none found",null],["R0004221",null,null,"10.1186/s40360-026-01149-5","42163419","PMC13371186","Effect of oral semaglutide on cardiometabolic risk factors in overweight and obese individuals with or without diabetes: a systematic review and meta-analysis.","2026","BMC pharmacology & toxicology","Seighali N","51","43","20","none found",null],["R0004228",null,null,"10.1016/j.jinf.2025.106645","41173399",null,"Association of glucagon-like peptide-1 receptor agonist use with risk of infections: A systematic review and meta-analysis.","2025","The Journal of infection","Han S","40","18","3","none found",null],["R0004236","CRD420251014401",null,"10.1007/s40618-026-03006-y","42560457","PMC13627233","Analysis of the efficacy and safety of liraglutide, semaglutide, and tirzepatide for the treatment of overweight and obesity: a systematic review and network meta-analysis.","2026","Journal of endocrinological investigation","Pałka W","45","26","23","PROSPERO","PROSPERO:CRD420251014401"],["R0004241",null,null,"10.1111/dom.15576","38558280",null,"Effect of combination pioglitazone with sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta-analysis, and real-world study from an international federated database.","2024","Diabetes, obesity & metabolism","Anson M","57","15","8","none found",null],["R0004243",null,null,"10.1097/md.0000000000049916","42499082","PMC13406235","Therapeutic role of semaglutide in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis of placebo-controlled trials with GRADE evidence assessment.","2026","Medicine","Khan S","36","15","10","none found",null],["R0004257",null,null,"10.1089/thy.2023.0530","38343381","PMC10998705","Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review.","2024","Thyroid : official journal of the American Thyroid Association","Espinosa De Ycaza AE","55","40","5","none found",null],["R0004258",null,null,"10.3389/fphar.2021.759262","35002700","PMC8741261","Comparative Cardio-Renal Outcomes of Type 2 Diabetes Patients Administered Glucagon-Like Peptide-1 Receptor Agonists: A Network Meta-Analysis.","2021","Frontiers in pharmacology","Zhuo C","44","23","11","none found",null],["R0004261",null,null,"10.1186/s13098-024-01497-4","39456002","PMC11515276","Effects of glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in high-risk type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.","2024","Diabetology & metabolic syndrome","Chen X","33","25","10","none found",null],["R0004274","CRD420251059430",null,"10.21203/rs.3.rs-10976576/v1",null,null,"Semaglutide and Suicidality in Adults with Overweight or Obesity: A Bayesian Meta-Analysis of Randomized Trials","2026","Research Square","Campos-Garcia F",null,"0","0","PROSPERO","PROSPERO:CRD420251059430"],["R0004281",null,null,"10.1124/pharmrev.123.001045","39952695",null,"Emerging pharmacotherapies for obesity: A systematic review.","2025","Pharmacological reviews","Kokkorakis M","155","65","26","none found",null],["R0004286","CRD42023409585",null,"10.1111/jebm.12620","38858300",null,"Comparation of fixed-ratio (IDegLira and iGlarLixi) versus free combination of basal insulin and glucagon-like peptide-1 receptor agonist for uncontrolled type 2 diabetes: A systematic review and network meta-analysis.","2024","Journal of evidence-based medicine","Weng J","24","14","2","PROSPERO","PROSPERO:CRD42023409585"],["R0004303",null,null,"10.1016/j.jaut.2025.103414","40174283",null,"Exploring glucagon-like peptide-1 receptor agonists as potential disease-modifying agents in autoimmune diseases.","2025","Journal of autoimmunity","Yang Y","56","35","3","none found",null],["R0004306",null,null,"10.1016/j.cpcardiol.2024.102403","38237815",null,"Safety and efficacy of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese non-diabetic patients.","2024","Current problems in cardiology","Singh S","28","18","11","none found",null],["R0004320",null,null,"10.3350/cmh.2022.0330","36907574","PMC10366812","Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis.","2023","Clinical and molecular hepatology","Park MJ","48","17","4","none found",null],["R0004327",null,null,"10.1016/j.obpill.2025.100162","39980735","PMC11840199","Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials.","2025","Obesity pillars","Guo H","33","17","0","none found",null],["R0004337",null,null,"10.1097/mao.0000000000004373","39666743",null,"GLP-1 Receptor Agonist Induced Eustachian Tube Dysfunction: Database and Systematic Review of Otolaryngologic Adverse Events.","2025","Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology","Pak KY","5","0","0","none found",null],["R0004340",null,null,"10.21203/rs.3.rs-9727771/v1",null,null,"Beyond Cardiology's Pillars: A Network Meta-Analysis Comparing the Recombinant Zoster Vaccine (Shingrix/RZV) with SGLT2 Inhibitors and GLP-1 Receptor Agonists for Prevention of Major Adverse Cardiovascular Events and Dementia in Adults Aged ≥50 Years","2026","Research Square","Ahmed A",null,"0","0","none found",null],["R0004342",null,null,"10.7759/cureus.66697","39262558","PMC11390157","Evaluating Cardiovascular Benefits of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) in Type 2 Diabetes Mellitus: A Systematic Review.","2024","Cureus","Sreenivasan C","29","22","6","none found",null],["R0004347",null,null,"10.1111/dom.15538","38449004",null,"Glucagon-like peptide-1 receptor agonists and mental health: A meta-analysis of randomized controlled trials.","2024","Diabetes, obesity & metabolism","Silverii GA","17","8","3","none found",null],["R0004362",null,null,"10.7759/cureus.71366","39534801","PMC11556413","Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","2024","Cureus","Njei B","71","48","24","none found",null],["R0004363",null,null,"10.4103/ijem.ijem_162_23","38107730","PMC10723608","Role of Novel Glucagon-like Peptide-1 Receptor Analogue Polyethylene Glycol Loxenatide in Type 2 Diabetes: A Systematic Review and Meta-analysis.","2023","Indian journal of endocrinology and metabolism","Dutta D","20","14","6","none found",null],["R0004364",null,null,"10.1111/dom.15588","38576082",null,"A comment on 'Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials'.","2024","Diabetes, obesity & metabolism","Goldenberg RM","6","3","2","none found",null],["R0004369","CRD420251229397",null,"10.1186/s40842-025-00270-4","41715239","PMC12922244","Efficacy and safety of orforglipron, an oral small-molecule GLP-1 receptor agonist, on cardiometabolic outcomes: a meta-analysis and systematic review.","2026","Cardiovascular diabetology. Endocrinology reports","Alper A","47","27","13","PROSPERO","PROSPERO:CRD420251229397"],["R0004385","CRD42021259661",null,"10.1007/s10557-022-07360-w","35819544",null,"Effects of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) on Cardiac Structure and Function: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.","2024","Cardiovascular drugs and therapy","Wong SY","56","30","21","PROSPERO","PROSPERO:CRD42021259661"],["R0004388",null,null,"10.1371/journal.pone.0278685","36696429","PMC9876280","Effect of glucagon-like peptide-1 receptor agonists on glycemic control, and weight reduction in adults: A multivariate meta-analysis.","2023","PloS one","Yeh TL","61","57","33","none found",null],["R0004390",null,null,"10.1007/s11695-026-08588-3","41954719",null,"Glucagon-Like Peptide-1 Receptor Agonists vs. Bariatric Endoscopy: A Systematic Review and Meta Analysis of Efficacy, Safety, and Metabolic Outcomes.","2026","Obesity surgery","Khan S","24","23","6","none found",null],["R0004401","CRD42023390735",null,"10.1016/j.pcd.2024.03.005","38555202",null,"Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis.","2024","Primary care diabetes","Fang L","44","15","4","PROSPERO","PROSPERO:CRD42023390735"],["R0004404",null,null,"10.1007/s10741-025-10523-0","40399552",null,"The effect of GLP-1 receptor agonists on cardiac remodeling in heart failure patients with preserved and reduced ejection fraction: a systematic review and meta-analysis.","2025","Heart failure reviews","Siddiqui HF","40","26","9","none found",null],["R0004424",null,null,"10.1186/s13098-024-01371-3","38877565","PMC11177512","Efficacy and safety of glucagon-like peptide-1 receptor agonists on prediabetes: a systematic review and meta-analysis of randomized controlled trials.","2024","Diabetology & metabolic syndrome","Salamah HM","51","24","10","none found",null],["R0004432",null,null,"10.1055/a-2569-7315","40409279",null,"Efficacy, Safety, and Future of GLP-1 Receptor Agonists: A Systematic Literature Review and Meta-Analysis.","2025","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","Katz G","47","35","15","none found",null],["R0004438",null,null,"10.1016/j.ejogrb.2025.114836","41313865",null,"Impact of semaglutide exposure on fetal and neonatal outcomes in pregnant women: a systematic review.","2026","European journal of obstetrics, gynecology, and reproductive biology","Mandal L","36","15","4","none found",null],["R0004439",null,null,"10.1155/jobe/3442754","40746703","PMC12313391","Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration.","2025","Journal of obesity","Khawaji A","39","27","15","none found",null],["R0004443",null,null,"10.1002/dmrr.3680","37356073",null,"Effects of treatment with Glucagon-like peptide-1 receptor agonist on prediabetes with overweight/obesity: A systematic review and meta-analysis.","2023","Diabetes/metabolism research and reviews","Wang W","41","23","15","none found",null],["R0004444",null,null,"10.2217/fca-2022-0093","36975720",null,"Effect of glucagon-like peptide-1 receptor agonists administration during coronary artery bypass grafting: a systematic review and meta-analysis of randomized control trials.","2023","Future cardiology","Watkins AR","0","0","0","none found",null],["R0004446",null,null,"10.1093/eurjpc/zwaf257","40294206",null,"Reduction of New Onset of Atrial Fibrillation in Patients Treated with Semaglutide: An updated systematic review and meta regression analysis of randomized controlled trials.","2025","European journal of preventive cardiology","Cesaro A","51","37","30","none found",null],["R0004448",null,null,"10.3390/nu17081303","40284168","PMC12029897","Effects of GLP-1 Analogues and Agonists on the Gut Microbiota: A Systematic Review.","2025","Nutrients","Gofron KK","64","40","3","none found",null],["R0004450",null,null,"10.7759/cureus.80932","40255755","PMC12009492","Comparative Cardiovascular and Renal Outcomes of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: A Systematic Review.","2025","Cureus","Khan HK","21","12","7","none found",null],["R0004455",null,null,"10.21203/rs.3.rs-9079798/v1",null,null,"Comparative Efficacy of Tirzepatide Versus GLP-1 Receptor Agonists on Glycaemic Control and Body Weight in Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis of Head-to-Head Randomised Controlled Trials","2026","Research Square","Khan OO",null,"0","0","none found",null],["R0004457",null,null,"10.1177/17474930241253988","38676552",null,"Glucagon-like peptide-1 receptor agonists and stroke: A systematic review and meta-analysis of cardiovascular outcome trials.","2024","International journal of stroke : official journal of the International Stroke Society","Adamou A","47","24","12","none found",null],["R0004466",null,null,"10.1016/j.bone.2024.117338","39603373",null,"Association of Glucagon-like peptide-1 receptor agonists use with fracture risk in type 2 diabetes: A meta-analysis of randomized controlled trials.","2025","Bone","Zhang Y","75","63","48","none found",null],["R0004471",null,null,"10.1016/j.jdiacomp.2024.108743","38688179",null,"Influence of glucagon-like peptide-1 receptor agonists on fat accumulation in patients with diabetes mellitus and non-alcoholic fatty liver disease or obesity: A systematic review and meta-analysis of randomized control trials.","2024","Journal of diabetes and its complications","Xie W","42","20","13","none found",null],["R0004481","CRD420251248437",null,"10.1097/jcp.0000000000002234","42503999",null,"Semaglutide and Other GLP-1 Agonists for Antipsychotic-Associated Metabolic Dysfunction in Schizophrenia: A Systematic Review and Meta-Analysis.","2026","Journal of clinical psychopharmacology","Abbas N","0","0","0","PROSPERO","PROSPERO:CRD420251248437"],["R0004483",null,null,"10.2337/db24-0688","39932725",null,"Comparison of the Effects of SGLT-2i Versus GLP-1RA on Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes, Based on Baseline Renal Function.","2025","Diabetes","Wang Y","0","0","0","none found",null],["R0004486",null,null,"10.1186/s12933-024-02192-4","38500154","PMC10949729","Effectiveness and safety of the combination of sodium-glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies.","2024","Cardiovascular diabetology","Ahmad A","75","53","13","none found",null],["R0004492","CRD42024538789",null,"10.1007/s12272-025-01552-2","40542285","PMC12241289","Evaluation of bone health and fracture risk in type 2 diabetes: a network meta-analysis of anti-diabetic treatments versus placebo.","2025","Archives of pharmacal research","Oh S","52","7","0","PROSPERO","PROSPERO:CRD42024538789"],["R0004494","CRD42024600250",null,"10.1016/j.eclinm.2025.103464","40926900","PMC12414836","Efficacy of lifestyle modification combined with GLP-1 receptor agonists on body weight and cardiometabolic biomarkers in individuals with overweight or obesity: a systematic review and meta-analysis.","2025","EClinicalMedicine","Chu J","64","50","32","PROSPERO","PROSPERO:CRD42024600250"],["R0004505",null,null,"10.1111/dom.16660","40726453","PMC12515783","Evaluating biased agonism of glucagon-like peptide-1 (GLP-1) receptors to improve cellular bioenergetics: A systematic review.","2025","Diabetes, obesity & metabolism","Wong S","35","22","3","none found",null],["R0004534","CRD420251276594",null,"10.3390/healthcare14070850","41975852","PMC13073533","Comparative Efficacy and Safety of Tirzepatide Versus Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.","2026","Healthcare (Basel, Switzerland)","Qazi S","23","18","6","PROSPERO","PROSPERO:CRD420251276594"],["R0004544",null,null,"10.61882/zwq4sh57","42234904",null,"Efficacy and Safety of Oral Antidiabetic Drugs in People with Diabetes and Chronic Kidney Disease: A Systematic Review.","2025","Iranian journal of kidney diseases","Borooghani H","0","0","0","none found",null],["R0004545",null,null,"10.4239/wjd.v16.i4.101731","40236848","PMC11947928","Reasons for discontinuing tirzepatide in randomized controlled trials: A systematic review and meta-analysis.","2025","World journal of diabetes","Kamrul-Hasan ABM","49","42","28","none found",null],["R0004552",null,null,"10.1002/hsr2.70490","39980820","PMC11839483","Association Between GLP1 RAs Use and Risk of Colorectal Cancer: A Systematic Review and Meta-Analysis.","2025","Health science reports","Bushi G","39","20","0","none found",null],["R0004578",null,null,"10.3892/br.2024.1913","39781043","PMC11704830","Semaglutide vs. dulaglutide for glycemic and weight control in patients with type 2 diabetes mellitus: A systematic review and meta‑analysis.","2025","Biomedical reports","Xia L","24","15","5","none found",null],["R0004600","CRD42023418166",null,"10.1155/2024/1785321","39309475","PMC11416174","Effects of Glucagon-Like Peptide-1 Receptor Agonists on Bone Metabolism in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.","2024","International journal of endocrinology","Li X","30","19","8","PROSPERO","PROSPERO:CRD42023418166"],["R0004605","CRD42025631539",null,"10.1136/heartjnl-2026-327872","42571647",null,"Effects of pharmacological blood pressure lowering in heart failure with mildly reduced or preserved ejection fraction: a meta-analysis.","2026","Heart (British Cardiac Society)","Pack SJJ","0","0","0","PROSPERO","PROSPERO:CRD42025631539"],["R0004609",null,null,"10.3760/cma.j.cn112137-20250416-00945","41218895",null,"[A meta-analysis of efficacy and safety of anti-obesity medications in the treatment of childhood obesity].","2025","Zhonghua yi xue za zhi","Zhou XL","0","0","0","none found",null],["R0004615","CRD42023476762",null,"10.1016/j.phrs.2024.107401","39251099",null,"Glucagon-like peptide-1 receptor agonists and risk of gastrointestinal cancers: A systematic review and meta-analysis of randomized controlled trials.","2024","Pharmacological research","Figlioli G","42","28","3","PROSPERO","PROSPERO:CRD42023476762"],["R0004616","CRD42022325948",null,"10.1136/bmj-2024-083039","40813122",null,"Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis.","2025","BMJ (Clinical research ed.)","Nong K","51","12","1","PROSPERO","PROSPERO:CRD42022325948"],["R0004619",null,null,"10.1111/cts.70127","39930946","PMC11811509","Once-Weekly Semaglutide Versus Once-Daily Liraglutide for Weight Loss in Adults: A Meta-Analysis of Randomized Controlled Trials.","2025","Clinical and translational science","Hashmi TM","25","19","4","none found",null],["R0004622","CRD42023472186",null,"10.1093/jcag/gwae057","40224572","PMC11991874","Effects of GLP-1 receptor agonist therapy on resolution of steatohepatitis in non-alcoholic fatty liver disease: a systematic review and meta-analysis.","2025","Journal of the Canadian Association of Gastroenterology","Potter KJ","39","25","6","PROSPERO","PROSPERO:CRD42023472186"],["R0004629",null,null,"10.1507/endocrj.ej23-0384","38644220",null,"Efficacy and safety of glucagon-like peptide-1 receptor agonists in the elderly versus non-elderly patients with type 2 diabetes mellitus: insights from a systematic review.","2024","Endocrine journal","Wang Y","53","30","15","none found",null],["R0004632",null,null,"10.3390/jcm13195786","39407846","PMC11476433","Antidiabetic Treatment and Prevention of Ischemic Stroke: A Systematic Review.","2024","Journal of clinical medicine","Prentza V","71","25","17","none found",null],["R0004634",null,null,"10.1097/crd.0000000000001057","40968407",null,"Efficacy and Safety of Semaglutide on Cardiovascular Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","2025","Cardiology in review","Bacha Z","37","21","8","none found",null],["R0004640",null,null,"10.1001/jamapsychiatry.2025.0679","40366681","PMC12079569","Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis.","2025","JAMA psychiatry","Pierret ACS","114","103","77","none found",null],["R0004645",null,null,"10.1111/dom.15043","36864658",null,"Effects of glucagon-like peptide-1 receptor agonists on major coronary events in patients with type 2 diabetes.","2023","Diabetes, obesity & metabolism","Guo X","44","33","12","none found",null],["R0004649",null,null,"10.1371/journal.pone.0270899","35797355","PMC9262225","The effects of glucagon-like peptide-1 receptor agonists on adipose tissues in patients with type 2 diabetes: A meta-analysis of randomised controlled trials.","2022","PloS one","Liu F","46","17","12","none found",null],["R0004650",null,null,"10.1111/dom.70666","41877354",null,"Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.","2026","Diabetes, obesity & metabolism","Eisa N","49","18","15","none found",null],["R0004656","CRD420251068833",null,"10.1007/s00228-025-03899-3","40788386",null,"The correlation between novel antidiabetic agents utilization and hepatocellular carcinoma incidence in type 2 diabetes patients: a network meta-analysis.","2025","European journal of clinical pharmacology","Lin J","71","13","0","PROSPERO","PROSPERO:CRD420251068833"],["R0004668","CRD42023473991",null,"10.1007/s11695-024-07175-8","38502519",null,"Glucagon-Like Peptide-1 Receptor Agonists in Post-bariatric Surgery Patients: A Systematic Review and Meta-analysis.","2024","Obesity surgery","Dutta D","28","22","9","PROSPERO","PROSPERO:CRD42023473991"],["R0004669",null,null,"10.1016/j.ajcnut.2023.04.017","37661106",null,"The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials.","2023","The American journal of clinical nutrition","Liu Y","68","44","42","none found",null],["R0004673",null,null,"10.3390/biomedicines11030669","36979648","PMC10045529","Effect of Glucagon-like Peptide-1 Receptor Agonists on Cardio-Metabolic Risk Factors among Obese/Overweight Individuals Treated with Antipsychotic Drug Classes: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.","2023","Biomedicines","Patoulias D","44","22","6","none found",null],["R0004680",null,null,"10.1016/j.dld.2025.03.002","40133086",null,"Glucagon-like peptide-1 receptor agonists increase the risk of residual gastric content and pulmonary aspiration on upper endoscopy: A meta-analysis.","2025","Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver","Tan Y","69","26","2","none found",null],["R0004686",null,null,"10.1002/oby.24002","38413012",null,"Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis.","2024","Obesity (Silver Spring, Md.)","Pan XH","100","26","14","none found",null],["R0004693",null,null,"10.1186/s13098-025-01635-6","39994802","PMC11849334","Safety, efficacy, and cardiovascular benefits of combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists in patients with diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.","2025","Diabetology & metabolic syndrome","Mousavi A","66","52","30","none found",null],["R0004705",null,null,"10.1016/j.jdiacomp.2023.108529","37301063",null,"Effect of semaglutide versus other glucagon-like peptide-1 receptor agonists on cardio-metabolic risk factors in patients with type 2 diabetes: A systematic review and meta-analysis of head-to-head, phase 3, randomized controlled trials.","2023","Journal of diabetes and its complications","Patoulias D","39","34","8","none found",null],["R0004736","CRD420251055134",null,"10.3389/fonc.2026.1751628","41858365","PMC12995638","Pharmacotherapy agents in prevention and treatment of breast cancer-related lymphedema: a systematic scoping review.","2026","Frontiers in oncology","Lommer C","45","3","0","PROSPERO","PROSPERO:CRD420251055134"],["R0004738",null,null,"10.20944/preprints202604.1938.v1",null,null,"Appetite Dysregulation as a Driver of Weight Regain After GLP-1 Receptor Agonist-Induced Weight Loss: A Systematic Review","2026","Preprints.org","Mısırlıoğlu PE",null,"0","0","none found",null],["R0004742",null,null,"10.22541/au.174919687.75586804/v1",null,null,"Efficacy of Liraglutide on Metabolic and Reproductive Outcomes in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis","2025","Authorea Preprints","Lu Y",null,"0","0","none found",null],["R0004750",null,null,"10.1002/cpt.70315","42104724","PMC13339527","A Systematic Review on Disease-Modifying Therapies in Parkinsonian Disorders.","2026","Clinical pharmacology and therapeutics","Eijsvogel PPNM","147","9","6","none found",null],["R0004751",null,null,"10.4093/dmj.2024.0660","40300775","PMC12620703","Initial Pharmacological Strategies in People with Early Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-Analysis.","2025","Diabetes & metabolism journal","Choi JH","9","2","0","none found",null],["R0004752",null,null,"10.1002/oby.70100","41326176","PMC13032060","Comparative Efficacy of Metabolic/Bariatric Surgery Versus GLP-1 Receptor Agonists: A Network Meta-Analysis of Randomized Controlled Trials.","2026","Obesity (Silver Spring, Md.)","Sabatella L","58","34","18","none found",null],["R0004779",null,null,"10.1016/j.medj.2025.100959","41610839",null,"Divergent effect of diabetes on fibrosis response to semaglutide and resmetirom in noncirrhotic MASH: A meta-analysis of randomized trials.","2026","Med (New York, N.Y.)","Musso G","56","8","3","none found",null],["R0004783",null,null,"10.3390/ijms25094972","38732190","PMC11084700","A Systematic Review of Semaglutide's Influence on Cognitive Function in Preclinical Animal Models and Cell-Line Studies.","2024","International journal of molecular sciences","Tipa RO","70","45","3","none found",null],["R0004791",null,null,"10.3389/fendo.2023.1170881","37342259","PMC10277636","Comparing the effectiveness of long-term use of daily and weekly glucagon-like peptide-1 receptor agonists treatments in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus: a network meta-analysis.","2023","Frontiers in endocrinology","Yuan X","42","29","18","none found",null],["R0004795","CRD42023410345",null,"10.1155/2024/8145388","39072050","PMC11283333","Comparison of GLP-1 Receptor Agonists, SGLT-2 Inhibitors, and DPP-4 Inhibitors as an Add-On Drug to Insulin Combined With Oral Hypoglycemic Drugs: Umbrella Review.","2024","Journal of diabetes research","Chai S","28","9","0","PROSPERO","PROSPERO:CRD42023410345"],["R0004805","CRD42021226231",null,"10.1016/j.clinthera.2022.12.006","36604209",null,"Effect of Glucagon-like Peptide-1 Receptor Agonists on Prognosis of Heart Failure and Cardiac Function: A Systematic Review and Meta-analysis of Randomized Controlled Trials.","2023","Clinical therapeutics","Huixing L","49","39","24","PROSPERO","PROSPERO:CRD42021226231"],["R0004811",null,null,"10.1111/dom.71031","42337824","PMC13448877","Efficacy and Safety of GLP-1 Receptor Agonists on Combined Cardiovascular and Renal Outcomes in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis.","2026","Diabetes, obesity & metabolism","Kaur R","30","22","16","none found",null],["R0004824",null,null,"10.1080/13813455.2024.2380422","39084250",null,"Efficacy and safety of glucagon-like peptide-1 receptor agonists in the treatment of polycystic ovary syndrome-A systematic review and meta-analysis.","2024","Archives of physiology and biochemistry","Tong X","47","29","9","none found",null],["R0004831",null,null,"10.1111/dom.70201","41104525",null,"Effects of GLP-1 receptor agonists on cognitive function in patients with type 2 diabetes: A systematic review and meta-analysis based on randomized controlled trials.","2026","Diabetes, obesity & metabolism","Wan S","57","27","6","none found",null],["R0004848",null,null,"10.1111/jdi.14015","37147888","PMC10286783","Cognitive protection of incretin-based therapies in patients with type 2 diabetes mellitus: A systematic review and meta-analysis based on clinical studies.","2023","Journal of diabetes investigation","Chai S","52","20","6","none found",null],["R0004850",null,null,"10.7759/cureus.93284","41146812","PMC12554296","Mechanistic Insights Into the Cardioprotective Effects of Modern Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review.","2025","Cureus","Ratnala M","24","9","2","none found",null],["R0004857",null,null,"10.3390/jcm13216292","39518431","PMC11547001","The Therapeutic Potential of GLP-1 Receptor Agonists in the Management of Hidradenitis Suppurativa: A Systematic Review of Anti-Inflammatory and Metabolic Effects.","2024","Journal of clinical medicine","Krajewski PK","82","36","2","none found",null],["R0004859",null,null,"10.3389/fmed.2025.1509947","40051726","PMC11882565","Gastrointestinal adverse events associated with GLP-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis.","2025","Frontiers in medicine","Huang X","44","32","16","none found",null],["R0004868",null,null,"10.14740/cr1600","38464707","PMC10923257","Pulse of Progress: A Systematic Review of Glucagon-Like Peptide-1 Receptor Agonists in Cardiovascular Health.","2024","Cardiology research","Sabina M","31","31","26","none found",null],["R0004870",null,null,"10.1016/j.diabet.2025.101664","40383371",null,"What the diabetologist needs to know about the risk of non-arteritic anterior ischaemic optic neuropathy and GLP-1 receptor agonist use in patients with type 2 diabetes.","2025","Diabetes & metabolism","Feldman-Billard S","15","13","2","none found",null],["R0004877",null,null,"10.1007/s12325-021-01637-6","33582976","PMC7932945","Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Network Meta-analysis.","2021","Advances in therapy","Jiang Y","17","7","1","none found",null],["R0004895",null,null,"10.1002/phar.70014","40152479",null,"Updates in chronic kidney disease management: A systematic review.","2025","Pharmacotherapy","Ammar A","135","38","13","none found",null],["R0004899","CRD42023418551",null,"10.1111/dom.15342","37860884",null,"Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis.","2024","Diabetes, obesity & metabolism","Yang Y","46","28","10","PROSPERO","PROSPERO:CRD42023418551"],["R0004905",null,null,"10.1111/dom.70454","41508745",null,"GLP1-1RAs improve walking distance and reduce amputation in people with type 2 diabetes and peripheral artery disease: A systematic review and meta-analysis of randomised controlled trials and cohort studies.","2026","Diabetes, obesity & metabolism","Giugliano D","44","18","7","none found",null],["R0004910","CRD42024623312",null,"10.1136/bmjopen-2024-098205","41371743","PMC12699605","Effects of glucagon-like peptide-1 analogues on hard binary outcomes for patients at increased risk of cardiovascular events: a protocol for a systematic review with network meta-analysis and Trial Sequential Analysis.","2025","BMJ open","Sillassen CDB","61","14","3","PROSPERO","PROSPERO:CRD42024623312"],["R0004920",null,null,"10.1111/obr.13686","38204284",null,"The effects of incretin-based therapies on weight reduction and metabolic parameters in children with obesity: A systematic review and meta-analysis.","2024","Obesity reviews : an official journal of the International Association for the Study of Obesity","Wang JY","47","19","14","none found",null],["R0004924",null,null,"10.1002/osp4.743","38414573","PMC10896246","Orforglipron, a novel non-peptide oral daily glucagon-like peptide-1 receptor agonist as an anti-obesity medicine: A systematic review and meta-analysis.","2024","Obesity science & practice","Dutta D","25","16","11","none found",null],["R0004929",null,null,"10.1111/dom.15557","38528818",null,"The effect of glucagon-like peptide-1 receptor agonists on cardiac function and structure in patients with or without type 2 diabetes mellitus: An updated systematic review and meta-analysis.","2024","Diabetes, obesity & metabolism","Zhang Y","48","33","23","none found",null],["R0004945",null,null,"10.22541/au.175641359.91480737/v1",null,null,"The Hidden Costs of GLP-1 Agonists: A Meta-Analysis of Sarcopenia, Psychiatric Risks, and Long-Term Health Implications","2025","Authorea Preprints","Chtatbi A",null,"0","0","none found",null],["R0004957",null,null,"10.1111/dom.70773","42050884","PMC13243967","Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity.","2026","Diabetes, obesity & metabolism","Ciudin A","28","19","9","none found",null],["R0004959",null,null,"10.1097/md.0000000000046671","41465949","PMC12746972","Gastrointestinal side effects of the non-peptide GLP-1 receptor agonists: A systematic review and meta-analysis.","2025","Medicine","Bhattarai HB","27","21","10","none found",null],["R0004960",null,null,"10.1001/jamapediatrics.2025.3243","40952752","PMC12439189","Efficacy and Safety of GLP-1 RAs in Children and Adolescents With Obesity or Type 2 Diabetes: A Systematic Review and Meta-Analysis.","2025","JAMA pediatrics","Kotecha P","44","33","16","none found",null],["R0004961",null,null,"10.1186/s13098-025-01730-8","40410888","PMC12102854","Expanding therapeutic horizons: glucagon-like peptide-1 receptor agonists and sodium glucose transporter-2 inhibitors in poly cystic ovarian syndrome: a comprehensive review including systematic review and network meta-analysis of randomized clinical trials.","2025","Diabetology & metabolic syndrome","Sridharan K","74","52","22","none found",null],["R0004962",null,null,"10.7759/cureus.111641","42524101","PMC13409016","A Systematic Review and Meta-Analysis Evaluating the Role of GLP-1 Receptor Agonists in Substance Use Disorders.","2026","Cureus","Sarma I","25","14","5","none found",null],["R0004964",null,null,"10.1186/s13098-025-01995-z","41286982","PMC12642090","The impact of semaglutide on liver outcomes in patients with or at risk of MASH: a dose and duration response meta-analysis of randomized trials.","2025","Diabetology & metabolic syndrome","Kan R","53","33","24","none found",null],["R0004990",null,null,"10.1097/md.0000000000035739","37904378","PMC10615555","Effect of long-acting versus short-acting glucagon-like peptide-1 receptor agonists on improving body weight and related metabolic parameters in type 2 diabetes: A head-to-head meta-analysis.","2023","Medicine","Yuan X","27","13","7","none found",null],["R0005011","CRD42020173199",null,"10.1055/a-1844-1176","35512849",null,"The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis.","2022","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","Guo X","38","31","20","PROSPERO","PROSPERO:CRD42020173199"],["R0005013",null,null,"10.1016/j.metabol.2023.155710","37852529",null,"Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials.","2023","Metabolism: clinical and experimental","Karakasis P","53","32","12","none found",null],["R0005022",null,null,"10.1111/liv.70643","41999054","PMC13090617","Effects of GLP-1 Receptor Agonists on Muscle Mass, Strength, and Quality in MASLD: A Systematic Review.","2026","Liver international : official journal of the International Association for the Study of the Liver","Iorra F","52","26","10","none found",null],["R0005028",null,null,"10.1111/dom.71128","42530338","PMC13538750","Effect of Medications for Type 2 Diabetes on Cardiovascular Events and Mortality: A Comprehensive Pairwise and Network Meta-Analysis.","2026","Diabetes, obesity & metabolism","Silverii GA","35","13","4","none found",null],["R0005033","CRD42022332339",null,"10.1007/s40264-023-01392-3","38273155","PMC11018670","Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review.","2024","Drug safety","Calvarysky B","44","27","7","PROSPERO","PROSPERO:CRD42022332339"],["R0005038",null,null,"10.1016/j.eprac.2024.11.013","39638244",null,"Dose-Response Relationship of Glucagon-like Peptide-1 Receptor Agonists on HbA1c and Body Weight in Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-Analysis.","2025","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Chen QQ","40","13","4","none found",null],["R0005046","CRD42024562853",null,"10.1080/20018525.2025.2484048","40144943","PMC11938315","Safety and efficacy of glucagon-like peptide-1 receptor agonists in patients with obstructive sleep apnea: a systematic review and meta-analysis of randomized controlled trials.","2025","European clinical respiratory journal","Altobaishat O","48","17","4","PROSPERO","PROSPERO:CRD42024562853"],["R0005055",null,null,"10.14715/cmb/2023.69.4.13","37329543",null,"Clinical Efficacy of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Meta-analysis.","2023","Cellular and molecular biology (Noisy-le-Grand, France)","Shi L","0","0","0","none found",null],["R0005060",null,null,"10.3389/fphar.2022.838277","35185588","PMC8854770","The Efficacy and Safety of the Combination Therapy With GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis.","2022","Frontiers in pharmacology","Li C","42","31","7","none found",null],["R0005064",null,null,"10.4239/wjd.v15.i10.2135","39493569","PMC11525725","Combining GLP-1 receptor agonists and SGLT-2 inhibitors for cardiovascular disease prevention in type 2 diabetes: A systematic review with multiple network meta-regressions.","2024","World journal of diabetes","Zhu JJ","47","20","11","none found",null],["R0005068",null,null,"10.23736/s2724-6507.20.03219-8","32720500",null,"Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials.","2023","Minerva endocrinology","Nreu B","65","59","44","none found",null],["R0005071",null,null,"10.1093/eurheartj/ehag021","41603358","PMC13268693","Non-antiarrhythmic pharmacotherapy in cardio-renal-metabolic disease and incident atrial fibrillation: a trial meta-analysis.","2026","European heart journal","Raveendra K","36","4","1","none found",null],["R0005075",null,null,"10.1093/ndt/gfaf193","40982219","PMC13037467","The effect of GLP-1 receptor agonists on renal outcomes: a systematic review and meta-analysis.","2026","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","Sasaki T","32","27","19","none found",null],["R0005091",null,null,"10.1007/s11695-025-07856-y","40237975",null,"Efficacy and Safety of GLP- 1 Receptor Agonists in the Management of Weight Recurrence or Suboptimal Clinical Response after Undergoing Metabolic Bariatric Surgeries: A Meta-Analysis.","2025","Obesity surgery","Arrowaili A","62","31","13","none found",null],["R0005095",null,null,"10.1097/ms9.0000000000005353","42583410","PMC13461105","Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.","2026","Annals of medicine and surgery (2012)","Yaseen M","22","11","5","none found",null],["R0005116","CRD42024576314",null,"10.2147/dmso.s537229","40821754","PMC12357579","Comparative Safety of GLP-1/GIP Co-Agonists Versus GLP-1 Receptor Agonists for Weight Loss in Patients with Obesity or Overweight: A Systematic Review.","2025","Diabetes, metabolic syndrome and obesity : targets and therapy","Xie Z","36","32","24","PROSPERO","PROSPERO:CRD42024576314"],["R0005121",null,null,"10.1111/dom.16078","39568391",null,"One or two? Comparison of the cardiorenal effects between combination therapy and monotherapy with SGLT2i or GLP1RA.","2025","Diabetes, obesity & metabolism","Zhang M","60","14","3","none found",null],["R0005125","CRD420261323497",null,"10.21203/rs.3.rs-9973131/v1",null,null,"DXA-Measured Body Composition Effects of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Adults with Obesity or Type 2 Diabetes: A Systematic Review and Meta-Analysis of Phase 3 Randomized Trials","2026","Research Square","Alaycı B",null,"0","0","PROSPERO","PROSPERO:CRD420261323497"],["R0005130",null,null,"10.1016/j.eprac.2023.11.007","38029929",null,"Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis.","2024","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Ansari HUH","55","43","25","none found",null],["R0005154",null,null,"10.7759/cureus.95938","41341350","PMC12670982","Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis.","2025","Cureus","Mohamed Ali Elbashir R","22","21","16","none found",null],["R0005163",null,null,"10.1111/dom.70667","41834765",null,"Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.","2026","Diabetes, obesity & metabolism","Ahmed M","21","10","8","none found",null],["R0005164","CRD420251027809",null,"10.1016/j.eclinm.2025.103408","41054439","PMC12496209","Evaluation of safety of preoperative GLP-1 receptor agonists in patients undergoing elective surgery: a systematic review, meta-analysis and meta-regression.","2025","EClinicalMedicine","Kamarajah SK","60","32","6","PROSPERO","PROSPERO:CRD420251027809"],["R0005172","CRD42023426190",null,"10.1093/ckj/sfae018","38410684","PMC10896177","Safety and efficacy of glucagon-like peptide-1 receptor agonists among kidney transplant recipients: a systematic review and meta-analysis.","2024","Clinical kidney journal","Krisanapan P","59","33","12","PROSPERO","PROSPERO:CRD42023426190"],["R0005177","CRD42022347233",null,"10.3389/fendo.2024.1289643","38348420","PMC10860745","First-line treatment with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in type 2 diabetic population at low risk of cardiovascular disease: a meta-analysis.","2024","Frontiers in endocrinology","Deng R","39","18","10","PROSPERO","PROSPERO:CRD42022347233"],["R0005198",null,null,"10.1001/jamapediatrics.2026.2248","42329656","PMC13288192","Obesity Management Pharmacotherapies and Lifestyle Treatment for Pediatric Obesity Management: A Systematic Review and Network Meta-Analysis.","2026","JAMA pediatrics","Wan KW","107","22","10","none found",null],["R0005208",null,null,"10.1111/obr.70189","42444070","PMC13460723","Comparative Efficacy of GLP-1 Receptor Agonists, Exercise, and Their Combination on Body Composition and Glucolipid Metabolism in Adults With Overweight or Obesity: A Network Meta-Analysis of Randomized Controlled Trials.","2026","Obesity reviews : an official journal of the International Association for the Study of Obesity","Vandoni M","53","19","6","none found",null],["R0005211",null,null,"10.3389/fphar.2023.1205207","37771725","PMC10525376","Glucagon-like peptide 1 (GLP-1) receptor agonists in experimental Alzheimer's disease models: a systematic review and meta-analysis of preclinical studies.","2023","Frontiers in pharmacology","Kong F","179","59","3","none found",null],["R0005212",null,null,"10.1111/dom.16147","39723481","PMC12135018","Assessing the benefit-risk profile of newer glucose-lowering drugs: A systematic review and network meta-analysis of randomized outcome trials.","2025","Diabetes, obesity & metabolism","Tang H","68","30","9","none found",null],["R0005215",null,null,"10.1007/s40200-026-01887-7","41743894","PMC12929769","Enteroendocrine hormones and gut microbiota in obesity: a systematic review from mechanistic insight to precision metabolic care.","2026","Journal of diabetes and metabolic disorders","Jayathilaka NS","0","0","0","none found",null],["R0005228",null,null,"10.1002/dmrr.70077","40847599",null,"Advancements in Pharmacotherapy for Diabetic Kidney Disease: A Systematic Review.","2025","Diabetes/metabolism research and reviews","Zhang H","125","9","5","none found",null],["R0005237",null,null,"10.20944/preprints202410.0929.v1",null,null,"SGLT2 Inhibitors vs. GLP-1 Receptor Agonists in Reducing Heart Failure Hospitalizations in Type-2 Diabetes. A Systematic Review and Meta-Analysis","2024","Preprints.org","Asifa F",null,"0","0","none found",null],["R0005238",null,null,"10.22541/au.175023393.36965849/v1",null,null,"Impact of Semaglutide Exposure on Neonatal Outcomes in Pregnant Women: A Systematic Review","2025","Authorea Preprints","Hansen LMH",null,"0","0","none found",null],["R0005242",null,null,"10.1093/asjof/ojaf056","40626110","PMC12232544","\"Ozempic Face\" in Plastic Surgery: A Systematic Review of the Literature on GLP-1 Receptor Agonist Mediated Weight Loss and Analysis of Public Perceptions.","2025","Aesthetic surgery journal. Open forum","Daneshgaran G","33","30","4","none found",null],["R0005250","CRD42024532600",null,"10.1186/s40001-025-03445-y","41287008","PMC12642067","Comparative efficacy of multiple drugs for non-alcoholic fatty liver disease: a Bayesian network meta-analysis.","2025","European journal of medical research","Xiao Z","77","7","6","PROSPERO","PROSPERO:CRD42024532600"],["R0005266","CRD42020188247",null,"10.1097/md.0000000000032312","36637917","PMC9839209","Effects of GLP-1 on ovarian dysfunction in polycystic ovary syndrome: A protocol for systematic review and meta-analysis.","2023","Medicine","Zhang C","19","5","0","PROSPERO","PROSPERO:CRD42020188247"],["R0005286",null,null,"10.1016/j.clinre.2026.102784","41679467",null,"Effect of common diabetes medications on metabolic dysfunction-associated steatotic liver disease as measured by transient elastography and other metabolic parameters: A systematic review.","2026","Clinics and research in hepatology and gastroenterology","Thompson K","57","8","7","none found",null],["R0005296",null,null,"10.7759/cureus.73705","39568487","PMC11578637","Long-Term Cardiovascular Outcomes of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Type 2 Diabetes: A Systematic Review.","2024","Cureus","Tariq S","42","36","14","none found",null],["R0005302",null,null,"10.1101/2025.09.01.25334855",null,null,"Comparative Efficacy and Safety of GLP-1 Receptor Agonists in Neurological and Nephrological Outcomes of Type 2 Diabetes: A Systematic Review and Network Meta-Analysis","2025","medRxiv","Ramteke HD",null,"0","0","none found",null],["R0005309",null,null,"10.7759/cureus.114454","42732434","PMC13570719","Comparative Efficacy and Safety of Tirzepatide Versus Semaglutide for Obesity: A Systematic Review.","2026","Cureus","Mohamed Abdalla SA","27","22","14","none found",null],["R0005323","CRD42025645378",null,"10.3390/jcm15176818","42739822","PMC13566191","The Impact of Glucagon-like Peptide-1 (GLP-1) Receptor Agonists on Body Composition in Individuals with Overweight and Obesity: A Systematic Review and Meta-Analysis.","2026","Journal of clinical medicine","Woźniak M","26","16","6","PROSPERO","PROSPERO:CRD42025645378"],["R0005333",null,null,"10.3390/biomedicines13051128","40426955","PMC12108654","GLP-1R Agonists and Their Therapeutic Potential in Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases, a Systematic Review of the Literature.","2025","Biomedicines","Thin L","58","36","5","none found",null],["R0005342","CRD42022331547",null,"10.1210/clinem/dgad076","36800286",null,"GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","2023","The Journal of clinical endocrinology and metabolism","Banerjee M","59","40","32","PROSPERO","PROSPERO:CRD42022331547"],["R0005344","CRD42018115577",null,"10.1016/j.numecd.2020.03.013","32448716",null,"Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials.","2020","Nutrition, metabolism, and cardiovascular diseases : NMCD","Nreu B","66","63","40","PROSPERO","PROSPERO:CRD42018115577"],["R0005357",null,null,"10.1016/j.soard.2026.06.012","42442963",null,"The long-term cardiovascular benefits of metabolic and bariatric surgery versus pharmacological therapies in patients with type 2 diabetes and obesity: a systematic review and meta-analysis.","2026","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","Tong J","54","18","7","none found",null],["R0005363",null,null,"10.1016/j.cpcardiol.2024.102721","38908729",null,"Semaglutide and heart failure: Updated meta-analysis.","2024","Current problems in cardiology","Barbagelata L","32","18","9","none found",null],["R0005371","CRD420251128528",null,"10.22541/au.176361875.58584436/v1",null,null,"Cagrilintide–Semaglutide Combination Therapy Versus Monotherapy or Placebo: A Systematic Review and Meta-Analysis","2025","Authorea Preprints","Laguna MAS",null,"0","0","PROSPERO","PROSPERO:CRD420251128528"],["R0005372",null,null,"10.3389/fendo.2026.1883559","42558249","PMC13437389","Metabolic dysfunction, antidiabetic drugs, and asthma: bibliometric evidence, emerging trends, and translational frontiers from 2006 to 2025.","2026","Frontiers in endocrinology","Jiang R","70","12","0","none found",null],["R0005379",null,null,"10.1016/j.numecd.2026.104859","42469143",null,"Coronary artery disease -related outcomes associated with semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis.","2026","Nutrition, metabolism, and cardiovascular diseases : NMCD","Zhou XY","86","68","47","none found",null],["R0005382",null,null,"10.1097/md.0000000000038236","38787986","PMC11124640","Gastrointestinal safety evaluation of semaglutide for the treatment of type 2 diabetes mellitus: A meta-analysis.","2024","Medicine","Huang X","51","40","20","none found",null],["R0005385",null,null,"10.1093/jsxmed/qdag272","42704281",null,"Treatment strategies for functional hypogonadism in obese men: a systematic review and network meta-analysis.","2026","The journal of sexual medicine","Yang L","58","7","2","none found",null],["R0005396","CRD42025646185",null,"10.1016/j.eclinm.2025.103680","41399474","PMC12702299","Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis.","2025","EClinicalMedicine","Tzang CC","45","40","19","PROSPERO","PROSPERO:CRD42025646185"],["R0005397",null,null,"10.3892/etm.2023.12054","37324512","PMC10265718","Therapeutic management of atypical antipsychotic‑related metabolic dysfunctions using GLP‑1 receptor agonists: A systematic review.","2023","Experimental and therapeutic medicine","Vasiliu O","58","34","13","none found",null],["R0005398","CRD42024539634",null,"10.1111/dom.70698","41872986",null,"GLP-1 Receptor/Dual Agonists for Weight Loss: A Systematic Review and Network Meta-Analysis of RCTs.","2026","Diabetes, obesity & metabolism","Vienghirun J","0","0","0","PROSPERO","PROSPERO:CRD42024539634"],["R0005405",null,null,"10.1093/asj/sjad240","37493261",null,"The Emerging Role of Injectable Weight Loss Medications in Plastic Surgery: A Systematic Review.","2023","Aesthetic surgery journal","Shridharani SM","43","17","13","none found",null],["R0005421",null,null,"10.1016/j.metabol.2024.156043","39357599",null,"Comparative efficacy of THR-β agonists, FGF-21 analogues, GLP-1R agonists, GLP-1-based polyagonists, and Pan-PPAR agonists for MASLD: A systematic review and network meta-analysis.","2024","Metabolism: clinical and experimental","Lin RT","60","16","10","none found",null],["R0005423",null,null,"10.1186/s12902-025-01985-2","40665260","PMC12265122","The effects of non-insulin anti-diabetic medications on the diabetic microvascular complications: a systematic review and meta-analysis of randomized clinical trials.","2025","BMC endocrine disorders","Wen S","69","13","6","none found",null],["R0005444",null,null,"10.2147/vhrm.s578698","41953528","PMC13054715","Clinical Advances in Heart Failure with Preserved Ejection Fraction: A Systematic Review of Therapeutic and Mechanistic Evidence.","2026","Vascular health and risk management","Parizad R","102","5","3","none found",null],["R0005465",null,null,"10.1007/s40200-026-01942-3","42180166","PMC13190888","Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis.","2026","Journal of diabetes and metabolic disorders","Rao H","0","0","0","none found",null],["R0005471",null,null,"10.1007/s11739-026-04363-5","42091826","PMC13263266","Venous thromboembolism with modern glucose-lowering agents in diabetes: active-comparator evidence beyond placebo-based meta-analyses.","2026","Internal and emergency medicine","Boccatonda A","32","9","1","none found",null],["R0005472",null,null,"10.1111/dom.14776","35589615","PMC9541913","Effect of glucagon-like peptide 1 receptor agonists on albuminuria in adult patients with type 2 diabetes mellitus: A systematic review and meta-analysis.","2022","Diabetes, obesity & metabolism","Yuan D","49","38","26","none found",null],["R0005488",null,null,"10.1177/03000605231177191","37317834","PMC10278420","PPAR-alpha/gamma agonists, glucagon-like peptide-1 receptor agonists and metformin for non-alcoholic fatty liver disease: A network meta-analysis.","2023","The Journal of international medical research","Zhang ZY","57","16","8","none found",null],["R0005489",null,null,"10.1016/j.ajpc.2024.100679","38779187","PMC11108827","Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials.","2024","American journal of preventive cardiology","Rivera FB","43","28","14","none found",null],["R0005492",null,null,"10.1017/s1092852926100844","41607204","PMC13076071","Investigating the functional connectivity between central glucagon-like peptide-1 (GLP-1) and glutamatergic signaling: a systematic review.","2026","CNS spectrums","Wong S","61","36","0","none found",null],["R0005515","CRD42025100858",null,"10.1016/j.ejphar.2025.177953","40675357",null,"Impact of semaglutide on lipid profiles in overweight and obese non-diabetic adults: A systematic review and meta-analysis of randomized controlled trials.","2025","European journal of pharmacology","Miranda S","23","12","6","PROSPERO","PROSPERO:CRD42025100858"],["R0005519",null,null,"10.1007/s12325-024-02959-x","39141282",null,"Effects of Glucagon-Like Peptide 1 Receptor Agonists on Atrial Fibrillation Recurrence After Catheter Ablation: A Systematic Review and Meta-analysis.","2024","Advances in therapy","Karakasis P","31","12","0","none found",null],["R0005527",null,null,"10.1097/md.0000000000044917","41054173","PMC12499737","New developments in GLP-1 agonist therapy for gestational diabetes: Systematic review on liraglutide, semaglutide, and exenatide from ClinicalTrials.gov.","2025","Medicine","Alshehri FS","54","28","5","none found",null],["R0005530","CRD42020165720",null,"10.1007/s13300-021-01021-1","33635502","PMC7994483","Glucagon-Like Peptide 1 Receptor Agonist (GLP1RA) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies.","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","Caparrotta TM","42","37","8","PROSPERO","PROSPERO:CRD42020165720"],["R0005536",null,null,"10.1111/dom.14136","32627297",null,"Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison.","2020","Diabetes, obesity & metabolism","Home PD","22","12","8","none found",null],["R0005539",null,null,"10.1111/ijpo.13169","39238400",null,"Effectiveness of pharmacological interventions for managing obesity in children and adolescents: A systematic review and meta-analysis framed using minimal important difference estimates based on GRADE guidance to inform a clinical practice guideline.","2024","Pediatric obesity","Wahi G","83","7","7","none found",null],["R0005549","CRD42021271599",null,"10.1001/jamainternmed.2022.0338","35344001","PMC8961394","Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials.","2022","JAMA internal medicine","He L","29","22","10","PROSPERO","PROSPERO:CRD42021271599"],["R0005552","CRD420261340457",null,"10.1002/edm2.70247","42175595","PMC13240113","Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis.","2026","Endocrinology, diabetes & metabolism","Kamrul-Hasan ABM","21","11","5","PROSPERO","PROSPERO:CRD420261340457"],["R0005559","CRD42021226307",null,"10.1038/s41380-025-03129-3","40707785","PMC12532590","Systemic medications and dementia risk: a systematic umbrella review.","2025","Molecular psychiatry","Belessiotis-Richards C","116","9","2","PROSPERO","PROSPERO:CRD42021226307"],["R0005561",null,null,"10.1159/000552201","42030206","PMC13313621","Divergent Renal Benefits of Sodium-Glucose Cotransporter-2 Inhibitors and Mineralocorticoid Receptor Antagonists in Nondiabetic Kidney Disease.","2026","Kidney & blood pressure research","Chen R","37","4","2","none found",null],["R0005564",null,null,"10.1016/j.eprac.2026.07.018","42551699",null,"Safety and Efficacy of Glucagon Like Peptide-1 Receptor Agonism-Based Therapies in End-Stage Renal Disease: A Systematic Review and Meta-Analysis.","2026","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Dutta D","42","28","5","none found",null],["R0005568",null,null,"10.1007/s00228-026-04095-7","42265474","PMC13249686","SGLT2 inhibitors and incretin-based therapies for metabolic dysfunction-associated steatohepatitis: a systematic review.","2026","European journal of clinical pharmacology","Cruz AM","28","8","5","none found",null],["R0005572",null,null,"10.1007/s11695-024-07486-w","39215779",null,"Role of GLP1-RA in Optimizing Weight Loss Post-Bariatric Surgery: A Systematic Review and Meta-Analysis.","2024","Obesity surgery","Pereira M","11","7","6","none found",null],["R0005576",null,null,"10.3389/fendo.2025.1644442","41113714","PMC12527879","What should the doctor prescribe-formula diet or antidiabetics? Effectiveness of formula diet-based lifestyle intervention vs. pharmacological antiglycemic therapy on weight loss and HbA1c reduction in type 2 diabetes patients-a systematic review.","2025","Frontiers in endocrinology","Kempf K","71","35","30","none found",null],["R0005584","CRD420251019235",null,"10.1002/edm2.70136","41276951","PMC12640882","Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta-Analysis.","2025","Endocrinology, diabetes & metabolism","Abdullah A","36","20","6","PROSPERO","PROSPERO:CRD420251019235"],["R0005604",null,null,"10.1186/s12933-023-01993-3","37833776","PMC10576408","Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop.","2023","Cardiovascular diabetology","Ceriello A","22","8","3","none found",null],["R0005615",null,null,"10.1002/oby.24172","39710882","PMC11774015","GLP1Ra-based therapies and DXA-acquired musculoskeletal health outcomes: a focused meta-analysis of placebo-controlled trials.","2025","Obesity (Silver Spring, Md.)","Beavers KM","63","24","14","none found",null],["R0005626","CRD420261327235",null,"10.3389/fendo.2026.1934027","42798476","PMC13612292","Dose-response and time-course effects of ecnoglutide in type 2 diabetes: a systematic review and meta-analysis of efficacy.","2026","Frontiers in endocrinology","Feng Y","39","24","11","PROSPERO","PROSPERO:CRD420261327235"],["R0005633",null,null,"10.1016/j.diabres.2021.108899","34098057",null,"Effect of glucagon-like peptide-1 receptor agonists on circulating levels of leptin and resistin: A meta-analysis of randomized controlled trials.","2021","Diabetes research and clinical practice","Simental-Mendía LE","32","16","13","none found",null],["R0005653",null,null,"10.2459/jcm.0000000000001430","36583981",null,"Effects of glucagon-like peptide-1 receptor agonists on patients with heart failure: a meta-analysis of randomized controlled trials.","2023","Journal of cardiovascular medicine (Hagerstown, Md.)","Obata S","12","11","7","none found",null],["R0005655",null,null,"10.1016/j.clinthera.2024.04.013","38796335",null,"Newer Glucose-Lowering Drugs and Risk of Gout: A Network Meta-Analysis of Randomized Outcomes Trials.","2024","Clinical therapeutics","Wang A","19","6","0","none found",null],["R0005661",null,null,"10.7717/peerj.20710","41660088","PMC12880101","The effects of GLP-1 receptor agonists on metabolic inflammatory markers in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.","2026","PeerJ","Zhao F","61","44","27","none found",null],["R0005665",null,null,"10.1186/s40001-024-02241-4","39773332","PMC11706166","Comparative efficacy of GLP-1 RAs/SGLT-2 inhibitors in reducing cardiovascular events in type 2 diabetes according to baseline use of metformin: a systematic review and meta-analysis of randomized controlled trials.","2025","European journal of medical research","Zhang Y","38","14","5","none found",null],["R0005681",null,null,"10.21203/rs.3.rs-3834867/v1",null,null,"Change on glycosylated hemoglob with glucagon-like peptide-1 receptor agonists affecting the progress of diabetes retinopathy in type 2 diabetes– A systematic review and meta-analysis","2024","Research Square","Wang w",null,"0","0","none found",null],["R0005683",null,null,"10.7759/cureus.102516","41769499","PMC12949042","GLP-1 Receptor Agonists in the Management of Post-bariatric Weight Regain and Dysglycemia: A Systematic Review and Meta-Analysis.","2026","Cureus","Natche J","30","19","6","none found",null],["R0005696",null,null,"10.1097/crd.0000000000000925","40310127",null,"Semaglutide in Patients with Obesity and Heart Failure Irrespective of Their Baseline Ejection Fraction: An Efficacy and Safety Meta-analysis of Randomized Controlled Trials.","2025","Cardiology in review","Otmani Z","23","11","8","none found",null],["R0005702","CRD42020199840",null,"10.3389/fphar.2023.975880","38249345","PMC10797415","Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus.","2023","Frontiers in pharmacology","Tan X","40","19","9","PROSPERO","PROSPERO:CRD42020199840"],["R0005716","CRD42022333040",null,"10.3389/fpsyt.2023.1153648","37215670","PMC10196269","Glucagon-like peptide-1 receptor-agonists treatment for cardio-metabolic parameters in schizophrenia patients: a systematic review and meta-analysis.","2023","Frontiers in psychiatry","Khaity A","60","32","14","PROSPERO","PROSPERO:CRD42022333040"],["R0005724",null,null,"10.1016/j.diabet.2023.101474","37678760",null,"Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies.","2023","Diabetes & metabolism","Scheen AJ","124","75","9","none found",null],["R0005725",null,null,"10.3803/enm.2024.2164","39814031","PMC11898313","Tirzepatide and Cancer Risk in Individuals with and without Diabetes: A Systematic Review and Meta-Analysis.","2025","Endocrinology and metabolism (Seoul, Korea)","Kamrul-Hasan ABM","40","25","13","none found",null],["R0005726",null,null,"10.1089/thy.2024.0387","39772758",null,"Glucagon-Like Peptide 1 Receptor Agonists and Risk of Thyroid Cancer: An International Multisite Cohort Study.","2025","Thyroid : official journal of the American Thyroid Association","Baxter SM","41","20","3","none found",null],["R0005746",null,null,"10.1111/obr.70200","42503568",null,"Nonadherence to GLP-1 Receptor Agonists Among Individuals With Overweight or Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","2026","Obesity reviews : an official journal of the International Association for the Study of Obesity","Shegena EA","0","0","0","none found",null],["R0005757","CRD42022337559",null,"10.1016/j.dsx.2024.102943","38211482",null,"GLP-1 receptor agonists, SGLT2 inhibitors and noncardiovascular mortality in type 2 diabetes: Insights from a meta-analysis.","2024","Diabetes & metabolic syndrome","Banerjee M","0","0","0","PROSPERO","PROSPERO:CRD42022337559"],["R0005760",null,null,"10.1007/s10557-024-07547-3","38214869",null,"Association Between the Magnitude of Glycemic Control and Body Weight Loss With GLP-1 Receptor Agonists and Risk of Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-analyses of Randomized Diabetes Cardiovascular Outcomes Trials.","2025","Cardiovascular drugs and therapy","Gomes DA","38","20","13","none found",null],["R0005763",null,null,"10.1016/j.numecd.2026.104994","42772984",null,"The effects of tirzepatide and semaglutide on clinical and metabolic outcomes in patients with heart failure with preserved ejection fraction and obesity: a systematic review and meta-analysis.","2026","Nutrition, metabolism, and cardiovascular diseases : NMCD","AlAraibi AJ","0","0","0","none found",null],["R0005772",null,null,"10.1080/14017431.2024.2418086","39425977",null,"Cardiovascular and kidney benefits of SGLT-2is and GLP-1RAs according to baseline blood pressure in type 2 diabetes: a systematic meta-analysis of cardiovascular outcome trials.","2024","Scandinavian cardiovascular journal : SCJ","Kunutsor SK","57","16","8","none found",null],["R0005780",null,null,"10.1016/j.cpcardiol.2023.101940","37422042",null,"Ethnic/Racial and Geographic Disparities on Major Cardiovascular Events in Glucagon Like Peptide-1 receptor Agonists Trials: A Meta-Analysis.","2023","Current problems in cardiology","Lavalle Cobo A","37","10","7","none found",null],["R0005783",null,null,"10.1016/j.dsx.2021.04.005","33866119",null,"Cardioprotective properties of glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus patients: A systematic review.","2021","Diabetes & metabolic syndrome","Widiarti W","43","21","12","none found",null],["R0005795",null,null,"10.1016/j.jagp.2023.08.010","37684186",null,"The Antidepressant Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis.","2024","The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry","Chen X","32","17","7","none found",null],["R0005804","CRD42021260167",null,"10.1016/j.jdiacomp.2024.108783","38870731",null,"Effects of newer anti-hyperglycemic agents on cardiovascular outcomes in older adults: Systematic review and meta-analysis.","2024","Journal of diabetes and its complications","Bilal A","54","15","9","PROSPERO","PROSPERO:CRD42021260167"],["R0005812",null,null,"10.20944/preprints202610.0314.v1",null,null,"GLP-1 Receptor Agonists and Dual GIP/GLP-1 and Reduction in Major Cardiovascular Events: A Systematic Review and Network Meta-Analysis","2026","Preprints.org","Campos García FJ",null,"0","0","none found",null],["R0005828",null,null,"10.1002/cpdd.1624","41238444",null,"Integrating Pharmacogenomic Insights in GLP-1 Receptor Agonist Therapy: Direct GLP1R and ARRB1 Variants and Indirect CYP2D6 Influences in Personalized Obesity Management.","2026","Clinical pharmacology in drug development","Jayathilaka NS","0","0","0","none found",null],["R0005845",null,null,"10.7759/cureus.32610","36654602","PMC9840940","Efficacy of Semaglutide in Treating Obesity: A Systematic Review of Randomized Controlled Trials (RCTs).","2022","Cureus","Anam M","27","16","12","none found",null],["R0005859",null,null,"10.1111/dom.14707","35373878",null,"Effect of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese adults without diabetes: A meta-analysis of placebo-controlled randomized trials.","2022","Diabetes, obesity & metabolism","Leite AR","14","9","7","none found",null],["R0005866","CRD42021282668",null,"10.1080/17512433.2024.2363838","38832475",null,"Lipid profile changes induced by glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis.","2024","Expert review of clinical pharmacology","Chae Y","36","31","24","PROSPERO","PROSPERO:CRD42021282668"],["R0005871",null,null,"10.22541/au.173199831.11097717/v1",null,null,"Examining the Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on the Human Gut Microbiome: A Systematic Review","2024","Authorea Preprints","Au H",null,"0","0","none found",null],["R0005873",null,null,"10.1111/dom.70073","40859897",null,"Efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg for the management of overweight or obesity in Asian populations: A systematic review, meta-analysis and meta-regression of randomised trials.","2025","Diabetes, obesity & metabolism","Zufry H","33","8","4","none found",null],["R0005888",null,null,"10.1097/fjc.0000000000000916","33136765",null,"Comparative Efficacy of Glucagon-like Peptide 1 Receptor Agonists and Sodium Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular Events in Type 2 Diabetes: A Network Meta-analysis.","2021","Journal of cardiovascular pharmacology","Qiu M","19","12","7","none found",null],["R0005907",null,null,"10.1177/00033197231183229","37326223",null,"GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Patients With Versus Without Cardiovascular Disease: A Systematic Review, Meta-analysis, and Trial Sequential Analysis.","2024","Angiology","Kilickap M","33","8","7","none found",null],["R0005912",null,null,"10.1186/s13024-025-00894-1","41146261","PMC12560610","Effect of antidiabetic drugs in Alzheimer´s disease: a systematic review of preclinical and clinical studies.","2025","Molecular neurodegeneration","Corraliza-Gomez M","421","90","6","none found",null],["R0005932",null,null,"10.1111/jdi.13775","35191185","PMC9248433","Effect of glucagon-like peptide-1 receptor agonists on fat distribution in patients with type 2 diabetes: A systematic review and meta-analysis.","2022","Journal of diabetes investigation","Duan K","35","16","12","none found",null],["R0005936",null,null,"10.1016/j.conctc.2022.100944","35812819","PMC9260263","The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: A systematic review and network meta-analysis.","2022","Contemporary clinical trials communications","Alhindi Y","55","39","21","none found",null],["R0005941",null,null,"10.1111/obr.13435","35194917",null,"Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials.","2022","Obesity reviews : an official journal of the International Association for the Study of Obesity","Iqbal J","35","12","7","none found",null],["R0005942",null,null,"10.1097/md.0000000000026431","34397684","PMC8322563","Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials.","2021","Medicine","Duan XY","20","10","7","none found",null],["R0005948",null,null,"10.1016/j.pcd.2020.08.017","32912710",null,"Comparison of the effects of 10 GLP-1 RA and SGLT2 inhibitor interventions on cardiovascular, mortality, and kidney outcomes in type 2 diabetes: A network meta-analysis of large randomized trials.","2021","Primary care diabetes","Wei XB","24","14","9","none found",null],["R0005949",null,null,"10.1111/dom.70182","41126557",null,"Antidiabetic agents and dementia risk in type 2 diabetes: A systematic review and network meta-analysis.","2026","Diabetes, obesity & metabolism","Kato S","31","8","0","none found",null],["R0005957",null,null,"10.1080/07853890.2025.2455539","39834076","PMC11753015","Risk factors for hepatocellular carcinoma: an umbrella review of systematic review and meta-analysis.","2025","Annals of medicine","Wang J","149","2","0","none found",null],["R0005965",null,null,"10.1111/dom.71359","42736042",null,"GLP-1 Receptor Agonist-Based Prandial Insulin De-Intensification in Outpatients With Type 2 Diabetes Receiving Basal-Bolus Insulin Therapy or Multiple Daily Injections: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.","2026","Diabetes, obesity & metabolism","Yang H","0","0","0","none found",null],["R0005967","CRD42022339389",null,"10.1186/s13098-022-00970-2","36572913","PMC9791739","Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized controlled trials.","2022","Diabetology & metabolic syndrome","Wu S","43","34","11","PROSPERO","PROSPERO:CRD42022339389"],["R0005972",null,null,"10.1007/s12020-023-03543-z","37768513",null,"IDegLira for type 2 diabetes: a systematic review and meta-analysis.","2024","Endocrine","Liu Y","30","21","17","none found",null],["R0005979",null,null,"10.7759/cureus.86080","40666599","PMC12263181","Tirzepatide Versus Semaglutide for Weight Loss in Overweight and Obese Adults: A Systematic Review and Meta-Analysis of Direct Comparative Studies.","2025","Cureus","Munawar N","22","18","9","none found",null],["R0005980",null,null,"10.1001/jamaneurol.2025.0360","40193122","PMC11976645","Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis.","2025","JAMA neurology","Seminer A","59","18","13","none found",null],["R0005985",null,null,"10.1177/10600280251414107","41723102",null,"Efficacy and Safety of GLP-1 Receptor Agonists for the Management of Antipsychotic-Induced Weight Gain.","2026","The Annals of pharmacotherapy","Pascale S","24","12","9","none found",null],["R0005999",null,null,"10.2147/dmso.s503216","39990178","PMC11844210","Effects of Anti-Diabetic Drugs on Erectile Dysfunction: A Systematic Review and Meta-Analysis.","2025","Diabetes, metabolic syndrome and obesity : targets and therapy","Yang B","81","16","3","none found",null],["R0006012",null,null,"10.3390/metabo11020073","33513761","PMC7911747","Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials.","2021","Metabolites","Mantovani A","65","36","17","none found",null],["R0006013",null,null,"10.1016/s2213-8587(24)00155-4","38991584",null,"Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials.","2024","The lancet. Diabetes & endocrinology","Apperloo EM","36","13","6","none found",null],["R0006029","CRD420251007431",null,"10.1016/j.eclinm.2025.103506","41181824","PMC12572806","Prevention of cardiovascular events in heart failure with mildly reduced or preserved ejection fraction: a comprehensive network meta-analysis of eight randomized controlled trials using reconstructed individual patient's data.","2025","EClinicalMedicine","Diallo A","28","6","5","PROSPERO","PROSPERO:CRD420251007431"],["R0006037",null,null,"10.1111/bcp.15344","35384008",null,"The effect of glucagon-like peptide-1 receptor agonists on serum uric acid concentration: A systematic review and meta-analysis.","2022","British journal of clinical pharmacology","Najafi S","78","35","10","none found",null],["R0006041",null,null,"10.1159/000553479","42611799","PMC13485284","Using GLP-1 Receptor Agonists in Patients with Inflammatory Bowel Disease: A Systematic Review and Single-Arm Meta-Analysis.","2026","Digestive diseases (Basel, Switzerland)","Khasawneh O","33","20","2","none found",null],["R0006061",null,null,"10.1186/s13741-024-00439-y","39039540","PMC11264430","The impact of glucagon-like peptide-1 receptor agonists in the patients undergoing anesthesia or sedation: systematic review and meta-analysis.","2024","Perioperative medicine (London, England)","do Nascimento TS","58","38","14","none found",null],["R0006064","CRD420251138529",null,"10.1016/j.amjcard.2026.04.046","42069283",null,"Divergent Efficacy of GLP-1 Receptor Agonists in HFpEF Versus HFrEF: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","2026","The American journal of cardiology","Ahmed HM","48","24","10","PROSPERO","PROSPERO:CRD420251138529"],["R0006067",null,null,"10.1038/s41598-023-46274-x","37923756","PMC10624877","Efficacy and safety of polyethylene glycol loxenatide in type 2 diabetic patients: a systematic review and meta-analysis of randomized controlled trials.","2023","Scientific reports","Salamah HM","42","15","8","none found",null],["R0006069",null,null,"10.1186/s12933-024-02154-w","38360604","PMC10870515","The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis.","2024","Cardiovascular diabetology","Ali MU","28","10","7","none found",null],["R0006078",null,null,"10.12688/f1000research.185053.1",null,null,"Comparative effectiveness of metabolic bariatric surgery versus incretin-based and medical therapies for weight loss and glycemic outcomes: a systematic review and meta-analysis","2026","F1000Res","Alshahrani SD",null,"0","0","none found",null],["R0006084","CRD420250654193",null,"10.1002/14651858.cd015092.pub2","41161683","PMC12571522","Semaglutide for adults living with obesity.","2025","The Cochrane database of systematic reviews","Bracchiglione J","4","1","1","PROSPERO","PROSPERO:CRD420250654193"],["R0006091",null,null,"10.1111/dom.16489","40437949","PMC12232360","GLP-1 receptor agonists and the risk for cancer: A meta-analysis of randomized controlled trials.","2025","Diabetes, obesity & metabolism","Silverii GA","101","76","54","none found",null],["R0006104","CRD42022367633",null,"10.1007/s10557-023-07432-5","36696050",null,"Impact of Heart Failure History at Baseline on Cardiovascular Effects of GLP-1 Receptor Agonists in Type 2 Diabetes: a Meta-analysis.","2024","Cardiovascular drugs and therapy","Banerjee M","10","6","4","PROSPERO","PROSPERO:CRD42022367633"],["R0006115",null,null,"10.1016/j.cpcardiol.2023.101602","36682393",null,"The Safety and Efficacy of GLP-1 Receptor Agonists in Heart Failure Patients: A Systematic Review and Meta-Analysis.","2023","Current problems in cardiology","Merza N","23","12","10","none found",null],["R0006126",null,null,"10.1097/mbp.0000000000000537","33741774",null,"The effect of glucagon-like peptide-1 receptor agonists on 24-hour ambulatory blood pressure: a confirmatory meta-analysis.","2021","Blood pressure monitoring","Patoulias D","19","15","9","none found",null],["R0006128","CRD420261361351",null,"10.1002/edm2.70291","42487213","PMC13392206","Comparative Efficacy and Safety of Tirzepatide in Asian and Non-Asian Adults With Obesity Without Diabetes: A Systematic Review and Meta-Analysis.","2026","Endocrinology, diabetes & metabolism","Kamrul-Hasan ABM","20","10","6","PROSPERO","PROSPERO:CRD420261361351"],["R0006148",null,null,"10.21203/rs.3.rs-6482330/v1",null,null,"Efficacy and Safety of GLP-1 Receptor Agonists for the Management of Knee Osteoarthritis: A Systematic Review and Meta-Analysis","2025","Research Square","Singh MP",null,"0","0","none found",null],["R0006156","CRD420250654193",null,"10.1002/14651858.cd016017","41161684","PMC12571521","Liraglutide for adults living with obesity.","2025","The Cochrane database of systematic reviews","Meza N","3","1","1","PROSPERO","PROSPERO:CRD420250654193"],["R0006159",null,null,null,null,"PMC12438424","The Impact of GLP-1 Receptor Agonists (GLP-1 RAs) on Mental Health: A Systematic Review","2025","European psychiatry : the journal of the Association of European Psychiatrists","Tempia Valenta S","0","0","0","none found",null],["R0006165",null,null,"10.1111/dom.15009","36751968",null,"Comparative efficacy of sodium-glucose co-transporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic review and network meta-analysis.","2023","Diabetes, obesity & metabolism","Nguyen BN","56","17","10","none found",null],["R0006169",null,null,"10.21203/rs.3.rs-4159026/v1",null,null,"Tirzepatide cardiovascular benefits and adverse events assessment: a Bayesian network meta-analysis","2024","Research Square","gong x",null,"0","0","none found",null],["R0006177",null,null,"10.1016/j.jdiacomp.2022.108255","35817678",null,"Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes - A systematic review and meta-analysis.","2022","Journal of diabetes and its complications","Yoshida Y","49","25","17","none found",null],["R0006189",null,null,"10.1016/j.jdiacomp.2022.108285","35998555",null,"Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes - A systematic review and meta-analysis.","2022","Journal of diabetes and its complications","Goldenberg RM","4","4","3","none found",null],["R0006192",null,null,"10.21203/rs.3.rs-5687083/v1",null,null,"Semaglutide and major adverse cardiovascular events in patients with and without DM: a systematic review and meta-analysis","2024","Research Square","Li Y",null,"0","0","none found",null],["R0006205",null,null,"10.1161/jaha.119.015323","32223390","PMC7428598","Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta-Analysis.","2020","Journal of the American Heart Association","Hu M","240","109","97","none found",null],["R0006206",null,null,"10.1016/j.drugalcdep.2024.112424","39288591",null,"Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: A systematic review of randomized trials.","2024","Drug and alcohol dependence","Martinelli S","56","26","6","none found",null],["R0006219",null,null,"10.21203/rs.3.rs-4098611/v1",null,null,"Effect of GLP-1RA on diabetes retinopathy with blood glucose variation at different levels of baseline HbAlc– A systematic review and meta-analysis","2024","Research Square","Wang W",null,"0","0","none found",null],["R0006239",null,null,"10.7759/cureus.64038","39114239","PMC11303570","Assessing the Renal Outcomes of Semaglutide in Diabetic Kidney Disease: A Systematic Review.","2024","Cureus","Rehman SU","20","14","2","none found",null],["R0006241",null,null,"10.3389/fphar.2025.1438318","40444045","PMC12120964","Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis.","2025","Frontiers in pharmacology","Karimi MA","57","33","3","none found",null],["R0006272",null,null,"10.3390/ijms24087184","37108347","PMC10138454","The Effects of Cardioprotective Antidiabetic Therapy on Microbiota in Patients with Type 2 Diabetes Mellitus-A Systematic Review.","2023","International journal of molecular sciences","Bica IC","74","18","6","none found",null],["R0006279",null,null,"10.1186/s13195-024-01645-y","39716328","PMC11668108","Anti-diabetic agents and the risks of dementia in patients with type 2 diabetes: a systematic review and network meta-analysis of observational studies and randomized controlled trials.","2024","Alzheimer's research & therapy","Li Z","80","14","3","none found",null],["R0006295",null,null,"10.1007/s00592-024-02289-y","38714558",null,"A comprehensive meta-analysis on the association of SGLT2is and GLP-1RAs with vascular diseases, digestive diseases and fractures.","2024","Acta diabetologica","Wang DH","41","18","9","none found",null],["R0006299",null,null,"10.1016/j.clinthera.2021.08.015","34728099",null,"Lifetime Cost-effectiveness of Oral Semaglutide Versus Dulaglutide and Liraglutide in Patients With Type 2 Diabetes Inadequately Controlled With Oral Antidiabetics.","2021","Clinical therapeutics","Risebrough NA","45","4","1","none found",null],["R0006302",null,null,"10.1007/s11695-026-08629-x","41951956",null,"Association Between Preoperative GLP-1 Receptor Agonists Use and Perioperative Complications in Metabolic Bariatric Surgery: A Meta-Analysis.","2026","Obesity surgery","Zhu C","34","24","2","none found",null],["R0006303",null,null,"10.1007/s13300-023-01520-3","38175486","PMC10838895","Glycemic Control, Weight Management, Cardiovascular Safety, and Cost-Effectiveness of Semaglutide for Patients with Type 2 Diabetes Mellitus: A Rapid Review and Meta-analysis of Real-World Studies.","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","Wang S","59","48","1","none found",null],["R0006312",null,null,"10.3967/bes2024.067","38988111",null,"The Association between GLP-1 Receptor-Based Agonists and the Incidence of Asthma in Patients with Type 2 Diabetes and/or Obesity: A Meta-Analysis.","2024","Biomedical and environmental sciences : BES","Zhang MQ","0","0","0","none found",null],["R0006329",null,null,"10.7759/cureus.78555","40062102","PMC11887937","Semaglutide in Obesity and Type 2 Diabetes Management: A Systematic Review of Clinical Outcomes.","2025","Cureus","Gundapaneni SRC","34","31","14","none found",null],["R0006334",null,null,"10.1111/jog.16296","40301112",null,"Effects of Exenatide plus Metformin versus Metformin alone on insulin resistance in women with Polycystic Ovary Syndrome: A systematic review and meta-analysis.","2025","The journal of obstetrics and gynaecology research","Al-Qudah AA","45","16","4","none found",null],["R0006337",null,"osf.io/xpngy","10.1111/obr.70077","41491340",null,"A Systematic Review Identifying Critical Evidence Gaps in Reporting Dietary Change in Randomized Controlled Trials Prescribing Liraglutide, Semaglutide, or Tirzepatide.","2026","Obesity reviews : an official journal of the International Association for the Study of Obesity","Jansson AK","94","71","46","OSF",null],["R0006353",null,null,"10.1016/j.diabet.2022.101325","35121148",null,"Lower limb amputations: protection with GLP-1 receptor agonists rather than increased risk with SGLT2 inhibitors?","2022","Diabetes & metabolism","Scheen AJ","25","17","4","none found",null],["R0006355",null,null,"10.3389/fphar.2022.825417","35847027","PMC9285982","Risk of Fracture With Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, or Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis Combining 177 Randomized Controlled Trials With a Median Follow-Up of 26 weeks.","2022","Frontiers in pharmacology","Chai S","39","9","1","none found",null],["R0006363",null,null,"10.1111/dom.12849","27981757",null,"Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.","2017","Diabetes, obesity & metabolism","Htike ZZ","66","51","40","none found",null],["R0006364",null,null,"10.1016/j.dsx.2023.102834","37531876",null,"Semaglutide and cancer: A systematic review and meta-analysis.","2023","Diabetes & metabolic syndrome","Nagendra L","101","80","37","none found",null],["R0006366",null,null,"10.7759/cureus.89207","40895654","PMC12399046","Recent Trends in the Prevention and Management of Obesity Among Adults: A Systematic Review.","2025","Cureus","Shankar G","34","8","4","none found",null],["R0006369","CRD42024498939",null,"10.1016/j.pcd.2024.09.007","39366881",null,"Cardiovascular effectiveness of newer glucose-lowering agents, with and without baseline lipid-lowering therapy in type 2 diabetes: A systematic meta-analysis of cardiovascular outcome trials and real-world evidence.","2024","Primary care diabetes","Kunutsor SK","53","11","3","PROSPERO","PROSPERO:CRD42024498939"],["R0006385",null,null,"10.1016/j.jogoh.2025.103046","41052543",null,"Evaluation of GLP-1 receptor agonists in obstetrics and perinatal outcomes: A systematic review and meta-analysis.","2025","Journal of gynecology obstetrics and human reproduction","Armstrong BBS","30","12","2","none found",null],["R0006396",null,null,"10.1186/s40842-026-00333-0","42681675","PMC13536828","Cardiometabolic outcomes of once-weekly IcoSema in adults with type 2 diabetes: systematic review and meta-analysis of the COMBINE trials.","2026","Cardiovascular diabetology. Endocrinology reports","Alper A","30","12","4","none found",null],["R0006403",null,null,"10.1093/ageing/afae175","39137064",null,"Evaluation of glucose-lowering medications in older people: a comprehensive systematic review and network meta-analysis of randomized controlled trials.","2024","Age and ageing","Pan SY","63","12","7","none found",null],["R0006411",null,null,"10.1002/edm2.70217","41937314","PMC13052322","Comparative Efficacy and Safety of Ecnoglutide in Type 2 Diabetes: A Systematic Review and Meta-Analysis.","2026","Endocrinology, diabetes & metabolism","Kumar M","31","22","9","none found",null],["R0006430","CRD42022329878",null,"10.1016/j.eclinm.2023.102181","37719418","PMC10500557","Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis.","2023","EClinicalMedicine","Caruso I","47","34","14","PROSPERO","PROSPERO:CRD42022329878"],["R0006446",null,null,"10.1016/j.diabres.2021.108904","34102249",null,"Comparative efficacy and safety of 8 GLP-1RAs in patients with type 2 diabetes: A network meta-analysis.","2021","Diabetes research and clinical practice","Xia L","49","44","36","none found",null],["R0006450",null,null,"10.1016/j.pcd.2021.04.005","33926837",null,"Heart failure outcomes and glucagon-like peptide-1 receptor agonists: A systematic review of observational studies.","2021","Primary care diabetes","Alkhezi OS","0","0","0","none found",null],["R0006459",null,null,"10.1016/j.pan.2026.03.021","41927408",null,"Dose-response analysis of tirzepatide and acute pancreatitis: An international systematic review and quantitative meta-analysis of randomised trials.","2026","Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]","Benny O","0","0","0","none found",null],["R0006466",null,null,"10.12788/cutis.1385","42411880",null,"The Effect of GLP-1 Receptor Agonists on Hidradenitis Suppurativa: A Comprehensive Systematic Review.","2026","Cutis","Kassira NR","0","0","0","none found",null],["R0006467",null,null,"10.1007/s10072-025-08680-z","41402646",null,"Effect of Tirzepatide on arrhythmic, major cardiovascular, and neurological outcomes in patients with type 2 diabetes: A systematic review and meta-analysis.","2025","Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","Wu R","32","27","13","none found",null],["R0006478","CRD420251151419",null,"10.1186/s13045-026-01788-5","41957612","PMC13063595","Agent-specific, histopathology-stratified hematologic malignancy risk among dpp-4 inhibitors, glp-1 receptor agonists, and SGLT2 inhibitors: a network meta-analysis of 270,471 participants.","2026","Journal of hematology & oncology","Lin PY","10","2","1","PROSPERO","PROSPERO:CRD420251151419"],["R0006483",null,null,"10.1016/j.amjsurg.2024.116119","39615284",null,"A systematic review of the use of GLP-1 receptor agonists in surgery.","2025","American journal of surgery","Ihnat JMH","52","34","16","none found",null],["R0006492","CRD42021260040",null,"10.1007/s40292-021-00479-1","34705249",null,"Glucagon-like Peptide-1 Receptor Agonists and Cardioprotective Benefit in Patients with Type 2 Diabetes Without Baseline Metformin: A Systematic Review and Update Meta-analysis.","2021","High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension","Lavalle-Cobo A","27","11","6","PROSPERO","PROSPERO:CRD42021260040"],["R0006494",null,null,"10.1007/s00392-025-02710-8","40637782",null,"Impact of GLP-1 receptor agonists on cardiovascular outcomes in heart failure with preserved ejection fraction (HFpEF): systematic review and meta-analysis.","2026","Clinical research in cardiology : official journal of the German Cardiac Society","Gonzales-Uribe A","35","16","6","none found",null],["R0006500",null,null,"10.1111/bcp.14855","33835520",null,"Impact of glucagon-like peptide-1 receptor agonists on adiponectin concentrations: A meta-analysis of randomized controlled trials.","2021","British journal of clinical pharmacology","Simental-Mendía LE","43","24","19","none found",null],["R0006502",null,null,"10.1111/ijcp.14060","33527605",null,"Medication adherence to injectable glucagon-like peptide-1 (GLP-1) receptor agonists dosed once weekly vs once daily in patients with type 2 diabetes: A meta-analysis.","2021","International journal of clinical practice","Weeda ER","36","13","0","none found",null],["R0006508",null,null,"10.7759/cureus.78570","40062142","PMC11888795","Comparing Glucagon-Like Peptide-1 Receptor Agonists to Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure With Preserved Ejection Fraction: A Systematic Review.","2025","Cureus","Al-Shudifat M","40","8","4","none found",null],["R0006509",null,null,"10.1007/s40256-021-00515-4","34958423",null,"Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Cardiovascular Disease: The Past, Present, and Future.","2022","American journal of cardiovascular drugs : drugs, devices, and other interventions","Ferrari F","75","49","17","none found",null],["R0006524",null,null,"10.1016/j.cmi.2026.01.014","41610949",null,"The effect of GLP-1 receptor agonist and SGLT2 inhibitor on infection risk: network meta-analysis.","2026","Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases","Zeng BS","149","69","58","none found",null],["R0006527",null,null,"10.1186/s12933-020-01070-z","32571416","PMC7310317","Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis.","2020","Cardiovascular diabetology","Alfayez OM","35","25","8","none found",null],["R0006536",null,null,"10.1007/s10072-025-08568-y","41077616",null,"Evaluating the neuroprotective effect of GLP-1 receptor agonists in parkinson's disease: a systematic review and meta-analysis of randomized controlled trials.","2025","Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","Pessoa-Gonçalves YM","24","14","7","none found",null],["R0006547","CRD420251003374",null,"10.1136/bmjopen-2025-103668","40976663","PMC12458674","Cardiovascular effects of incretin-based drugs in patients with and without a history of heart failure: a protocol for a systematic review, meta-analysis and trial sequential analysis of randomised controlled trials.","2025","BMJ open","El-Sheikh M","81","50","21","PROSPERO","PROSPERO:CRD420251003374"],["R0006551","CRD42024498538",null,"10.1007/s40256-025-00726-z","40246808",null,"The Efficacy and Safety of GLP-1 RAs in the Modification of Cardiovascular Morbidity in Patients with Obesity Without Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials Involving 32,884 Patients.","2025","American journal of cardiovascular drugs : drugs, devices, and other interventions","Tanashat M","45","32","15","PROSPERO","PROSPERO:CRD42024498538"],["R0006559",null,null,"10.1007/s12020-023-03636-9","38097902","PMC10902041","The effect of semaglutide on blood pressure in patients with type-2 diabetes: a systematic review and meta-analysis.","2024","Endocrine","Wu W","45","39","31","none found",null],["R0006565",null,null,"10.1007/s43441-025-00875-y","40993341",null,"Incretin Dominance and Emerging Mechanisms in Obesity Pharmacotherapy: Insights from 275 Registered Clinical Trials (2019-2024).","2026","Therapeutic innovation & regulatory science","Dos Santos Barbosa LA","17","6","1","none found",null],["R0006566",null,null,"10.1371/journal.pone.0126769","26121478","PMC4487255","The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis.","2015","PloS one","Potts JE","39","34","30","none found",null],["R0006573",null,null,"10.1111/jcpt.13502","34355405",null,"Effect of glucagon-like peptide-1 receptor agonists in subjects with type 2 diabetes mellitus: A meta-analysis.","2021","Journal of clinical pharmacy and therapeutics","Qian W","0","0","0","none found",null],["R0006581",null,null,"10.1186/s12916-025-04200-0","40691794","PMC12281790","Trajectory of the body weight after drug discontinuation in the treatment of anti-obesity medications.","2025","BMC medicine","Wu H","52","15","13","none found",null],["R0006582",null,null,"10.3389/fendo.2023.1121387","37051199","PMC10084319","A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?","2023","Frontiers in endocrinology","Meng Z","30","23","11","none found",null],["R0006596",null,null,"10.1007/s11695-025-08414-2","41313431",null,"Effects of Semaglutide and Tirzepatide on Recurrent Weight Gain After Bariatric Surgery: A Systematic Review and Meta-analysis.","2025","Obesity surgery","Osorio Manyari AA","34","21","4","none found",null],["R0006597",null,null,"10.1186/s12933-024-02203-4","38555463","PMC10981817","Evidence that tirzepatide protects against diabetes-related cardiac damages.","2024","Cardiovascular diabetology","Taktaz F","52","29","6","none found",null],["R0006608",null,null,"10.1161/jaha.122.026791","37158069","PMC10227303","Ethnic Variations in Cardiovascular and Renal Outcomes From Newer Glucose-Lowering Drugs: A Meta-Analysis of Randomized Outcome Trials.","2023","Journal of the American Heart Association","Tang H","14","5","5","none found",null],["R0006611",null,null,"10.1080/14656566.2024.2343092","38629387",null,"A systematic review of the effect of semaglutide on lean mass: insights from clinical trials.","2024","Expert opinion on pharmacotherapy","Bikou A","54","23","8","none found",null],["R0006621","CRD42023398452",null,"10.3390/diseases12010014","38248365","PMC10814593","Safety and Efficacy of GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus with Advanced and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis.","2024","Diseases (Basel, Switzerland)","Krisanapan P","50","33","14","PROSPERO","PROSPERO:CRD42023398452"],["R0006625",null,null,"10.1016/j.cjca.2022.05.011","35961756",null,"The Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists on Cardiorenal Outcomes: Systematic Review and Meta-analysis.","2022","The Canadian journal of cardiology","Ali MU","0","0","0","none found",null],["R0006632",null,null,"10.1210/clinem/dgaf289","40652449",null,"A Systematic Review Supporting the Clinical Practice Guidelines on the Management of Preexisting Diabetes and Pregnancy.","2025","The Journal of clinical endocrinology and metabolism","Al Nofal A","44","1","0","none found",null],["R0006635",null,null,"10.1111/obr.13725","38346789",null,"Weight reduction and the risk of gallbladder and biliary disease: A systematic review and meta-analysis of randomized clinical trials.","2024","Obesity reviews : an official journal of the International Association for the Study of Obesity","Yang W","21","8","2","none found",null],["R0006639",null,null,"10.1007/s40261-026-01530-6","41811592","PMC12999595","Global Long-Term Cost Effectiveness of Newer Antidiabetic Drugs for Type 2 Diabetes Mellitus: A Systematic Review.","2026","Clinical drug investigation","Li D","46","15","3","none found",null],["R0006645",null,null,"10.3390/jcm13061797","38542021","PMC10971133","Novel Antidiabetic Drugs and the Risk of Diabetic Retinopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","2024","Journal of clinical medicine","Małyszczak A","102","47","33","none found",null],["R0006657","CRD42022299690",null,"10.1111/dom.14859","36057779","PMC10087851","Larger effect size in composite kidney outcomes than in major cardiovascular events associated with sodium-glucose cotransporter-2 (SGLT2) inhibitors compared with glucagon-like peptide-1 receptor agonists (GLP-1RAs): A pooled analysis of type 2 diabetes trials.","2023","Diabetes, obesity & metabolism","Diallo A","29","13","7","PROSPERO","PROSPERO:CRD42022299690"],["R0006662",null,null,"10.4103/ijem.ijem_45_24","39676787","PMC11642503","Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis.","2024","Indian journal of endocrinology and metabolism","Dutta D","26","15","8","none found",null],["R0006666",null,null,"10.1097/md.0000000000038568","38905435","PMC11192004","Efficacy and safety of albiglutide, a once-weekly glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes: A systematic review and meta-analysis.","2024","Medicine","Kamrul-Hasan ABM","40","33","18","none found",null],["R0006680",null,null,"10.1007/s00210-026-05257-1","41879841",null,"Efficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis: a GRADE-assessed meta-analysis of randomized controlled trials.","2026","Naunyn-Schmiedeberg's archives of pharmacology","Rajab I","14","7","5","none found",null],["R0006684",null,null,"10.1186/s13098-024-01518-2","39716250","PMC11665059","Hypoglycemic agents and bone health; an umbrella systematic review of the clinical trials' meta-analysis studies.","2024","Diabetology & metabolic syndrome","Khashayar P","100","18","0","none found",null],["R0006694",null,null,"10.1016/j.dsx.2024.103067","38955095",null,"Semaglutide for the prevention of atrial fibrillation: A systematic review and meta-analysis.","2024","Diabetes & metabolic syndrome","Zhang HD","36","31","19","none found",null],["R0006696",null,null,"10.1007/s40265-021-01525-x","33929717",null,"Is it Time to Expand Glucagon-like Peptide-1 Receptor Agonist Use for Weight Loss in Patients Without Diabetes?","2021","Drugs","Updike WH","6","6","5","none found",null],["R0006700",null,null,"10.1161/jaha.123.032463","38362889","PMC11010086","Potential Mediators for Treatment Effects of Novel Diabetes Medications on Cardiovascular and Renal Outcomes: A Meta-Regression Analysis.","2024","Journal of the American Heart Association","Rodriguez-Valadez JM","88","28","16","none found",null],["R0006711",null,null,"10.1016/j.rce.2021.04.001","33935292","PMC8075844","[Meta-analysis evaluating the risk of respiratory tract infections and acute respiratory distress syndrome with glucagon-like peptide-1 receptor agonists in cardiovascular outcome trials: Useful implications for the COVID-19 pandemic].","2022","Revista clinica espanola","Patoulias D","15","11","7","none found",null],["R0006716",null,null,"10.21203/rs.3.rs-9709510/v1",null,null,"Are Semaglutide and Tirzepatide Cost-Effective for Weight Management? A Systematic Review and Meta-analysis","2026","Research Square","Xu Y",null,"0","0","none found",null],["R0006725",null,null,"10.7759/cureus.108005","42220875","PMC13221614","Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Thyroid Function Tests: A Systematic Review Identifying a Critical Evidence Gap.","2026","Cureus","Salama S","24","17","4","none found",null],["R0006728",null,null,"10.1038/s41366-023-01321-5","37253796",null,"Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis.","2023","International journal of obesity (2005)","Tan B","44","18","9","none found",null],["R0006735",null,null,"10.1111/dom.70864","42115753",null,"GLP-1 Receptor Agonists and Psychiatric Outcomes in Adolescents: A Systematic Review and Meta-Analysis.","2026","Diabetes, obesity & metabolism","Silva CFXCA","47","19","7","none found",null],["R0006736",null,null,"10.1007/s10741-020-09936-w","32080782",null,"Effects of oral antidiabetic drugs and glucagon-like peptide-1 receptor agonists on left ventricular diastolic function in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis.","2021","Heart failure reviews","Ida S","40","8","5","none found",null],["R0006744",null,null,"10.1097/md.0000000000047994","41824845","PMC12991648","GLP-1 receptor agonists for weight loss: A systematic review and meta-analysis of randomized controlled trials.","2026","Medicine","Ahmad N","41","36","25","none found",null],["R0006757",null,null,"10.3389/fendo.2022.1007980","36545339","PMC9760859","Risk of stroke and retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: An eight RCTs meta-analysis.","2022","Frontiers in endocrinology","Wei J","44","28","9","none found",null],["R0006762",null,null,"10.1016/j.amjcard.2021.12.040","35045931",null,"Meta-Analysis Assessing the Impact of Previous Heart Failure and Chronic Kidney Disease on the Cardiovascular Efficacy of Glucagon-Like Peptide-1 Receptor Agonists.","2022","The American journal of cardiology","Patoulias D","8","5","3","none found",null],["R0006778",null,null,"10.21203/rs.3.rs-664920/v1",null,null,"Glucagon-like Peptide-1 Receptor Agonists and Cardioprotective Benefit in Patients With Type 2 Diabetes Without Baseline Metformin: An Update Meta-analysis","2021","Research Square","Cobo AL",null,"0","0","none found",null],["R0006780",null,null,"10.1186/s12876-025-04358-0","41146009","PMC12560356","Efficacy of GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists in managing MALFD: a meta-analysis of randomized controlled trials.","2025","BMC gastroenterology","Tamilwanan S","83","59","28","none found",null],["R0006793",null,null,"10.3390/biom15111622","41301540","PMC12650725","Divergent Risks of Hematologic Malignancies Associated with GLP-1 Receptor Agonists and SGLT2 Inhibitors: Preliminary Findings from a Pilot Network Meta-Analysis.","2025","Biomolecules","Lin PY","85","40","30","none found",null],["R0006806",null,null,"10.1111/jgh.16559","38627972",null,"Efficacy of pharmacologic interventions on magnetic resonance imaging biomarkers in patients with nonalcoholic fatty liver disease: systematic review and network meta-analysis.","2024","Journal of gastroenterology and hepatology","Malandris K","87","11","7","none found",null],["R0006813",null,null,"10.7759/cureus.45927","37885518","PMC10599090","Safety and Efficacy of Efpeglenatide in Patients With Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.","2023","Cureus","Escobar J","14","12","10","none found",null],["R0006815",null,null,"10.3390/ijms27020608","41596262","PMC12841245","Agent- and Dose-Specific Intestinal Obstruction Safety of GLP-1 Receptor Agonists and SGLT2 Inhibitors: A Network Meta-Analysis of Randomized Trials.","2026","International journal of molecular sciences","Chen JJ","189","113","87","none found",null],["R0006829","CRD42025637054",null,"10.1007/s11739-026-04326-w","41917519",null,"Efficacy of tirzepatide, lanifibranor, and resmetirom in metabolic dysfunction-associated steatotic liver disease: a meta-analysis of high-quality randomized controlled trials.","2026","Internal and emergency medicine","Zhao S","26","7","4","PROSPERO","PROSPERO:CRD42025637054"],["R0006830",null,null,"10.1002/dmrr.3752","38013215",null,"Efficacy and safety of fixed-ratio combination insulin degludec/liraglutide in type 2 diabetes: A systematic review and meta-analysis of randomised controlled trials.","2024","Diabetes/metabolism research and reviews","Wang R","33","11","6","none found",null],["R0006834",null,null,"10.1097/md.0000000000026295","34115034","PMC8202615","The therapeutic effects of glucagon-like peptide-1 receptor agonists and metformin on polycystic ovary syndrome: A protocol for systematic review and meta-analysis.","2021","Medicine","Ma R","33","15","11","none found",null],["R0006840",null,null,"10.1155/2024/9900213","38500709","PMC10948218","Comparative Effectiveness of Antidiabetic Drugs as an Additional Therapy to Metformin in Women with Polycystic Ovary Syndrome: A Systematic Review of Metabolic Approaches.","2024","International journal of endocrinology","Heidarpour M","44","13","8","none found",null],["R0006850",null,null,"10.1016/j.jad.2024.11.019","39515485",null,"A systematic review in effects of glucagon-like peptide-1 (GLP-1) mono-agonists on functional connectivity: Target engagement and rationale for the development in mental disorders.","2025","Journal of affective disorders","Au HCT","43","18","4","none found",null],["R0006857",null,null,"10.3389/fendo.2022.870722","35669682","PMC9165059","Free Versus Fixed-Ratio Combination of Basal Insulin and GLP-1 Receptor Agonists in Type 2 Diabetes Uncontrolled With GLP-1 Receptor Agonists: A Systematic Review and Indirect Treatment Comparison.","2022","Frontiers in endocrinology","Jung HN","24","15","6","none found",null],["R0006863",null,null,"10.26355/eurrev_202308_33290","37606127",null,"Is tirzepatide 15 mg the preferred treatment strategy for type 2 diabetes? A meta-analysis and trial-sequence-analysis.","2023","European review for medical and pharmacological sciences","Yang XY","0","0","0","none found",null],["R0006881",null,null,"10.4239/wjd.v16.i2.101282","39959269","PMC11718474","Renal effects and safety of tirzepatide in subjects with and without diabetes: A systematic review and meta-analysis.","2025","World journal of diabetes","Kamrul-Hasan A","57","36","27","none found",null],["R0006895","CRD42021258103",null,"10.1136/bmjopen-2022-061807","36882248","PMC10008474","Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis.","2023","BMJ open","Ma H","31","10","4","PROSPERO","PROSPERO:CRD42021258103"],["R0006899",null,null,"10.2337/dc21-1113","35100355",null,"Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes.","2022","Diabetes care","Wright AK","57","28","8","none found",null],["R0006903",null,null,"10.7759/cureus.94926","41116804","PMC12535773","Rebound or Retention: A Meta-Analysis of Weight Regain After the Discontinuation of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Other Anti-obesity Drugs.","2025","Cureus","Kolli RT","53","29","26","none found",null],["R0006905",null,null,"10.3390/jcm12030772","36769420","PMC9917722","The Effect of Semaglutide on Blood Pressure in Patients without Diabetes: A Systematic Review and Meta-Analysis.","2023","Journal of clinical medicine","Kennedy C","29","15","7","none found",null],["R0006924",null,null,"10.1111/dom.14565","34605124",null,"Effects of glucagon-like peptide-1 receptor agonists on histopathological and secondary biomarkers of non-alcoholic steatohepatitis: A systematic review and meta-analysis.","2022","Diabetes, obesity & metabolism","Borodavkin P","19","11","4","none found",null],["R0006927",null,null,"10.7759/cureus.100927","41523725","PMC12781563","Comparative Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors Versus Glucagon-Like Peptide-1 (GLP-1) Agonists on Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.","2026","Cureus","Alqurain AA","50","26","14","none found",null],["R0006942",null,null,"10.1111/dom.15500","38379094",null,"Glycaemic control and macrovascular and microvascular outcomes in type 2 diabetes: Systematic review and meta-analysis of cardiovascular outcome trials of novel glucose-lowering agents.","2024","Diabetes, obesity & metabolism","Kunutsor SK","37","8","2","none found",null],["R0006945",null,null,"10.1111/dom.16599","40642833",null,"Quantitative analysis of the efficacy characteristics and influencing factors of weight loss drugs in children and adolescents.","2025","Diabetes, obesity & metabolism","Wang Y","52","14","5","none found",null],["R0006962",null,null,"10.3389/fendo.2025.1550938","40852189","PMC12367517","The effects of GLP-1 agonists on HbA1c and insulin dose among patients with type 1 diabetes.","2025","Frontiers in endocrinology","Alhowiti A","43","31","15","none found",null],["R0006968",null,null,"10.1111/dom.15251","37649320",null,"Cardiovascular efficacy and safety of antidiabetic agents: A network meta-analysis of randomized controlled trials.","2023","Diabetes, obesity & metabolism","Sohn M","93","38","22","none found",null],["R0006973",null,null,"10.1111/dom.12885","28105738",null,"Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes.","2017","Diabetes, obesity & metabolism","Storgaard H","15","10","5","none found",null],["R0006993",null,null,"10.1016/j.amjcard.2021.08.009","34497008",null,"Updated Meta-Analysis of Cardiovascular Outcome Trials Evaluating Cardiovascular Efficacy of Glucagon-Like Peptide-1 Receptor Agonists.","2021","The American journal of cardiology","Patoulias D","14","11","8","none found",null],["R0006996",null,null,"10.1111/dom.14666","35137511",null,"Effects of glucagon-like peptide-1 receptor agonists on cardiovascular and renal outcomes: A meta-analysis and meta-regression analysis.","2022","Diabetes, obesity & metabolism","Yoshiji S","41","28","17","none found",null],["R0006997",null,null,"10.1186/s12902-023-01500-5","37940910","PMC10631119","Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review.","2023","BMC endocrine disorders","Zhou L","51","32","10","none found",null],["R0007009",null,null,"10.1007/s12020-017-1293-6","28401444",null,"Fixed ratio combinations of glucagon like peptide 1 receptor agonists with basal insulin: a systematic review and meta-analysis.","2017","Endocrine","Liakopoulou P","19","12","10","none found",null],["R0007012",null,null,"10.1097/js9.0000000000001514","38701500","PMC11325911","Association of glucagon-like peptide-1 receptor agonists with risk of cancers-evidence from a drug target Mendelian randomization and clinical trials.","2024","International journal of surgery (London, England)","Sun Y","40","15","2","none found",null],["R0007015",null,null,"10.7759/cureus.111728","42529769","PMC13418920","Efficacy and Safety of Dual and Triple Glucagon-Like Peptide-1-Based Polyagonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Meta-Analysis.","2026","Cureus","Santos Solis R","27","14","10","none found",null],["R0007021",null,null,"10.4093/dmj.2021.0314","35410110","PMC9723196","Effect of the Glucagon-Like Peptide-1 Receptor Agonists on Autonomic Function in Subjects with Diabetes: A Systematic Review and Meta-Analysis.","2022","Diabetes & metabolism journal","Greco C","41","22","14","none found",null],["R0007049",null,null,"10.3389/fcvm.2022.1019120","36277800","PMC9581215","A meta-analysis evaluating indirectly GLP-1 receptor agonists and arrhythmias in patients with type 2 diabetes and myocardial infarction.","2022","Frontiers in cardiovascular medicine","Liu Z","35","22","8","none found",null],["R0007056",null,null,"10.1186/s12933-024-02415-8","39217337","PMC11366143","Comparative effects of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors on heart failure with preserved ejection fraction in diabetic patients: a meta-analysis.","2024","Cardiovascular diabetology","Albulushi A","28","7","1","none found",null],["R0007059",null,null,"10.1101/2021.10.14.21264803",null,null,"Effects of Glucagon-like Peptide-1 Receptor Agonists on Cardiovascular and Renal Outcomes: A Meta-Analysis and Meta-Regression Analysis","2021","medRxiv","Yoshiji S",null,"0","0","none found",null],["R0007060",null,null,"10.1016/j.amjcard.2021.12.001","34974899",null,"Meta-Analysis of Randomized Controlled Trials Evaluating the Effect of Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonists on Blood Pressure Levels in Patients With Type 2 Diabetes Mellitus.","2022","The American journal of cardiology","Patoulias D","14","10","6","none found",null],["R0007062","CRD42024565765",null,"10.1161/circulationaha.124.071689","39210781",null,"Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis.","2024","Circulation","Neuen BL","30","16","9","PROSPERO","PROSPERO:CRD42024565765"],["R0007065",null,null,"10.18332/tid/219815","42529623","PMC13417961","GLP-1 agonists for smoking cessation and post-cessation weight management: A systematic review and meta-analysis of randomized trials.","2026","Tobacco induced diseases","Heshmati J","51","26","2","none found",null],["R0007081",null,null,"10.1016/j.atherosclerosis.2024.117490","38452432",null,"Comparative effects of glucose-lowering agents on endothelial function and arterial stiffness in patients with type 2 diabetes: A network meta-analysis.","2024","Atherosclerosis","Kim H","50","7","0","none found",null],["R0007085",null,null,"10.1002/clc.70234","41388927","PMC12701558","GLP-1 and Dual GLP-1/GIP Receptor Agonists in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.","2025","Clinical cardiology","Ahmed M","20","12","7","none found",null],["R0007087",null,null,"10.1016/j.ijcard.2022.03.032","35306033",null,"The effect of GLP-1 receptor agonists on N-terminal pro-brain natriuretic peptide. A scoping review and metanalysis.","2022","International journal of cardiology","Avogaro A","29","16","9","none found",null],["R0007097",null,null,"10.1007/s11695-024-07127-2","38436920",null,"Adjuvant Glucose-Like Peptide 1 Receptor Agonist Therapy for Suboptimal Weight Loss After Bariatric Surgery: a Systematic Review.","2024","Obesity surgery","Dréant A","45","19","11","none found",null],["R0007099",null,null,"10.1016/s2468-1253(21)00261-2","35030323",null,"Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review.","2022","The lancet. Gastroenterology & hepatology","Mantovani A","70","17","12","none found",null],["R0007101",null,null,"10.1210/clinem/dgaa891","33248445","PMC8089886","Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-analysis.","2021","The Journal of clinical endocrinology and metabolism","Piccoli GF","0","0","0","none found",null],["R0007106",null,null,"10.7759/cureus.103927","41873309","PMC13006129","Effects of GLP-1 Receptor Agonists vs Metformin in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis.","2026","Cureus","Almubaddil K","20","12","4","none found",null],["R0007108",null,null,"10.1111/cob.70111","42670242","PMC13527552","Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis of Head-to-Head Studies.","2026","Clinical obesity","Paccola GP","42","32","14","none found",null],["R0007109",null,null,"10.3390/biom15010039","39858434","PMC11764242","Comparative Efficacy and Safety of Cardio-Renoprotective Pharmacological Interventions in Chronic Kidney Disease: An Umbrella Review of Network Meta-Analyses and a Multicriteria Decision Analysis.","2024","Biomolecules","Bellos I","120","28","12","none found",null],["R0007110",null,null,"10.3390/medicina61111987","41303824","PMC12654588","Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review.","2025","Medicina (Kaunas, Lithuania)","Takrori E","26","17","10","none found",null],["R0007121","CRD42022357886",null,"10.1007/s40265-023-01932-2","37639180",null,"Clinical Outcomes with GLP-1 Receptor Agonists in Patients with Heart Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials.","2023","Drugs","Zhao H","31","17","9","PROSPERO","PROSPERO:CRD42022357886"],["R0007122",null,null,"10.1186/s12933-020-01197-z","33413348","PMC7792332","Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis.","2021","Cardiovascular diabetology","Yamada T","54","24","12","none found",null],["R0007125",null,null,"10.1177/03000605211066306","34939442","PMC8721710","Effects of incretin-based therapies on β-cell function in type 1 diabetes mellitus: a systematic review and meta-analysis.","2021","The Journal of international medical research","Wu Y","29","9","4","none found",null],["R0007128",null,null,"10.1186/s12933-022-01474-z","35296336","PMC8925229","The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs.","2022","Cardiovascular diabetology","Giugliano D","26","11","1","none found",null],["R0007134",null,null,"10.21203/rs.3.rs-58029/v3",null,null,"Cardiovascular and Renal Outcomes with SGLT-2 Inhibitors versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Systematic Review and Network Meta-analysis","2020","Research Square","Yamada T",null,"0","0","none found",null],["R0007141","CRD42023458228",null,"10.1371/journal.pone.0297488","38408098","PMC10896528","Comparative effectiveness of glucagon-like peptide-1 receptor agonists on body composition and anthropometric indices: A protocol for a systematic review and network meta-analysis of randomized controlled trials.","2024","PloS one","Wachiraphansakul N","45","17","5","PROSPERO","PROSPERO:CRD42023458228"],["R0007143",null,null,"10.1186/s12933-022-01489-6","35484580","PMC9052629","Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6.","2022","Cardiovascular diabetology","Husain M","26","16","9","none found",null],["R0007144",null,null,"10.7759/cureus.44314","37779743","PMC10536403","Comparing Efficacy and Safety of Different Doses of Tirzepatide for the Treatment of Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials.","2023","Cureus","Khan Z","26","15","10","none found",null],["R0007148",null,null,"10.1097/mjt.0000000000001418","34224428",null,"Meta-Analysis of the Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Patients With Polycystic Ovary Syndrome.","2021","American journal of therapeutics","Li L","10","5","5","none found",null],["R0007152",null,null,"10.1111/dme.15083","36905324",null,"Impact of novel glucose-lowering therapies on physical function in people with type 2 diabetes: A systematic review and meta-analysis of randomised placebo-controlled trials.","2023","Diabetic medicine : a journal of the British Diabetic Association","Ahmad E","50","20","4","none found",null],["R0007154",null,null,"10.2147/dmso.s443396","38371390","PMC10873148","The Effect of Tirzepatide on Weight, Lipid Metabolism and Blood Pressure in Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.","2024","Diabetes, metabolic syndrome and obesity : targets and therapy","Lv X","27","18","11","none found",null],["R0007158",null,null,"10.3803/enm.2024.2120","39805574","PMC12061750","Effectiveness and Safety of Oral Quadruple Combination Therapy in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.","2025","Endocrinology and metabolism (Seoul, Korea)","Bae J","32","4","1","none found",null],["R0007165","CRD42021283449",null,"10.1007/s00125-022-05715-4","35579691","PMC9112245","Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.","2022","Diabetologia","Karagiannis T","29","21","12","PROSPERO","PROSPERO:CRD42021283449"],["R0007175",null,null,"10.1080/0886022x.2025.2478488","40230199","PMC12001840","Glucagon-like peptide-1 receptor agonists, inflammation, and kidney diseases: evidence from Mendelian randomization.","2025","Renal failure","Yao YX","32","9","1","none found",null],["R0007186","CRD42018094433",null,"10.1007/s00198-018-4649-8","30083774",null,"Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials.","2018","Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","Zhang YS","23","5","0","PROSPERO","PROSPERO:CRD42018094433"],["R0007191",null,null,"10.1080/00015385.2022.2087839","35699112",null,"Meta-analysis of cardiovascular outcome trials assessing the impact of glucagon-like peptide-1 receptor agonists on major cardiac arrhythmias.","2023","Acta cardiologica","Boulmpou A","30","20","9","none found",null],["R0007200",null,null,"10.1111/dom.14888","36205446",null,"Effects of glucose-lowering agents on cardiovascular and renal outcomes in subjects with type 2 diabetes: An updated meta-analysis of randomized controlled trials with external adjudication of events.","2023","Diabetes, obesity & metabolism","Mannucci E","70","10","3","none found",null],["R0007222","CRD420251170117",null,"10.1016/j.disamonth.2026.102099","41862384",null,"Efficacy and safety of Tirzepatide in patients with heart failure with preserved ejection fraction: A systematic review and meta-analysis.","2026","Disease-a-month : DM","Sebastian SA","32","13","7","PROSPERO","PROSPERO:CRD420251170117"],["R0007229",null,null,"10.1177/13872877251319054","40017057","PMC12231844","Effect of diabetes medications on the risk of developing dementia, mild cognitive impairment, or cognitive decline: A systematic review and meta-analysis.","2025","Journal of Alzheimer's disease : JAD","Hui EK","85","8","5","none found",null],["R0007233","CRD42023401734",null,"10.1177/01410768231198442","37734450","PMC11450921","Racial, ethnic and regional differences in the effect of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes: a systematic review and meta-analysis of cardiovascular outcome trials.","2024","Journal of the Royal Society of Medicine","Kunutsor SK","65","13","7","PROSPERO","PROSPERO:CRD42023401734"],["R0007243",null,null,"10.1002/clc.70249","41450071","PMC12741511","Critical Evaluation of \"GLP-1 and Dual GLP-1/GIP Receptor Agonists in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis\".","2025","Clinical cardiology","Bibi Z","6","2","1","none found",null],["R0007252",null,null,"10.1016/j.pcd.2021.11.006","34953749",null,"Cardiovascular effectiveness of glucagon-like peptide 1 receptor agonists versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes: A meta-analysis based on propensity score-matched studies.","2022","Primary care diabetes","Xu L","0","0","0","none found",null],["R0007256",null,null,"10.4239/wjd.v16.i10.110174","41113488","PMC12531691","Association between antidiabetic drugs and cancer risk in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis.","2025","World journal of diabetes","An XD","41","13","0","none found",null],["R0007270",null,null,"10.1016/j.ajo.2024.12.024","39732312",null,"GLP-1 Receptor Agonists Use and Incidence of Glaucoma: A Systematic Review and Meta-Analysis.","2025","American journal of ophthalmology","Amaral DC","34","12","1","none found",null],["R0007284","CRD42022342373",null,"10.1186/s12916-023-03129-6","37974258","PMC10655371","Comparative effectiveness of multiple different treatment regimens for nonalcoholic fatty liver disease with type 2 diabetes mellitus: a systematic review and Bayesian network meta-analysis of randomised controlled trials.","2023","BMC medicine","Deng M","88","22","12","PROSPERO","PROSPERO:CRD42022342373"],["R0007286",null,null,"10.1016/j.numecd.2026.104714","41997798",null,"Rethinking diabetes as a modifier of the weight-loss response to incretin-based therapies. A twin trial meta-regression.","2026","Nutrition, metabolism, and cardiovascular diseases : NMCD","Marassi M","30","20","16","none found",null],["R0007294",null,null,"10.1007/s42000-023-00493-z","37770761","PMC10651545","Comparative efficacy of glucose-lowering drugs on liver steatosis as assessed by means of magnetic resonance imaging in patients with type 2 diabetes mellitus: systematic review and network meta-analysis.","2023","Hormones (Athens, Greece)","Malandris K","71","28","16","none found",null],["R0007302",null,null,"10.1111/dom.14108","32476254",null,"Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis.","2020","Diabetes, obesity & metabolism","Mantsiou C","40","19","9","none found",null],["R0007309",null,null,"10.1111/ijcp.12847","27456750",null,"Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials.","2016","International journal of clinical practice","Xue X","35","23","16","none found",null],["R0007310",null,null,"10.1111/dom.15367","38031234",null,"Incretin-based drugs and the risk of diabetic retinopathy among individuals with type 2 diabetes: A systematic review and meta-analysis of observational studies.","2024","Diabetes, obesity & metabolism","Igweokpala S","50","11","1","none found",null],["R0007311",null,null,"10.1097/mcg.0000000000001556","34039937",null,"Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Metabolic Associated Fatty Liver Disease: A Systematic Review and Meta-analysis.","2021","Journal of clinical gastroenterology","Jianping W","34","19","14","none found",null],["R0007320",null,null,"10.1186/s13098-023-01251-2","38212831","PMC10782753","Effects of finerenone and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus: a systematic review and meta-analysis.","2024","Diabetology & metabolic syndrome","Gu X","45","23","12","none found",null],["R0007322",null,null,"10.1002/dmrr.3739","37862117",null,"Sodium-glucose co-transporter-2 inhibitors and the risk of venous thromboembolism: A nationwide population-based study and meta-analysis.","2024","Diabetes/metabolism research and reviews","Tsai HR","56","3","1","none found",null],["R0007324",null,null,"10.1016/j.apjo.2025.100245","40962119",null,"Does semaglutide increase the risk of non-arteritic anterior ischemic optic neuropathy? A systematic review and meta-analysis of emerging evidence.","2026","Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)","Chen KY","46","22","6","none found",null],["R0007331",null,null,"10.64898/2026.04.19.26351196",null,null,"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults: 2026 Update","2026","medRxiv","Ciudin A",null,"0","0","none found",null],["R0007353",null,null,"10.1097/md.0000000000023489","33285754","PMC7717767","Effects of glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors on major adverse cardiovascular events in type 2 diabetes by race, ethnicity, and region: A meta-analysis.","2020","Medicine","Qiu M","24","13","7","none found",null],["R0007358",null,null,"10.1007/s13300-021-01034-w","33723769","PMC8099977","Once-Daily Oral Semaglutide Versus Injectable GLP-1 RAs in People with Type 2 Diabetes Inadequately Controlled on Basal Insulin: Systematic Review and Network Meta-analysis.","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","Chubb B","40","28","22","none found",null],["R0007361",null,null,"10.1080/00325481.2020.1845534","33151791",null,"Patient initiation and maintenance of GLP-1 RAs for treatment of obesity: a narrative review and practical considerations for primary care providers.","2021","Postgraduate medicine","Fitch A","73","24","12","none found",null],["R0007367",null,null,"10.3389/fphar.2022.998816","36313305","PMC9613929","Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: A bayesian network meta-analysis.","2022","Frontiers in pharmacology","Guan R","38","23","9","none found",null],["R0007369","CRD420250654193",null,"10.1002/14651858.cd016018","41161687","PMC12571520","Tirzepatide for adults living with obesity.","2025","The Cochrane database of systematic reviews","Franco JV","2","0","0","PROSPERO","PROSPERO:CRD420250654193"],["R0007388",null,null,"10.1016/j.dsx.2025.103186","39793280",null,"Evaluating the causal effect of using glucagon-like peptide-1 receptor agonists on the risk of autoimmune diseases.","2025","Diabetes & metabolic syndrome","Sun Y","41","10","2","none found",null],["R0007391",null,null,"10.3389/fendo.2022.920541","36157450","PMC9494570","Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis.","2022","Frontiers in endocrinology","Lisco G","73","54","25","none found",null],["R0007416",null,null,"10.1111/dom.12926","28244632",null,"Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.","2017","Diabetes, obesity & metabolism","Monami M","41","28","5","none found",null],["R0007431",null,null,"10.1186/s40001-024-01954-w","39085898","PMC11290211","Effect of different hypoglycemic drugs and insulin on the risk of new-onset atrial fibrillation in people with diabetes: a network meta-analysis.","2024","European journal of medical research","Lv Q","100","19","3","none found",null],["R0007436",null,null,"10.1007/s43441-024-00633-6","38683419",null,"The Effect of Antihyperglycemic Medications on COVID-19: A Meta-analysis and Systematic Review from Observational Studies.","2024","Therapeutic innovation & regulatory science","Song ZH","79","11","2","none found",null],["R0007442",null,null,"10.1016/j.amjcard.2024.04.041","38679221",null,"Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","2024","The American journal of cardiology","Moiz A","25","17","8","none found",null],["R0007451",null,null,"10.1016/j.jdiacomp.2024.108781","38833853",null,"The effect of SGLT2 inhibitors and GLP1 receptor agonists on arterial stiffness: A meta-analysis of randomized controlled trials.","2024","Journal of diabetes and its complications","Rizos EC","51","19","15","none found",null],["R0007453",null,null,"10.17219/acem/161734","37077141",null,"Evaluating the effects of glucagon-like peptide-1 receptor agonists on cognitive function in Alzheimer's disease: A systematic review and meta-analysis.","2023","Advances in clinical and experimental medicine : official organ Wroclaw Medical University","Bi Z","0","0","0","none found",null],["R0007461",null,null,"10.2337/dc25-0282","40392994",null,"Sodium-Glucose Cotransporter 2 Inhibitor Use and Risk of Liver-Related Events in Patients With Type 2 Diabetes: A Meta-analysis of Observational Cohort Studies.","2025","Diabetes care","Mantovani A","35","10","3","none found",null],["R0007465",null,null,"10.1111/dom.14735","35491523","PMC9543971","Non-inferiority and clinical superiority of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors: Systematic analysis of cardiorenal outcome trials in type 2 diabetes.","2022","Diabetes, obesity & metabolism","Zaccardi F","22","4","1","none found",null],["R0007472",null,null,"10.1016/j.cgh.2025.03.003","40220846",null,"Change in cT1 Following Interventions in MASLD: A Systematic Review and Meta-Analysis.","2026","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","Andersson A","65","5","2","none found",null],["R0007488",null,null,"10.3389/fpubh.2024.1277113","38356942","PMC10864442","Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials.","2024","Frontiers in public health","Cai W","51","35","14","none found",null],["R0007493",null,null,"10.1038/s41366-025-02002-1","41491273",null,"Mental health outcomes in obesity interventions with GLP-1 receptor agonists: is it similar to other obesity interventions? A narrative review with systematic evidence synthesis.","2026","International journal of obesity (2005)","Osborne D","39","12","2","none found",null],["R0007494",null,null,"10.1111/dom.70997","42331714","PMC13448983","Effects of Weight-Loss Interventions on Kidney, Cardiometabolic and Anthropometric Outcomes in Adults With CKD and Overweight or Obesity: A Systematic Review and Meta-Analysis.","2026","Diabetes, obesity & metabolism","Stamatiou A","63","15","9","none found",null],["R0007496",null,null,"10.1186/s12933-023-01877-6","37381019","PMC10303335","Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study.","2023","Cardiovascular diabetology","Sohn M","35","16","10","none found",null],["R0007501","CRD42024601021",null,"10.1177/01410768251395877","41359407","PMC12685696","The concentration-dependent protective effects by new generation hypoglycemic agents on delirium, depression, dementia and coma: evidence from a network meta-analysis.","2026","Journal of the Royal Society of Medicine","Tseng PT","25","11","2","PROSPERO","PROSPERO:CRD42024601021"],["R0007505",null,null,"10.1016/j.diabet.2020.04.001","32437914",null,"Glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints.","2020","Diabetes & metabolism","Patoulias D","44","20","8","none found",null],["R0007511",null,null,"10.1016/j.biopha.2024.116150","38242040",null,"Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysis.","2024","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","Li H","59","38","31","none found",null],["R0007512","CRD42023400899",null,"10.1007/s00592-023-02154-4","37439858",null,"Blood pressure-lowering effects of SGLT2 inhibitors and GLP-1 receptor agonists for preventing of cardiovascular events and death in type 2 diabetes: a systematic review and meta-analysis.","2023","Acta diabetologica","Diallo A","27","7","6","PROSPERO","PROSPERO:CRD42023400899"],["R0007513",null,null,"10.1016/j.jcte.2024.100333","38449772","PMC10915596","GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)? A systematic review.","2024","Journal of clinical & translational endocrinology","Aoun L","41","19","4","none found",null],["R0007529","CRD42021283449",null,"10.3390/ph18050668","40430487","PMC12114739","The Efficacy and Safety of Tirzepatide in Patients with Diabetes and/or Obesity: Systematic Review and Meta-Analysis of Randomized Clinical Trials.","2025","Pharmaceuticals (Basel, Switzerland)","Liu L","50","33","15","PROSPERO","PROSPERO:CRD42021283449"],["R0007532",null,null,"10.1007/s00592-017-1031-9","28748377",null,"Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials.","2017","Acta diabetologica","Dicembrini I","23","10","4","none found",null],["R0007533","CRD42022348576",null,"10.1038/s41366-023-01337-x","37460681",null,"Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials.","2023","International journal of obesity (2005)","de Mesquita YLL","31","21","11","PROSPERO","PROSPERO:CRD42022348576"],["R0007536",null,null,"10.1002/edm2.163","32704576","PMC7375121","Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review.","2020","Endocrinology, diabetes & metabolism","Lv X","100","33","15","none found",null],["R0007554","CRD42018091598",null,"10.3390/healthcare9091125","34574899","PMC8466858","Weekly Semaglutide vs. Liraglutide Efficacy Profile: A Network Meta-Analysis.","2021","Healthcare (Basel, Switzerland)","Alsugair HA","39","28","14","PROSPERO","PROSPERO:CRD42018091598"],["R0007559",null,null,"10.3390/metabo12020183","35208256","PMC8879165","Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Studies.","2022","Metabolites","Caruso I","54","50","16","none found",null],["R0007563","CRD420251008614",null,"10.1177/17562864251378845","41180125","PMC12575947","The effect of GLP-1 agonist on idiopathic intracranial hypertension: a systematic review and meta-analysis.","2025","Therapeutic advances in neurological disorders","Ahmad J","33","16","1","PROSPERO","PROSPERO:CRD420251008614"],["R0007570",null,null,"10.1016/j.ejphar.2020.173823","33352183",null,"The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.","2021","European journal of pharmacology","Nowrouzi-Sohrabi P","56","28","8","none found",null],["R0007572","CRD42024538847",null,"10.1186/s12872-025-05278-3","41272444","PMC12752371","Cardiovascular benefits of semaglutide: a systematic review and meta-analysis of randomized controlled trials.","2025","BMC cardiovascular disorders","Sadraei S","52","34","9","PROSPERO","PROSPERO:CRD42024538847"],["R0007590",null,null,"10.1111/dom.15226","37529868",null,"Cardiovascular prevention with glucose-lowering drugs in type 2 diabetes: An evidence-based approach to the categories of primary and secondary prevention.","2023","Diabetes, obesity & metabolism","Mannucci E","38","7","6","none found",null],["R0007594","CRD42018090506",null,"10.1007/s11606-021-07105-9","34508290","PMC8810987","The Longer-Term Benefits and Harms of Glucagon-Like Peptide-1 Receptor Agonists: a Systematic Review and Meta-Analysis.","2022","Journal of general internal medicine","Alexander JT","34","25","6","PROSPERO","PROSPERO:CRD42018090506"],["R0007597",null,null,"10.2174/0115748863330434241015125302","39484756",null,"Role of Dual GIP and GLP-1 Receptor Agonist, Tirzepatide in the Management of Weight Loss; A Systematic Review.","2026","Current drug safety","Rangraze IR","0","0","0","none found",null],["R0007598",null,null,"10.1111/obr.13811","39134066",null,"Safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in patients with weight regain or insufficient weight loss after metabolic bariatric surgery: A systematic review and meta-analysis.","2024","Obesity reviews : an official journal of the International Association for the Study of Obesity","Esparham A","59","22","9","none found",null],["R0007603",null,null,"10.1111/obr.70198","42483841",null,"Cardiovascular Outcomes of GLP-1-Based Medicines Among People With Overweight and Obesity: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials.","2026","Obesity reviews : an official journal of the International Association for the Study of Obesity","Rashid M","50","28","14","none found",null],["R0007604","CRD42021248314",null,"10.1007/s40265-022-01779-z","36129662",null,"The Effect of Oral Antidiabetic Drugs on Improving the Endocrine and Metabolic States in Women with Polycystic Ovary Syndrome: A Systematic Review and Network Meta-analysis.","2022","Drugs","Yang S","25","5","2","PROSPERO","PROSPERO:CRD42021248314"],["R0007618",null,null,"10.1093/annalsats/aaoag177","42479131",null,"Respiratory Adverse Events of Weight-Loss Drugs: A Systematic Review and Meta-Analysis.","2026","Annals of the American Thoracic Society","Zeng L","0","0","0","none found",null],["R0007622",null,null,"10.1007/s11606-026-10178-z","41838266","PMC13421548","Association of Social Determinants of Health with Utilization of SGLT2 Inhibitors and GLP1 Receptor Agonists: A Systematic Review and Meta-Analysis.","2026","Journal of general internal medicine","Shah N","43","23","2","none found",null],["R0007624",null,null,"10.1080/00325481.2020.1788340","32643514",null,"Practical guidance for use of oral semaglutide in primary care: a narrative review.","2020","Postgraduate medicine","Morales J","75","39","20","none found",null],["R0007676",null,null,"10.1210/clinem/dgae602","39210612",null,"Low C-Reactive Protein Alleles in Hepatocyte Nuclear Factor 1A Are Associated With an Increased Risk of Cardiovascular Disease.","2025","The Journal of clinical endocrinology and metabolism","Yang C","87","3","1","none found",null],["R0007678",null,null,"10.2147/ccid.s591676","41869434","PMC13005274","Effectiveness and Safety of Antidiabetic Medications in Hidradenitis Suppurativa: A Systematic Review.","2026","Clinical, cosmetic and investigational dermatology","Almukhadeb E","31","7","0","none found",null],["R0007680",null,null,"10.1111/dom.14066","32372425",null,"Number needed to treat in cardiovascular outcome trials of glucagon-like peptide-1 receptor agonists: A systematic review with temporal analysis.","2020","Diabetes, obesity & metabolism","Davies MJ","18","8","2","none found",null],["R0007696",null,null,"10.1016/j.diabres.2021.108656","33434602",null,"Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.","2021","Diabetes research and clinical practice","Li J","0","0","0","none found",null],["R0007697",null,null,"10.2174/1573399813666170414101450","28413990",null,"Effect of Glucagon-like Peptide-1 Receptor Agonists on All-cause Mortality and Cardiovascular Outcomes: A Meta-analysis.","2018","Current diabetes reviews","Peterson SC","0","0","0","none found",null],["R0007703",null,null,"10.1111/dom.70742","41992023","PMC13243969","Cardiometabolic Profiles of Oral and Subcutaneous Glucagon-Like Peptide-1 Receptor Mono-Agonists in Adults With Overweight or Obesity: A Systematic Review and Network Meta-Analysis.","2026","Diabetes, obesity & metabolism","Lu Y","13","7","0","none found",null],["R0007707",null,null,"10.7326/m15-1432","26642233",null,"Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments: A Systematic Review and Network Meta-analysis.","2016","Annals of internal medicine","Zaccardi F","65","45","33","none found",null],["R0007709",null,null,"10.2337/dc21-1722","35349656",null,"Comparable Cardiorenal Benefits of SGLT2 Inhibitors and GLP-1RAs in Asian and White Populations: An Updated Meta-analysis of Results From Randomized Outcome Trials.","2022","Diabetes care","Tang H","37","10","7","none found",null],["R0007716",null,null,"10.1016/j.dsx.2022.102427","35217468",null,"Adverse drug reactions of GLP-1 agonists: A systematic review of case reports.","2022","Diabetes & metabolic syndrome","Shetty R","137","76","1","none found",null],["R0007718",null,null,"10.1016/j.jad.2026.121310","41621451",null,"The effect of glucagon-like peptide 1 (GLP-1) receptor agonists on cognition: A systematic review of systematic reviews and meta-analyses.","2026","Journal of affective disorders","Ballum H","43","19","3","none found",null],["R0007721",null,null,"10.1111/dom.14399","33830637",null,"Glucagon-like peptide-1 receptor agonists improve biomarkers of inflammation and oxidative stress: A systematic review and meta-analysis of randomised controlled trials.","2021","Diabetes, obesity & metabolism","Bray JJH","90","47","37","none found",null],["R0007744","CRD42022371697",null,"10.3389/fendo.2026.1870008","42718598","PMC13553220","Use of incretin receptor agonists in patients submitted to metabolic bariatric surgery - a systematic review and meta-analysis.","2026","Frontiers in endocrinology","Santos-Pereira M","59","43","14","PROSPERO","PROSPERO:CRD42022371697"],["R0007747",null,null,"10.1007/s13300-020-00882-2","32734559","PMC7434822","Subpopulation Differences in the Cardiovascular Efficacy of Long-Acting Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis.","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","He L","31","23","11","none found",null],["R0007754",null,null,"10.1038/s41390-025-04228-1","40588554",null,"GLP-1 receptor agonists for the treatment of obesity in children and adolescents: a meta-analysis of randomized controlled trials.","2026","Pediatric research","Romariz LM","24","14","10","none found",null],["R0007758",null,null,"10.1111/obr.13717","38463003",null,"Potent incretin-based therapy for obesity: A systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety.","2024","Obesity reviews : an official journal of the International Association for the Study of Obesity","Müllertz ALO","75","25","17","none found",null],["R0007761",null,null,"10.1007/s10354-025-01108-5","40900212",null,"Treatment outcomes and safety profile of SGLT2 inhibitors versus GLP-1 agonists in type 2 diabetes mellitus : Systematic review of real-world observational studies.","2026","Wiener medizinische Wochenschrift (1946)","Alam A","45","31","5","none found",null],["R0007763",null,null,"10.1161/strokeaha.119.027557","31813360",null,"Glucagon-Like Peptide-1 Receptor Agonists and Prevention of Stroke Systematic Review of Cardiovascular Outcome Trials With Meta-Analysis.","2020","Stroke","Bellastella G","13","10","7","none found",null],["R0007771",null,null,"10.1111/dom.15331","37869901",null,"Diabetes, antidiabetic medications and risk of dementia: A systematic umbrella review and meta-analysis.","2024","Diabetes, obesity & metabolism","Kuate Defo A","145","7","1","none found",null],["R0007773",null,null,"10.1007/s12020-026-04757-7","42603240",null,"Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis.","2026","Endocrine","Chen QX","62","52","33","none found",null],["R0007804",null,null,"10.1016/j.diabet.2022.101366","35760374",null,"Effect of glucagon-like peptide 1 receptor agonists on the renal protection in patients with type 2 diabetes: A systematic review and meta-analysis.","2022","Diabetes & metabolism","Li X","63","33","12","none found",null],["R0007811",null,null,"10.3389/fendo.2020.00553","32973680","PMC7466678","Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With Type 1 Diabetes: A Network Meta-Analysis.","2020","Frontiers in endocrinology","Kim YJ","66","11","8","none found",null],["R0007816",null,"osf.io/s3a5e","10.7326/annals-25-00478","41996180",null,"Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition : A Systematic Review.","2026","Annals of internal medicine","Batsis JA","141","78","63","OSF",null],["R0007819",null,null,"10.1016/j.amjms.2024.07.011","38977245",null,"Efficacy and safety of the combination or monotherapy with GLP-1 receptor agonists and SGLT-2 inhibitors in Type 2 diabetes mellitus: An update systematic review and meta-analysis.","2024","The American journal of the medical sciences","Tuersun A","26","17","8","none found",null],["R0007821",null,null,"10.2337/dc22-0772","37220263","PMC10234755","Cardiovascular and Renal Benefits of Novel Diabetes Drugs by Baseline Cardiovascular Risk: A Systematic Review, Meta-analysis, and Meta-regression.","2023","Diabetes care","Rodriguez-Valadez JM","60","19","14","none found",null],["R0007836",null,null,"10.1007/s13300-023-01391-8","36913143","PMC10126195","Comparative Efficacy of Novel Antidiabetic Drugs on Albuminuria Outcomes in Type 2 Diabetes: A Systematic Review.","2023","Diabetes therapy : research, treatment and education of diabetes and related disorders","Liu G","71","20","11","none found",null],["R0007838","CRD42018091306",null,"10.1111/dom.14008","32077218",null,"Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A systematic review and network meta-analysis.","2020","Diabetes, obesity & metabolism","Hussein H","36","10","4","PROSPERO","PROSPERO:CRD42018091306"],["R0007839",null,null,"10.7759/cureus.114404","42729808","PMC13564011","Diabetes, Adiposity, and Functional Phenotypes in HFpEF: A Systematic Review of Recent Treatment-Response Evidence.","2026","Cureus","Goshe M","20","8","6","none found",null],["R0007845",null,null,"10.1111/dom.14361","33606897",null,"Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors: A real-world study in two Italian cohorts.","2021","Diabetes, obesity & metabolism","Baviera M","47","12","2","none found",null],["R0007848",null,null,"10.3390/medicina58020224","35208548","PMC8878541","The Impact of GLP1 Agonists on Bone Metabolism: A Systematic Review.","2022","Medicina (Kaunas, Lithuania)","Daniilopoulou I","53","37","7","none found",null],["R0007849",null,null,"10.1002/osp4.70032","39720158","PMC11667760","Pancreatic Safety of Tirzepatide and Its Effects on Islet Cell Function: A Systematic Review and Meta-Analysis.","2024","Obesity science & practice","Kamrul-Hasan ABM","59","48","29","none found",null],["R0007856",null,null,"10.1016/j.clinthera.2023.06.008","37455226",null,"Effect of the Dual Glucose‐Dependent Insulinotropic Peptide/Gulcagon‐like Peptide 1 Receptor Agonist Tirzepatide on Lipid Profile and Waist Circumference: A Systematic Review and Meta‐analysis.","2023","Clinical therapeutics","Yu D","36","11","10","none found",null],["R0007875",null,"osf.io/gd67x","10.1016/j.metop.2024.100284","38699397","PMC11064603","Comparative efficacy and safety of weekly dulaglutide versus weekly insulin in type 2 diabetes: A network meta-analysis of randomized clinical trials.","2024","Metabolism open","Ayesh H","22","11","5","OSF",null],["R0007899",null,null,"10.1016/j.diabres.2021.109146","34780865",null,"Comparison of effects of SGLT-2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus patients with/without albuminuria: A systematic review and network meta-analysis.","2022","Diabetes research and clinical practice","Kawai Y","52","15","6","none found",null],["R0007900","CRD420251045700",null,"10.1186/s13048-026-02078-x","41862977","PMC13126963","The efficacy and safety of novel antidiabetic agents in polycystic ovary syndrome: a network meta-analysis.","2026","Journal of ovarian research","Lin J","72","33","18","PROSPERO","PROSPERO:CRD420251045700"],["R0007907",null,null,"10.3389/fendo.2024.1378291","38868747","PMC11167098","Liraglutide, a glucagon-like peptide-1 receptor agonist, inhibits bone loss in an animal model of osteoporosis with or without diabetes.","2024","Frontiers in endocrinology","Wu Z","54","19","2","none found",null],["R0007914",null,null,"10.1016/j.diabres.2019.107927","31733280",null,"Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.","2019","Diabetes research and clinical practice","Patoulias D","59","21","12","none found",null],["R0007915",null,null,"10.1002/edm2.70325","42673571","PMC13529306","Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate-Data Bayesian Longitudinal Meta-Analysis.","2026","Endocrinology, diabetes & metabolism","Kow CS","16","12","6","none found",null],["R0007944",null,null,"10.1016/j.eprac.2021.09.013","34606980",null,"Antidiabetic Medications for Type 2 Diabetics with Nonalcoholic Fatty Liver Disease: Evidence From a Network Meta-Analysis of Randomized Controlled Trials.","2022","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Ng CH","73","17","11","none found",null],["R0007947",null,null,"10.3389/fphys.2022.1028486","36419835","PMC9676496","Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients.","2022","Frontiers in physiology","Du L","19","13","4","none found",null],["R0007949",null,null,null,"27318907",null,"[Impact of glucagon-like peptide-1 receptor agonists on nasopharyngitis and upper respiratory tract infection among patients with type 2 diabetes: a network meta-analysis].","2016","Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences","Li ZX","0","0","0","none found",null],["R0007960",null,null,"10.2174/1381612827666210119103153","33463455",null,"Cardio-protective Effects of Glucagon-like Peptide-1 Receptor Agonists: An Overview of Systematic Reviews and Publication Overlap.","2021","Current pharmaceutical design","Zafeiropoulos S","0","0","0","none found",null],["R0007996",null,null,"10.1007/s40261-016-0389-8","26979594",null,"Tumour Risk with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients: A Systematic Review.","2016","Clinical drug investigation","Guo X","22","15","4","none found",null],["R0008003",null,null,"10.1007/s12020-020-02193-9","31927749",null,"Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes: a systematic review and meta-analysis of 21 randomized controlled trials.","2020","Endocrine","Qie S","1","0","0","none found",null],["R0008009",null,null,"10.1016/j.amjcard.2020.10.004","33045202",null,"Updated Meta-Analysis of Trials Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Black Patients.","2020","The American journal of cardiology","Patoulias D","0","0","0","none found",null],["R0008034",null,null,"10.1016/j.archger.2025.105981","40812084",null,"Efficacy of GLP-1 receptor agonists among older adults: a meta-analysis of cardio-kidney outcome trials.","2025","Archives of gerontology and geriatrics","Waqas SA","50","36","18","none found",null],["R0008035",null,null,"10.1016/j.dsx.2021.102382","35030451",null,"Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A meta-analysis with the FREEDOM cardiovascular outcomes trial.","2022","Diabetes & metabolic syndrome","Lee MMY","4","2","1","none found",null],["R0008037",null,null,"10.1186/s12933-021-01366-8","34526024","PMC8442438","GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs.","2021","Cardiovascular diabetology","Giugliano D","33","24","11","none found",null],["R0008058",null,null,"10.1016/j.diabet.2018.09.002","30243806",null,"Comparing once-weekly semaglutide to incretin-based therapies in patients with type 2 diabetes: a systematic review and meta-analysis.","2019","Diabetes & metabolism","Mishriky BM","36","16","9","none found",null],["R0008067",null,null,"10.1111/dom.13522","30187620",null,"Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis.","2019","Diabetes, obesity & metabolism","Siskind D","60","16","6","none found",null],["R0008069",null,null,"10.1007/s12325-023-02612-z","37515713","PMC10499965","Cost-Effectiveness of Newer Antidiabetic Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review.","2023","Advances in therapy","Zhu J","46","18","4","none found",null],["R0008083",null,null,"10.14336/ad.2019.0303","31788342","PMC6844583","Neurological Manifestation of Incretin-Based Therapies in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.","2019","Aging and disease","Gao L","39","19","0","none found",null],["R0008093",null,null,"10.1177/1060028020935105","32571083",null,"A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease.","2021","The Annals of pharmacotherapy","Dougherty JA","71","20","8","none found",null],["R0008096",null,null,"10.17235/reed.2020.6392/2019","32496108",null,"The efficacy of glucagon-like peptide 1 receptor agonists in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials.","2020","Revista espanola de enfermedades digestivas","Fan S","0","0","0","none found",null],["R0008098",null,null,"10.1016/j.diabres.2014.01.010","24485345",null,"Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials.","2014","Diabetes research and clinical practice","Monami M","16","11","0","none found",null],["R0008100",null,null,"10.1007/s40618-017-0698-7","28569363",null,"Glucagon-like peptide-1 receptor agonists and atrial fibrillation: a systematic review and meta-analysis of randomised controlled trials.","2017","Journal of endocrinological investigation","Monami M","22","13","3","none found",null],["R0008104",null,null,"10.1016/j.jacc.2023.05.048","37532422",null,"GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes.","2023","Journal of the American College of Cardiology","Neves JS","26","17","8","none found",null],["R0008110",null,null,"10.1111/dom.14997","36722252",null,"Glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: A meta-analysis of randomized placebo-controlled outcome trials.","2023","Diabetes, obesity & metabolism","Ferreira JP","31","15","13","none found",null],["R0008120",null,null,"10.1038/s41598-021-89620-7","33986377","PMC8119733","Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients.","2021","Scientific reports","Uneda K","47","19","11","none found",null],["R0008129",null,null,"10.1177/13872877251395086","41252314",null,"Incidence of dementia in patients with type 2 diabetes using SGLT2 inhibitors versus GLP-1 receptor agonists or DPP-4 inhibitors: A systematic review and meta-analysis of cohort studies.","2026","Journal of Alzheimer's disease : JAD","Milori PH","54","12","2","none found",null],["R0008131","CRD42024573542",null,"10.1038/s41366-025-01860-z","40715579","PMC12532613","Effects of weight control interventions on cardiovascular outcomes: an umbrella review of systematic reviews and meta-analyses.","2025","International journal of obesity (2005)","Chen X","65","20","1","PROSPERO","PROSPERO:CRD42024573542"],["R0008137","CRD42023429701",null,"10.1007/s00228-023-03561-w","37682287",null,"Comparison of the efficacy and safety of hypoglycemic treatments in patients with non-alcoholic fatty liver disease and type-2 diabetes: a systematic review and Bayesian network analysis.","2023","European journal of clinical pharmacology","Guo N","35","9","5","PROSPERO","PROSPERO:CRD42023429701"],["R0008141",null,null,"10.1002/oby.23563","36321278",null,"Weight loss between glucagon-like peptide-1 receptor agonists and bariatric surgery in adults with obesity: A systematic review and meta-analysis.","2022","Obesity (Silver Spring, Md.)","Sarma S","57","21","14","none found",null],["R0008155",null,null,"10.3389/fendo.2023.1215356","37881498","PMC10597691","Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence.","2023","Frontiers in endocrinology","Muller DRP","38","10","2","none found",null],["R0008175",null,null,"10.1016/j.amjcard.2021.05.043","34266665",null,"Usefulness of Glucagon-Like Peptide-1 Receptor Agonists to Reduce Adverse Cardiovascular Disease Events in Patients with Type 2 Diabetes Mellitus.","2021","The American journal of cardiology","Grewal S","29","11","7","none found",null],["R0008184",null,null,"10.1210/jendso/bvaf075","40607042","PMC12214030","Effect of GLP-1 RA and SGLT2I on Biomarkers of Oxidative Stress in T2DM: A Systematic Review and Meta-analysis.","2025","Journal of the Endocrine Society","Wei H","54","11","6","none found",null],["R0008186",null,null,"10.1002/pds.5550","36224724",null,"A systematic review and meta-analysis of observational studies of the association between the use of incretin-based therapies and the risk of pancreatic cancer.","2023","Pharmacoepidemiology and drug safety","Hidayat K","57","23","1","none found",null],["R0008191",null,null,"10.1186/s12933-023-01775-x","36894938","PMC9999488","Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes.","2023","Cardiovascular diabetology","Ferdinand KC","46","24","9","none found",null],["R0008197",null,null,"10.1111/ijcp.13553","32452094",null,"Cardiovascular outcomes, heart failure and mortality in type 2 diabetic patients treated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs): A systematic review and meta-analysis of observational cohort studies.","2020","International journal of clinical practice","Herrera Comoglio R","0","0","0","none found",null],["R0008199",null,null,"10.1016/j.clinre.2022.101970","35659603",null,"Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: A systematic review and meta-analysis.","2022","Clinics and research in hepatology and gastroenterology","Zafar Y","30","6","1","none found",null],["R0008209",null,null,"10.2337/dc26-1127","42627353",null,"Cardiometabolic Effects of Dual GLP-1 and Glucagon Receptor Agonists: A Systematic Review and Meta-analysis of Randomized Controlled Trials.","2026","Diabetes care","Roessler J","0","0","0","none found",null],["R0008226",null,null,"10.1016/j.metabol.2020.154190","32109448",null,"Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies.","2020","Metabolism: clinical and experimental","Morieri ML","39","31","12","none found",null],["R0008236",null,null,"10.1007/s43032-023-01222-y","37002532","PMC10354168","The Effectiveness and Safety of Exenatide Versus Metformin in Patients with Polycystic Ovary Syndrome: A Meta-Analysis of Randomized Controlled Trials.","2023","Reproductive sciences (Thousand Oaks, Calif.)","Ye ZR","53","17","5","none found",null],["R0008257",null,null,"10.4093/dmj.2018.0070","30604598","PMC6712219","Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials.","2019","Diabetes & metabolism journal","Kang YM","11","7","2","none found",null],["R0008259",null,null,"10.1155/2020/1626484","33061964","PMC7539133","Comparing the Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists with Sodium-Glucose Cotransporter 2 Inhibitors for Obese Type 2 Diabetes Patients Uncontrolled on Metformin: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.","2020","International journal of endocrinology","Ding L","22","9","4","none found",null],["R0008269",null,null,"10.1111/dom.13888","31595657",null,"Glucagon-like peptide-1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: An updated meta-analysis and subgroup analysis of randomized controlled trials.","2020","Diabetes, obesity & metabolism","Mannucci E","33","21","11","none found",null],["R0008270",null,null,"10.2337/dc20-0498","32910778",null,"Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis.","2020","Diabetes care","Huthmacher JA","44","31","21","none found",null],["R0008277",null,null,"10.1186/s12902-022-01036-0","35546664","PMC9097124","Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials.","2022","BMC endocrine disorders","Qin J","30","16","7","none found",null],["R0008290",null,null,"10.1097/js9.0000000000003450","40990658","PMC12825905","The different colorectal tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 68 randomized controlled trials.","2026","International journal of surgery (London, England)","Hung CM","114","61","38","none found",null],["R0008294",null,null,"10.1111/dom.70224","41147324","PMC12673457","Comparison of the renal outcomes of novel antidiabetic agents in patients with type 2 diabetes with chronic kidney disease: A systematic review and network meta-analysis of randomized controlled trials.","2026","Diabetes, obesity & metabolism","Lin R","53","14","8","none found",null],["R0008307",null,null,"10.1186/s12933-023-01738-2","36721184","PMC9890718","Efficacy of cardiometabolic drugs in reduction of epicardial adipose tissue: a systematic review and meta-analysis.","2023","Cardiovascular diabetology","Myasoedova VA","64","13","5","none found",null],["R0008310",null,null,"10.7759/cureus.100224","41607973","PMC12835569","Outcomes of Beinaglutide on Weight Loss in Patients With Diabetes or Obesity: A Systematic Review and Meta-Analysis.","2025","Cureus","Wen J","29","23","8","none found",null],["R0008317",null,null,"10.1097/hjh.0000000000004158","41230897",null,"Ambulatory blood pressure monitoring strengthens the cardiovascular signal of GLP-1RA: a meta-analysis of blood pressure and weight mediation.","2026","Journal of hypertension","Renna NF","19","10","10","none found",null],["R0008336",null,null,"10.3967/bes2020.005","32029057",null,"Effects of Incretin-based Therapies on Weight-related Indicators among Patients with Type 2 Diabetes: A Network Meta-analysis.","2020","Biomedical and environmental sciences : BES","Xu L","0","0","0","none found",null],["R0008343",null,null,"10.1007/s00592-017-1054-2","28932989",null,"Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trials.","2017","Acta diabetologica","Monami M","44","25","21","none found",null],["R0008357",null,null,"10.1080/08998280.2025.2480512","40557198","PMC12184113","Evaluating the efficacy and safety of survodutide for obesity: a systematic review and meta-analysis of randomized controlled trials.","2025","Proceedings (Baylor University. Medical Center)","Awad AA","26","17","7","none found",null],["R0008358",null,null,"10.70252/fhzh8622","40190743","PMC11970413","Comparative Effects of Exercise and GLP-1 RAs on Type 2 Diabetic Rat Model: A Systematic Review.","2025","International journal of exercise science","Afzal S","29","13","4","none found",null],["R0008362",null,null,"10.1016/j.dsx.2022.102696","36596264",null,"Glucagon-like peptide 1-receptor agonists and A1c: Good for the heart but less so for the eyes?","2023","Diabetes & metabolic syndrome","Albert SG","37","26","17","none found",null],["R0008375",null,null,"10.1007/s13300-016-0155-1","26886440","PMC4801811","A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus.","2016","Diabetes therapy : research, treatment and education of diabetes and related disorders","Kayaniyil S","43","36","24","none found",null],["R0008381",null,null,"10.1007/s12020-020-02223-6","32103407",null,"GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: data from cardiovascular outcome trials.","2020","Endocrine","Cao C","33","17","8","none found",null],["R0008382","CRD42024595241",null,"10.2174/0118743064372550250603061720","41036293","PMC12481593","GLP-1 Agonists and the Risk of Pulmonary Aspiration during Elective Upper Endoscopy: A Systematic Review and Meta-analysis.","2025","The open respiratory medicine journal","Elmati PR","34","28","2","PROSPERO","PROSPERO:CRD42024595241"],["R0008387","CRD420251150683",null,"10.3389/fendo.2026.1937754","42775225","PMC13595571","Efficacy and safety of GLP-1RAs, SGLT2is, and nsMRAs for cardiovascular and renal outcomes in T2DM with CKD: a systematic review and network meta-analysis.","2026","Frontiers in endocrinology","Chen H","66","24","9","PROSPERO","PROSPERO:CRD420251150683"],["R0008389",null,null,"10.1002/mdc3.13893","37982117","PMC10654811","Meta-analysis of Association between Newer Glucose-Lowering Drugs and Risk of Parkinson's Disease.","2023","Movement disorders clinical practice","Tang H","39","12","9","none found",null],["R0008407",null,null,"10.1111/dom.71058","42410325","PMC13538747","Efficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis.","2026","Diabetes, obesity & metabolism","Kamrul-Hasan ABM","42","28","10","none found",null],["R0008421",null,null,"10.1111/jdi.13872","35726690","PMC9889671","Characteristics of subjects with type 2 diabetes enrolled in randomized controlled trials and non-randomized controlled trials in Japan: A systematic review.","2023","Journal of diabetes investigation","Kadowaki T","19","4","0","none found",null],["R0008422",null,null,"10.1038/s41366-026-02118-y","42321502","PMC13461373","Effect of GLP-1 receptor agonists at doses for obesity management on muscle health: systematic review and meta-analysis of randomized controlled trials (RCTs).","2026","International journal of obesity (2005)","Laverde LP","27","18","10","none found",null],["R0008428",null,null,"10.21203/rs.3.rs-3150409/v1",null,null,"Clinical assessment of liraglutide use in prediabetic and obese schizophrenic patients: A systematic literature review and meta-analysis","2023","Research Square","Abbas A",null,"0","0","none found",null],["R0008431","CRD42019138777",null,"10.1007/s00592-020-01529-1","32300876",null,"The effects of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide 1 receptor agonists on cognitive functions in adults with type 2 diabetes mellitus: a systematic review and meta-analysis.","2020","Acta diabetologica","Jin Y","2","0","0","PROSPERO","PROSPERO:CRD42019138777"],["R0008432","CRD42024571544",null,"10.3389/fphar.2025.1517272","40213686","PMC11983143","Clinical efficacy and safety of sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor, glucagon-like peptide-1 (GLP-1) receptor agonist, and Finerenone in type 2 diabetes mellitus with non-dialysis chronic kidney disease: a network meta-analysis of randomized clinical trials.","2025","Frontiers in pharmacology","Guo J","78","19","3","PROSPERO","PROSPERO:CRD42024571544"],["R0008439",null,null,"10.1007/s00464-026-12940-0","42260171",null,"Differential impact of glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss in the type 2 diabetic and non-diabetic populations.","2026","Surgical endoscopy","Jia IT","35","33","21","none found",null],["R0008445",null,null,"10.2147/dmso.s130834","28435305","PMC5389657","Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research.","2017","Diabetes, metabolic syndrome and obesity : targets and therapy","Levin PA","77","74","50","none found",null],["R0008457",null,null,"10.7759/cureus.90335","40978842","PMC12444735","Comparative Efficacy and Tolerability of Tirzepatide Versus Semaglutide at Varying Doses for Weight Loss in Non-diabetic Adults With Obesity: A Network Meta-Analysis of Randomized Controlled Trials.","2025","Cureus","Kasagga A","24","17","9","none found",null],["R0008459",null,null,"10.1371/journal.pone.0154206","27158818","PMC4861281","Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.","2016","PloS one","Li Z","129","90","76","none found",null],["R0008468",null,null,"10.3389/fendo.2022.910256","36034440","PMC9403613","Effects of GLP-1 receptor agonists on arrhythmias and its subtypes in patients with type 2 diabetes: A systematic review and meta-analysis.","2022","Frontiers in endocrinology","Wei J","47","29","11","none found",null],["R0008469",null,null,"10.1101/2022.02.06.22270446",null,null,"Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis","2022","medRxiv","Ma H",null,"0","0","none found",null],["R0008499",null,null,"10.1016/j.jacc.2025.03.516","40368575","PMC12186526","Effects of Tirzepatide in Type 2 Diabetes: Individual Variation and Relationship to Cardiometabolic Outcomes.","2025","Journal of the American College of Cardiology","Aminorroaya A","30","19","13","none found",null],["R0008514",null,null,"10.1080/09513590.2019.1703943","31858859",null,"The effect of dipeptidyl peptidase-4 inhibitor and glucagon-like peptide-1 receptor agonist in gestational diabetes mellitus: a systematic review.","2020","Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology","Chen C","39","6","4","none found",null],["R0008519",null,null,"10.1002/dmrr.3168","30974033",null,"Glucagon-like peptide-1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.","2019","Diabetes/metabolism research and reviews","Cheng L","30","14","4","none found",null],["R0008520",null,null,"10.1155/2019/1534365","31396537","PMC6664552","Risk of Malignant Neoplasia with Glucagon-Like Peptide-1 Receptor Agonist Treatment in Patients with Type 2 Diabetes: A Meta-Analysis.","2019","Journal of diabetes research","Liu Y","52","47","35","none found",null],["R0008551","CRD42024532368",null,"10.1007/s00592-025-02534-y","40471293","PMC12433336","Beyond GLP-1: efficacy and safety of dual and triple incretin agonists in personalized type 2 diabetes care-a systematic review and network meta-analysis.","2025","Acta diabetologica","Yan K","38","34","14","PROSPERO","PROSPERO:CRD42024532368"],["R0008562",null,null,"10.1111/dom.13847","31373167",null,"GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis including the REWIND and PIONEER 6 trials.","2019","Diabetes, obesity & metabolism","Giugliano D","24","17","12","none found",null],["R0008574",null,null,"10.1111/dom.70915","42219271","PMC13341365","The Impact of GLP-1-Based Therapies on Cardiovascular Outcomes in Type 2 Diabetes: A Comprehensive Systematic Review and Network Meta-Analysis.","2026","Diabetes, obesity & metabolism","Chuang SM","33","23","16","none found",null],["R0008581",null,null,"10.1007/s40292-026-00812-6","42371360",null,"Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials.","2026","High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension","Simental-Mendía LE","37","14","7","none found",null],["R0008591",null,null,"10.1016/j.diabres.2021.108737","33705820",null,"GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis.","2021","Diabetes research and clinical practice","Karagiannis T","45","14","10","none found",null],["R0008592",null,null,"10.1155/2012/672658","22675341","PMC3362858","Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis.","2012","Experimental diabetes research","Monami M","33","29","22","none found",null],["R0008593",null,null,"10.1530/ec-18-0546","30694794","PMC6410765","Incretin-based therapies for patients with type 1 diabetes: a meta-analysis.","2019","Endocrine connections","Liu L","36","15","8","none found",null],["R0008613",null,null,"10.1177/20420986231178126","37332886","PMC10272677","Risk of lower limb amputation in diabetic patients using SGLT2 inhibitors versus DPP4 inhibitors or GLP-1 agonists: a meta-analysis of 2 million patients.","2023","Therapeutic advances in drug safety","Lu Y","32","14","2","none found",null],["R0008628","CRD42025649619",null,"10.1016/j.dsx.2025.103303","41151201",null,"Interventions for prediabetes: an umbrella review of systematic reviews and meta-analyses of randomized controlled trials.","2025","Diabetes & metabolic syndrome","Veronese N","43","5","1","PROSPERO","PROSPERO:CRD42025649619"],["R0008649",null,"osf.io/3fgu8","10.1097/md.0000000000020343","32481324","PMC7249859","Acupuncture for patients with glucagon-like peptide-1 receptor agonists-induced nausea and vomiting: A systematic review protocol.","2020","Medicine","Ding N","19","10","7","OSF",null],["R0008656",null,null,"10.1177/15209156261420404","41640110",null,"Efficacy and Safety of Oral GLP-1 RA Orforglipron on Weight and Glycemic Control According to Diabetes Status: A Systematic Review and Meta-Analysis.","2026","Diabetes technology & therapeutics","Hammad N","12","9","6","none found",null],["R0008676",null,null,"10.1016/j.phrs.2022.106094","35074527",null,"Antidiabetic medications and the risk of prostate cancer in patients with diabetes mellitus: A systematic review and meta-analysis.","2022","Pharmacological research","Cui H","119","8","4","none found",null],["R0008685","CRD42024565439",null,"10.3389/fendo.2025.1627909","41210503","PMC12588854","GLP1 receptor agonists and SGLT2 inhibitors for the prevention or delay of type 2 diabetes mellitus onset: a systematic review and meta-analysis.","2025","Frontiers in endocrinology","Ghobar F","25","9","6","PROSPERO","PROSPERO:CRD42024565439"],["R0008689",null,null,"10.1007/s11695-025-07723-w","39910018",null,"The Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonists for Insufficient Weight Loss or Regain After Metabolic/Bariatric Surgery: A Systematic Review and Meta-analysis.","2025","Obesity surgery","Kellett J","35","17","7","none found",null],["R0008695",null,null,"10.1016/j.diabres.2021.109080","34626677",null,"Association between novel Glucose-Lowering drugs and risk of Asthma: A network Meta-Analysis of cardiorenal outcome trials.","2022","Diabetes research and clinical practice","Wang A","40","10","7","none found",null],["R0008704",null,null,"10.1111/bcp.15304","35277985",null,"Effect of glucagon-like peptide-1 receptor agonists on renal function: A meta-analysis of randomized controlled trials.","2022","British journal of clinical pharmacology","Simental-Mendía M","40","18","13","none found",null],["R0008709",null,null,"10.3389/fendo.2026.1869479","42676363","PMC13526671","Efficacy of SGLT2 inhibitors, GLP-1 receptor agonists, and aerobic exercise for moderate-to-severe obstructive sleep apnea in overweight or obese patients: a network meta-analysis.","2026","Frontiers in endocrinology","Zheng J","69","17","7","none found",null],["R0008731",null,"osf.io/dm2nc","10.1186/s12967-026-08219-6","42192439","PMC13386775","Efficacy of pharmacotherapies in improving liver fibrosis among patients with MASLD and fibrosis stages of F1-F3: systematic review and network meta-analysis.","2026","Journal of translational medicine","Sun XY","58","9","3","OSF",null],["R0008749",null,null,"10.1016/j.ijcard.2017.03.163","28501352",null,"Effects of glucagon-like peptide-1 receptor agonists on mortality and cardiovascular events: A comprehensive meta-analysis of randomized controlled trials.","2017","International journal of cardiology","Monami M","24","15","3","none found",null],["R0008780",null,null,"10.3389/fphar.2026.1859388","42453588","PMC13365254","Anti-obesity medications and cognitive disorder risk: a discrepancy between RCTs and real-world evidence.","2026","Frontiers in pharmacology","Li C","23","12","3","none found",null],["R0008792",null,null,"10.1016/j.diabres.2022.110019","35931222",null,"Effectiveness and safety of new oral and injectable agents for in-hospital management of type 2 diabetes in general wards: Systematic review and meta-analysis.","2022","Diabetes research and clinical practice","Soto-Chávez MJ","0","0","0","none found",null],["R0008793","CRD420251008819",null,"10.1186/s13098-026-02163-7","42316327","PMC13523518","Cardiovascular outcomes of semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis.","2026","Diabetology & metabolic syndrome","Zhou XY","70","65","48","PROSPERO","PROSPERO:CRD420251008819"],["R0008804",null,null,"10.1016/j.acra.2025.09.020","41033966",null,"Diagnostic Performance of Exendin-4 PET/CT in Localizing Insulinomas: A Systematic Review and Meta-analysis.","2025","Academic radiology","Qi-Chang W","47","24","2","none found",null],["R0008812",null,null,"10.1159/000528026","36623489",null,"Effect of Different Types of Hypoglycemic Medications on Psoriasis: An Analysis of Current Evidence.","2023","Dermatology (Basel, Switzerland)","Sun X","0","0","0","none found",null],["R0008827",null,null,"10.1111/jgs.18306","36821780","PMC10363181","Newer glucose-lowering drugs and risk of dementia: A systematic review and meta-analysis of observational studies.","2023","Journal of the American Geriatrics Society","Tang H","54","12","7","none found",null],["R0008838",null,null,"10.1111/dom.15519","38425176",null,"Assessing the potential for precision medicine in body weight reduction with regard to type 2 diabetes mellitus therapies: A meta-regression analysis of 120 randomized controlled trials.","2024","Diabetes, obesity & metabolism","Vargas KG","27","10","4","none found",null],["R0008844","CRD42021256363",null,"10.1177/14791641221106866","35686694","PMC9189550","Hypoglycemic agents and glycemic variability in individuals with type 2 diabetes: A systematic review and network meta-analysis.","2022","Diabetes & vascular disease research","Oh S","61","10","4","PROSPERO","PROSPERO:CRD42021256363"],["R0008851",null,null,"10.1007/s40292-026-00814-4","42458197",null,"Exploratory Cardiovascular Risk Modeling of Orforglipron Using the PREVENT Equations Compared with the Pooled Cohort Equations: A Post-Hoc Analysis from a Systematic Review and Meta-analysis.","2026","High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension","Alper A","21","7","4","none found",null],["R0008853",null,null,"10.1111/dom.12805","27717130","PMC5299485","Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis.","2017","Diabetes, obesity & metabolism","Singh S","38","28","18","none found",null],["R0008880",null,null,"10.1001/jamapsychiatry.2026.1814","42418179","PMC13347271","Pharmacological Interventions for Weight Reduction in Patients With Schizophrenia Treated With Antipsychotics: A Systematic Review and Network Meta-Analysis.","2026","JAMA psychiatry","Stogios N","27","4","0","none found",null],["R0008885",null,null,"10.1097/hep.0000000000001254","39903735","PMC12614381","Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis.","2025","Hepatology (Baltimore, Md.)","Souza M","54","6","4","none found",null],["R0008891",null,null,"10.1080/09513590.2025.2553052","40960939",null,"Meta-analysis of the effects of semaglutide on body mass index (BMI) and blood lipid levels in polycystic ovary syndrome patients.","2025","Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology","Chen W","40","26","5","none found",null],["R0008892",null,null,"10.1016/j.eclinm.2021.101213","34877513","PMC8633575","Association of Glucagon-like Peptide 1 Analogs and Agonists Administered for Obesity with Weight Loss and Adverse Events: A Systematic Review and Network Meta-analysis.","2021","EClinicalMedicine","Vosoughi K","92","78","72","none found",null],["R0008922","CRD420251003016",null,"10.1186/s13045-025-01750-x","41310711","PMC12661836","The gynecologic tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 91 randomized controlled trials.","2025","Journal of hematology & oncology","Tseng PT","141","71","54","PROSPERO","PROSPERO:CRD420251003016"],["R0008929",null,null,"10.1111/dom.14702","35665989","PMC9541855","Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: A systematic review and network meta-analysis.","2022","Diabetes, obesity & metabolism","Cao H","48","8","5","none found",null],["R0008935",null,null,"10.3390/ph14100991","34681215","PMC8537322","Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials.","2021","Pharmaceuticals (Basel, Switzerland)","Bhagavathula AS","23","12","5","none found",null],["R0008939","CRD42020159284",null,"10.1136/bmjopen-2021-049130","34244276","PMC8273479","Values, preferences and burden of treatment for the initiation of GLP-1 receptor agonists and SGLT-2 inhibitors in adult patients with type 2 diabetes: a systematic review.","2021","BMJ open","González-González JG","36","26","10","PROSPERO","PROSPERO:CRD42020159284"],["R0008988",null,null,"10.1016/j.diabres.2018.05.034","29857094",null,"The effect of glucagon-like peptide 1 and glucagon-like peptide 1 receptor agonists on energy expenditure: A systematic review and meta-analysis.","2018","Diabetes research and clinical practice","Maciel MG","57","20","8","none found",null],["R0008994",null,null,"10.7759/cureus.93065","41141191","PMC12549411","Efficacy and Safety of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Spinal Fusion Outcomes: A Comprehensive Meta-Analysis.","2025","Cureus","Zahed M","34","18","1","none found",null],["R0009013",null,null,"10.3390/ijms26178202","40943127","PMC12428495","The Preventive Effects of GLP-1 Receptor Agonists and SGLT2 Inhibitors on Cancer Metastasis: A Network Meta-Analysis of 67 Randomized Controlled Trials.","2025","International journal of molecular sciences","Hsu CW","173","104","88","none found",null],["R0009017","CRD42021251704",null,"10.3389/fendo.2022.923606","35909522","PMC9325993","GLP-1 RAs and SGLT-2 Inhibitors for Insulin Resistance in Nonalcoholic Fatty Liver Disease: Systematic Review and Network Meta-Analysis.","2022","Frontiers in endocrinology","Yan H","57","18","5","PROSPERO","PROSPERO:CRD42021251704"],["R0009032",null,null,"10.1038/s41591-025-03978-z","41039116","PMC12532627","A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults.","2025","Nature medicine","McGowan B","69","36","23","none found",null],["R0009037",null,null,"10.1159/000547055","40743996","PMC12503748","GLP-1 Receptor Analogs: Evidence Linking to Effect on Metabolic and Reproductive Functions in Patients with PCOS and Obesity.","2026","Obesity facts","Celik O","83","43","19","none found",null],["R0009048",null,null,"10.1586/17446651.2015.1057502","30058866",null,"A systematic review of the safety of incretin-based therapies in type 2 diabetes.","2016","Expert review of endocrinology & metabolism","Evans M","174","73","54","none found",null],["R0009050","CRD42022332052",null,"10.3389/fendo.2023.1303238","38239984","PMC10795175","Associations of antidiabetic drugs with diabetic retinopathy in people with type 2 diabetes: an umbrella review and meta-analysis.","2023","Frontiers in endocrinology","Tan L","49","21","1","PROSPERO","PROSPERO:CRD42022332052"],["R0009054",null,null,"10.1186/s10194-024-01821-3","38997662","PMC11241973","Glucagon-like peptide-1 (GLP-1) receptor agonists for headache and pain disorders: a systematic review.","2024","The journal of headache and pain","Halloum W","59","44","3","none found",null],["R0009060","CRD42022343601",null,"10.1016/j.diabres.2023.110592","36842477",null,"Efficacy and safety of drugs for people with type 2 diabetes mellitus and chronic kidney disease on kidney and cardiovascular outcomes: A systematic review and network meta-analysis of randomized controlled trials.","2023","Diabetes research and clinical practice","Yang Q","52","6","2","PROSPERO","PROSPERO:CRD42022343601"],["R0009062",null,null,"10.1016/j.clinre.2022.102053","36403941",null,"Comparative efficacy of diabetes medications on liver enzymes and fat fraction in patients with nonalcoholic fatty liver disease: A network meta-analysis,","2023","Clinics and research in hepatology and gastroenterology","Zou CY","74","22","15","none found",null],["R0009063",null,null,"10.1007/s13300-019-00706-y","31599391","PMC6848399","Orally Administered Semaglutide Versus GLP-1 RAs in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Antidiabetics: Systematic Review and Network Meta-Analysis.","2019","Diabetes therapy : research, treatment and education of diabetes and related disorders","Nuhoho S","80","58","48","none found",null],["R0009073",null,null,"10.1111/dom.13613","30536884",null,"The effects of incretin-based therapies on β-cell function and insulin resistance in type 2 diabetes: A systematic review and network meta-analysis combining 360 trials.","2019","Diabetes, obesity & metabolism","Wu S","34","12","3","none found",null],["R0009099","CRD42024599035",null,"10.1186/s12916-026-04824-w","41896878","PMC13147618","The adverse effects associated with tirzepatide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis.","2026","BMC medicine","Sillassen CDB","57","42","20","PROSPERO","PROSPERO:CRD42024599035"],["R0009107","CRD42023475226",null,"10.1007/s40256-024-00647-3","38734847",null,"Cardiovascular Benefits of GLP-1 Receptor Agonists in Patients Living with Obesity or Overweight: A Meta-analysis of Randomized Controlled Trials.","2024","American journal of cardiovascular drugs : drugs, devices, and other interventions","de Oliveira Almeida G","41","28","14","PROSPERO","PROSPERO:CRD42023475226"],["R0009127",null,null,"10.1080/00325481.2017.1297669","28294702",null,"Safety and efficacy of a glucagon-like peptide-1 receptor agonist added to basal insulin therapy versus basal insulin with or without a rapid-acting insulin in patients with type 2 diabetes: results of a meta-analysis.","2017","Postgraduate medicine","Wysham CH","48","35","21","none found",null],["R0009132","CRD42022371264",null,"10.1007/s00392-023-02362-6","38252145",null,"GLP-1-ra and heart failure-related outcomes in patients with and without history of heart failure: an updated systematic review and meta-analysis.","2024","Clinical research in cardiology : official journal of the German Cardiac Society","Villaschi A","37","22","13","PROSPERO","PROSPERO:CRD42022371264"],["R0009158",null,null,"10.3390/jcm11237094","36498669","PMC9740076","Choice of Glucose-Lowering Drugs as Initial Monotherapy for Type 2 Diabetes Patients with Contraindications or Intolerance to Metformin: A Systematic Review and Meta-Analysis.","2022","Journal of clinical medicine","Gu S","145","14","10","none found",null],["R0009170",null,null,"10.3390/ph18091337","41011208","PMC12472923","Efficacy of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Moderate-to-Severe COPD Exacerbations Among Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.","2025","Pharmaceuticals (Basel, Switzerland)","Pirera E","48","18","3","none found",null],["R0009189",null,null,"10.1007/s43032-025-01788-9","39881036",null,"Comparison of GLP-1 Receptor Agonists Combined with Metformin Versus Metformin Alone in the Management of PCOS: A Comprehensive Meta-Analysis.","2025","Reproductive sciences (Thousand Oaks, Calif.)","Zhao Y","27","16","8","none found",null],["R0009191",null,null,"10.1186/s12872-023-03324-6","37296380","PMC10251583","Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis.","2023","BMC cardiovascular disorders","Huang YL","43","7","2","none found",null],["R0009195",null,null,"10.3390/pharmaceutics18010086","41599194","PMC12844962","The Effect of GLP-1 Agonists on Patients with Metabolic-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis.","2026","Pharmaceutics","Tornea DA","50","30","23","none found",null],["R0009215",null,null,"10.7759/cureus.114962","42769739","PMC13591238","Long-Term Clinical Outcomes and Real-World Effectiveness of Tirzepatide in Adults With Overweight or Obesity: A Systematic Review.","2026","Cureus","Olaniyi AO","57","33","18","none found",null],["R0009216",null,null,"10.1186/s12933-022-01676-5","36335326","PMC9637313","Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease.","2022","Cardiovascular diabetology","Zhang Y",null,"0","0","none found",null],["R0009227",null,null,"10.3390/jcm11185435","36143082","PMC9504435","Comparison of Glucose-Lowering Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis.","2022","Journal of clinical medicine","Gu S","36","8","1","none found",null],["R0009234",null,null,"10.1016/j.jdiacomp.2016.08.018","29074120",null,"Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis.","2018","Journal of diabetes and its complications","Waldrop G","87","33","29","none found",null],["R0009239",null,null,"10.1111/dom.13484","30058208",null,"Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis.","2019","Diabetes, obesity & metabolism","Avgerinos I","35","24","19","none found",null],["R0009245",null,null,"10.1001/jamanetworkopen.2022.44652","36472874","PMC9856231","Association of Glucose-Lowering Drugs With Outcomes in Patients With Diabetes Before Hospitalization for COVID-19: A Systematic Review and Network Meta-analysis.","2022","JAMA network open","Zhu Z","66","8","2","none found",null],["R0009258",null,null,"10.1111/dom.70859","42115707",null,"Tirzepatide Versus Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes With Established Cardiovascular Disease: An Indirect Treatment Comparison Meta-Analysis.","2026","Diabetes, obesity & metabolism","Goldenberg RM","18","9","6","none found",null],["R0009284",null,null,"10.1177/14791641261487590","42821775",null,"Impact of antidiabetic agents on COPD exacerbations in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis.","2026","Diabetes & vascular disease research","Shabil M","0","0","0","none found",null],["R0009298",null,null,"10.1111/jcpt.13398","33675117",null,"Efficacy and safety of dulaglutide compared with glargine in patients with type 2 diabetes: A systematic review and meta-analysis.","2021","Journal of clinical pharmacy and therapeutics","Xu J","27","15","8","none found",null],["R0009299",null,null,"10.1002/ehf2.14726","38419382","PMC11098653","Comparison of cardiovascular outcomes of new antihyperglycemic agents in Type 2 Diabetes Mellitus: a meta-analysis.","2024","ESC heart failure","Zhou Z","64","33","13","none found",null],["R0009301",null,null,"10.1111/dom.12541","26395850",null,"Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.","2015","Diabetes, obesity & metabolism","Karagiannis T","67","42","29","none found",null],["R0009302","CRD42021228824",null,"10.1038/s41598-021-01663-y","34764398","PMC8586228","A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D).","2021","Scientific reports","Ghosal S","19","14","8","PROSPERO","PROSPERO:CRD42021228824"],["R0009303",null,null,"10.1097/fjc.0000000000001197","34935705",null,"Comparison of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide Receptor Agonists for Atrial Fibrillation in Type 2 Diabetes Mellitus: Systematic Review With Network Meta-analysis of Randomized Controlled Trials.","2022","Journal of cardiovascular pharmacology","Li W","57","31","19","none found",null],["R0009320",null,null,"10.1016/j.pcd.2021.12.007","34930687",null,"Effect of SGLT2 inhibitors versus DPP4 inhibitors or GLP-1 agonists on diabetic foot-related extremity amputation in patients with T2DM: A meta-analysis.","2022","Primary care diabetes","Du Y","25","3","0","none found",null],["R0009332","CRD42022320157",null,"10.1002/phar.2737","36271706","PMC10099849","Effects of GLP-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and meta-analysis.","2022","Pharmacotherapy","Kelly M","24","11","5","PROSPERO","PROSPERO:CRD42022320157"],["R0009345","CRD420251237462",null,"10.1186/s12872-026-05808-7","41906074","PMC13154893","GLP-1 and dual GIP/GLP-1 agonists in obese patients with HFpEF: a systematic review and meta-analysis of RCTs.","2026","BMC cardiovascular disorders","Musa EYA","11","6","4","PROSPERO","PROSPERO:CRD420251237462"],["R0009359",null,null,"10.3390/ijms27093967","42123553","PMC13163320","The Role of Antidiabetic Therapies in Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review of Metformin, Pioglitazone, and GLP-1 Receptor Agonists.","2026","International journal of molecular sciences","Mahoon DA","41","10","4","none found",null],["R0009360",null,null,"10.1080/14737167.2022.2042255","35152812",null,"Pharmacoeconomic evaluation of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus: a systematic literature review.","2022","Expert review of pharmacoeconomics & outcomes research","Ruan Z","72","24","6","none found",null],["R0009361",null,null,"10.1016/j.jcjd.2019.04.003","31175007",null,"Update on Cardiovascular Safety of Incretin-Based Therapy in Adults With Type 2 Diabetes Mellitus: A Meta-Analysis of Cardiovascular Outcome Trials.","2019","Canadian journal of diabetes","Alfayez OM","0","0","0","none found",null],["R0009363",null,null,"10.1136/bmjdrc-2021-002708","35351688","PMC8966566","Insulin treatment in patients with diabetes mellitus and heart failure in the era of new antidiabetic medications.","2022","BMJ open diabetes research & care","Staszewsky L","29","12","4","none found",null],["R0009380","CRD42021271647",null,"10.1136/bmj-2021-068882","35764326","PMC9237836","Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials.","2022","BMJ (Clinical research ed.)","He L","123","9","3","PROSPERO","PROSPERO:CRD42021271647"],["R0009430",null,null,"10.1097/jxx.0000000000001303","42250233",null,"Use of second-generation incretin analogs (GLP-1 and GIP receptor agonists) in type 1 diabetes and latent autoimmune diabetes in adults: A systematic review.","2026","Journal of the American Association of Nurse Practitioners","Horne MP","0","0","0","none found",null],["R0009434","CRD42020195869",null,"10.1016/j.jpeds.2021.05.009","33984333",null,"Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity: A Meta-Analysis.","2021","The Journal of pediatrics","Ryan PM","44","34","22","PROSPERO","PROSPERO:CRD42020195869"],["R0009446","CRD42019122043",null,"10.7326/m20-0864","32598218",null,"Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.","2020","Annals of internal medicine","Tsapas A","35","12","2","PROSPERO","PROSPERO:CRD42019122043"],["R0009465",null,null,"10.17925/ee.2024.20.2.10","39526060","PMC11548363","Efficacy and Safety of Novel Twincretin Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, as an Anti-obesity Medicine in Individuals Without Diabetes: A Systematic Review and Meta-analysis.","2024","TouchREVIEWS in endocrinology","Dutta D","27","18","4","none found",null],["R0009478",null,null,"10.1177/2047487320903638","32089007",null,"Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.","2020","European journal of preventive cardiology","Pulipati VP","25","14","7","none found",null],["R0009486",null,null,"10.1016/j.metop.2023.100236","36923991","PMC10009293","Effects of incretin-based therapeutic agents including tirzepatide on renal outcomes in patients with type 2 diabetes: A systemic review and meta-analysis.","2023","Metabolism open","Mima A","36","18","9","none found",null],["R0009497",null,null,"10.1038/s41598-019-38956-2","30787365","PMC6382780","Glucagon-like peptide-1 receptor agonists and pancreatic cancer: a meta-analysis with trial sequential analysis.","2019","Scientific reports","Pinto LC","24","14","2","none found",null],["R0009506",null,null,"10.1111/acps.13734","39048532",null,"Glucagon-like peptide agonists for weight management in antipsychotic-induced weight gain: A systematic review and meta-analysis.","2024","Acta psychiatrica Scandinavica","Bak M","69","25","10","none found",null],["R0009516",null,null,"10.2147/dmso.s27528","22826635","PMC3402010","Glucagon-like peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a systematic review.","2012","Diabetes, metabolic syndrome and obesity : targets and therapy","Berlie H","22","8","2","none found",null],["R0009520",null,null,"10.1111/dom.14518","34402153","PMC9290816","Efficacy and safety of iGlarLixi versus IDegAsp: Results of a systematic literature review and indirect treatment comparison.","2021","Diabetes, obesity & metabolism","Home PD","32","15","10","none found",null],["R0009527","CRD42021265806",null,"10.3389/fendo.2021.769069","34956080","PMC8696030","Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.","2021","Frontiers in endocrinology","Zhu Y","64","26","17","PROSPERO","PROSPERO:CRD42021265806"],["R0009536",null,null,"10.7417/ct.2026.2083","42340790",null,"Long-Term Safety and Renal Outcomes of Semaglutide in Non-Diabetic Obesity with Chronic Kidney Disease or Hypertension: A Systematic Review and Meta-Analysis.","2026","La Clinica terapeutica","Elganyny MKE","0","0","0","none found",null],["R0009538",null,null,"10.2174/1573399816666200705210006","32628589",null,"Effects of Antidiabetic Drugs on Muscle Mass in Type 2 Diabetes Mellitus.","2021","Current diabetes reviews","Ida S","49","6","5","none found",null],["R0009577","CRD42017067889",null,"10.3389/fstro.2024.1363954","41542235","PMC12802736","The impacts of new antidiabetic drugs on the risk of ischemic and hemorrhagic strokes: a comprehensive review and meta-analysis of clinical trials.","2024","Frontiers in stroke","Azhari HF","38","6","3","PROSPERO","PROSPERO:CRD42017067889"],["R0009579",null,null,"10.1111/eci.14125","37950521",null,"The effect of subcutaneous dulaglutide on weight loss in patients with Type 2 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials.","2024","European journal of clinical investigation","Li Y","44","27","20","none found",null],["R0009592",null,null,"10.1016/j.diabres.2021.109031","34461139","PMC8397482","Pre-admission glucagon-like peptide-1 receptor agonist (GLP-1RA) and mortality from coronavirus disease 2019 (Covid-19): A systematic review, meta-analysis, and meta-regression.","2021","Diabetes research and clinical practice","Hariyanto TI","50","19","5","none found",null],["R0009595","CRD42023449059",null,"10.1053/j.ajkd.2024.11.013","39863261",null,"Kidney and Cardiovascular Outcomes Among Patients With CKD Receiving GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomized Trials.","2025","American journal of kidney diseases : the official journal of the National Kidney Foundation","Chen JY","68","39","22","PROSPERO","PROSPERO:CRD42023449059"],["R0009610",null,null,"10.3389/fendo.2020.622589","33664710","PMC7924308","Comparison of the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Metabolic Associated Fatty Liver Disease: Updated Systematic Review and Meta-Analysis.","2020","Frontiers in endocrinology","Dai Y","35","21","12","none found",null],["R0009617",null,null,"10.1186/s12933-026-03215-y","42186086","PMC13479731","Effects of semaglutide on mortality, cardiovascular, and kidney outcomes across the cardio-kidney-metabolic continuum: a systematic review and meta-analysis.","2026","Cardiovascular diabetology","Marzano F","27","19","10","none found",null],["R0009647",null,null,"10.1007/s00125-021-05436-0","33765180",null,"Impact of high glucose levels and glucose lowering on risk of ischaemic stroke: a Mendelian randomisation study and meta-analysis.","2021","Diabetologia","Benn M","39","10","6","none found",null],["R0009658",null,null,"10.1002/edm2.70134","41296780","PMC12653021","Efficacy and Safety of Orforglipron in Obese Adults With or Without Diabetes: A Systematic Review and Meta-Analysis.","2025","Endocrinology, diabetes & metabolism","Pandey RK","45","27","16","none found",null],["R0009659","CRD42021247584",null,"10.1186/s40001-026-03986-w","41620788","PMC12952054","The comparative efficacy of SGLT-2 inhibitors and GLP-1 receptor agonists on metabolic benefits in T2DM patients: a systematic review and network meta-analysis.","2026","European journal of medical research","Tong J","41","16","7","PROSPERO","PROSPERO:CRD42021247584"],["R0009665",null,null,"10.1007/s00592-021-01830-7","34988690",null,"Sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists versus thiazolidinediones for non-alcoholic fatty liver disease: A network meta-analysis.","2022","Acta diabetologica","Ding C","52","9","5","none found",null],["R0009674",null,null,"10.1016/j.diabet.2020.05.002","32439471",null,"Do GLP-1RAs and SGLT-2is reduce cardiovascular events in women with type 2 diabetes? A systematic review and meta-analysis.","2021","Diabetes & metabolism","Mishriky BM","34","13","6","none found",null],["R0009680",null,null,"10.1111/dme.13898","30653708",null,"Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis.","2019","Diabetic medicine : a journal of the British Diabetic Association","Hussein H","43","14","5","none found",null],["R0009704",null,null,"10.1093/eurheartj/ehaa082","32077924",null,"Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials.","2020","European heart journal","Marsico F","27","20","12","none found",null],["R0009725",null,null,"10.1016/s2213-8587(17)30412-6","29221659",null,"Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.","2018","The lancet. Diabetes & endocrinology","Bethel MA","15","10","7","none found",null],["R0009738",null,null,"10.1111/bcp.13807","30394576","PMC6339993","Efficacy of DPP-4 inhibitors, GLP-1 analogues, and SGLT2 inhibitors as add-ons to metformin monotherapy in T2DM patients: a model-based meta-analysis.","2019","British journal of clinical pharmacology","Inoue H","38","7","2","none found",null],["R0009747","CRD42017057115",null,"10.1111/dom.13137","29364587",null,"Efficacy of glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes: A meta-analysis of randomized clinical trials.","2018","Diabetes, obesity & metabolism","Tran S","50","35","27","PROSPERO","PROSPERO:CRD42017057115"],["R0009777",null,null,"10.1016/j.dsx.2020.04.051","32470852",null,"Cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in Asians with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials.","2020","Diabetes & metabolic syndrome","Singh AK","50","11","7","none found",null],["R0009789",null,null,"10.22541/au.171585503.34303032/v1",null,null,"Efficacy and Safety of GLP-1 Receptor Agonists in Patients with MASLD: A Systematic Review and Meta-analysis of Randomized Clinical Trials","2024","Authorea Preprints","Njei B",null,"0","0","none found",null],["R0009820",null,null,"10.1016/j.parkreldis.2025.108171","41468681",null,"Incretin-based therapy and Parkinson's disease risk among patients with type 2 diabetes: Retrospective cohort study and meta-analysis.","2026","Parkinsonism & related disorders","Barer Y","0","0","0","none found",null],["R0009822",null,null,"10.1111/dom.70187","41063381",null,"Histological efficacy of anti-diabetic agents in MASH and the mediating role of weight loss: A network meta-analysis.","2026","Diabetes, obesity & metabolism","Banerjee M","48","16","6","none found",null],["R0009830",null,null,"10.1097/md.0000000000030072","36042668","PMC9410596","Meta-analysis of the association between new hypoglycemic agents and digestive diseases.","2022","Medicine","Wang YW","35","16","7","none found",null],["R0009836",null,null,"10.1089/dia.2014.0188","25375397","PMC4290796","Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis.","2015","Diabetes technology & therapeutics","Sun F","42","24","14","none found",null],["R0009839",null,null,"10.1111/dom.70986","42310900","PMC13448963","Pharmacotherapy for Children and Adolescents With Overweight or Obesity: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.","2026","Diabetes, obesity & metabolism","Luo L","56","15","7","none found",null],["R0009852",null,null,"10.1002/edm2.70313","42706739","PMC13550879","Efficacy and Safety of Tirzepatide Versus Dulaglutide in Type 2 Diabetes With or Without Established Atherosclerotic Cardiovascular Disease: A Network Meta-Analysis of Randomized Clinical Trials.","2026","Endocrinology, diabetes & metabolism","Hageen AW","41","26","10","none found",null],["R0009856",null,null,"10.23736/s2724-5683.22.05900-2","35195376",null,"Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis.","2023","Minerva cardiology and angiology","Sabouret P","0","0","0","none found",null],["R0009885","CRD42020173199",null,"10.1155/2021/6616693","33679973","PMC7910049","The Antiobesity Effect of GLP-1 Receptor Agonists Alone or in Combination with Metformin in Overweight /Obese Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis.","2021","International journal of endocrinology","Lyu X","39","18","8","PROSPERO","PROSPERO:CRD42020173199"],["R0009905",null,null,"10.7570/jomes24008","39681390","PMC11704219","The Effects of Tirzepatide on Lipid Profile: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","2024","Journal of obesity & metabolic syndrome","Mahar MU","48","30","14","none found",null],["R0009911",null,null,"10.1007/s13300-022-01359-0","36566447","PMC9943809","Assessing the Effects of Modern Renoprotective Agents in Preventing Progression of Renal Composite Outcomes in Patients with Type 2 Diabetes: A Network Meta-analysis.","2023","Diabetes therapy : research, treatment and education of diabetes and related disorders","Ghosal S","28","8","5","none found",null],["R0009929",null,null,"10.1111/obr.70161","42140745",null,"Effects of Semaglutide on Dumping Syndrome and Reactive Hypoglycemia After Bariatric Surgery: A Systematic Review and Meta-Analysis.","2026","Obesity reviews : an official journal of the International Association for the Study of Obesity","Eisa N","26","3","0","none found",null],["R0009932",null,null,"10.1111/ijd.70133","41174840","PMC13067326","Effects of GLP-1 Receptor Agonists on Hair Loss and Regrowth: A Systematic Review.","2026","International journal of dermatology","Branyiczky MK","7","6","0","none found",null],["R0009935","CRD42024606997",null,"10.3390/jcm15124450","42355618","PMC13301924","The Efficacy of Glucagon-like Peptide-1 Based Therapies in Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Systematic Review and Meta-Analysis.","2026","Journal of clinical medicine","Christophides T","34","24","14","PROSPERO","PROSPERO:CRD42024606997"],["R0009937",null,null,"10.1016/j.orcp.2026.02.002","41723034",null,"Head-to-head comparison of tirzepatide and semaglutide for weight loss: A systematic review and meta-analysis.","2026","Obesity research & clinical practice","Zufry H","31","21","7","none found",null],["R0009947",null,null,"10.1111/1753-0407.13359","36690377","PMC9934962","Noninsulin-based antihyperglycemic medications in patients with diabetes and COVID-19: A systematic review and meta-analysis.","2023","Journal of diabetes","Nassar M","60","11","2","none found",null],["R0009967",null,null,"10.2337/dc20-1815","33444163","PMC7783944","HbA1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression.","2021","Diabetes care","Bethel MA","27","11","7","none found",null],["R0009971",null,null,"10.1007/s10072-026-08843-6","41772331",null,"Therapeutic role of GLP-1 receptor agonists in idiopathic intracranial hypertension: a systematic review and meta-analysis.","2026","Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","Gadelmawla AF","41","11","1","none found",null],["R0009979",null,null,"10.1093/eurjpc/zwaa074","33606884",null,"Novel antidiabetic drugs and risk of cardiovascular events in patients without baseline metformin use: a meta-analysis.","2021","European journal of preventive cardiology","Masson W","0","0","0","none found",null],["R0009983",null,null,"10.1007/s00198-019-04968-x","31134305",null,"Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies.","2019","Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","Hidayat K","65","14","3","none found",null],["R0009984",null,null,"10.1016/j.jacadv.2026.102649","41925658","PMC13309306","GLP-1 Receptor Agonist Exposure During Pregnancy: A Systematic Review and Meta-Analysis of Adverse Pregnancy Outcomes.","2026","JACC. Advances","Kodali LSM","5","4","0","none found",null],["R0009996",null,null,"10.1007/s40261-021-01110-w","34894326",null,"Semaglutide and Diabetic Retinopathy Risk in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials.","2022","Clinical drug investigation","Wang F","52","47","22","none found",null],["R0010007",null,null,"10.1016/j.diabres.2020.108087","32084455",null,"Cholelithiasis in patients treated with Glucagon-Like Peptide-1 Receptor: An updated meta-analysis of randomized controlled trials.","2020","Diabetes research and clinical practice","Nreu B","17","11","8","none found",null],["R0010064","CRD420251007882",null,"10.3389/fmed.2025.1639704","41488069","PMC12756447","Association of glucagon-like peptide-1 (GLP-1) receptor agonists and diabetic retinopathy (DR) - a systematic review and meta-analysis.","2025","Frontiers in medicine","Alwafi H","63","55","29","PROSPERO","PROSPERO:CRD420251007882"],["R0010086",null,null,"10.1371/journal.pone.0289616","37616255","PMC10449217","The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: A systematic review and meta-analysis.","2023","PloS one","Liao C","79","43","33","none found",null],["R0010096","CRD42021245678",null,"10.1016/s0140-6736(24)00351-9","38582569",null,"Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.","2024","Lancet (London, England)","Shi Q","43","12","6","PROSPERO","PROSPERO:CRD42021245678"],["R0010100",null,null,"10.1007/s40519-025-01720-9","39891848","PMC11787217","The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis.","2025","Eating and weight disorders : EWD","Radkhah H","58","29","6","none found",null],["R0010106",null,null,"10.3390/jpm15110539","41295241","PMC12653122","Exploring the Evidence for Personalized Pharmacotherapy in Type 2 Diabetes-A Systematic Review.","2025","Journal of personalized medicine","Altabas V","120","9","2","none found",null],["R0010119",null,null,"10.1002/dmrr.70202","42455922","PMC13372237","Network and Pairwise Meta-Analysis of the Association Between Novel Hypoglycemic Agents and Atrial Fibrillation Risk in Patients With Type 2 Diabetes Mellitus.","2026","Diabetes/metabolism research and reviews","Ye X","74","22","5","none found",null],["R0010121",null,null,"10.1093/eurjpc/zwab221","34939100",null,"Cardiorenal benefits of glucagon-like peptide-1 analogues vs. exendin-4 analogues in patients with type 2 diabetes: a meta-analysis based on cardiovascular outcome trials.","2022","European journal of preventive cardiology","Qiu M","11","11","8","none found",null],["R0010123",null,null,"10.2337/dc20-3007","33707305",null,"Meta-analyses of Results From Randomized Outcome Trials Comparing Cardiovascular Effects of SGLT2is and GLP-1RAs in Asian Versus White Patients With and Without Type 2 Diabetes.","2021","Diabetes care","Lee MMY","30","9","7","none found",null],["R0010128",null,null,"10.1111/dom.70642","41804222",null,"Impact of GLP-1 Receptor Agonist Discontinuation on Liver-Related Parameters: A Systematic Review and Meta-Analysis.","2026","Diabetes, obesity & metabolism","Souza M","0","0","0","none found",null],["R0010131",null,null,"10.1080/14740338.2025.2586703","41200927",null,"The efficacy and safety of dual GIP/GLP1 receptor agonists (tirzepatide) in diabetes and obesity: a systematic review and network meta-analysis.","2026","Expert opinion on drug safety","Hoffmann K","80","65","24","none found",null],["R0010142",null,null,"10.1097/crd.0000000000001209","41711462",null,"Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis.","2026","Cardiology in review","Chan ZH","57","34","11","none found",null],["R0010155","CRD42022306164",null,"10.1080/17512433.2023.2174099","36706368",null,"Real-world clinical effectiveness of once-weekly semaglutide in patients with type 2 diabetes: a systematic literature review.","2023","Expert review of clinical pharmacology","Ruan Z","54","30","13","PROSPERO","PROSPERO:CRD42022306164"],["R0010163",null,null,"10.1111/dom.13361","29756388",null,"Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis.","2018","Diabetes, obesity & metabolism","Andreadis P","35","19","13","none found",null],["R0010171",null,null,"10.1097/crd.0000000000000915","40243299",null,"Efficacy of Semaglutide and Other GLP-1 Agonists in Patients with Heart Failure With Preserved Ejection Fraction and Obesity: A Systemic Review and Meta-Analysis.","2025","Cardiology in review","Beshr MS","0","0","0","none found",null],["R0010183",null,null,"10.1186/s12902-018-0332-5","30616638","PMC6323665","Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials.","2019","BMC endocrine disorders","Zhao X","69","54","34","none found",null],["R0010189",null,null,"10.1016/j.clinre.2016.11.009","28065744",null,"Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis.","2017","Clinics and research in hepatology and gastroenterology","Dong Y","67","26","6","none found",null],["R0010208",null,null,"10.1016/j.dsx.2020.02.012","32142999",null,"Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: A systematic review and meta-analysis of cardio-vascular outcome trials.","2020","Diabetes & metabolic syndrome","Singh AK","50","11","7","none found",null],["R0010237",null,null,"10.1002/14651858.cd015849.pub2","39963952","PMC11834151","Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes.","2025","The Cochrane database of systematic reviews","Natale P","148","129","78","none found",null],["R0010240","CRD42024528864",null,"10.1016/s2213-8587(24)00271-7","39608381",null,"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials.","2025","The lancet. Diabetes & endocrinology","Badve SV","48","16","14","PROSPERO","PROSPERO:CRD42024528864"],["R0010247",null,null,"10.1111/crj.13372","33825329",null,"Use of GLP1RAs and occurrence of respiratory disorders: A meta-analysis of large randomized trials of GLP1RAs.","2021","The clinical respiratory journal","Wei JP","15","11","7","none found",null],["R0010266",null,null,"10.1007/s00592-025-02635-8","41498807",null,"Efficacy and safety of orforglipron in type 2 diabetes mellitus and obesity: a GRADE-assessed meta-analysis and trial sequential analysis with subgroup evaluations by diabetic status, obesity status, and dose regimens.","2026","Acta diabetologica","Jamal A","25","15","3","none found",null],["R0010268",null,null,"10.3390/jcm15082909","42074711","PMC13116881","Effects of GLP-1 Agonists on Patients with Hidradenitis Suppurativa: A Systematic Review.","2026","Journal of clinical medicine","Caliezi A","50","22","3","none found",null],["R0010269",null,null,"10.12688/f1000research.186694.1",null,null,"Efficacy and Safety of Mazdutide for Type 2 Diabetes: a GRADE assessed systematic review and meta-analysis of randomized controlled trials","2026","F1000Res","Mahmood A",null,"0","0","none found",null],["R0010274","CRD42022382165",null,"10.4239/wjd.v16.i7.106890","40697609","PMC12278083","Pharmacological management of type 2 diabetes mellitus in children and adolescents: A systematic review and network meta-analysis.","2025","World journal of diabetes","Gagnon CA","42","16","7","PROSPERO","PROSPERO:CRD42022382165"],["R0010276","CRD42024511703",null,"10.4239/wjd.v16.i12.112830","41480597","PMC12754120","Glycemic control, weight-loss effects, and safety of cotadutide in individuals with type 2 diabetes: A systematic review and meta-analysis.","2025","World journal of diabetes","Kamrul-Hasan ABM","36","29","12","PROSPERO","PROSPERO:CRD42024511703"],["R0010289",null,null,"10.14309/ajg.0000000000002820","38634551","PMC11150091","Quantified Metrics of Gastric Emptying Delay by Glucagon-Like Peptide-1 Agonists: A Systematic Review and Meta-Analysis With Insights for Periprocedural Management.","2024","The American journal of gastroenterology","Hiramoto B","66","50","29","none found",null],["R0010292",null,null,"10.62347/mcee4840","39678621","PMC11645625","Efficacy and safety of GLP-1 receptor agonists combined with SGLT-2 inhibitors in elderly patients with type 2 diabetes: a meta-analysis.","2024","American journal of translational research","Wu Y","42","29","9","none found",null],["R0010299",null,null,"10.21203/rs.3.rs-9477385/v1",null,null,"Efficacy and Safety of Mazdutide in Adults with Obesity or Overweight, With or Without Diabetes: A Bayesian Network Meta-Analysis","2026","Research Square","Tuersun A",null,"0","0","none found",null],["R0010318","CRD42021288200",null,"10.3389/fendo.2022.895458","35692410","PMC9186017","The Association Between Antidiabetic Agents and Clinical Outcomes of COVID-19 Patients With Diabetes: A Bayesian Network Meta-Analysis.","2022","Frontiers in endocrinology","Chen Y","73","10","2","PROSPERO","PROSPERO:CRD42021288200"],["R0010319",null,null,"10.1155/2015/157201","25688373","PMC4320855","Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis.","2015","Journal of diabetes research","Sun F","32","21","7","none found",null],["R0010323",null,null,"10.1111/dme.14858","35460294","PMC9546240","Five comparative cohorts to assess the risk of genital tract infections associated with sodium-glucose cotransporter-2 inhibitors initiation in type 2 diabetes mellitus.","2022","Diabetic medicine : a journal of the British Diabetic Association","Alkabbani W","34","3","0","none found",null],["R0010330",null,null,"10.1002/phar.1962","28556176",null,"Lixisenatide, a Once-Daily Prandial Glucagon-Like Peptide-1 Receptor Agonist for the Treatment of Adults with Type 2 Diabetes.","2017","Pharmacotherapy","Trujillo JM","66","42","28","none found",null],["R0010332",null,null,"10.1007/s11154-025-09991-4","41032183",null,"Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis.","2026","Reviews in endocrine & metabolic disorders","Masson W","40","20","8","none found",null],["R0010335",null,null,"10.24875/ric.20000308","33861731",null,"Effects of Incretin-based Therapy on High-sensitivity C-reactive Protein in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.","2020","Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion","Wu Y","0","0","0","none found",null],["R0010339",null,null,"10.1177/02698811211035391","34311625",null,"Efficacy and tolerability of pharmacological interventions on metabolic disturbance induced by atypical antipsychotics in adults: A systematic review and network meta-analysis.","2021","Journal of psychopharmacology (Oxford, England)","Wang Y","33","5","3","none found",null],["R0010348",null,null,"10.59556/japi.73.1184","41100333",null,"Achieving Diabetes Remission: Current Guidelines and Emerging Pharmacotherapies in India.","2025","The Journal of the Association of Physicians of India","Arpan","0","0","0","none found",null],["R0010354",null,null,"10.1080/14656566.2018.1444882","29471700",null,"Methodological concerns with the meta-analysis comparing insulin degludec/liraglutide and insulin glargine/lixisenatide.","2018","Expert opinion on pharmacotherapy","Eggert S","10","9","8","none found",null],["R0010366",null,null,"10.1016/j.diabres.2021.108921","34144086",null,"GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials.","2021","Diabetes research and clinical practice","Tsapas A","26","10","5","none found",null],["R0010415","CRD42018091306",null,"10.1136/bmjopen-2018-023206","30413509","PMC6231581","Efficacy and safety of sodium-glucose cotransporter 2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes: a systematic review and network meta-analysis study protocol.","2018","BMJ open","Hussein H","44","7","2","PROSPERO","PROSPERO:CRD42018091306"],["R0010419",null,null,"10.1111/dom.13178","29364585",null,"What have we learnt from \"real world\" data, observational studies and meta-analyses.","2018","Diabetes, obesity & metabolism","Chatterjee S","67","41","15","none found",null],["R0010446",null,null,"10.1111/obr.70100","41554634","PMC13243349","Efficacy of Weight-Lowering Agents on Fat Distribution: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.","2026","Obesity reviews : an official journal of the International Association for the Study of Obesity","Qiao X","61","21","16","none found",null],["R0010450",null,null,"10.1007/s40200-025-01741-2","41084518","PMC12515190","A systematic review and meta-analysis comparing the cardiovascular effects of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 agonists in type 2 diabetes.","2025","Journal of diabetes and metabolic disorders","Khan LA","0","0","0","none found",null],["R0010483",null,null,"10.4239/wjd.v16.i5.103244","40487607","PMC12142189","Effect of beinaglutide, a thrice-daily GLP-1 receptor agonist, on body weight and metabolic parameters: A systematic review and meta-analysis.","2025","World journal of diabetes","Kamrul-Hasan ABM","30","20","6","none found",null],["R0010484",null,null,"10.1016/j.parkreldis.2024.107220","39642803",null,"GLP-1 receptor agonists for Parkinson's disease: An updated meta-analysis.","2025","Parkinsonism & related disorders","Albuquerque MB","12","4","4","none found",null],["R0010493",null,null,null,null,"PMC12544991","SUN-659 Comparative Efficacy and Safety of Tirzepatide vs Retatrutide in Weight Loss: A Network Meta-Analysis of Clinical Trials","2025","Journal of the Endocrine Society",null,"0","0","0","none found",null],["R0010531",null,null,"10.1007/s10557-018-6773-2","29445896",null,"GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials.","2018","Cardiovascular drugs and therapy","Jia X","49","42","10","none found",null],["R0010565",null,null,"10.21203/rs.2.16671/v3",null,null,"Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of double-blind, randomized, placebo-controlled clinical trials","2020","Research Square","Qin J",null,"0","0","none found",null],["R0010600",null,null,"10.1371/journal.pone.0314787","40014613","PMC11867386","Pharmacological interventions for addressing pediatric and adolescent obesity: A systematic review and network meta-analysis.","2025","PloS one","Yang S","37","9","6","none found",null],["R0010614",null,null,"10.1210/clinem/dgad471","37561012",null,"Glucagon-Like Peptide 1 Analogues as Adjunctive Therapy for Patients With Type 1 Diabetes: An Updated Systematic Review and Meta-analysis.","2023","The Journal of clinical endocrinology and metabolism","Park J","68","41","28","none found",null],["R0010619",null,null,"10.1007/s13300-017-0282-3","28616805","PMC5544618","Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.","2017","Diabetes therapy : research, treatment and education of diabetes and related disorders","Wang W","34","18","7","none found",null],["R0010631",null,null,"10.1530/joe-23-0226","38451873",null,"The GLP-1R as a model for understanding and exploiting biased agonism in next-generation medicines.","2024","The Journal of endocrinology","Douros JD","98","0","0","none found",null],["R0010653",null,null,"10.2215/cjn.11220720","33376101","PMC7792639","Network Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury.","2020","Clinical journal of the American Society of Nephrology : CJASN","Zhao M","40","10","7","none found",null],["R0010668",null,null,"10.2174/1573399816666200522214554","32442089",null,"Glucagon-like Peptide-1 Receptor Agonists Cardio-protective Effects: An Umbrella Review.","2020","Current diabetes reviews","Elnour AA","0","0","0","none found",null],["R0010681",null,null,"10.1111/ene.13905","30629331",null,"Protection against stroke with glucagon-like peptide 1 receptor agonists: a systematic review and meta-analysis.","2019","European journal of neurology","Barkas F","25","13","5","none found",null],["R0010686",null,null,"10.1007/s10840-025-02233-2","41493516",null,"GLP-1 receptor agonist therapy is associated with reduced atrial fibrillation recurrence after catheter ablation: a meta-analysis.","2026","Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing","Kilic ME","4","0","0","none found",null],["R0010688",null,null,"10.7759/cureus.89656","40926946","PMC12415119","Semaglutide and Non-arteritic Anterior Ischemic Optic Neuropathy: A Systematic Review.","2025","Cureus","Hidalgo Ramos RA","11","11","1","none found",null],["R0010690",null,null,"10.1345/aph.1q024","21730278",null,"Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.","2011","The Annals of pharmacotherapy","Pinelli NR","55","29","22","none found",null],["R0010703",null,null,"10.7759/cureus.82497","40385819","PMC12085783","Comparative Effectiveness and Safety of Oral Versus Subcutaneous Semaglutide in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.","2025","Cureus","Karedath J","18","14","2","none found",null],["R0010704",null,null,"10.1097/js9.0000000000004566","41738616","PMC13105548","Effect of bariatric surgery and pharmacological treatments on cardiovascular risk factors for adults with overweight and obesity: a systematic review and network meta-analysis.","2026","International journal of surgery (London, England)","Yang Y","74","14","9","none found",null],["R0010719",null,null,"10.1016/j.aed.2025.07.012","41048697","PMC12495584","Efficacy and Safety of Once-Weekly IcoSema in Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis.","2025","AACE endocrinology and diabetes","Kamrul-Hasan ABM","29","9","6","none found",null],["R0010723",null,null,"10.1002/cpt.1307","30457671",null,"A Model-Based Meta-Analysis of 24 Antihyperglycemic Drugs for Type 2 Diabetes: Comparison of Treatment Effects at Therapeutic Doses.","2019","Clinical pharmacology and therapeutics","Maloney A","46","14","8","none found",null],["R0010735",null,null,"10.1186/s13098-025-01888-1","40849485","PMC12374370","GLP-1 receptor agonists in Parkinson's disease: an updated comprehensive systematic review with meta-analysis.","2025","Diabetology & metabolic syndrome","Helal MM","49","23","10","none found",null],["R0010756",null,null,"10.1007/s12020-014-0361-4","25074632",null,"Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials.","2015","Endocrine","Su B","49","32","16","none found",null],["R0010775",null,null,"10.1038/s41366-025-01807-4","40382437",null,"Obesity medications in patients with recurrent weight gain or suboptimal clinical response following bariatric surgery: a meta-analysis.","2025","International journal of obesity (2005)","Golzarand M","56","33","7","none found",null],["R0010779",null,null,"10.3389/fendo.2025.1562815","40556828","PMC12185272","Evaluation of three mechanisms of action (SGLT2 inhibitors, GLP-1 receptor agonists, and sulfonylureas) in treating type 2 diabetes with heart failure: a systematic review and network meta-analysis of RCTs.","2025","Frontiers in endocrinology","Gao H","30","8","3","none found",null],["R0010808","CRD42020206600",null,"10.1007/s00125-021-05529-w","34536085",null,"The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials.","2021","Diabetologia","Lin DS","32","13","6","PROSPERO","PROSPERO:CRD42020206600"],["R0010875",null,null,"10.3389/fphar.2023.1102792","36992825","PMC10040540","Comparative efficacy of 5 sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor and 4 glucagon-like peptide-1 (GLP-1) receptor agonist drugs in non-alcoholic fatty liver disease: A GRADE-assessed systematic review and network meta-analysis of randomized controlled trials.","2023","Frontiers in pharmacology","Gu Y","71","23","19","none found",null],["R0010898",null,null,"10.1016/j.jdiacomp.2020.107803","33293207",null,"Comparison of the risk of SGLT2is and NonSGLT2is in leading to amputation: A network meta-analysis.","2021","Journal of diabetes and its complications","Qiu M","27","5","0","none found",null],["R0010899",null,null,"10.1007/s13300-020-00912-z","32852698","PMC7509017","GLP-1RAs and SGLT2is Reduce Cardiovascular Events Independent of Reductions of Systolic Blood Pressure and Body Weight: A Meta-Analysis with Meta-Regression.","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","Qiu M","32","20","8","none found",null],["R0010908",null,null,"10.1016/s2213-8587(24)00098-6","38723646",null,"Sex, race, and BMI in clinical trials of medications for obesity over the past three decades: a systematic review.","2024","The lancet. Diabetes & endocrinology","Alsaqaaby MS","56","17","13","none found",null],["R0010920",null,null,"10.21203/rs.3.rs-3894429/v1",null,null,"Efficacy and safety of different doses of tirzepatide in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis","2024","Research Square","Zhu J",null,"0","0","none found",null],["R0010934",null,null,"10.1016/j.hrthm.2021.03.007","33684547",null,"Comparison of the effect of glucose-lowering agents on the risk of atrial fibrillation: A network meta-analysis.","2021","Heart rhythm","Shi W","22","5","0","none found",null],["R0010946","CRD42023491646",null,"10.7326/annals-24-03766","42296505",null,"Cost-Effectiveness of Pharmacologic Treatments in Adults With Overweight or Obesity: A Systematic Review for the American College of Physicians.","2026","Annals of internal medicine","Jenniskens K","44","10","0","PROSPERO","PROSPERO:CRD42023491646"],["R0010958",null,null,"10.1016/j.metabol.2022.155196","35367460","PMC8970613","Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis.","2022","Metabolism: clinical and experimental","Nguyen NN","89","8","1","none found",null],["R0010970",null,null,"10.3389/fphar.2026.1849647","42389271","PMC13318716","Pharmacological mechanisms and clinical impacts of antidiabetic drugs on colorectal cancer risk: a systematic review.","2026","Frontiers in pharmacology","Yang Y","140","18","1","none found",null],["R0010993",null,null,"10.1016/j.metop.2026.100495","42750798","PMC13578459","Therapeutic modulation of the gut-brain axis in alcohol use disorder: A systematic review.","2026","Metabolism open","Bhandari P","49","6","5","none found",null],["R0010994",null,null,null,null,"PMC7207432","SAT-662 Effects of SGLT Inhibitors or GLP1 Analogues on Glucose Homeostasis and Body Weight in Patients with Type 1 Diabetes: A Network Meta-Analysis","2020","Journal of the Endocrine Society","Lim S","0","0","0","none found",null],["R0010995",null,null,"10.1002/oby.70054","41189318","PMC13535721","Weight Loss, Obesity Medication, and Risk of Obesity-Associated Cancer: A Meta-Analysis of Randomized Controlled Trials.","2026","Obesity (Silver Spring, Md.)","Li C","46","16","4","none found",null],["R0011003",null,null,"10.1111/dom.15111","37202870",null,"Sodium-glucose cotransporter-2 inhibitors and kidney outcomes in real-world type 2 diabetes populations: A systematic review and meta-analysis of observational studies.","2023","Diabetes, obesity & metabolism","Forbes AK","58","9","1","none found",null],["R0011028",null,null,"10.1111/dme.14502","33368612",null,"SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose-lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review.","2021","Diabetic medicine : a journal of the British Diabetic Association","Escobar C","38","12","8","none found",null],["R0011034",null,null,"10.1016/j.clinthera.2014.11.008","25554560",null,"Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis.","2015","Clinical therapeutics","Sun F","46","22","14","none found",null],["R0011038",null,null,"10.3389/fendo.2026.1758755","41890182","PMC13013066","Glucagon-like peptide-1 agonists' effects on glycemic control, weight loss, and beta cells function in type 1 diabetes.","2026","Frontiers in endocrinology","Mirghani HO","62","43","22","none found",null],["R0011041",null,null,"10.7759/cureus.92976","41141089","PMC12547187","Microvascular Outcomes of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Type 2 Diabetes: A Systematic Review of Retinopathy and Nephropathy Evidence.","2025","Cureus","Arif A","24","14","6","none found",null],["R0011052","CRD420251083622",null,"10.1007/s11892-026-01619-4","41806022",null,"Glucagon-Like Peptide-1 and Dual Incretin Agonists in Type 2 Diabetes with Peripheral Artery Disease: A Systematic Review and Meta-Analysis of Vascular, Cardiovascular, Metabolic, and Mortality Outcomes : Incretin Therapy in T2DM and PAD.","2026","Current diabetes reports","Araújo de Lucena L","17","13","9","PROSPERO","PROSPERO:CRD420251083622"],["R0011059",null,null,"10.1080/17512433.2020.1736041","32129106",null,"Risk of acute pancreatitis with incretin-based therapy: a systematic review and updated meta-analysis of cardiovascular outcomes trials.","2020","Expert review of clinical pharmacology","Singh AK","46","28","10","none found",null],["R0011067","CRD420261425340",null,"10.1111/dom.71046","42387279","PMC13449067","Positioning Incretin-Based and Next-Generation Obesity Management Medications: A Methodological Framework for a Series of Systematic Reviews and Network Meta-Analyses.","2026","Diabetes, obesity & metabolism","Monami M","33","19","11","PROSPERO","PROSPERO:CRD420261425340"],["R0011091",null,null,"10.1111/dom.12448","25656522",null,"Cardiovascular safety of the glucagon-like peptide-1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials.","2015","Diabetes, obesity & metabolism","Seshasai SR","21","14","9","none found",null],["R0011093",null,null,"10.4103/ijpvm.ijpvm_368_24","41098876","PMC12520633","Economic Evaluation of Medications in Prevention and Treatment of Obesity: A Systematic Review.","2025","International journal of preventive medicine","Afshari S","33","19","5","none found",null],["R0011095",null,null,null,null,"PMC11455214","8699 ​​Efficacy of Glucagon-like Peptide-1 Analogs In Women With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomized Clinical Trials","2024","Journal of the Endocrine Society",null,"0","0","0","none found",null],["R0011113",null,null,"10.1007/s00592-025-02468-5","39985672",null,"Effect of GLP-1 receptor agonists on bone mineral density, bone metabolism markers, and fracture risk in type 2 diabetes: a systematic review and meta-analysis.","2025","Acta diabetologica","Tan Y","41","31","11","none found",null],["R0011122",null,null,"10.1007/s11914-020-00638-8","33165875",null,"Glucose-Lowering Drugs and Fracture Risk-a Systematic Review.","2020","Current osteoporosis reports","Al-Mashhadi Z","111","12","2","none found",null],["R0011134",null,null,"10.1016/j.eprac.2026.04.014","42061648",null,"Tirzepatide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits.","2026","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Eisa N","33","21","15","none found",null],["R0011142","CRD42019132807",null,"10.1210/clinem/dgaa534","32797182",null,"Patient-centered Management of Type 2 Diabetes Mellitus Based on Specific Clinical Scenarios: Systematic Review, Meta-analysis and Trial Sequential Analysis.","2020","The Journal of clinical endocrinology and metabolism","Pinto LC","40","13","7","PROSPERO","PROSPERO:CRD42019132807"],["R0011149",null,null,"10.1097/js9.0000000000003969","41222906",null,"On \"The different colorectal tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use a network meta-analysis of 68 randomized controlled trials\" - correspondence.","2026","International journal of surgery (London, England)","Wang B","8","1","1","none found",null],["R0011157","CRD42017053952",null,"10.1080/14656566.2017.1400011","29090600",null,"Comparison between insulin degludec/liraglutide treatment and insulin glargine/lixisenatide treatment in type 2 diabetes: a systematic review and meta-analysis.","2017","Expert opinion on pharmacotherapy","Cai X","31","26","20","PROSPERO","PROSPERO:CRD42017053952"],["R0011163",null,null,"10.1177/1060028020951955","32795145",null,"Review of Newer Antidiabetic Agents for Diabetes Management in Kidney Transplant Recipients.","2021","The Annals of pharmacotherapy","Anderson S","85","13","6","none found",null],["R0011190",null,null,"10.14218/jcth.2025.00596","42724131","PMC13558243","Comparative Efficacy of Promising Targets in the Treatment of Metabolic Dysfunction-associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Network Meta-analysis.","2026","Journal of clinical and translational hepatology","Ni W","46","20","10","none found",null],["R0011192",null,null,"10.2337/dc19-2419","33534728","PMC7372059","Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials.","2020","Diabetes care","Gan S","82","25","22","none found",null],["R0011204",null,null,"10.1186/s12933-020-01211-4","33468131","PMC7816439","Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review.","2021","Cardiovascular diabetology","Yang CY","49","31","9","none found",null],["R0011229",null,null,"10.1002/14651858.cd015906.pub2","41263251","PMC12631961","Dipeptidyl peptidase 4 (DPP-4) inhibitors for people with chronic kidney disease and diabetes.","2025","The Cochrane database of systematic reviews","Natale P","96","2","1","none found",null],["R0011241",null,null,"10.21203/rs.3.rs-6863965/v1",null,null,"Geographic Variation in Cardiovascular Disease Prevention by GLP-1 Receptor Agonists and SGLT2 Inhibitors: A Meta-Analysis","2025","Research Square","Ilany J",null,"0","0","none found",null],["R0011246",null,null,"10.1177/10815589221149188","36695427",null,"Network meta-analysis of glucose-lowering drug treatment regimens with the potential risk of hypoglycemia in patients with type 2 diabetes mellitus in terms of glycemic control and severe hypoglycemia.","2023","Journal of investigative medicine : the official publication of the American Federation for Clinical Research","Kodama S","36","2","0","none found",null],["R0011279","CRD42020168322",null,"10.1111/dme.14780","34962662",null,"Comparative effectiveness of cardiovascular, renal and safety outcomes of second-line antidiabetic drugs use in people with type 2 diabetes: A systematic review and network meta-analysis of randomised controlled trials.","2022","Diabetic medicine : a journal of the British Diabetic Association","Sim R","78","17","4","PROSPERO","PROSPERO:CRD42020168322"],["R0011300",null,null,"10.1097/mjt.0000000000001756","39292847",null,"Mazdutide Versus Dulaglutide for Weight Loss and Diabetes Management: Meta-Analysis of Randomized Clinical Trials.","2024","American journal of therapeutics","Ayesh H","7","5","4","none found",null],["R0011305",null,null,"10.1186/s13098-023-01202-x","38012781","PMC10683270","Prevalence and predictors of chronic kidney disease among type 2 diabetic patients worldwide, systematic review and meta-analysis.","2023","Diabetology & metabolic syndrome","Fenta ET","75","4","0","none found",null],["R0011313",null,null,"10.1111/dom.13805","31168889",null,"Do GLP-1RAs and SGLT-2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta-analysis.","2019","Diabetes, obesity & metabolism","Mishriky BM","50","11","5","none found",null],["R0011327",null,null,"10.1016/j.clinthera.2012.04.013","22608780",null,"Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review.","2012","Clinical therapeutics","Aroda VR","115","43","32","none found",null],["R0011331",null,null,"10.22037/ijpr.2019.14733.12619","32184883","PMC7059053","Efficacy and Safety of Dulaglutide Compared to Liraglutide: A Systematic Review and Meta-analysis in Patients with Type 2 Diabetes Mellitus.","2019","Iranian journal of pharmaceutical research : IJPR","Taheri S","40","22","4","none found",null],["R0011340",null,null,"10.1093/eurjpc/zwad280","37648659",null,"Down the rabbit hole: reviewing the evidence for primary prevention of cardiovascular disease in people with obesity.","2023","European journal of preventive cardiology","Stumpf MAM","0","0","0","none found",null],["R0011356",null,null,"10.4239/wjd.v12.i9.1576","34630909","PMC8472495","Effectiveness of drug interventions in nonalcoholic fatty liver disease: A network meta-analysis.","2021","World journal of diabetes","Huang YZ","43","10","5","none found",null],["R0011370",null,null,"10.1007/s00464-025-12086-5","41028671",null,"Analysis of the long-term impact of glucagon-like peptide-1 (GLP-1) receptor agonists for control of obesity and obesity-related comorbidities: a meta-analysis.","2025","Surgical endoscopy","Jia IT","45","44","24","none found",null],["R0011376","CRD42021283129",null,"10.3389/fmed.2022.793203","35280867","PMC8914474","Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.","2022","Frontiers in medicine","Luo Q","56","15","7","PROSPERO","PROSPERO:CRD42021283129"],["R0011387","CRD42024626613",null,"10.1016/j.eclinm.2026.104026","42376494","PMC13311999","Reassessing the risk-modifying effects of novel antidiabetic agents on asthma-COPD overlap syndrome: a dose-stratified network meta-analysis of 316,832 adults from 128 randomised trials.","2026","EClinicalMedicine","Zeng BY","151","64","54","PROSPERO","PROSPERO:CRD42024626613"],["R0011394",null,null,"10.1186/s13098-023-01198-4","37904255","PMC10614386","Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.","2023","Diabetology & metabolic syndrome","Zhou Q","62","33","15","none found",null],["R0011400",null,null,"10.1186/s12874-023-01925-5","37087450","PMC10122363","Hierarchical network meta-analysis models for synthesis of evidence from randomised and non-randomised studies.","2023","BMC medical research methodology","Hussein H","15","1","0","none found",null],["R0011429",null,null,"10.1111/dom.14819","35848464",null,"Revisiting 'intensive' blood glucose control: A causal directed acyclic graph-guided systematic review of randomized controlled trials.","2022","Diabetes, obesity & metabolism","Huang CJ","53","12","1","none found",null],["R0011441",null,null,"10.1007/s12020-014-0373-0","25115635",null,"Effect of GLP-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and network meta-analysis.","2015","Endocrine","Sun F","50","30","19","none found",null],["R0011448","CRD420251165267",null,"10.1016/j.rmed.2026.108671","41616874",null,"Comparative effectiveness and safety of novel antidiabetic agents in the management of obstructive sleep apnea: a systematic review, meta-analysis, and network meta-analysis.","2026","Respiratory medicine","Yang YT","73","15","6","PROSPERO","PROSPERO:CRD420251165267"],["R0011486",null,null,"10.64898/2025.12.22.25342824",null,null,"Efficacy and Safety of Pemvidutide in Patients with Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Dose-Specific Meta-Analysis of Randomized Controlled Trials","2025","medRxiv","Abdu E",null,"0","0","none found",null],["R0011507","CRD420251077610",null,"10.3390/ph18071058","40732345","PMC12300051","Weight Loss Effects of Once-Weekly Semaglutide 2.4 mg in Adults with and Without Type 2 Diabetes: A Systematic Review and Meta-Analysis.","2025","Pharmaceuticals (Basel, Switzerland)","Hong B","52","41","23","PROSPERO","PROSPERO:CRD420251077610"],["R0011535",null,null,"10.3390/ijms25084346","38673931","PMC11050669","Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review.","2024","International journal of molecular sciences","Feier CVI","50","44","28","none found",null],["R0011536",null,null,"10.1016/j.dsx.2025.103212","40086043",null,"Comparative efficacy and safety of semaglutide 2.4 mg and tirzepatide 5-15 mg in obesity with or without type 2 diabetes: A systematic review of Phase 3 clinical trials.","2025","Diabetes & metabolic syndrome","Singh A","31","24","20","none found",null],["R0011548",null,null,"10.1111/dom.14047","32250550",null,"Relationship between improvement of glycaemic control and reduction of major cardiovascular events in 15 cardiovascular outcome trials: A meta-analysis with meta-regression.","2020","Diabetes, obesity & metabolism","Giugliano D","36","11","7","none found",null],["R0011556",null,null,"10.1007/s13300-018-0428-y","29713961","PMC5984931","A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving Basal Insulin.","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","Witkowski M","41","31","18","none found",null],["R0011560",null,null,"10.1002/epi4.13091","39487832","PMC11633680","Newer glucose-lowering drugs reduce the risk of late-onset seizure and epilepsy: A meta-analysis.","2024","Epilepsia open","Sindhu U","22","10","2","none found",null],["R0011562",null,null,"10.1016/j.disamonth.2026.102112","41936525",null,"Forward for: Approved weight loss drugs for obesity with a thorough emphasis on GLP-1 agonist medications: A systematic review.","2026","Disease-a-month : DM","Leikin JB","2","1","0","none found",null],["R0011566",null,null,"10.4103/sjg.sjg_455_25","41848415","PMC13441243","Efficacy and safety of glucagon-like peptide-1 (GLP-1) agonists in pediatric obesity: A systematic review and meta-analysis.","2026","Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association","Sukkar GA","37","24","6","none found",null],["R0011571",null,null,"10.1016/j.jse.2025.12.005","41619919",null,"GLP-1 receptor agonist therapy is not associated with adverse events following shoulder surgery: a systematic review and meta-analysis.","2026","Journal of shoulder and elbow surgery","Moews LD","25","8","1","none found",null],["R0011574",null,null,"10.7150/ijms.133077","42328113","PMC13280743","Genetic Evidence for the Benefits and Risks of Glucose-Lowering Drugs on Cardiovascular-Kidney-Metabolic Syndrome: A Drug-Target Mendelian Randomization Study.","2026","International journal of medical sciences","Lu J","99","23","7","none found",null],["R0011592",null,null,"10.1111/jgh.13026","26111358",null,"Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.","2016","Journal of gastroenterology and hepatology","Carbone LJ","48","17","3","none found",null],["R0011600",null,null,"10.1111/dom.70643","41804840",null,"Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials.","2026","Diabetes, obesity & metabolism","Azam MH","31","10","7","none found",null],["R0011601",null,null,"10.1016/j.diabres.2019.06.009","31238059",null,"The good companions: insulin and glucagon-like peptide-1 receptor agonist in type 2 diabetes. A systematic review and meta-analysis of randomized controlled trials.","2019","Diabetes research and clinical practice","Maiorino MI","62","45","35","none found",null],["R0011630",null,null,"10.1053/j.gastro.2025.06.039","41422838",null,"Refining Meta-Analyses of GLP-1RA Safety: Sparse Event Data, Confounding, and Sex Differences.","2026","Gastroenterology","Huang J","0","0","0","none found",null],["R0011638",null,null,"10.1111/dom.12804","27717195",null,"A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients.","2017","Diabetes, obesity & metabolism","Abd El Aziz MS","70","49","32","none found",null],["R0011643",null,null,"10.3389/fphar.2024.1235639","38469407","PMC10925615","Efficacy of polyethylene glycol loxenatide for type 2 diabetes mellitus patients: a systematic review and meta-analysis.","2024","Frontiers in pharmacology","Liu Y","38","16","7","none found",null],["R0011644",null,null,"10.1016/j.diabres.2015.07.015","26358202",null,"Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis.","2015","Diabetes research and clinical practice","Sun F","42","12","1","none found",null],["R0011646",null,null,"10.1002/14651858.cd013650.pub2","34693515","PMC8812344","Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.","2021","The Cochrane database of systematic reviews","Kanie T","258","66","46","none found",null],["R0011647",null,null,"10.1016/j.psyneuen.2025.107415","40138849",null,"The effect of GLP-1RAs on mental health and psychotropics-induced metabolic disorders: A systematic review.","2025","Psychoneuroendocrinology","Breit S","118","79","25","none found",null],["R0011652",null,null,"10.1155/2019/8083417","31772945","PMC6854923","The Effects of Exenatide Once Weekly (EXQW) and Exenatide Twice a Day (EXBID) on Beta-Cell Function in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.","2019","Journal of diabetes research","Wang J","33","24","15","none found",null],["R0011662",null,null,"10.14740/jocmr6231","40503067","PMC12151102","Comparative Efficacy of Tirzepatide vs. Semaglutide in Reducing Body Weight in Humans: A Systematic Review and Meta-Analysis of Clinical Trials and Real-World Data.","2025","Journal of clinical medicine research","Aamir AB","26","23","10","none found",null],["R0011669","CRD42022325948",null,"10.1136/bmj-2022-074068","37024129","PMC10077111","Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.","2023","BMJ (Clinical research ed.)","Shi Q","41","13","7","PROSPERO","PROSPERO:CRD42022325948"],["R0011676","CRD42024618146",null,"10.3389/fendo.2025.1554795","40933383","PMC12417197","Effect of semaglutide on arrhythmic, major cardiovascular, and microvascular outcomes in patients with type 2 diabetes: a systematic review and meta-analysis.","2025","Frontiers in endocrinology","Wu R","52","47","31","PROSPERO","PROSPERO:CRD42024618146"],["R0011681",null,null,"10.1111/j.1365-2710.2012.01342.x","22436069",null,"Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.","2012","Journal of clinical pharmacy and therapeutics","Cornell S","96","47","28","none found",null],["R0011696",null,null,"10.1111/dom.14988","36700380",null,"Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP-1 receptor co-agonist tirzepatide.","2023","Diabetes, obesity & metabolism","Nauck MA","33","24","13","none found",null],["R0011707","CRD420251077729",null,"10.1038/s41433-026-04904-4","42786281",null,"Potential protective associations of antidiabetic and lipid-lowering therapies with retinal vein occlusion risk: a systematic review and meta-analysis.","2026","Eye (London, England)","Alamoudi A","35","4","0","PROSPERO","PROSPERO:CRD420251077729"],["R0011718",null,null,"10.1016/j.sleep.2025.106708","40763546",null,"Comment on: \"Efficacy and safety of GLP-1 receptor agonists in obstructive sleep apnea - a systematic review and meta-analysis\" by Kow et al.","2025","Sleep medicine","Sharma A","1","1","0","none found",null],["R0011721",null,null,"10.1186/s12933-020-01133-1","32993654","PMC7525990","Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis.","2020","Cardiovascular diabetology","D'Andrea E","37","18","9","none found",null],["R0011745",null,null,"10.1093/bjs/znag022","41783935",null,"Pancreaticobiliary side effects of GLP-1 agonists: a meta-analysis of published randomized control trials and a real-world pharmacovigilance profile.","2026","The British journal of surgery","Hughes A","5","4","2","none found",null],["R0011749","CRD42017079547",null,"10.1002/dmrr.3082","30270567",null,"GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: A systematic review and meta-analysis.","2019","Diabetes/metabolism research and reviews","Castellana M","36","25","15","PROSPERO","PROSPERO:CRD42017079547"],["R0011773",null,null,"10.1016/j.hlc.2018.03.018","29887418",null,"Update in Cardiovascular Safety of Glucagon Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes. A Mixed Treatment Comparison Meta-Analysis of Randomised Controlled Trials.","2018","Heart, lung & circulation","Al Yami MS","0","0","0","none found",null],["R0011775","CRD42022347901",null,"10.1016/j.eclinm.2022.101697","36263397","PMC9574412","Age, sex, race, BMI, and duration of diabetes differences in cardiovascular outcomes with glucose lowering drugs in type 2 diabetes: A systematic review and meta-analysis.","2022","EClinicalMedicine","Diallo A","28","15","7","PROSPERO","PROSPERO:CRD42022347901"],["R0011784",null,null,"10.1002/dmrr.3515","34951928",null,"Comparative efficacy and safety of antihyperglycemic drug classes for patients with type 2 diabetes following failure with metformin monotherapy: A systematic review and network meta-analysis of randomized controlled trials.","2022","Diabetes/metabolism research and reviews","Zheng H","49","11","2","none found",null],["R0011815",null,null,"10.1007/s13300-026-01884-2","42295651","PMC13388877","Treatment Options for Patients with Maturity-Onset Diabetes of the Young (MODY): A Systematic Review of Literature: 2026 Update.","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","Zagaroli L","127","12","1","none found",null],["R0011826",null,null,"10.1007/s12020-019-01931-y","31028667",null,"Type 2 diabetes and risk of heart failure: a systematic review and meta-analysis from cardiovascular outcome trials.","2019","Endocrine","Giugliano D","30","10","5","none found",null],["R0011840",null,null,"10.1111/dom.16360","40176458","PMC12046479","Efficacy and safety of iGlarLixi versus IDegAsp in people with type 2 diabetes inadequately controlled with basal insulin: A systematic literature review and network meta-analysis of non-Asian studies.","2025","Diabetes, obesity & metabolism","Home P","38","15","11","none found",null],["R0011846",null,null,"10.1111/j.1463-1326.2012.01603.x","22471248",null,"Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.","2012","Diabetes, obesity & metabolism","Deacon CF","45","20","12","none found",null],["R0011860",null,null,"10.1053/j.ajkd.2016.06.014","27528374",null,"Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis.","2016","American journal of kidney diseases : the official journal of the National Kidney Foundation","Howse PM","49","8","2","none found",null],["R0011862",null,null,"10.1080/14737167.2021.1860022","33317348",null,"The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 Diabetes: a systematic literature review.","2021","Expert review of pharmacoeconomics & outcomes research","Ruan Z","65","42","15","none found",null],["R0011867",null,null,"10.51821/85.2.9775","35709779",null,"Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients: what do we know so far ?","2022","Acta gastro-enterologica Belgica","Binet Q","0","0","0","none found",null],["R0011880",null,null,"10.3390/biomedicines12091943","39335457","PMC11428590","Comparative Efficacy and Safety of Weekly GLP-1/GIP Agonists vs. Weekly Insulin in Type 2 Diabetes: A Network Meta-Analysis of Randomized Controlled Trials.","2024","Biomedicines","Ayesh H","54","30","27","none found",null],["R0011887",null,null,"10.1002/dmrr.3223","31642583",null,"Meta-analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add-on to metformin in type 2 diabetes.","2020","Diabetes/metabolism research and reviews","Zhou Y","35","10","4","none found",null],["R0011894",null,null,"10.1210/clinem/dgaa178","32271381",null,"Effects of Basal Insulin on Lipid Profile Compared to Other Classes of Antihyperglycemic Agents in Type 2 Diabetic Patients.","2020","The Journal of clinical endocrinology and metabolism","Rigato M","69","27","17","none found",null],["R0011898",null,null,"10.1111/dom.16603","40654219",null,"Cardiorenal outcomes and mortality with GLP-1 receptor agonists combined with SGLT2 inhibitors in type 2 diabetes: An updated systematic review and meta-analysis.","2025","Diabetes, obesity & metabolism","Neves JS","9","5","2","none found",null],["R0011906",null,null,"10.2147/dmso.s116810","28435304","PMC5386609","Comparative effectiveness of glycemic control in patients with type 2 diabetes treated with GLP-1 receptor agonists: a network meta-analysis of placebo-controlled and active-comparator trials.","2017","Diabetes, metabolic syndrome and obesity : targets and therapy","Orme ME","60","36","28","none found",null],["R0011933",null,null,"10.7759/cureus.85531","40630338","PMC12234836","Dose-Dependent Efficacy and Safety of Tirzepatide for Weight Loss in Non-diabetic Adults With Obesity: A Systematic Review and Meta-analysis of Randomized Controlled Trials.","2025","Cureus","Kasagga A","15","9","6","none found",null],["R0011936",null,null,"10.1155/2018/1232583","30622967","PMC6304901","Effects of Newer Antidiabetic Drugs on Endothelial Function and Arterial Stiffness: A Systematic Review and Meta-Analysis.","2018","Journal of diabetes research","Batzias K","56","14","8","none found",null],["R0011943",null,null,"10.1016/j.psyneuen.2025.107572","40803162",null,"Response to \"Letter to the Editor: The effect of GLP-1RAs on mental health and psychotropics induced metabolic disorders: A systematic review\".","2025","Psychoneuroendocrinology","Breit S","12","9","2","none found",null],["R0011953",null,null,"10.1016/j.sleep.2025.106709","40795454",null,"Response to comment on \"Efficacy and safety of GLP-1 receptor agonists in the management of obstructive sleep apnea in individuals without diabetes: A systematic review and meta-analysis of randomized, placebo-controlled trials\".","2025","Sleep medicine","Kow CS","3","3","0","none found",null],["R0011963",null,null,"10.1007/s11892-020-1292-5","32166504",null,"A Systematic Review of Cost-Effectiveness of Sodium-Glucose Cotransporter Inhibitors for Type 2 Diabetes.","2020","Current diabetes reports","Yoshida Y","41","5","0","none found",null],["R0011984",null,null,"10.1161/jaha.119.012356","31166153","PMC6645638","Glycemic Control, Preexisting Cardiovascular Disease, and Risk of Major Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: Systematic Review With Meta-Analysis of Cardiovascular Outcome Trials and Intensive Glucose Control Trials.","2019","Journal of the American Heart Association","Giugliano D","47","11","6","none found",null],["R0012033",null,null,"10.1038/s41598-018-22443-1","29511288","PMC5840350","Comparison of non-insulin antidiabetic agents as an add-on drug to insulin therapy in type 2 diabetes: a network meta-analysis.","2018","Scientific reports","Yoon JH","67","14","12","none found",null],["R0012041",null,null,"10.1016/j.jchf.2025.03.035","40434323",null,"GLP-1 Receptor Agonists in Heart Failure With Reduced Ejection Fraction: Meta-Analysis of Randomized Clinical Trials.","2025","JACC. Heart failure","Neves JS","5","5","3","none found",null],["R0012051",null,null,"10.1097/mjt.0000000000001743","38976545",null,"Comparative Meta-Analysis of Retatrutide Versus Placebo and Dulaglutide for Weight Loss and Diabetes Management: Insights From Clinical Trials.","2024","American journal of therapeutics","Ayesh H","6","6","3","none found",null],["R0012065",null,null,"10.1161/jaha.125.044249","42714458",null,"Tirzepatide and the Incidence of Atrial Fibrillation in Adults With Overweight or Obesity: An Updated Meta-Analysis of Randomized Controlled Trials.","2026","Journal of the American Heart Association","Mansouri ES","41","26","15","none found",null],["R0012066","CRD42024537006",null,"10.1186/s12902-024-01805-z","39719583","PMC11668020","Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis.","2024","BMC endocrine disorders","Teng Y","50","20","11","PROSPERO","PROSPERO:CRD42024537006"],["R0012073",null,null,"10.1007/s00266-025-05112-3","40835770",null,"Plastic Surgery in the Ozempidemic: Considerations for the Timing of Body Contouring Surgery in Patients with Semaglutide-Associated Weight Loss.","2025","Aesthetic plastic surgery","Garbaccio NC","48","19","13","none found",null],["R0012084",null,null,"10.1186/s12933-021-01401-8","34663316","PMC8522255","Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression.","2021","Cardiovascular diabetology","Maiorino MI","44","16","9","none found",null],["R0012105",null,null,"10.1111/dme.13185","27412701","PMC5248619","Efficacy and safety of liraglutide, a once-daily human glucagon-like peptide-1 receptor agonist, in African-American people with Type 2 diabetes: a meta-analysis of sub-population data from seven phase III trials.","2017","Diabetic medicine : a journal of the British Diabetic Association","Shomali ME","25","11","8","none found",null],["R0012127",null,null,"10.1212/cpj.0000000000200548","41089206","PMC12516850","The Effect of GLP-1RA on the Motor Function of Patients With Parkinson Disease: A Systematic Review and Meta-Analysis.","2025","Neurology. Clinical practice","Ristori Costa G","22","11","5","none found",null],["R0012150",null,null,"10.2147/clep.s391819","36510488","PMC9738168","Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review.","2022","Clinical epidemiology","Xie Z","32","29","22","none found",null],["R0012151",null,null,null,null,"PMC12544629","SUN-576 Glucagon-like Peptide-1 (GLP-1) Receptor Agonists For Alcohol Use Disorder: a Systematic Review and Meta-analysis","2025","Journal of the Endocrine Society",null,"0","0","0","none found",null],["R0012155",null,null,"10.1016/j.ijcard.2025.133683","40752805",null,"Effects of oral semaglutide on cardiovascular outcomes: A systematic review and meta-analysis.","2025","International journal of cardiology","Rebelo TG","20","10","7","none found",null],["R0012157",null,null,"10.3390/ijms21041509","32098413","PMC7073149","GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease-A Systematic Review.","2020","International journal of molecular sciences","Mori Y","146","19","7","none found",null],["R0012159",null,null,"10.1016/j.orcp.2025.01.009","39904668",null,"Effects of liraglutide on body composition in people living with obesity or overweight: A systematic review.","2025","Obesity research & clinical practice","Schmidt PHS","46","31","21","none found",null],["R0012162",null,null,"10.1007/s10792-025-03768-z","41042286",null,"SGLT2 inhibitors for delaying diabetic retinopathy: a systematic review and meta-analysis.","2025","International ophthalmology","Goodarzi S","56","12","0","none found",null],["R0012168",null,null,null,null,"PMC12544773","MON-826 Impact Of Demographic And Social Determinants On Access To SGLT2 Inhibitors And GLP-1 Receptor Agonists: A Systematic Review And Meta-Analysis","2025","Journal of the Endocrine Society",null,"0","0","0","none found",null],["R0012183",null,null,"10.1007/s10787-025-01873-0","40762930","PMC12397177","Antidiabetic drugs in Parkinson's disease: a comprehensive meta-analysis on efficacy and safety with trial sequential analysis and GRADE evaluation.","2025","Inflammopharmacology","Abou Elezz AM","60","23","6","none found",null],["R0012185",null,null,"10.2337/dc16-1957","28325801",null,"Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials.","2017","Diabetes care","Maiorino MI","46","33","28","none found",null],["R0012188",null,null,null,null,"PMC12543721","MON-183 Effect of GLP-1 Receptor Agonists on Anthropometric, Metabolic and Fertility Parameters in Polycystic Ovarian Syndrome: A Systematic Review and Meta-Analysis","2025","Journal of the Endocrine Society",null,"0","0","0","none found",null],["R0012189",null,null,"10.1111/dom.13899","31637820",null,"Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis.","2020","Diabetes, obesity & metabolism","Avgerinos I","39","21","15","none found",null],["R0012212",null,null,"10.1016/j.jpsychires.2023.05.041","37331261",null,"Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: A systematic review.","2023","Journal of psychiatric research","Cooper DH","47","23","3","none found",null],["R0012220",null,null,"10.1371/journal.pone.0285197","37141329","PMC10159347","Weight loss efficiency and safety of tirzepatide: A Systematic review.","2023","PloS one","Lin F","43","33","10","none found",null],["R0012248",null,null,"10.1007/s10840-026-02297-8","41843238","PMC13221330","Comparing GLP-1 agonists versus other weight loss interventions on risk of atrial fibrillation recurrence after catheter ablation: a meta-analysis.","2026","Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing","Li HY","49","16","1","none found",null],["R0012252",null,null,"10.1038/s41591-022-01707-4","35210595","PMC8938269","Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis.","2022","Nature medicine","Sattar N","36","21","12","none found",null],["R0012276",null,null,"10.1007/s10557-025-07680-7","40088397",null,"GLP-1 Receptor Agonists and Cardiac Health: Insights from a Systematic Review.","2025","Cardiovascular drugs and therapy","Pedrosa MR","4","1","0","none found",null],["R0012286",null,null,"10.21203/rs.3.rs-7884657/v1",null,null,"Efficacy of Mazdutide in Nondiabetic Adults with Overweight or Obesity: A Meta-Analysis","2025","Research Square","Yassin MN",null,"0","0","none found",null],["R0012292",null,null,"10.1016/j.amepre.2021.10.020","35151523","PMC10420389","Interventions for Reversing Prediabetes: A Systematic Review and Meta-Analysis.","2022","American journal of preventive medicine","Galaviz KI","90","3","3","none found",null],["R0012310",null,null,"10.1038/s41598-017-16018-9","29167470","PMC5700049","Glucagon-like peptide-1 mimetics, optimal for Asian type 2 diabetes patients with and without overweight/obesity: meta-analysis of randomized controlled trials.","2017","Scientific reports","Zhang F","44","33","28","none found",null],["R0012311",null,null,"10.7759/cureus.111786","42534203","PMC13419888","Post-cessation Weight Regain After Weight Management Medications: A Systematic Review and Meta-Analysis.","2026","Cureus","Patel H","37","26","16","none found",null],["R0012316",null,null,"10.1111/dom.12085","23433305",null,"Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.","2013","Diabetes, obesity & metabolism","Wang B","77","49","30","none found",null],["R0012320",null,null,"10.1016/j.jclinepi.2025.111872","40550404",null,"Target trial emulation of cardiovascular outcome trials of medications used to treat type 2 diabetes using real-world data: a systematic review of observational studies.","2025","Journal of clinical epidemiology","Wang W","44","17","8","none found",null],["R0012339",null,null,"10.1097/mjt.0000000000001968","40304630",null,"Comparison of SGLT2 Inhibitors and GLP-1 Receptor Agonists on the Risk of Atrial Fibrillation in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis.","2026","American journal of therapeutics","Kumar A","18","11","1","none found",null],["R0012347",null,null,"10.3389/fphar.2026.1882227","42851802","PMC13646529","SGLT2 inhibitors, semaglutide, and finerenone in diabetic kidney disease: a Bayesian network meta-analysis.","2026","Frontiers in pharmacology","He Z","0","0","0","none found",null],["R0012360",null,null,"10.1186/s12872-019-01275-5","31870322","PMC6927173","Targeting the DPP-4-GLP-1 pathway improves exercise tolerance in heart failure patients: a systematic review and meta-analysis.","2019","BMC cardiovascular disorders","Chen C","51","17","9","none found",null],["R0012365",null,null,"10.1016/s2213-8587(19)30249-9","31422062",null,"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.","2019","The lancet. Diabetes & endocrinology","Kristensen SL","29","23","14","none found",null],["R0012367",null,null,"10.1016/j.eprac.2025.11.010","41297885",null,"Cardiovascular Outcomes in Adults With Type 2 Diabetes Treated With Tirzepatide: A Systematic Review and Meta-Analysis of Real-World Studies.","2026","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Kamrul-Hasan ABM","44","30","14","none found",null],["R0012376","CRD42024554005",null,"10.3389/fendo.2025.1513641","39968298","PMC11832366","Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with/without type 2 diabetes: a systematic review and network meta-analysis.","2025","Frontiers in endocrinology","Liu S","31","21","10","PROSPERO","PROSPERO:CRD42024554005"],["R0012385",null,null,"10.1007/s11892-018-1052-y","30187176",null,"Diabetes Treatment in the Elderly: Incorporating Geriatrics, Technology, and Functional Medicine.","2018","Current diabetes reports","Valencia WM","123","13","7","none found",null],["R0012389",null,null,"10.1111/1753-0407.12102","24164867",null,"Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials.","2014","Journal of diabetes","Mabilleau G","33","10","5","none found",null],["R0012390",null,null,"10.1111/dom.14322","33464677","PMC8248154","Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review.","2021","Diabetes, obesity & metabolism","Cariou B","152","19","7","none found",null],["R0012409",null,null,"10.1001/jama.2024.27402","39899304","PMC11791772","Age and Sex Differences in Efficacy of Treatments for Type 2 Diabetes: A Network Meta-Analysis.","2025","JAMA","Hanlon P","47","13","9","none found",null],["R0012432",null,null,"10.1111/dom.12213","24495116",null,"Glucagon-like peptide-1 receptor agonists vs. insulin in inadequately controlled patients with type 2 diabetes. Is this meta-analysis miscalculated?","2014","Diabetes, obesity & metabolism","Liatis S","2","2","1","none found",null],["R0012459",null,null,"10.1007/s13300-018-0424-2","29675798","PMC5984927","A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Anti-Diabetic Drugs.","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","Witkowski M","60","43","35","none found",null],["R0012507","CRD42024614466",null,"10.1111/cob.70042","40832978",null,"Effect of Tirzepatide on the Risk of Developing Type 2 Diabetes Mellitus Among the People Living With Obesity or Overweight: A Systematic Review.","2026","Clinical obesity","Pardeshi G","28","10","4","PROSPERO","PROSPERO:CRD42024614466"],["R0012525",null,null,"10.1016/j.dsx.2022.102562","35816950",null,"Effect of glucagon-like peptide-1 (GLP-1) analogues on epicardial adipose tissue: A meta-analysis.","2022","Diabetes & metabolic syndrome","Berg G","50","16","7","none found",null],["R0012544",null,null,"10.1016/j.physbeh.2019.03.029","30946836","PMC6520118","The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder (SUD)-related behavioural effects of drugs and alcohol: A systematic review.","2019","Physiology & behavior","Brunchmann A","36","24","0","none found",null],["R0012553",null,null,"10.1186/s12872-016-0260-0","27169565","PMC4863354","Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies.","2016","BMC cardiovascular disorders","Li L","41","21","11","none found",null],["R0012565",null,null,"10.1111/dom.12810","27762096",null,"Beneficial effect of lixisenatide after 76 weeks of treatment in patients with type 2 diabetes mellitus: A meta-analysis from the GetGoal programme.","2017","Diabetes, obesity & metabolism","Broglio F","43","39","18","none found",null],["R0012574",null,null,"10.1016/j.diabres.2026.113431","42442557",null,"Tirzepatide, cardiovascular outcomes and mortality in obesity and diabetes: a systematic review and meta-analysis.","2026","Diabetes research and clinical practice","Spiazzi BF","53","29","23","none found",null],["R0012592",null,null,"10.1002/edm2.100","31922027","PMC6947712","Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with type 2 diabetes: A systematic review and meta-analysis.","2020","Endocrinology, diabetes & metabolism","Kamalinia S","206","34","22","none found",null],["R0012618",null,null,"10.1016/j.diabres.2024.111816","39147102",null,"Glucose lowering drug or strategy dependent impact of weight reduction on the prevention of CVD outcomes in Type 2 diabetes: a systematic review of CVOTs.","2024","Diabetes research and clinical practice","Lalić NM","47","13","8","none found",null],["R0012673","CRD42021259711",null,"10.1016/s2213-8587(21)00203-5","34425083",null,"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.","2021","The lancet. Diabetes & endocrinology","Sattar N","30","22","12","PROSPERO","PROSPERO:CRD42021259711"],["R0012683",null,null,"10.3390/life13040989","37109517","PMC10142629","Role of Exendin-4 Functional Imaging in Diagnosis of Insulinoma: A Systematic Review.","2023","Life (Basel, Switzerland)","Sidrak MMA","52","28","4","none found",null],["R0012688","CRD42022322129",null,"10.7326/m23-1490","38639549",null,"Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians.","2024","Annals of internal medicine","Drake T","109","47","41","PROSPERO","PROSPERO:CRD42022322129"],["R0012706",null,null,"10.2337/dc25-0267","40392995",null,"Comment on Wong et al. Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference for Patients With Obesity or Overweight: A Systematic Review, Meta-analysis, and Meta-regression of 47 Randomized Controlled Trials. Diabetes Care 2025;48:292-300.","2025","Diabetes care","Huang J","0","0","0","none found",null],["R0012724","CRD42022382594",null,"10.1007/s00125-024-06144-1","38613667","PMC11153294","Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.","2024","Diabetologia","Karagiannis T","60","42","28","PROSPERO","PROSPERO:CRD42022382594"],["R0012733","CRD42025649542",null,"10.1002/jcph.70248","42612051","PMC13485131","Semaglutide-Induced Nonarteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis.","2026","Journal of clinical pharmacology","Khani E","22","14","1","PROSPERO","PROSPERO:CRD42025649542"],["R0012749",null,null,"10.2337/dci25-0023","40392996",null,"Response to Comment on Wong et al. Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference for Patients With Obesity or Overweight: A Systematic Review, Meta-analysis, and Meta-regression of 47 Randomized Controlled Trials. Diabetes Care 2025;48:292-300.","2025","Diabetes care","Wong HJ","3","3","0","none found",null],["R0012784",null,null,"10.1155/2011/215764","21584276","PMC3092497","Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials.","2011","Experimental diabetes research","Monami M","51","34","32","none found",null],["R0012792","CRD42023433123",null,"10.1002/14651858.cd015986","42125960","PMC13169147","Pharmacological interventions for the treatment of obesity in children and adolescents.","2026","The Cochrane database of systematic reviews","Gerardi C","3","3","0","PROSPERO","PROSPERO:CRD42023433123"],["R0012795",null,null,"10.1111/dom.12653","26936426",null,"Efficacy and safety of liraglutide, a once-daily human glucagon-like peptide-1 analogue, in Latino/Hispanic patients with type 2 diabetes: post hoc analysis of data from four phase III trials.","2016","Diabetes, obesity & metabolism","Davidson JA","9","7","5","none found",null],["R0012796",null,null,"10.1111/obr.13574","37191219",null,"GLP-1 analogs and regional adiposity: A systematic review and meta-analysis.","2023","Obesity reviews : an official journal of the International Association for the Study of Obesity","Akoumianakis I","74","37","32","none found",null],["R0012799",null,null,"10.1002/ehf2.14979","39041458","PMC11631328","Effect of sex on sodium-glucose co-transporter-2 antagonists and glucagon-like peptide-1 agonists in heart failure.","2024","ESC heart failure","Philip MA","38","12","4","none found",null],["R0012820",null,null,"10.1038/s41366-026-02189-x","42668312",null,"Effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults with overweight or obesity without diabetes: a systematic review and meta-analysis.","2026","International journal of obesity (2005)","Milluzzo A","18","13","9","none found",null],["R0012832",null,null,"10.1111/jcpt.13270","33067896",null,"Anticipatory guidance and systematic review of prescribing combination incretin therapy in the treatment of type 2 diabetes.","2021","Journal of clinical pharmacy and therapeutics","Cowart K","23","17","6","none found",null],["R0012835",null,null,"10.3390/children9101572","36291508","PMC9600106","Systematic Review and Meta-Analysis of the Efficacy and Safety of Metformin and GLP-1 Analogues in Children and Adolescents with Diabetes Mellitus Type 2.","2022","Children (Basel, Switzerland)","Carydias E","34","9","3","none found",null],["R0012837",null,null,"10.1080/27697061.2026.2650457","42008388",null,"Harnessing Herbal Power: A Systematic Review of Phytopharmaceuticals in Type 2 Diabetes Management.","2026","Journal of the American Nutrition Association","Chattopadhyay K","133","0","0","none found",null],["R0012849",null,null,null,null,"PMC10553987","FRI067 Efficacy And Safety Of Glucagon-like Peptide 1 Analogs And Agonists (aGLP1) In Overweight/Obese Patients: A Systematic Review And An Updated Network Meta-analysis","2023","Journal of the Endocrine Society",null,"0","0","0","none found",null],["R0012860","CRD42021259336",null,"10.3389/fendo.2023.1182037","37441498","PMC10335801","New anti-diabetic agents for the treatment of non-alcoholic fatty liver disease: a systematic review and network meta-analysis of randomized controlled trials.","2023","Frontiers in endocrinology","Kongmalai T","77","28","15","PROSPERO","PROSPERO:CRD42021259336"],["R0012867",null,null,"10.2174/0115733998359708250822102217","40947681",null,"Efficacy and Safety of IDegLira in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.","2026","Current diabetes reviews","Bai L","41","31","15","none found",null],["R0012874","CRD42022335504",null,"10.1177/14791641231221740","38111352","PMC10734357","Cardiovascular and renal outcomes of GLP-1 receptor agonists vs. DPP-4 inhibitors and basal insulin in type 2 diabetes mellitus: A systematic review and meta-analysis.","2023","Diabetes & vascular disease research","Evans M","49","27","5","PROSPERO","PROSPERO:CRD42022335504"],["R0012882",null,null,"10.1016/j.clinthera.2017.07.036","28827024",null,"Gastrointestinal Adverse Events of Dipeptidyl Peptidase 4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-analysis.","2017","Clinical therapeutics","Wu S","40","7","3","none found",null],["R0012900",null,null,"10.1007/s13300-019-0617-3","31054132","PMC6531561","Injectable Antihyperglycemics: A Systematic Review and Critical Analysis of the Literature on Adherence, Persistence, and Health Outcomes.","2019","Diabetes therapy : research, treatment and education of diabetes and related disorders","Hamersky CM","56","14","1","none found",null],["R0012914",null,null,"10.1017/rsm.2026.10107","42527984",null,"Incorporating estimands into meta-analyses of clinical trials.","2026","Research synthesis methods","Remiro-Azócar A","0","0","0","none found",null],["R0012966",null,null,"10.1210/clinem/dgab428","34125217",null,"Glucose-lowering Drugs and Hospitalization for Heart Failure: A Systematic Review and Additive-effects Network Meta-analysis With More Than 500 000 Patient-years.","2021","The Journal of clinical endocrinology and metabolism","Cintra RM","39","9","2","none found",null],["R0012981",null,null,"10.1111/dom.12025","23061470","PMC3662998","Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature.","2013","Diabetes, obesity & metabolism","Balena R","61","42","13","none found",null],["R0012987",null,null,"10.21203/rs.3.rs-4184273/v1",null,null,"Efficacy and safety of tirzepatide in overweight or obese adults without diabetes: systematic review and meta-analysis of randomized controlled trials","2024","Research Square","Liu L",null,"0","0","none found",null],["R0012989",null,null,"10.1007/s40200-024-01409-3","38932865","PMC11196538","Evaluating the impact of efpeglenatide on cardiometabolic and safety outcomes in individuals with diabetes: a systematic review and meta-analysis.","2024","Journal of diabetes and metabolic disorders","Qazi SU","26","20","12","none found",null],["R0012991",null,null,"10.1016/j.ijcard.2017.12.039","29277321",null,"Network meta-analysis of cardiovascular outcomes in randomized controlled trials of new antidiabetic drugs.","2018","International journal of cardiology","Fei Y","46","9","6","none found",null],["R0012997","CRD42024511198",null,"10.1038/s41598-025-00080-9","40419497","PMC12106727","Registered clinical trials targeting type 2 diabetes remission with pharmacological interventions.","2025","Scientific reports","Shoung N","39","10","4","PROSPERO","PROSPERO:CRD42024511198"],["R0013021",null,null,null,null,"PMC9624572","PSUN192 Therapeutic Benefit of GLP-1 Agonists in Patients with Type 1 Diabetes on Insulin Therapy: an Updated Systematic Review and Meta-analysis","2022","Journal of the Endocrine Society",null,"0","0","0","none found",null],["R0013022",null,null,"10.1016/j.cpcardiol.2026.103423","42586458",null,"From pathobiology to prescribing in obesity-driven HFpEF: A systematic review and practical therapeutic framework.","2026","Current problems in cardiology","Alhazmi AM","46","15","12","none found",null],["R0013030",null,null,"10.1016/j.diabres.2020.108604","33338553",null,"Incretin based therapies and SGLT-2 inhibitors in kidney transplant recipients with diabetes: A systematic review and meta-analysis.","2021","Diabetes research and clinical practice","Oikonomaki D","52","11","4","none found",null],["R0013034",null,null,"10.1007/s12020-018-1708-z","30101378",null,"The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis.","2018","Endocrine","Li X","52","30","17","none found",null],["R0013035",null,null,"10.7759/cureus.99805","41438726","PMC12720054","Reducing Periprosthetic Joint Infection in Patients With Obesity: A Systematic Review and Meta-Analysis of the Emerging Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists.","2025","Cureus","Fernandes A","25","16","7","none found",null],["R0013037",null,null,"10.7759/cureus.89969","40951083","PMC12426967","Pathogenesis and Treatment of Non-alcoholic Steatohepatitis and Its Fibrosis: A Systematic Review.","2025","Cureus","Ahmed T","46","3","3","none found",null],["R0013046",null,null,"10.3390/ijms23020739","35054924","PMC8775408","GLP-1a: Going beyond Traditional Use.","2022","International journal of molecular sciences","Laurindo LF","102","71","27","none found",null],["R0013063",null,null,"10.1007/s11695-020-04750-7","32500274",null,"GLP-1 Analogues as a Complementary Therapy in Patients after Metabolic Surgery: a Systematic Review and Qualitative Synthesis.","2020","Obesity surgery","Schneider R","29","19","12","none found",null],["R0013078","CRD420212716429",null,"10.1002/oby.23600","36502288","PMC10107620","The efficacy of GLP-1RAs for the management of postprandial hypoglycemia following bariatric surgery: a systematic review.","2023","Obesity (Silver Spring, Md.)","Llewellyn DC","61","20","5","PROSPERO","PROSPERO:CRD420212716429"],["R0013106","CRD42020189464",null,"10.3389/fendo.2021.735824","34721294","PMC8553257","Effects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis.","2021","Frontiers in endocrinology","Zhang YS","43","10","1","PROSPERO","PROSPERO:CRD42020189464"],["R0013112",null,null,"10.1007/s13300-018-0397-1","29574633","PMC5984907","A Network Meta-Analysis Comparing Semaglutide Once-Weekly with Other GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes.","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","Webb N","37","20","14","none found",null],["R0013113",null,null,"10.1111/jebm.70021","40229658",null,"Efficacy of Hypoglycemic Agents in Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD): A Systematic Review and Network Meta-Analysis.","2025","Journal of evidence-based medicine","Ren Q","78","15","8","none found",null],["R0013118","CRD42020212994",null,"10.21203/rs.3.rs-123781/v1",null,null,"What Is the Impact of Different Glucose-lowering Agents for Atrial Fibrillation Risk: A Systematic Review and a Network Meta-analysis&nbsp;","2020","Research Square","Shi W",null,"0","0","PROSPERO","PROSPERO:CRD42020212994"],["R0013136",null,null,"10.1111/dom.12175","23829656",null,"Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials.","2014","Diabetes, obesity & metabolism","Monami M","25","14","3","none found",null],["R0013155",null,null,"10.1111/dom.70391","41424191",null,"Impact of glucagon-like peptide-1 receptor agonism-based therapies on limb outcomes in peripheral artery disease and type 2 diabetes: An updated systematic review and meta-analysis.","2026","Diabetes, obesity & metabolism","Dutta D","43","36","11","none found",null],["R0013164",null,null,"10.1007/s40200-026-01928-1","41822052","PMC12976236","Comparative efficacy and safety of non-insulin antihyperglycemic agents versus insulin in patients over 65 years with type 2 diabetes and advanced or end-stage chronic kidney disease on dialysis: a systematic review of studies published in the last 10 years.","2026","Journal of diabetes and metabolic disorders","Marroquín JJ","0","0","0","none found",null],["R0013170",null,null,"10.1111/dom.13125","28950422","PMC5836948","Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials.","2018","Diabetes, obesity & metabolism","Davies MJ","28","8","7","none found",null],["R0013191",null,null,"10.1111/dme.15157","37249579",null,"Effects of DPP-4 inhibitors, GLP-1 receptor agonists, SGLT-2 inhibitors and sulphonylureas on mortality, cardiovascular and renal outcomes in type 2 diabetes: A network meta-analyses-driven approach.","2023","Diabetic medicine : a journal of the British Diabetic Association","Brønden A","27","9","6","none found",null],["R0013197",null,null,"10.1007/s40618-019-01047-0","30955180",null,"Cardiovascular outcome trials and major cardiovascular events: does glucose matter? A systematic review with meta-analysis.","2019","Journal of endocrinological investigation","Giugliano D","20","6","5","none found",null],["R0013199",null,null,"10.1080/14656566.2023.2181693","36799287",null,"The correlations between steady-state concentration, duration of action and molecular weight of GLP-1RAs and their efficacy and gastrointestinal side effects in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.","2023","Expert opinion on pharmacotherapy","Jiao R","0","0","0","none found",null],["R0013219","CRD42024625338",null,"10.21203/rs.3.rs-6449183/v1",null,null,"Pharmacological management of obesity in adults: a systematic review and meta-analysis of randomized controlled trials to evaluate the efficacy and safety of obesity management medications","2025","Research Square","Ciudin A",null,"0","0","PROSPERO","PROSPERO:CRD42024625338"],["R0013234",null,null,"10.1016/j.ejim.2024.10.017","39613702",null,"Validating ChatGPT's role in systematic reviews and meta-analyses: A case study on GLP-1 receptor agonists and all-cause mortality.","2025","European journal of internal medicine","Teperikidis L","10","3","0","none found",null],["R0013239",null,null,"10.1186/s12933-019-0916-z","31462224","PMC6714383","Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis.","2019","Cardiovascular diabetology","Fei Y","58","24","9","none found",null],["R0013240",null,null,"10.1111/dom.13343","29732679",null,"Free and fixed-ratio combinations of basal insulin and GLP-1 receptor agonists versus basal insulin intensification in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.","2018","Diabetes, obesity & metabolism","Maiorino MI","16","9","2","none found",null],["R0013249",null,null,"10.1007/s12020-019-02055-z","31420784",null,"GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials.","2019","Endocrine","Cao C","61","49","37","none found",null],["R0013254",null,null,null,null,"PMC11454423","12590 Glp1 Agonists Role On Prediabetes Reversal, A Meta-analysis","2024","Journal of the Endocrine Society",null,"0","0","0","none found",null],["R0013258",null,null,"10.1007/s12020-024-03857-6","38740695",null,"Safety and efficacy of GLP-1 and glucagon receptor dual agonist for the treatment of type 2 diabetes and obesity: a systematic review and meta-analysis of randomized controlled trials.","2024","Endocrine","Deng B","31","22","8","none found",null],["R0013278",null,null,"10.2147/dmso.s387116","36890965","PMC9987242","The Efficacy of GLP-1 Analogues on Appetite Parameters, Gastric Emptying, Food Preference and Taste Among Adults with Obesity: Systematic Review of Randomized Controlled Trials.","2023","Diabetes, metabolic syndrome and obesity : targets and therapy","Aldawsari M","43","17","12","none found",null],["R0013289",null,null,"10.1371/journal.pone.0202563","30148851","PMC6110472","Comparison of antidiabetic drugs added to sulfonylurea monotherapy in patients with type 2 diabetes mellitus: A network meta-analysis.","2018","PloS one","Qian D","57","6","4","none found",null],["R0013300",null,null,"10.1016/j.diabet.2019.12.007","31923578",null,"Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials.","2020","Diabetes & metabolism","Mantovani A","52","9","6","none found",null],["R0013315",null,null,"10.1016/j.rceng.2021.09.003","34872879",null,"Incretin-based therapy for glycemic control of hospitalized patients with type 2 diabetes: a systematic review.","2022","Revista clinica espanola","Gracia-Ramos AE","0","0","0","none found",null],["R0013361","CRD42021245678",null,"10.1016/s0140-6736(21)01640-8","34895470",null,"Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.","2022","Lancet (London, England)","Shi Q","43","12","6","PROSPERO","PROSPERO:CRD42021245678"],["R0013375",null,null,"10.1002/jbm4.10817","38025038","PMC10652182","Effects of Incretin Therapy on Skeletal Health in Type 2 Diabetes-A Systematic Review.","2023","JBMR plus","Viggers R","108","60","16","none found",null],["R0013405",null,null,"10.3389/fendo.2025.1643386","40958912","PMC12434752","IDeglira vs insulin degludec for type 2 diabetes: a systematic review and meta-analysis.","2025","Frontiers in endocrinology","Liu Y","25","14","9","none found",null],["R0013438",null,null,"10.1007/s40615-025-02410-z","40259185",null,"Evidence-Based Practice in Prescribing SGLT2i and GLP-1 RA Across Ethnic and Racial Groups: a Systematic Review and Meta-analysis of Observational Studies.","2026","Journal of racial and ethnic health disparities","Ananthesh L","37","12","1","none found",null],["R0013447","CRD420261354386",null,"10.3389/fphar.2026.1916932","42757217","PMC13584767","Risk of neoplasms with semaglutide in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.","2026","Frontiers in pharmacology","Zhong Y","59","42","24","PROSPERO","PROSPERO:CRD420261354386"],["R0013461","CRD42024547905",null,"10.1016/j.eclinm.2024.103020","39834714","PMC11743856","Safety and effects of anti-obesity medications on weight loss, cardiometabolic, and psychological outcomes in people living with overweight or obesity: a systematic review and meta-analysis.","2025","EClinicalMedicine","Liu L","54","17","6","PROSPERO","PROSPERO:CRD42024547905"],["R0013464",null,null,"10.3390/nu17193038","41097116","PMC12526187","The Sweet Side of Constipation: Colonic Motor Dysfunction in Diabetes Mellitus.","2025","Nutrients","De Fano M","117","12","3","none found",null],["R0013468",null,null,"10.7759/cureus.109350","42326175","PMC13282936","Tirzepatide and Cardiometabolic Effects in Obese Non-diabetic Adults: A Systematic Review, Meta-Analysis, and Narrative Synthesis of Cardiovascular Outcomes.","2026","Cureus","Chaparala P","37","22","18","none found",null],["R0013479",null,null,"10.7759/cureus.56939","38665722","PMC11044191","Evaluating the Efficacy and Safety of Tirzepatide on Glycaemic and Non-glycaemic Outcomes in Diabetes: A Systematic Review of Meta-Analyses.","2024","Cureus","Kaore S","24","22","7","none found",null],["R0013483","CRD42024625338",null,"10.1111/dom.70204","41111360","PMC12673438","Efficacy and safety of European Medicines Agency (EMA)-approved pharmacological, endoscopic, and surgical treatments in different classes of obesity: A network meta-analysis of randomised controlled trials for the development of the SIO (Società Italiana Obesità) Italian guidelines for the diagnosis and treatment of overweight and obesity.","2026","Diabetes, obesity & metabolism","Barazzoni R","168","41","35","PROSPERO","PROSPERO:CRD42024625338"],["R0013491",null,null,"10.1210/jc.2019-01269","31365088",null,"Medications Affecting the Biochemical Conversion to Type 2 Diabetes: A Systematic Review and Meta-Analysis.","2019","The Journal of clinical endocrinology and metabolism","Domecq JP","85","4","2","none found",null],["R0013492","CRD42021252381",null,"10.1186/s12916-025-04018-w","40189519","PMC11974209","The pharmacodynamics-based prophylactic benefits of GLP-1 receptor agonists and SGLT2 inhibitors on neurodegenerative diseases: evidence from a network meta-analysis.","2025","BMC medicine","Tseng PT","181","104","77","PROSPERO","PROSPERO:CRD42021252381"],["R0013496",null,null,"10.1111/dom.12574","26343931","PMC5063148","Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes.","2016","Diabetes, obesity & metabolism","Rodbard HW","12","4","3","none found",null],["R0013505",null,null,"10.1007/s12020-024-03868-3","38740694",null,"iGlarLixi for type 2 diabetes: a systematic review and meta-analysis.","2024","Endocrine","Liu Y","24","16","11","none found",null],["R0013506",null,null,"10.26574/maedica.2025.20.4.824","41537067","PMC12767911","Efficacy and Safety of Retatrutide in the Treatment of Diabetes and/or Obesity Comorbid with Chronic Kidney disease: a Systematic Review and Meta-Analysis.","2025","Maedica","Pallavi K","42","25","6","none found",null],["R0013521",null,null,"10.1111/dom.70980","42297743","PMC13449091","Semaglutide and Risk of Pancreatic Cancer: A Meta-Analysis of Randomised Trials.","2026","Diabetes, obesity & metabolism","Chiang CH","13","11","6","none found",null],["R0013528",null,null,"10.1093/postmj/qgaf238","41536268",null,"Efficacy of tirzepatide in glycemic control and weight management in adults with type 2 diabetes: a systematic review and meta-analysis of real-world studies.","2026","Postgraduate medical journal","Kamrul-Hasan ABM","45","34","8","none found",null],["R0013531",null,null,"10.1038/s41366-024-01646-9","39396098",null,"Semaglutide effects on safety and cardiovascular outcomes in patients with overweight or obesity: a systematic review and meta-analysis.","2025","International journal of obesity (2005)","Cleto AS","23","22","17","none found",null],["R0013534",null,null,"10.3390/diseases12090204","39329873","PMC11431103","The Effect of Tirzepatide on Body Composition in People with Overweight and Obesity: A Systematic Review of Randomized, Controlled Studies.","2024","Diseases (Basel, Switzerland)","Rochira V","72","42","28","none found",null],["R0013537",null,null,"10.1007/s12325-021-01620-1","33502688","PMC7932977","Sulodexide for Diabetic-Induced Disabilities: A Systematic Review and Meta-Analysis.","2021","Advances in therapy","Bignamini AA","91","0","0","none found",null],["R0013541",null,null,"10.1001/jamaneurol.2020.2494","32716473",null,"New Horizons in Pharmacologic Therapy for Secondary Stroke Prevention.","2020","JAMA neurology","Katsanos AH","0","0","0","none found",null],["R0013582",null,null,"10.1007/s00210-025-03932-3","40067438","PMC12350457","Efficacy and safety of GLP-1 agonists in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials.","2025","Naunyn-Schmiedeberg's archives of pharmacology","Messak M","52","20","7","none found",null],["R0013631",null,null,"10.1002/14651858.cd015588.pub2","38770818","PMC11106805","Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes.","2024","The Cochrane database of systematic reviews","Natale P","261","3","1","none found",null],["R0013632",null,null,"10.1038/s41366-025-01719-3","39865161",null,"Association of long-term weight management pharmacotherapy with multiple health outcomes: an umbrella review and evidence map.","2025","International journal of obesity (2005)","Lu TT","37","13","2","none found",null],["R0013642",null,null,"10.1111/1753-0407.12198","25043423",null,"Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials.","2015","Journal of diabetes","Zhang F","57","26","13","none found",null],["R0013651",null,null,"10.1111/1753-0407.12372","26729046",null,"Once-daily liraglutide (1.2 mg) compared with twice-daily exenatide (10 μg) in the treatment of type 2 diabetes patients: An indirect treatment comparison meta-analysis.","2016","Journal of diabetes","Twigg SM","37","21","16","none found",null],["R0013669",null,null,"10.1101/2024.11.28.24317099",null,null,"Replicating cardiovascular outcome trials of medications used to treat type 2 diabetes using real-world data: A systematic review of observational studies","2024","medRxiv","Wang W",null,"0","0","none found",null],["R0013676","CRD42020168351",null,"10.1136/heartjnl-2021-319243","33833070",null,"Predictive models for cardiovascular and kidney outcomes in patients with type 2 diabetes: systematic review and meta-analyses.","2021","Heart (British Cardiac Society)","Buchan TA","44","0","0","PROSPERO","PROSPERO:CRD42020168351"],["R0013680",null,null,"10.1111/dom.13185","29205774",null,"Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials.","2018","Diabetes, obesity & metabolism","Zaccardi F","35","11","4","none found",null],["R0013699",null,null,"10.3390/jcm14072239","40217690","PMC11990051","The Effect of Oral Semaglutide on Cardiovascular Risk Factors in Patients with Type 2 Diabetes: A Systematic Review.","2025","Journal of clinical medicine","Krishnanda SI","32","29","11","none found",null],["R0013705",null,null,"10.1210/clinem/dgab905","34922383","PMC9016460","An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression.","2022","The Journal of clinical endocrinology and metabolism","Lingvay I","16","12","7","none found",null],["R0013713",null,null,"10.1111/dom.70992","42297754","PMC13448870","The Effect of Semaglutide on Quality of Life in Adults With Overweight or Obesity: A Brief Systematic Review and Meta-Analysis.","2026","Diabetes, obesity & metabolism","Eisa N","13","8","8","none found",null],["R0013739",null,null,"10.1111/cob.70030","40530685",null,"The Role of the Dietitian in Weight Management of Adults With Obesity Without Diabetes Using Glucagon Like Peptide-1 Agonist Receptors: A Systematic Review and Meta-Analysis of Randomised Controlled Clinical Trials.","2025","Clinical obesity","Moetaz I","38","16","13","none found",null],["R0013745",null,null,"10.1080/14740338.2018.1424826","29320889",null,"The cardiovascular effect of incretin-based therapies among type 2 diabetes: a systematic review and network meta-analysis.","2018","Expert opinion on drug safety","Wu S","40","12","6","none found",null],["R0013755",null,null,"10.1002/edm2.70157","41466530","PMC12750095","Comparative Analysis of Glucagon Receptor Agonists vs. Resmetirom in MASLD and MASH: Network Meta-Analysis of Clinical Trials.","2026","Endocrinology, diabetes & metabolism","Andonie CR","31","9","5","none found",null],["R0013776",null,null,null,null,"PMC11807682","A81 GASTROINTESTINAL ADVERSE EVENTS ASSOCIATED WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) AGONISTS IN OVERWEIGHT PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS","2025","Journal of the Canadian Association of Gastroenterology",null,"0","0","0","none found",null],["R0013780",null,null,null,null,"PMC12544221","SUN-031 Efficacy Of The Glp-1 Agonists In The Treatment Of Idiopathic Intracranial Hypertension: A Systematic Review And Meta-analysis","2025","Journal of the Endocrine Society",null,"0","0","0","none found",null],["R0013791",null,null,"10.21203/rs.3.rs-7103001/v1",null,null,"Efficacy and safety of retatrutide for overweight/obesity or type 2 diabetes: a systematic review and meta-analysis","2025","Research Square","Xiao Y",null,"0","0","none found",null],["R0013808",null,null,"10.1016/j.dsx.2022.102511","35623229",null,"Semaglutide for the treatment of type 2 Diabetes Mellitus: A systematic review and network meta-analysis of safety and efficacy outcomes.","2022","Diabetes & metabolic syndrome","Zaazouee MS","53","45","26","none found",null],["R0013905","CRD420261288562",null,"10.1002/bcp.70629","42273973","PMC13420891","Clinical evidence of semaglutide for metabolic dysfunction-associated steatotic liver disease (MASLD): An updated meta-analysis.","2026","British journal of clinical pharmacology","Peng TR","31","15","6","PROSPERO","PROSPERO:CRD420261288562"],["R0013908","CRD420251154851",null,"10.3389/fphar.2026.1735987","41908834","PMC13021596","Safety and efficacy of tirzepatide in transplant recipients: a systematic review and meta-analysis.","2026","Frontiers in pharmacology","Provenzani A","34","15","4","PROSPERO","PROSPERO:CRD420251154851"],["R0013920",null,null,"10.1055/s-0045-1806824","40288416","PMC12034413","Efficacy and safety of glucagon-like peptide 1 agonists for Parkinson's disease: a systematic review and meta-analysis.","2025","Arquivos de neuro-psiquiatria","Nogueira LOS","30","14","5","none found",null],["R0013925",null,null,"10.1111/dom.14148","32700442",null,"Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta-analysis.","2020","Diabetes, obesity & metabolism","Home P","46","12","5","none found",null],["R0013943",null,null,"10.1136/bmj.d7771","22236411","PMC3256253","Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.","2012","BMJ (Clinical research ed.)","Vilsbøll T","48","26","26","none found",null],["R0013945",null,null,"10.1002/14651858.cd007654.pub6","42318855","PMC13281032","Long-term effects of weight-reducing drugs in people with hypertension.","2026","The Cochrane database of systematic reviews","Spary-Kainz U","41","15","7","none found",null],["R0013955",null,null,"10.1111/dom.70105","40922121",null,"Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis.","2025","Diabetes, obesity & metabolism","Xiao YJ","52","32","12","none found",null],["R0013968",null,null,"10.1007/s00415-026-14048-w","42547656","PMC13433482","Peripheral nerve complications from medications utilised for weight loss: a systematic review.","2026","Journal of neurology","O'Gorman C","95","29","0","none found",null],["R0013977",null,null,"10.4103/ijem.ijem_366_24","40688625","PMC12274044","Efficacy and Safety of Twincretin Survodutide, a Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist as an Anti-Obesity and Anti-Diabetes Medication: A Systematic Review and Meta-Analysis.","2025","Indian journal of endocrinology and metabolism","Dutta D","21","14","4","none found",null],["R0013981",null,null,"10.1111/1753-0407.12200","25047138",null,"Glucagon-like peptide 1 receptor agonist therapy is more efficacious than insulin glargine for poorly controlled type 2 diabetes: A systematic review and meta-analysis.","2015","Journal of diabetes","Liu FP","26","9","4","none found",null],["R0013987",null,null,"10.1515/jbcpp-2025-0113","40728138",null,"Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials.","2025","Journal of basic and clinical physiology and pharmacology","Misra S","38","19","4","none found",null],["R0013988",null,null,"10.1136/bmjdrc-2019-000679","31641521","PMC6777409","Addition of a single short-acting insulin bolus to basal insulin-supported oral therapy: a systematic review of data on the basal-plus regimen.","2019","BMJ open diabetes research & care","Seufert J","47","5","3","none found",null],["R0014005","CRD42024623707",null,"10.1002/oby.70083","41539943","PMC12850565","Efficacy and Safety of Pharmacological, Endoscopic, and Surgical Treatments for Obesity: A GRADE-Based Network Meta-Analysis.","2026","Obesity (Silver Spring, Md.)","De Luca M","60","19","14","PROSPERO","PROSPERO:CRD42024623707"],["R0014041","CRD42023420729","osf.io/2jvsx","10.1016/j.eclinm.2025.103529","41140453","PMC12547021","Effect of sleep apnoea interventions on multiple health outcomes: an umbrella review of meta-analyses of randomised controlled trials.","2025","EClinicalMedicine","Figard C","86","10","4","PROSPERO","PROSPERO:CRD42023420729"],["R0014042",null,null,"10.1111/dom.12986","28449324","PMC5655920","Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment.","2017","Diabetes, obesity & metabolism","Hanefeld M","34","18","13","none found",null],["R0014047",null,null,"10.3904/kjim.2017.298","29056038","PMC5668403","Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association.","2017","The Korean journal of internal medicine","Ko SH","57","11","4","none found",null],["R0014048",null,null,"10.1007/s12020-014-0386-8","25146552",null,"Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies.","2015","Endocrine","Giorda CB","38","23","1","none found",null],["R0014064",null,null,"10.1080/17446651.2025.2491404","40214160",null,"The effects of Beinaglutide on obesity and related factors: a systematic review and meta-analysis of randomized controlled trials.","2025","Expert review of endocrinology & metabolism","Poshtdar S","30","17","5","none found",null],["R0014087",null,null,"10.4103/ijem.ijem_365_24","40181850","PMC11964357","Efficacy and Safety of Glucagon Like Peptide-1 Receptor Agonism Based Therapies in Obstructive Sleep Apnoea: A Systematic Review and Meta-Analysis.","2025","Indian journal of endocrinology and metabolism","Dutta D","20","9","5","none found",null],["R0014124",null,null,"10.1016/j.parkreldis.2025.107798","40122718",null,"Concerns regarding the inclusion of a preprint in a meta-analysis on GLP-1 agonists in Parkinson's Disease.","2025","Parkinsonism & related disorders","Aubignat M","4","1","0","none found",null],["R0014128",null,null,"10.1002/jcph.2483","38874130",null,"Efficacy and Safety of Oral Semaglutide in the Treatment of Type 2 Diabetes: A Meta-Analysis.","2024","Journal of clinical pharmacology","Zhang L","37","15","7","none found",null],["R0014175",null,null,"10.3389/fendo.2022.1047883","36387915","PMC9650490","Impact of glucagon-like peptide 1 analogs on cognitive function among patients with type 2 diabetes mellitus: A systematic review and meta-analysis.","2022","Frontiers in endocrinology","Luan S","33","18","3","none found",null],["R0014185",null,null,"10.1161/hypertensionaha.120.14791","32639887",null,"Opportunities of Antidiabetic Drugs in Cardiovascular Medicine: A Meta-Analysis and Perspectives for Trial Design.","2020","Hypertension (Dallas, Tex. : 1979)","Yan C","85","30","21","none found",null],["R0014186",null,null,"10.1016/j.diabres.2012.09.004","23020934",null,"Cardiovascular safety and glycemic control of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus: a pairwise and network meta-analysis.","2012","Diabetes research and clinical practice","Sun F","51","24","5","none found",null],["R0014204",null,null,"10.1007/s12325-016-0432-4","27844335","PMC5216099","Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.","2017","Advances in therapy","Mannucci E","71","20","4","none found",null],["R0014223",null,null,null,null,"PMC12545291","SUN-653 Impact of GLP-1 Agonist on Outcomes in Patients with Heart Failure with Preserved Ejection Fraction and Obesity: A Systematic Review and Meta-Analysis","2025","Journal of the Endocrine Society",null,"0","0","0","none found",null],["R0014258","CRD42024507397",null,"10.3390/ph17101322","39458963","PMC11510241","Evaluating the Impact of Novel Incretin Therapies on Cardiovascular Outcomes in Type 2 Diabetes: An Early Systematic Review.","2024","Pharmaceuticals (Basel, Switzerland)","Salmen T","56","43","25","PROSPERO","PROSPERO:CRD42024507397"],["R0014265","CRD42020193692",null,"10.1007/s00125-023-05928-1","37204441","PMC10198038","Risk phenotypes of diabetes and association with COVID-19 severity and death: an update of a living systematic review and meta-analysis.","2023","Diabetologia","Schlesinger S","193","6","1","PROSPERO","PROSPERO:CRD42020193692"],["R0014274",null,null,"10.1111/dom.16585","40600452",null,"Cardiometabolic risk effects of weight-loss medications: An updated network meta-analysis.","2025","Diabetes, obesity & metabolism","Wang J","61","28","13","none found",null],["R0014307",null,null,"10.1016/s2213-8587(19)30422-x","32006518",null,"Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map.","2020","The lancet. Diabetes & endocrinology","Zhu J","32","6","0","none found",null],["R0014313","CRD420261292638",null,"10.3389/fendo.2026.1829315","42325618","PMC13275242","Updating the MASH pharmacotherapy landscape: a network meta-analysis incorporating SGLT2 inhibitors and emerging combination therapies.","2026","Frontiers in endocrinology","Tang M","40","9","7","PROSPERO","PROSPERO:CRD420261292638"],["R0014319","CRD42022347280",null,"10.1002/dmrr.3673","37302139",null,"Comparison on cognitive outcomes of antidiabetic agents for type 2 diabetes: A systematic review and network meta-analysis.","2023","Diabetes/metabolism research and reviews","Tian S","58","4","0","PROSPERO","PROSPERO:CRD42022347280"],["R0014320","CRD42013005779",null,"10.1136/bmjopen-2014-005325","25526792","PMC4275683","Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes.","2014","BMJ open","Gluud LL","36","21","12","PROSPERO","PROSPERO:CRD42013005779"],["R0014322",null,null,"10.1016/j.phrs.2021.105782","34302978",null,"Anti-diabetic drugs and weight loss in patients with type 2 diabetes.","2021","Pharmacological research","Lazzaroni E","74","26","18","none found",null],["R0014344",null,null,"10.1111/dom.70529","41705736",null,"Tirzepatide on physical function in adults with overweight or obesity: A systematic review and meta-analysis.","2026","Diabetes, obesity & metabolism","Schmidt PHS","43","19","11","none found",null],["R0014383",null,null,"10.21203/rs.3.rs-244365/v1",null,null,"Effect of the Glucagon-like Peptide-1 Receptor (GLP-1R) Agonists on Autonomic Function in Subjects With Diabetes: a Systematic Review and Meta-analysis.","2021","Research Square","Greco C",null,"0","0","none found",null],["R0014389",null,null,"10.1007/s12020-020-02376-4","32533507",null,"Glycemic control and the incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of randomized controlled trials.","2020","Endocrine","Lin C","34","0","0","none found",null],["R0014394",null,null,"10.7759/cureus.71739","39553106","PMC11568967","Effect of GLP-1 Receptor Agonists on Renal Functions and Diabetic Nephropathy in Type 2 Diabetes Mellitus (T2DM) Patients: A Systematic Review and Meta-Analysis.","2024","Cureus","Mohamed AJ","31","15","6","none found",null],["R0014403",null,null,"10.7759/cureus.45487","37859909","PMC10584355","Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiovascular Risk Management in Patients With Type 2 Diabetes Mellitus: A Systematic Review.","2023","Cureus","Parab P","33","23","5","none found",null],["R0014407",null,null,"10.1016/j.comppsych.2025.152632","40934730",null,"Comparative effects of pharmacological treatment for weight gain in patients treated with antipsychotics. A systematic review and network meta-analysis.","2025","Comprehensive psychiatry","Goetz-Kundera Z","61","9","4","none found",null],["R0014415",null,null,"10.1002/dmrr.2897","28303626","PMC5600123","Lixisenatide as add-on treatment among patients with different β-cell function levels as assessed by HOMA-β index.","2017","Diabetes/metabolism research and reviews","Bonadonna RC","51","19","11","none found",null],["R0014419",null,null,"10.1016/j.diabres.2015.05.048","26233934",null,"Effects of three injectable antidiabetic agents on glycaemic control, weight change and drop-out in type 2 diabetes suboptimally controlled with metformin and/or a sulfonylurea: A network meta-analysis.","2015","Diabetes research and clinical practice","Zhong X","42","24","18","none found",null],["R0014421",null,null,"10.2337/dc20-0654","32958618",null,"Incidence of Hospitalization for Heart Failure Relative to Major Atherosclerotic Events in Type 2 Diabetes: A Meta-analysis of Cardiovascular Outcomes Trials.","2020","Diabetes care","Sacre JW","0","0","0","none found",null],["R0014453",null,null,"10.1007/s00417-023-06236-5","37728754",null,"Effects of newer-generation anti-diabetics on diabetic retinopathy: a critical review.","2024","Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie","Ntentakis DP","78","28","8","none found",null],["R0014468",null,null,"10.1016/j.diabet.2016.11.007","28169086",null,"Basal insulin treatment intensification in patients with type 2 diabetes mellitus: A comprehensive systematic review of current options.","2017","Diabetes & metabolism","Raccah D","115","22","17","none found",null],["R0014469",null,null,"10.1016/j.diabres.2016.08.011","27622682",null,"Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review.","2016","Diabetes research and clinical practice","Bihan H","44","9","8","none found",null],["R0014496",null,null,"10.1111/dom.12007","22958381",null,"A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo.","2013","Diabetes, obesity & metabolism","Scott DA","50","28","22","none found",null],["R0014509",null,null,"10.1002/dmrr.2713","26381272",null,"Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies.","2016","Diabetes/metabolism research and reviews","Tang W","61","11","2","none found",null],["R0014513",null,null,"10.1002/ehf2.13822","35092176","PMC8934935","Can glucose-lowering medications improve outcomes in non-diabetic heart failure patients? A Bayesian network meta-analysis.","2022","ESC heart failure","Yeong T","64","25","11","none found",null],["R0014556",null,null,"10.1007/s12020-024-03896-z","38850440","PMC11445313","Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial.","2024","Endocrine","Qin W","46","27","20","none found",null],["R0014590",null,null,"10.1016/j.bcp.2025.117575","41330518",null,"Systematic review and synthesis without meta-analysis (SWiM) reveals lack of clinical studies and weak preclinical evidence for interaction between glucose regulating drugs and environmental contaminant exposure.","2026","Biochemical pharmacology","Bennett KA","165","8","3","none found",null],["R0014594","CRD42017071926",null,"10.1186/s13054-018-2197-4","30428906","PMC6236901","Systematic review of incretin therapy during peri-operative and intensive care.","2018","Critical care (London, England)","Hulst AH","45","12","8","PROSPERO","PROSPERO:CRD42017071926"],["R0014596","CRD42023412400",null,"10.3389/fendo.2023.1214334","37908750","PMC10613702","Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis.","2023","Frontiers in endocrinology","Zeng Q","41","29","12","PROSPERO","PROSPERO:CRD42023412400"],["R0014631",null,null,"10.3389/fmed.2026.1793349","42305970","PMC13265316","A systematic review of semaglutide-associated kidney injury case reports.","2026","Frontiers in medicine","Xiu X","31","27","2","none found",null],["R0014654",null,null,"10.1111/bcpt.12974","29411931",null,"Neuroprotective Mechanisms of Glucagon-like Peptide-1-based Therapies in Ischaemic Stroke: A Systematic Review based on Pre-Clinical Studies.","2018","Basic & clinical pharmacology & toxicology","Marlet IR","50","29","3","none found",null],["R0014655",null,null,"10.1016/j.prdoa.2022.100133","35128376","PMC8804263","The effect of GLP-1 receptor agonists in pre-clinical rodent models of Parkinson's disease: A systematic review and meta-analysis.","2022","Clinical parkinsonism & related disorders","Dahiya S","23","15","3","none found",null],["R0014713","CRD42020208090",null,"10.1371/journal.pone.0267025","35421174","PMC9009659","Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with kidney outcomes in patients with type 2 diabetes: A systematic review and network meta-analysis.","2022","PloS one","Yang S","27","5","0","PROSPERO","PROSPERO:CRD42020208090"],["R0014715",null,null,"10.1002/hsr2.1549","37720167","PMC10500111","The impact of preadmission/prediagnosis use of GLP-1 receptor agonists on COVID-19 mortality in patients with diabetes: A systematic review and meta-analysis.","2023","Health science reports","Kow CS","26","16","6","none found",null],["R0014739","CRD42016036868",null,"10.1016/j.jdiacomp.2016.05.022","28479155",null,"Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials.","2017","Journal of diabetes and its complications","Mazidi M","39","15","9","PROSPERO","PROSPERO:CRD42016036868"],["R0014749",null,null,"10.1007/s13300-019-0566-x","30689140","PMC6437246","Ertugliflozin Compared to Other Anti-hyperglycemic Agents as Monotherapy and Add-on Therapy in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis.","2019","Diabetes therapy : research, treatment and education of diabetes and related disorders","McNeill AM","43","2","1","none found",null],["R0014781",null,null,"10.1111/obr.13704","38355887",null,"Anti-obesity pharmacological agents for polycystic ovary syndrome: A systematic review and meta-analysis to inform the 2023 international evidence-based guideline.","2024","Obesity reviews : an official journal of the International Association for the Study of Obesity","Goldberg A","60","18","10","none found",null],["R0014804",null,null,"10.1002/oby.70267","42644866","PMC13511386","Body Composition and Lifestyle Interventions in Pharmacological Treatment of Acquired Hypothalamic Obesity: A Systematic Review of Randomized Controlled Trials.","2026","Obesity (Silver Spring, Md.)","Yu H","40","13","4","none found",null],["R0014815",null,null,"10.1111/bcp.13167","27780288","PMC5346876","The use of incretins and fractures - a meta-analysis on population-based real life data.","2017","British journal of clinical pharmacology","Driessen JH","13","5","0","none found",null],["R0014839",null,null,"10.4103/ijem.ijem_1037_25","42238556","PMC13229256","Efficacy and Safety of Semaglutide for Managing Antipsychotic-associated Weight Gain: A Systematic Review and Meta-analysis.","2026","Indian journal of endocrinology and metabolism","Jena S","35","21","9","none found",null],["R0014844",null,null,"10.1097/md.0000000000020695","32629641","PMC7337581","Efficacy and safety of incretin-based therapies in patients with nonalcoholic fatty liver disease: A protocol for a systematic review and meta-analysis.","2020","Medicine","Fan SM","23","8","5","none found",null],["R0014859",null,null,"10.1016/j.disamonth.2026.102098","41862385",null,"Forword for efficacy and safety of tirzepatide in patients with heart failure with preserved ejection fraction: A systematic review and meta-analysis.","2026","Disease-a-month : DM","Leikin JB","0","0","0","none found",null],["R0014915","CRD42022313002",null,"10.2147/dmso.s417374","37915772","PMC10617533","Effect of Liraglutide on Fat Mass Percentage Among Overweight and Obese Adults with Type 2 Diabetes: A Systematic Review.","2023","Diabetes, metabolic syndrome and obesity : targets and therapy","Aladel A","16","9","3","PROSPERO","PROSPERO:CRD42022313002"],["R0014919",null,null,"10.4103/0366-6999.235107","29941715","PMC6032690","Comparison of Placebo Effect between Asian and Caucasian Type 2 Diabetic Patients: A Meta-Analysis.","2018","Chinese medical journal","Guo W","48","0","0","none found",null],["R0014932",null,null,"10.1016/j.hrthm.2026.05.048","42217600",null,"Semaglutide use in patients undergoing atrial fibrillation ablation and recurrent arrhythmia: A focused time-to-event meta-analysis.","2026","Heart rhythm","Abomohsen M","5","4","0","none found",null],["R0014954",null,null,"10.1007/s40620-023-01858-8","38236473","PMC11043149","Absolute treatment effects of novel antidiabetic drugs on a composite renal outcome: meta-analysis of digitalized individual patient data.","2024","Journal of nephrology","Brockmeyer M","74","25","8","none found",null],["R0014956",null,null,"10.1530/eje-09-0101","19318378",null,"Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.","2009","European journal of endocrinology","Monami M","33","23","16","none found",null],["R0014961",null,null,"10.1007/s40520-025-03017-4","40325308","PMC12053337","Comparative efficacy and safety of antidiabetic drugs for obese patients with knee osteoarthritis: a network meta-analysis of randomized controlled trials.","2025","Aging clinical and experimental research","Jiang G","21","4","2","none found",null],["R0014973","CRD42024566153",null,"10.1080/17512433.2025.2450254","39817343",null,"Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis.","2025","Expert review of clinical pharmacology","Tewari J","18","9","4","PROSPERO","PROSPERO:CRD42024566153"],["R0014991",null,null,"10.1111/dom.13160","29135080",null,"Comparison of medication adherence and persistence in type 2 diabetes: A systematic review and meta-analysis.","2018","Diabetes, obesity & metabolism","McGovern A","11","0","0","none found",null],["R0014992",null,null,"10.4093/dmj.2022.0421","38273787","PMC10995485","Comparative Effect of Glucose-Lowering Drugs for Type 2 Diabetes Mellitus on Stroke Prevention: A Systematic Review and Network Meta-Analysis.","2024","Diabetes & metabolism journal","Kim JS","42","16","8","none found",null],["R0015002",null,null,"10.1111/dom.70314","41365848",null,"Meta-analysis of clinically available pharmacotherapy of biopsy confirmed metabolic dysfunction associated steatohepatitis (MASH).","2026","Diabetes, obesity & metabolism","Wood E","40","14","9","none found",null],["R0015036",null,null,"10.1007/s12020-025-04207-w","40011373",null,"Efficacy and safety of iGlarLixi versus insulin glargine in type 2 diabetes: a meta-analysis of randomized controlled trials.","2025","Endocrine","Li J","28","17","10","none found",null],["R0015168",null,null,"10.1007/s13300-016-0198-3","27655330","PMC5118236","Incretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials.","2016","Diabetes therapy : research, treatment and education of diabetes and related disorders","Chen H","65","24","4","none found",null],["R0015198",null,null,"10.1111/j.1463-1326.2011.01436.x","21651690",null,"Glucagon-like peptide-1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: a meta-analysis of clinical trials.","2011","Diabetes, obesity & metabolism","Wang Y","38","21","12","none found",null],["R0015206",null,null,"10.1080/09546634.2021.1882658","33934692",null,"Efficacy of GLP-1rA, liraglutide, in plaque psoriasis treatment with type 2 diabetes: a systematic review and meta-analysis of prospective cohort and before-after studies.","2022","The Journal of dermatological treatment","Chang G","26","14","3","none found",null],["R0015207",null,null,"10.1007/s12020-014-0179-0","24510630",null,"Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature.","2014","Endocrine","Giorda CB","54","16","3","none found",null],["R0015213",null,null,"10.1111/dom.70497","41574970","PMC13071184","Efficacy and safety of once-weekly insulins in type 2 diabetes: A systematic review and meta-analysis.","2026","Diabetes, obesity & metabolism","Bourron O","45","6","4","none found",null],["R0015227",null,null,"10.1016/j.ophtha.2026.05.017","42283648",null,"Re: Liu et al.: Rate and risk of nonarteritic anterior ischemic optic neuropathy with semaglutide use for diabetes and weight loss: a systematic review and meta-analysis (Ophthalmology. 2026;133;589-598).","2026","Ophthalmology","Nordvall LM","5","5","1","none found",null],["R0015265","CRD420251054743",null,"10.1186/s13098-025-02064-1","41390457","PMC12781576","The relation between tirzepatide and adverse cardiovascular events or renal adverse events: a meta-analysis based on randomized controlled trials.","2025","Diabetology & metabolic syndrome","Liu L","54","37","25","PROSPERO","PROSPERO:CRD420251054743"],["R0015307",null,null,"10.7717/peerj.1461","26664803","PMC4675096","Triple therapy in type 2 diabetes; a systematic review and network meta-analysis.","2015","PeerJ","Downes MJ","33","7","6","none found",null],["R0015324",null,null,"10.1111/dom.70452","41508932",null,"Efficacy of liraglutide on metabolic and reproductive outcomes in women with polycystic ovary syndrome: A systematic review and meta-analysis.","2026","Diabetes, obesity & metabolism","Lu YT","21","8","2","none found",null],["R0015336",null,null,"10.1080/17474124.2023.2172397","36689199",null,"Comparative efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists, pioglitazone and vitamin E for liver histology among patients with nonalcoholic fatty liver disease: systematic review and pilot network meta-analysis of randomized controlled trials.","2023","Expert review of gastroenterology & hepatology","Gu Y","39","10","3","none found",null],["R0015350",null,null,"10.2337/dc23-0925","38241493",null,"A Methodological Framework for Meta-analysis and Clinical Interpretation of Subgroup Data: The Case of Major Adverse Cardiovascular Events With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes.","2024","Diabetes care","Karagiannis T","54","20","10","none found",null],["R0015374",null,null,"10.1007/s00228-024-03755-w","39254692",null,"The cost-effectiveness analysis of semaglutide for the treatment of adult and adolescent patients with overweight and obesity: a systematic review.","2024","European journal of clinical pharmacology","Asiabar AS","38","20","3","none found",null],["R0015378","CRD42024620051",null,"10.1002/dmrr.70097","41100405",null,"Effect of Tirzepatide on Heart Failure in Type 2 Diabetes Mellitus and Obesity: A Systematic Review and Meta-Analysis.","2025","Diabetes/metabolism research and reviews","He YM","48","11","0","PROSPERO","PROSPERO:CRD42024620051"],["R0015385",null,null,"10.52787/agl.v56i1.591","42569707","PMC13450854","[Semaglutide and Metabolic Dysfunction-Associated Fatty Liver Disease: A Systematic Review].","2026","Acta gastroenterologica Latinoamericana","Masson W","37","28","12","none found",null],["R0015391","CRD42016042063",null,"10.1186/s12933-019-0853-x","30961600","PMC6454617","Comparative outcomes of heart failure among existent classes of anti-diabetic agents: a network meta-analysis of 171,253 participants from 91 randomized controlled trials.","2019","Cardiovascular diabetology","Yang DY","68","12","4","PROSPERO","PROSPERO:CRD42016042063"],["R0015397","CRD42025633998",null,"10.1007/s40200-026-01880-0","41883513","PMC13009421","Tirzepatide as adjunct therapy in patients with type 1 diabetes: a systematic review and meta-analysis.","2026","Journal of diabetes and metabolic disorders","Soliman A","0","0","0","PROSPERO","PROSPERO:CRD42025633998"],["R0015410",null,null,"10.1080/08998280.2025.2456441","40291085","PMC12026077","Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials.","2025","Proceedings (Baylor University. Medical Center)","Abdrabou Abouelmagd A","32","22","10","none found",null],["R0015419",null,null,"10.1055/a-2737-6110","41187775",null,"Efficacy of the Combination of Exenatide and Dapagliflozin in the Management of Diabetes and Weight Control: A Network Meta-Analysis.","2025","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","Abuali A","0","0","0","none found",null],["R0015427",null,null,"10.1016/bs.apha.2022.02.005","35659373",null,"Cardiovascular effects of GLP-1 receptor agonism.","2022","Advances in pharmacology (San Diego, Calif.)","Winquist RJ","170","87","15","none found",null],["R0015466",null,null,"10.1136/bmjopen-2026-117500","42772870","PMC13599885","Systematic review of cost-effectiveness analyses of weight loss interventions for knee osteoarthritis.","2026","BMJ open","Gao Y","30","4","3","none found",null],["R0015491",null,null,"10.1111/dom.70823","42082193",null,"Pharmacological Treatment for Gestational Diabetes Mellitus: A Systematic Review and Network Meta-Analysis of 71 Randomised Controlled Trial.","2026","Diabetes, obesity & metabolism","Liu X","93","0","0","none found",null],["R0015493",null,null,"10.1016/j.ejphar.2026.178587","41580006",null,"Efficacy and safety of semaglutide in non-diabetic adults with overweight or obesity: A meta-analysis of randomized controlled trials.","2026","European journal of pharmacology","Zhang S","47","27","13","none found",null],["R0015504","CRD420251017953",null,"10.20452/pamw.17141","41117588",null,"Assessment of noninferiority of oral vs subcutaneous semaglutide: a systematic review and meta-analysis.","2025","Polish archives of internal medicine","Drygalski K","0","0","0","PROSPERO","PROSPERO:CRD420251017953"],["R0015535",null,null,"10.1038/s41366-025-01920-4","41015578",null,"Effects of tirzepatide on weight management in patients with and without diabetes: a systematic review and meta-analysis.","2025","International journal of obesity (2005)","Cerchi E","40","27","21","none found",null],["R0015540",null,null,"10.1186/s13098-024-01501-x","39508238","PMC11542446","Effect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss: a meta-analysis of randomized controlled trials.","2024","Diabetology & metabolic syndrome","Wan H","39","13","5","none found",null],["R0015557",null,null,"10.1016/j.diabres.2023.110605","36871874",null,"Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: A systematic review and meta-analysis.","2023","Diabetes research and clinical practice","Li A","51","31","15","none found",null],["R0015606",null,null,"10.1186/s12905-025-03594-6","39955537","PMC11829492","Comparative efficacy of pharmacological interventions on metabolic and hormonal outcomes in polycystic ovary syndrome: a Network Meta-Analysis of Randomized controlled trials.","2025","BMC women's health","Bo Y","56","20","12","none found",null],["R0015613",null,null,"10.1016/j.tjpad.2025.100111","40023730","PMC12183985","Comparative efficacy and safety of antidiabetic agents in Alzheimer's disease: A network meta-analysis of randomized controlled trials.","2025","The journal of prevention of Alzheimer's disease","Cai Z","34","6","0","none found",null],["R0015616",null,null,"10.1016/j.ophtha.2025.12.022","41475544",null,"Rate and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy with Semaglutide Use for Diabetes and Weight Loss: A Systematic Review and Meta-Analysis.","2026","Ophthalmology","Liu Z","45","27","9","none found",null],["R0015658",null,null,"10.1016/j.aed.2026.01.001","41938304","PMC13043474","Semaglutide and Non-arteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Narrative Synthesis.","2026","AACE endocrinology and diabetes","Eisa N","18","6","3","none found",null],["R0015663",null,null,"10.1038/s41390-025-04537-5","41184626",null,"Long-term administration of liraglutide for weight management in pediatric patients under 18 years: evidence from 7 randomized controlled trials.","2026","Pediatric research","Dong J","25","14","5","none found",null],["R0015666",null,null,"10.1111/obr.13177","33354917",null,"GLP-1 agonists for obesity and type 2 diabetes in children: Systematic review and meta-analysis.","2021","Obesity reviews : an official journal of the International Association for the Study of Obesity","Chadda KR","35","23","11","none found",null],["R0015694",null,null,"10.17925/ee.2025.21.1.2","40485656","PMC12140633","Role of Sodium-Glucose Cotransporter-2 Inhibitors in Managing Polycystic Ovary Syndrome: A Systematic Review.","2025","TouchREVIEWS in endocrinology","Kamrul-Hasan A","36","3","1","none found",null],["R0015697",null,null,"10.20945/2359-4292-2023-0469","39420937","PMC11460968","Effects of once-daily oral orforglipron on weight and metabolic markers: a systematic review and meta-analysis of randomized controlled trials.","2024","Archives of endocrinology and metabolism","Lütkemeyer C","33","18","8","none found",null],["R0015709",null,null,"10.1016/j.dsx.2022.102640","36274410",null,"Efficacy and safety of tirzepatide as novel treatment for type 2 diabetes: A systematic review and meta-analysis of randomized clinical trials.","2022","Diabetes & metabolic syndrome","Permana H","33","19","9","none found",null],["R0015710",null,null,"10.1007/s00415-020-09813-4","32246253",null,"GLP-1 receptor agonists in diabetes for stroke prevention: a systematic review and meta-analysis.","2020","Journal of neurology","Malhotra K","13","9","7","none found",null],["R0015747",null,null,"10.1111/cen.14406","33386617",null,"Exendin-4-based imaging in insulinoma localization: Systematic review and meta-analysis.","2021","Clinical endocrinology","Shah R","35","22","3","none found",null],["R0015752",null,null,"10.7759/cureus.111603","42516458","PMC13403756","Integrated Management Strategies for Hypertension and Diabetes in Cardiovascular Disease Prevention: A Systematic Review.","2026","Cureus","Sen N","32","3","0","none found",null],["R0015754",null,null,"10.7759/cureus.89020","40895971","PMC12394919","Effects of Tirzepatide on Skeletal Muscle Mass in Adults: A Systematic Review.","2025","Cureus","Hidalgo Ramos RA","10","8","1","none found",null],["R0015765",null,null,"10.1007/s40615-025-02668-3","40971128",null,"Management of Type 2 Diabetes Mellitus in Native Americans and Alaska Natives: A Systematic Review.","2025","Journal of racial and ethnic health disparities","Norris Q","50","2","0","none found",null],["R0015770",null,null,"10.3390/ijerph13100941","27669277","PMC5086680","The Use of Exenatide in Managing Markers of Cardiovascular Risk in Patients with Type 2 Diabetes: A Systematic Review.","2016","International journal of environmental research and public health","Ojo O","30","21","15","none found",null],["R0015821",null,null,"10.1101/2025.09.29.25336760",null,null,"Body Composition Changes with Semaglutide: A Systematic Review and Meta-Analysis","2025","medRxiv","Giorelli G",null,"0","0","none found",null],["R0015827",null,null,"10.1111/dom.70301","41321175",null,"Efficacy and safety of liraglutide in non-alcoholic fatty liver disease with or without type 2 diabetes: A systematic review and meta-analysis.","2026","Diabetes, obesity & metabolism","Kong W","36","13","8","none found",null],["R0015830",null,null,"10.1016/s2213-8587(15)00233-8","26276240",null,"Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis.","2015","The lancet. Diabetes & endocrinology","Fisher M","25","14","9","none found",null],["R0015854",null,null,"10.1007/s00392-024-02474-7","38916609",null,"Comment on: GLP-1-ra and heart failure-related outcomes in patients with and without history of heart failure: an updated systematic review and meta-analysis.","2024","Clinical research in cardiology : official journal of the German Cardiac Society","Mao T","1","1","0","none found",null],["R0015861",null,null,"10.3390/biomedicines12102328","39457640","PMC11505228","Comparative Analysis of Resmetirom vs. FGF21 Analogs vs. GLP-1 Agonists in MASLD and MASH: Network Meta-Analysis of Clinical Trials.","2024","Biomedicines","Ayesh H","37","9","7","none found",null],["R0015881",null,null,"10.1002/dmrr.2548","24687427",null,"Lixisenatide as add-on to oral anti-diabetic therapy: an effective treatment for glycaemic control with body weight benefits in type 2 diabetes.","2014","Diabetes/metabolism research and reviews","Raccah D","32","17","10","none found",null],["R0015886",null,null,"10.1007/s00392-024-02475-6","38916608",null,"Reply to \"Comment on: GLP-1-ra and heart failure-related outcomes in patients with and without history of heart failure: an updated systematic review and meta-analysis\".","2024","Clinical research in cardiology : official journal of the German Cardiac Society","Villaschi A","1","1","0","none found",null],["R0015888",null,null,"10.1038/s41598-019-55524-w","31852920","PMC6920368","Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis.","2019","Scientific reports","Castellana M","40","26","11","none found",null],["R0015891",null,null,"10.4330/wjc.v13.i10.585","34754403","PMC8554356","Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of cardiovascular outcome trials.","2021","World journal of cardiology","Patoulias DI","27","7","0","none found",null],["R0015894",null,null,"10.1111/eci.70003","39937036","PMC11891831","Pharmacological treatment options for metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus: A systematic review.","2025","European journal of clinical investigation","Konings LAM","88","22","16","none found",null],["R0015895","CRD420251086132",null,"10.1016/j.xcrm.2026.102614","41850241","PMC13006432","Suboptimal therapeutic responses associated with semaglutide in type 2 diabetes and obesity: A meta-analysis of randomized controlled trials.","2026","Cell reports. Medicine","Ko D","64","49","37","PROSPERO","PROSPERO:CRD420251086132"],["R0015903",null,null,"10.1097/md.0000000000035488","37904345","PMC10615484","Gastrointestinal adverse events of tirzepatide in the treatment of type 2 diabetes mellitus: A meta-analysis and trials sequential analysis.","2023","Medicine","Tong K","31","17","8","none found",null],["R0015908",null,null,"10.1097/md.0000000000046446","41398803","PMC12708229","Impact of semaglutide use on glycemic and metabolic profile in adults with type 1 diabetes having overweight or obesity: A systematic review and meta-analysis.","2025","Medicine","Dutta D","29","18","3","none found",null],["R0015929",null,null,null,null,"PMC11453264","7792 Efficacy of Retatrutide for Weight Reduction and Its Cardiometabolic Effects Among Adults: A Systematic Review and Meta-Analysis","2024","Journal of the Endocrine Society",null,"0","0","0","none found",null],["R0016020",null,null,"10.7759/cureus.88390","40842811","PMC12365184","Effects of Tirzepatide on Low-Density Lipoprotein Cholesterol Levels in Adults: A Systematic Review.","2025","Cureus","Hong I","14","9","3","none found",null],["R0016032",null,null,"10.1001/jamanetworkopen.2026.3274","41885866","PMC13022736","Weight Changes With Tirzepatide and Concomitant Weight-Inducing Medications: Post Hoc Analysis of Randomized Clinical Trials.","2026","JAMA network open","Galindo RJ","38","6","3","none found",null],["R0016039",null,null,"10.1136/bmjdrc-2019-000728","31641525","PMC6777405","Effect of incretin-based therapies on cancers of digestive system among 101 595 patients with type 2 diabetes mellitus: a systematic review and network meta-analysis combining 84 trials with a median duration of 30 weeks.","2019","BMJ open diabetes research & care","Chai S","38","18","0","none found",null],["R0016040",null,null,"10.1016/j.metop.2024.100321","39318607","PMC11420505","Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials.","2024","Metabolism open","Pasqualotto E","31","21","6","none found",null],["R0016045",null,null,"10.1016/j.hrtlng.2025.07.009","40682989",null,"Cardiometabolic effects of GLP-1 analogs in obese and overweight patients with preexisting cardiovascular disease: A systematic review and meta analysis of randomized controlled trials.","2025","Heart & lung : the journal of critical care","Natali LD","24","10","3","none found",null],["R0016050",null,null,"10.1155/2021/8936865","34805029","PMC8604595","GLP-1 Receptor Agonist Effects on Lipid and Liver Profiles in Patients with Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis.","2021","Canadian journal of gastroenterology & hepatology","Rezaei S","37","26","9","none found",null],["R0016057",null,null,"10.1111/1753-0407.13405","37165762","PMC10415870","Effects of first-line antidiabetic drugs on the improvement of arterial stiffness: A Bayesian network meta-analysis.","2023","Journal of diabetes","Wang J","44","13","6","none found",null],["R0016083",null,null,"10.1111/obr.70087","41622606",null,"Effects of Glucose-Lowering Medications on Intrapancreatic Fat Deposition: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","2026","Obesity reviews : an official journal of the International Association for the Study of Obesity","Agon HC","50","1","1","none found",null],["R0016088",null,null,"10.3389/fendo.2025.1593134","40747302","PMC12310450","Efficacy and safety of tirzepatide for weight loss in patients with obesity or type 2 diabetes: a systematic review and meta-analysis.","2025","Frontiers in endocrinology","Tian Q","45","41","19","none found",null],["R0016089",null,null,"10.1111/dom.70617","41804193","PMC13071265","Weight Loss as a Determinant of Histological Improvement in Metabolic Dysfunction-Associated Steatotic Liver Disease in People With Obesity. A Systematic Review and Network Meta-Analysis of Randomised Clinical Trials.","2026","Diabetes, obesity & metabolism","Monami M","33","9","4","none found",null],["R0016116",null,null,"10.7759/cureus.89409","40918897","PMC12412261","Long-Term Efficacy of Bariatric Surgery Compared to Modern Medical Therapy in Type 2 Diabetes and Obesity: A Systematic Review.","2025","Cureus","Afzal A","23","3","0","none found",null],["R0016121",null,null,"10.1111/cob.70036","40685889",null,"Exploring the Efficacy and Safety of Tirzepatide in Obesity Management and Cardiometabolic Risk Factors: A Comprehensive Systematic Review and Meta-Analysis.","2025","Clinical obesity","Wang JY","42","27","15","none found",null],["R0016124",null,null,"10.7759/cureus.95400","41293379","PMC12643440","Effects of Contemporary Therapies on Cardiovascular and Renal Outcomes in Diabetic Kidney Disease: A Systematic Review of Randomized Controlled Trials (RCTs).","2025","Cureus","Bachar Al Sumodi W","24","4","1","none found",null],["R0016133",null,null,"10.1186/s40001-025-03241-8","41188987","PMC12584374","Semaglutide reduces cardiovascular events in type 2 diabetes: a systematic review and meta-analysis highlighting enhanced benefits in chronic kidney disease.","2025","European journal of medical research","Yao Y","72","40","12","none found",null],["R0016158",null,null,"10.1007/s11695-025-08415-1","41483046",null,"Recurrent Weight Gain after Weight Loss Induced by Lifestyle Intervention, Metabolic and Bariatric Surgery, or Semaglutide in Adults with Obesity: A Systematic Review of Randomized Controlled Trials.","2026","Obesity surgery","Chen H","46","5","3","none found",null],["R0016162",null,null,"10.3389/fendo.2022.818537","35370959","PMC8969579","Effects of Antidiabetic Drugs on Endothelial Function in Patients With Type 2 Diabetes Mellitus: A Bayesian Network Meta-Analysis.","2022","Frontiers in endocrinology","Wang Y","78","13","4","none found",null],["R0016181",null,null,"10.1007/s12325-014-0146-4","25143188",null,"Lixisenatide treatment for older patients with type 2 diabetes mellitus uncontrolled on oral antidiabetics: meta-analysis of five randomized controlled trials.","2014","Advances in therapy","Hanefeld M","50","21","16","none found",null],["R0016196",null,null,"10.1186/s12933-016-0355-z","26912057","PMC4765050","Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.","2016","Cardiovascular diabetology","Ferdinand KC","40","26","15","none found",null],["R0016207","CRD42018089761",null,"10.1016/j.clinthera.2019.01.001","30711143",null,"Effects of Sodium-glucose Cotransporter 2 Inhibitor Monotherapy on Weight Changes in Patients With Type 2 Diabetes Mellitus: a Bayesian Network Meta-analysis.","2019","Clinical therapeutics","Wang H","72","4","0","PROSPERO","PROSPERO:CRD42018089761"],["R0016233","CRD42016042063",null,"10.1186/s12933-018-0722-z","29871636","PMC5989345","Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: a comprehensive network meta-analysis of 166,371 participants from 170 randomized controlled trials.","2018","Cardiovascular diabetology","Zhuang XD","40","10","2","PROSPERO","PROSPERO:CRD42016042063"],["R0016240",null,null,"10.1186/s40959-025-00424-4","41540487","PMC12853835","Cardioprotective effect of diabetic medication on cancer patients undergoing proven cardiotoxic chemotherapy: a systematic review and meta-analysis.","2026","Cardio-oncology (London, England)","El-Helbawy A","33","4","0","none found",null],["R0016371",null,null,"10.1093/eurjpc/zwaf358","40567168",null,"Effect of semaglutide on mortality and cardiovascular events in patients at high cardiovascular risk: an updated systematic review and meta-analysis.","2026","European journal of preventive cardiology","Spagnolo M","7","6","5","none found",null],["R0016375",null,null,"10.21203/rs.3.rs-2346356/v1",null,null,"Effects of once-weekly semaglutide in obese/overweight patients: A systematic review and meta-analysis","2022","Research Square","Wang M",null,"0","0","none found",null],["R0016391",null,null,"10.1016/j.curtheres.2010.08.003","24688145","PMC3969618","Glucagon-like peptide-1 receptor agonists versus insulin glargine for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials.","2010","Current therapeutic research, clinical and experimental","Li WX","45","20","11","none found",null],["R0016399",null,null,"10.1001/jamaophthalmol.2025.2489","40810985","PMC12355393","Ocular Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis.","2025","JAMA ophthalmology","Natividade GR","69","56","50","none found",null],["R0016405",null,null,"10.1111/dom.16107","39639835",null,"SGLT2 inhibitors reduce epicardial adipose tissue more than GLP-1 agonists or exercise interventions in patients with type 2 diabetes mellitus and/or obesity: A systematic review and network meta-analysis.","2025","Diabetes, obesity & metabolism","Bao Y","77","11","3","none found",null],["R0016427",null,null,"10.1177/20406223221108064","35813188","PMC9260566","Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review.","2022","Therapeutic advances in chronic disease","Deng Y","51","37","17","none found",null],["R0016436",null,null,"10.1016/j.cardfail.2023.03.017","37028749",null,"Increased Risk of Heart Failure Hospitalization With GLP-1 Receptor Agonists in Patients With Reduced Ejection Fraction: A Meta-Analysis of the EXSCEL and FIGHT Trials.","2023","Journal of cardiac failure","Neves JS","5","5","3","none found",null],["R0016453","CRD420261411693",null,"10.1111/dom.71220","42608323","PMC13646380","Body Composition Remodelling During GLP-1-Based Therapy: A Systematic Review and Meta-Analysis Using a Hierarchical Physiological Framework.","2026","Diabetes, obesity & metabolism","Lopes Menezes ML","38","23","10","PROSPERO","PROSPERO:CRD420261411693"],["R0016514",null,null,"10.1016/j.xnsj.2026.100912","42569195","PMC13449414","The impact of morbid obesity and metabolic syndrome in elective spine surgery outcomes: A systematic review.","2026","North American Spine Society journal","Ferraz VR","55","1","0","none found",null],["R0016516",null,null,"10.1111/1753-0407.70044","39789833","PMC11717902","Cardiovascular Therapy Benefits of Novel Antidiabetic Drugs in Patients With Type 2 Diabetes Mellitus Complicated With Cardiovascular Disease: A Network Meta-Analysis.","2025","Journal of diabetes","Shi S","100","18","10","none found",null],["R0016533",null,null,"10.1002/wps.20614","30600626","PMC6313230","The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials.","2019","World psychiatry : official journal of the World Psychiatric Association (WPA)","Vancampfort D","64","1","0","none found",null],["R0016543",null,null,"10.1186/s40360-018-0246-x","30223891","PMC6142638","Cardiovascular and microvascular outcomes of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled cardiovascular outcome trials with trial sequential analysis.","2018","BMC pharmacology & toxicology","Zhang X","40","9","5","none found",null],["R0016556",null,null,"10.1111/ijcp.12775","26916354",null,"Network meta-analysis accurately predicted the outcome of a subsequent randomised trial comparing once weekly dulaglutide 1.5 mg and once daily liraglutide 1.8 mg.","2016","International journal of clinical practice","Fahrbach JL","21","16","16","none found",null],["R0016562",null,null,"10.1111/apt.70565","41645601",null,"Network Meta-Analysis: Comparison of Pharmacological Therapies in Compensated Metabolic Dysfunction-Associated Steatohepatitis Cirrhosis for Fibrosis Regression and MASH Resolution.","2026","Alimentary pharmacology & therapeutics","Souza M","58","8","2","none found",null],["R0016565",null,null,"10.1002/bcp.70286","41126794",null,"Overcoming barriers to adherence through innovative injectable medications: A systematic review of therapeutic options for cardiovascular disease, reported adherence, and perspectives on their use.","2026","British journal of clinical pharmacology","Bajorek B","83","20","6","none found",null],["R0016586",null,null,"10.1016/s2215-0366(25)00332-3","41506273",null,"Disparities in diabetes treatment and monitoring for people with and without mental disorders: a systematic review and meta-analysis.","2026","The lancet. Psychiatry","Wagner E","77","2","0","none found",null],["R0016623",null,null,"10.1111/iwj.14841","38512120","PMC10956537","Meta-analysis on GLP-1 mediated modulation of autophagy in islet β-cells: Prospectus for improved wound healing in type 2 diabetes.","2024","International wound journal","Xia W","32","18","7","none found",null],["R0016631",null,null,"10.3389/fnut.2022.825897","35923194","PMC9339904","Comparative analysis of the efficacies of probiotic supplementation and glucose-lowering drugs for the treatment of type 2 diabetes: A systematic review and meta-analysis.","2022","Frontiers in nutrition","Liang T","72","12","4","none found",null],["R0016634","CRD42021289121",null,"10.3389/fendo.2022.927859","35898463","PMC9309474","Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials.","2022","Frontiers in endocrinology","Hu W","76","61","45","PROSPERO","PROSPERO:CRD42021289121"],["R0016653",null,null,"10.1111/jdi.12764","29047219","PMC6031492","Addition of dipeptidyl peptidase-4 inhibitors to insulin treatment in type 2 diabetes patients: A meta-analysis.","2018","Journal of diabetes investigation","Yang W","50","10","7","none found",null],["R0016654",null,null,"10.1016/j.eprac.2025.11.018","41419187",null,"Semaglutide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits.","2026","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Eisa N","92","50","45","none found",null],["R0016670",null,null,"10.1007/s00592-020-01542-4","32514989",null,"Incretin mimetics and sodium-glucose co-transporter 2 inhibitors as monotherapy or add-on to metformin for treatment of type 2 diabetes: a systematic review and network meta-analysis.","2021","Acta diabetologica","Jia S","93","22","15","none found",null],["R0016701","CRD42018087262",null,"10.2147/hmer.s265631","33061687","PMC7522518","Efficacy of Glucagon-Like Peptide-1 Analogs in Nonalcoholic Fatty Liver Disease: A Systematic Review.","2020","Hepatic medicine : evidence and research","Teshome G","52","25","6","PROSPERO","PROSPERO:CRD42018087262"],["R0016738",null,null,"10.1038/s41598-017-16101-1","29150631","PMC5694013","Effect of Long-term Incretin-Based Therapies on Ischemic Heart Diseases in Patients with Type 2 Diabetes Mellitus: A Network Meta-analysis.","2017","Scientific reports","Chou CY","73","28","15","none found",null],["R0016743",null,null,"10.1016/j.eprac.2024.12.005","39672540",null,"Once-Weekly Tirzepatide Versus Once-Daily Basal Insulin in Managing Type 2 Diabetes Inadequately Controlled With Oral anti-Hyperglycemic Drugs: A Systematic Review and Meta-Analysis.","2025","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Kamrul-Hasan ABM","30","20","9","none found",null],["R0016766",null,null,"10.1002/14651858.cd012990.pub2","32700772","PMC7390475","GLP-1 receptor agonists for Parkinson's disease.","2020","The Cochrane database of systematic reviews","Mulvaney CA","65","25","8","none found",null],["R0016783",null,null,"10.1111/obr.70108","41766347","PMC13131993","A Systematic Review and Meta-Analysis of Semaglutide Effects on Adipose Tissue and Emerging Effects on Brain and Cognition.","2026","Obesity reviews : an official journal of the International Association for the Study of Obesity","Saghazadeh A","41","27","14","none found",null],["R0016792",null,null,"10.1177/02698811261443680","42104950",null,"Efficacy of pharmacological and nutritional interventions for glucose dysfunction in schizophrenia-A systematic review and network meta-analysis.","2026","Journal of psychopharmacology (Oxford, England)","Liu CI","0","0","0","none found",null],["R0016821",null,null,"10.3390/medicina60091542","39336583","PMC11434261","Cardiovascular Effectiveness and Safety of Antidiabetic Drugs in Patients with Type 2 Diabetes and Peripheral Artery Disease: Systematic Review.","2024","Medicina (Kaunas, Lithuania)","Cimellaro A","163","43","17","none found",null],["R0016841",null,null,"10.1016/j.rbmo.2019.04.017","31229399",null,"GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis.","2019","Reproductive biomedicine online","Han Y","44","16","7","none found",null],["R0016862","CRD42024599597",null,"10.1177/02698811251399544","41439550",null,"Efficacy and safety of pharmacological and non-pharmacological interventions for antipsychotic-induced weight gain in individuals with schizophrenia: A systematic review and network meta-analysis of 55 clinical trials.","2026","Journal of psychopharmacology (Oxford, England)","Mansour MEM","100","12","8","PROSPERO","PROSPERO:CRD42024599597"],["R0016877",null,null,"10.1186/s40001-025-02801-2","40696486","PMC12281775","Impact of liraglutide on albumin-to-creatinine ratio in type 2 diabetes mellitus: a meta-analysis.","2025","European journal of medical research","Wang F","41","24","11","none found",null],["R0016879","CRD42021178888",null,"10.1016/j.dsx.2022.102474","35378386",null,"Meta-analysis of seven heterogeneous studies on liraglutide add-on therapy in patients with type 2 diabetes mellitus treated with insulin.","2022","Diabetes & metabolic syndrome","Shibuki K","46","12","9","PROSPERO","PROSPERO:CRD42021178888"],["R0016883",null,null,"10.1111/cen.14583","34448208",null,"The effects of glucagon-like peptide (GLP)-1 receptor agonists on weight and glycaemic control in Prader-Willi syndrome: A systematic review.","2022","Clinical endocrinology","Ng NBH","46","20","4","none found",null],["R0016902",null,null,"10.1007/s11695-025-07848-y","40418526",null,"Impact of Semaglutide Administration on Weight Loss After Bariatric Surgery: A Meta-Analysis.","2025","Obesity surgery","Jamialahamdi T","17","11","4","none found",null],["R0016914","CRD42024499511",null,"10.1186/s12916-025-04486-0","41286875","PMC12642075","The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis.","2025","BMC medicine","Sillassen CDB","104","90","71","PROSPERO","PROSPERO:CRD42024499511"],["R0016924",null,null,"10.1016/s0140-6736(14)61335-0","25220191",null,"Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis.","2014","Lancet (London, England)","Eng C","31","20","13","none found",null],["R0016937",null,null,"10.1001/jama.2024.6739","38888913",null,"Interventions for Weight Management in Children and Adolescents: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.","2024","JAMA","O'Connor EA","102","4","4","none found",null],["R0016969",null,null,"10.4103/ijem.ijem_423_21","35355921","PMC8959203","Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis.","2021","Indian journal of endocrinology and metabolism","Dutta D","21","15","9","none found",null],["R0016981",null,null,"10.1007/s40256-025-00738-9","40493329",null,"Meta-analysis of the Effect of Semaglutide on Blood Pressure in Obese Populations.","2025","American journal of cardiovascular drugs : drugs, devices, and other interventions","Li Y","35","27","20","none found",null],["R0016991",null,null,"10.1111/cob.70092","42307450","PMC13274556","Weight-Lowering Drugs and Natural Female Fertility-A Systematic Review and Meta-Analysis.","2026","Clinical obesity","Alnaimi SJ","43","10","7","none found",null],["R0017001",null,null,"10.1016/j.jdiacomp.2024.108834","39178623",null,"The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: A meta-analysis of randomized controlled trials.","2024","Journal of diabetes and its complications","Austregésilo de Athayde De Hollanda Morais B","36","15","8","none found",null],["R0017002",null,null,"10.1161/circulationaha.118.038868","30786725",null,"Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.","2019","Circulation","Zelniker TA","37","13","8","none found",null],["R0017013",null,null,"10.1097/hep.0000000000001028","39028914","PMC11913421","Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content: Systematic review and network meta-analysis.","2026","Hepatology (Baltimore, Md.)","Koh B","37","4","3","none found",null],["R0017030",null,null,"10.1111/dom.15410","38116693",null,"Effect of tirzepatide on albuminuria levels and renal function in patients with type 2 diabetes mellitus: A systematic review and multilevel meta-analysis.","2024","Diabetes, obesity & metabolism","Karakasis P","53","16","4","none found",null],["R0017039",null,null,"10.3389/fphar.2018.00576","29915538","PMC5994433","Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","2018","Frontiers in pharmacology","Shi FH","42","30","12","none found",null],["R0017057",null,null,"10.1016/j.jad.2025.120783","41318004",null,"The association between depressive symptom severity and metabolic disturbances in major depressive and bipolar disorders: A systematic review and meta-analysis.","2026","Journal of affective disorders","Wong S","86","7","0","none found",null],["R0017083",null,null,"10.1097/md.0000000000038018","38758855","PMC11098233","Incretin-based drugs decrease the incidence of prostate cancer in type 2 diabetics: A pooling-up analysis.","2024","Medicine","Lin Y","42","15","1","none found",null],["R0017131",null,null,"10.1111/obr.13961","40510020","PMC12531717","Efficacy and Safety of Tirzepatide on Weight Loss in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","2025","Obesity reviews : an official journal of the International Association for the Study of Obesity","Kommu S","32","23","14","none found",null],["R0017205",null,null,"10.1097/hjh.0000000000000782","26682782",null,"Effects of dipeptidyl peptidase-4 inhibitors on blood pressure in patients with type 2 diabetes: A systematic review and meta-analysis.","2016","Journal of hypertension","Zhang X","47","15","5","none found",null],["R0017212",null,null,"10.1002/dmrr.2804","27037787",null,"Adverse effects of incretin-based therapies on major cardiovascular and arrhythmia events: meta-analysis of randomized trials.","2016","Diabetes/metabolism research and reviews","Wang T","146","39","30","none found",null],["R0017255",null,null,"10.1185/03007995.2011.590127","21663496",null,"GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials.","2011","Current medical research and opinion","Esposito K","42","31","24","none found",null],["R0017271",null,null,"10.1016/j.eprac.2025.11.002","41513086",null,"Weight Loss Medications for Adult Patients With Obesity and Binge Eating-A Systematic Review and Meta-analysis.","2026","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Violante-Cumpa JR","40","4","4","none found",null],["R0017298",null,null,"10.1111/jdi.14340","39569606","PMC11693576","Risk of biliary diseases in patients with type 2 diabetes or obesity treated with tirzepatide: A meta-analysis.","2025","Journal of diabetes investigation","Gong J","36","22","12","none found",null],["R0017333",null,null,"10.1007/s13300-024-01689-1","39797937","PMC11868037","Comparative Efficacy and Safety of Oral Semaglutide in Asians and Non-Asians Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","Wang T","25","20","12","none found",null],["R0017335",null,null,"10.21203/rs.3.rs-1930982/v1",null,null,"The Effect of SGLT-2 inhibitors and GLP-1RA on Major Cardiovascular Conditions: A Meta-Analysis","2022","Research Square","Jogimahanti A",null,"0","0","none found",null],["R0017368",null,null,"10.1111/bcp.12925","26935973","PMC4917794","The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis.","2016","British journal of clinical pharmacology","de Wit HM","101","22","20","none found",null],["R0017371",null,null,"10.17235/reed.2025.11719/2025","41410254",null,"Endoscopic sleeve gastroplasty (ESG) ‒ A semi-systematic review of current evidence, metabolic impact, special populations, and comparative strategies.","2025","Revista espanola de enfermedades digestivas","Espinet-Coll E","78","2","0","none found",null],["R0017405",null,null,"10.7759/cureus.85250","40605908","PMC12221394","Effect of Semaglutide Versus Placebo on Heart Failure With Preserved Ejection Fraction in Obese Patients: A Systematic Review.","2025","Cureus","Umaña Mejia CA","17","6","3","none found",null],["R0017441",null,null,"10.1111/ijcp.12698","26215321",null,"Comparative efficacy and safety of antidiabetic drug regimens added to stable and inadequate metformin and thiazolidinedione therapy in type 2 diabetes.","2015","International journal of clinical practice","Saulsberry WJ","30","6","4","none found",null],["R0017443",null,null,"10.1016/j.phrs.2026.108420","42668074",null,"Heterogeneous associations of antidiabetic medications with cancer prognosis: Evidence from 61 studies with over 1.1 million patients.","2026","Pharmacological research","Luo P","44","5","0","none found",null],["R0017455",null,null,"10.1186/s40001-025-03124-y","40890879","PMC12403603","Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis.","2025","European journal of medical research","Wu R","42","35","17","none found",null],["R0017461",null,null,"10.7759/cureus.83738","40486450","PMC12145503","Systematic Review and Meta-Analysis of Liraglutide Treatment in Children Who Are Overweight or Obese: A Therapeutic Paradigm Shift?","2025","Cureus","Muñoz Rossi FA","21","5","4","none found",null],["R0017489",null,null,"10.1016/j.ajmo.2025.100115","41473904","PMC12745141","The Impact of Different Antidiabetic Drugs on Fracture Risk in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials With a Focus on SGLT2 Inhibitors.","2025","American journal of medicine open","Admani B","33","5","2","none found",null],["R0017505","CRD42021284897",null,"10.3389/fendo.2022.897776","36034458","PMC9402979","Comparative efficacy and safety of glucose-lowering drugs in children and adolescents with type 2 diabetes: A systematic review and network meta-analysis.","2022","Frontiers in endocrinology","Wu S","38","8","5","PROSPERO","PROSPERO:CRD42021284897"],["R0017517","CRD42022330442",null,"10.3390/ijms24119760","37298707","PMC10253587","A Critical View over the Newest Antidiabetic Molecules in Light of Efficacy-A Systematic Review and Meta-Analysis.","2023","International journal of molecular sciences","Salmen T","91","33","20","PROSPERO","PROSPERO:CRD42022330442"],["R0017526",null,null,"10.1111/dom.12269","24476092",null,"A systematic review and meta-analysis of the efficacy of lixisenatide in the treatment of patients with type 2 diabetes.","2014","Diabetes, obesity & metabolism","Schmidt LJ","68","12","9","none found",null],["R0017527",null,null,"10.2337/dc24-2241","40392993","PMC12094200","Cost-effectiveness of Semaglutide Compared With Other Glucose-Lowering Medications in Treating Type 2 Diabetes: A Comprehensive Systematic Review and Meta-analysis.","2025","Diabetes care","Liu Z","38","17","5","none found",null],["R0017528",null,null,"10.1080/07853890.2023.2239830","37498865","PMC10375936","Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis.","2023","Annals of medicine","Patel T","28","17","10","none found",null],["R0017533",null,null,"10.1016/j.pcd.2017.06.009","28732654",null,"Effects of incretin-based therapies on neurocognitive function in humans: A systematic review of the literature.","2018","Primary care diabetes","Dumbrill JL","15","7","3","none found",null],["R0017535",null,null,"10.1371/journal.pone.0187537","29206832","PMC5716604","The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials.","2017","PloS one","Yang J","55","10","0","none found",null],["R0017536",null,null,"10.1111/j.1463-1326.2012.01639.x","22734440","PMC3533770","Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes.","2012","Diabetes, obesity & metabolism","Ridge T","25","23","8","none found",null],["R0017544","CRD42022349665",null,"10.1093/humupd/dmaf025","41065428","PMC13016750","The effect of obesity interventions on male fertility: a systematic review and meta-analysis.","2026","Human reproduction update","Peel A","190","23","8","PROSPERO","PROSPERO:CRD42022349665"],["R0017569",null,null,"10.1186/s40842-026-00275-7","41764584","PMC12950239","Metformin and beyond: glucose-lowering therapy as a potential modulator of abdominal aortic aneurysm growth and stability- systematic review with narrative synthesis.","2026","Cardiovascular diabetology. Endocrinology reports","Dimova MP","51","2","0","none found",null],["R0017577",null,null,"10.22541/au.174625036.66012183/v1",null,null,"Efficacy and safety of liraglutide plus acarbose in obese patients with type 2 diabetes mellitus: A meta-analysis","2025","Authorea Preprints","Wang Y",null,"0","0","none found",null],["R0017601",null,null,"10.1016/j.eprac.2021.12.007","34922031",null,"Comparison of New Glucose-Lowering Drugs on the Risk of Pancreatitis in Type 2 Diabetes: A Network Meta-Analysis.","2022","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Zhang X","43","19","7","none found",null],["R0017626",null,null,"10.1111/dom.14221","33026152",null,"The impact of pharmacological and lifestyle interventions on body weight in people with type 1 diabetes: A systematic review and meta-analysis.","2021","Diabetes, obesity & metabolism","Tandon S","88","19","11","none found",null],["R0017706",null,null,"10.1186/s12905-025-03787-z","40481408","PMC12143058","The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis.","2025","BMC women's health","Huang R","42","19","10","none found",null],["R0017749",null,null,"10.1177/10600280241312432","39885375","PMC12357981","Sodium-Glucose Co-Transporter 2 Inhibitors and Severe Urinary Tract Infections: Real-World Meta-Analysis of Cohort Studies.","2025","The Annals of pharmacotherapy","Aboukaoud M","32","9","1","none found",null],["R0017817",null,null,"10.1186/1472-6823-10-20","21143938","PMC3017518","Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis.","2010","BMC endocrine disorders","Shyangdan DS","55","39","29","none found",null],["R0017824",null,null,"10.1080/20009666.2018.1542919","30559943","PMC6292369","Anti-atherosclerotic effect of incretin mimetics: a meta-analysis of randomized controlled trials.","2018","Journal of community hospital internal medicine perspectives","Barbarawi M","40","12","3","none found",null],["R0017825",null,null,"10.1111/dom.70028","40855964","PMC12515772","Combined liraglutide and metformin therapy in overweight or obese women with polycystic ovary syndrome: A systematic review and meta-analysis.","2025","Diabetes, obesity & metabolism","Ling J","32","12","8","none found",null],["R0017859","CRD42023403859",null,"10.3389/fendo.2024.1309118","38440786","PMC10911117","Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials.","2024","Frontiers in endocrinology","Nalisa DL","34","17","9","PROSPERO","PROSPERO:CRD42023403859"],["R0017864","CRD42024599035",null,"10.1136/bmjopen-2024-094947","40233950","PMC12001356","Adverse effects with tirzepatide: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis.","2025","BMJ open","Sillassen CDB","43","6","1","PROSPERO","PROSPERO:CRD42024599035"],["R0017872",null,null,"10.1186/s12933-020-01148-8","33036617","PMC7547475","Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis.","2020","Cardiovascular diabetology","Chang KC","44","30","12","none found",null],["R0017902",null,null,"10.1016/j.eprac.2024.12.017","39733942",null,"Neuropsychiatric Effects of Tirzepatide: A Systematic Review and Meta-Analysis.","2025","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Kamrul-Hasan ABM","12","7","0","none found",null],["R0017907",null,null,"10.1111/dme.15437","39340770",null,"Glucose-lowering drugs and liver-related outcomes among individuals with type 2 diabetes: A systematic review of longitudinal population-based studies.","2024","Diabetic medicine : a journal of the British Diabetic Association","Khanmohammadi S","41","13","3","none found",null],["R0017939",null,null,"10.1111/dom.14451","34047443",null,"Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis.","2021","Diabetes, obesity & metabolism","Tsapas A","36","6","0","none found",null],["R0017949","CRD42024580784",null,"10.1007/s40256-025-00727-y","40106161",null,"Cardiovascular Safety Profile of Semaglutide and Variations by Sex, Race, and Kidney Function: A Systematic Review and Meta-analysis.","2025","American journal of cardiovascular drugs : drugs, devices, and other interventions","Hamayal M","32","25","7","PROSPERO","PROSPERO:CRD42024580784"],["R0017952",null,null,null,null,"PMC12545259","MON-241 Efficacy and Safety of Liraglutide in Managing Obesity in Children and Adolescents: A Systematic Review and Meta-Analysis","2025","Journal of the Endocrine Society",null,"0","0","0","none found",null],["R0017962","CRD42023493235",null,"10.1007/s12020-025-04179-x","39955702",null,"Effect of semaglutide with obesity or overweight individuals without diabetes: an Umbrella review of systematic reviews.","2025","Endocrine","Hu X","30","21","11","PROSPERO","PROSPERO:CRD42023493235"],["R0018002","CRD42025644064",null,"10.1007/s11886-026-02408-x","42714692",null,"Beyond the Liver: Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) Associated 35% Higher Risk of Clinically Diagnosed Heart Failure With Preserved Ejection Fraction (HFpEF).","2026","Current cardiology reports","Hegazy MA","34","3","2","PROSPERO","PROSPERO:CRD42025644064"],["R0018038",null,null,"10.3390/nu17203307","41156559","PMC12567062","Visceral Obesity and Metabolic Dysfunction in IgA Nephropathy: Nutritional and Metabolic Perspectives on Disease Progression.","2025","Nutrients","Skibicka A","56","0","0","none found",null],["R0018050","CRD42025637238",null,"10.7759/cureus.82479","40385831","PMC12085759","Efficacy of Liraglutide for Weight Loss in Overweight and Obese Non-diabetic Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","2025","Cureus","Quinapanta Castro NI","28","21","12","PROSPERO","PROSPERO:CRD42025637238"],["R0018051",null,null,"10.1002/ehf2.14213","36337026","PMC9871670","Meta-analysed numbers needed to treat of novel antidiabetic drugs for cardiovascular outcomes.","2023","ESC heart failure","Wolff G","44","11","7","none found",null],["R0018067",null,null,"10.1155/jdr/8464330","41925338","PMC13045289","Comparative Efficacy, Safety, and Cost-Utility of DPP-4 Inhibitors and Metformin Combination Therapy in Type 2 Diabetes: A Systematic Review of Real-World Clinical and Economic Outcomes.","2026","Journal of diabetes research","Jimoh AO","41","9","0","none found",null],["R0018092",null,null,"10.1515/jpem-2021-0533","36315979",null,"The efficacy and safety of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 agonists in pediatric patients with type 2 diabetes: a systematic review.","2022","Journal of pediatric endocrinology & metabolism : JPEM","Li X","23","9","6","none found",null],["R0018100",null,null,"10.1016/j.fjurol.2026.103100","41912112",null,"Kidney transplantation in adult candidates with obesity: Guidelines by the Association Française d'Urologie and Société Francophone de Transplantation.","2026","The French journal of urology","Timsit MO","196","16","5","none found",null],["R0018110",null,null,"10.1016/j.jacadv.2025.102356","41447282","PMC12834078","Patient-Centered Outcomes in Heart Failure Pharmacotherapy: A Meta-Analysis of Randomized Controlled Trials.","2025","JACC. Advances","Kido K","99","3","3","none found",null],["R0018167",null,"osf.io/gd67x","10.1111/dom.15725","38923379",null,"Comparative efficacy and safety of weekly tirzepatide versus weekly insulin in type 2 diabetes: A network meta-analysis of randomized clinical trials.","2024","Diabetes, obesity & metabolism","Ayesh H","32","3","1","OSF",null],["R0018182",null,null,"10.1016/j.diabres.2024.111617","38490492",null,"The effect of subcutaneous Lixisenatide on weight loss in patients with type 2 Diabetes Mellitus: Systematic review and Meta-Analysis of randomized controlled trials.","2024","Diabetes research and clinical practice","Sheng L","54","36","30","none found",null],["R0018191",null,null,"10.1002/14651858.cd012204.pub2","28489279","PMC6481586","Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.","2017","The Cochrane database of systematic reviews","Hemmingsen B","113","28","23","none found",null],["R0018243",null,null,"10.1371/journal.pone.0103798","25089625","PMC4121242","Comparison of GLP-1 analogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta-analysis of head-to-head studies.","2014","PloS one","Wang T","29","19","10","none found",null],["R0018253",null,null,"10.1097/md.0000000000010420","29668601","PMC5916683","Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes: Protocol for a systematic review and meta-analysis.","2018","Medicine","Shi FH","13","6","2","none found",null],["R0018267",null,null,"10.1007/s11096-024-01779-x","39037553","PMC11576767","Efficacy and safety of tirzepatide versus placebo in overweight or obese adults without diabetes: a systematic review and meta-analysis of randomized controlled trials.","2024","International journal of clinical pharmacy","Liu L","35","17","3","none found",null],["R0018275",null,null,"10.1007/s40256-025-00721-4","39907981",null,"Cardiovascular Effects of Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.","2025","American journal of cardiovascular drugs : drugs, devices, and other interventions","Sobral MVS","32","9","4","none found",null],["R0018276",null,null,null,null,"PMC12544276","MON-641 Effectiveness Of Semaglutide On Renal Outcomes In Chronic Kidney Disease (CKD) Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis","2025","Journal of the Endocrine Society",null,"0","0","0","none found",null],["R0018277",null,null,null,null,"PMC9212452","Mo1622: EFFICACY OF GLP-1 ANALOGS AND AGONISTS ON PROPORTION OF WEIGHT LOSS IN OVERWEIGHT OR OBESE DIABETICS AND NONDIABETICS: A SYSTEMATIC REVIEW AND META-ANALYSIS","2022","Gastroenterology",null,"0","0","0","none found",null],["R0018285",null,null,null,null,"PMC12546518","SUN-676 Impact Of Once-weekly Semaglutide On Heart Failure Hospitalizations And Weight Loss In Obese Patients With Preserved Ejection Fraction (Hfpef): A Meta-analysis","2025","Journal of the Endocrine Society",null,"0","0","0","none found",null],["R0018286",null,null,null,null,"PMC12545257","MON-516 Effectiveness of Semaglutide on Cardiovascular Outcomes in Chronic Kidney Disease (CKD) Patients with Type 2 Diabetes Mellitus: A Systemic Review and Meta-analysis","2025","Journal of the Endocrine Society",null,"0","0","0","none found",null],["R0018299",null,null,"10.1016/j.clnesp.2025.01.056","39892787",null,"Efficacy and safety of combination of semaglutide and basal insulin in patients with of type 2 diabetes mellitus: A systematic review and meta-analysis.","2025","Clinical nutrition ESPEN","Chen B","55","38","12","none found",null],["R0018305",null,null,"10.1101/2025.09.17.25335973",null,null,"Efficacy and Safety of Pharmacologic Therapies in HFpEF: A Systematic Review and Network Meta-Analysis","2025","medRxiv","Armani MN",null,"0","0","none found",null],["R0018334","CRD42021268563",null,"10.31083/j.rcm2204152","34957787",null,"Cardiovascular outcomes of glucose lowering therapy in chronic kidney disease patients: a systematic review with meta-analysis.","2021","Reviews in cardiovascular medicine","Kamdar A","39","7","4","PROSPERO","PROSPERO:CRD42021268563"],["R0018394","CRD42023404309",null,"10.1007/s40265-024-02015-6","38478331",null,"Comparative Efficacy of Drug Interventions on NAFLD Over 24 Weeks: A Traditional and Network Meta-Analysis of Randomized Controlled Trials.","2024","Drugs","Wang Y","67","6","5","PROSPERO","PROSPERO:CRD42023404309"],["R0018407",null,null,"10.1186/s13098-025-01988-y","41126373","PMC12542482","Managing post-bariatric hypoglycemia: a systematic review of pharmacological therapies.","2025","Diabetology & metabolic syndrome","Sridharan K","60","12","5","none found",null],["R0018411",null,null,"10.1016/j.ahj.2021.06.001","34107289",null,"Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials.","2021","American heart journal","Cotter G","26","9","7","none found",null],["R0018417",null,null,"10.1007/s40618-024-02459-3","39347905",null,"The blood pressure-lowering property of subcutaneous semaglutide: a systematic review, meta-analysis, and meta-regression.","2025","Journal of endocrinological investigation","Ala M","46","36","21","none found",null],["R0018435",null,null,"10.1007/s00592-019-01347-0","30993527",null,"Effects of exenatide long-acting release on cardiovascular events and mortality in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.","2019","Acta diabetologica","Bonora BM","0","0","0","none found",null],["R0018492",null,null,"10.1210/clinem/dgaa577","32827435","PMC7549924","Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis.","2020","The Journal of clinical endocrinology and metabolism","Lingvay I","23","6","4","none found",null],["R0018508",null,null,"10.1101/2024.06.23.24309242",null,null,"Age- and sex- differences in efficacy of treatments for type 2 diabetes: Network meta-analysis of aggregate and individual level data","2024","medRxiv","Hanlon P",null,"0","0","none found",null],["R0018511",null,null,"10.1080/14740338.2023.2284992","37986140",null,"Risk of pancreatitis and pancreatic carcinoma for anti-diabetic medications: findings from real-world safety data analysis and systematic review and meta-analysis of randomized controlled trials.","2024","Expert opinion on drug safety","Muhammed A","41","14","1","none found",null],["R0018520",null,null,"10.1080/03007995.2024.2383731","39046272",null,"Evaluating the safety profile of semaglutide: an updated meta-analysis.","2024","Current medical research and opinion","Rivera FB","23","21","19","none found",null],["R0018559",null,null,"10.1136/bmj.n1091","33975892",null,"SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline.","2021","BMJ (Clinical research ed.)","Li S","41","11","2","none found",null],["R0018582",null,null,"10.2147/dddt.s470826","38952487","PMC11215664","Clinical Pharmacokinetics of Semaglutide: A Systematic Review.","2024","Drug design, development and therapy","Yang XD","50","42","16","none found",null],["R0018598",null,null,null,null,"PMC11453669","5185 A Meta-Analysis Evaluating the Efficacy of Liraglutide in Reducing Cardiovascular Complications Among Patients With Type 2 Diabetes","2024","Journal of the Endocrine Society",null,"0","0","0","none found",null],["R0018609",null,null,null,null,"PMC11453676","7347 The Efficacy And Safety Of Oral Semaglutide In Asian Patients With Type 2 Diabetes:A Systematic Review And Meta-Analysis","2024","Journal of the Endocrine Society",null,"0","0","0","none found",null],["R0018672",null,null,"10.1016/j.diabres.2024.111758","38925294",null,"Tirzepatide use and the risk of cancer among individuals with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.","2024","Diabetes research and clinical practice","Popovic DS","18","10","0","none found",null],["R0018689",null,null,"10.1136/bmjopen-2012-001986","23355666","PMC3563145","Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis.","2013","BMJ open","Robinson LE","71","60","50","none found",null],["R0018701",null,null,"10.1038/s41366-024-01621-4","39210008",null,"Tirzepatide outcompetes long-acting insulin in managing type 2 diabetes: a meta-analysis of three phase 3 randomized controlled trials.","2024","International journal of obesity (2005)","Ala M","11","6","4","none found",null],["R0018708",null,null,"10.1007/s00592-022-01917-9","35879478","PMC9402762","Absolute treatment effects for the primary outcome and all-cause mortality in the cardiovascular outcome trials of new antidiabetic drugs: a meta-analysis of digitalized individual patient data.","2022","Acta diabetologica","Kuss O","33","6","3","none found",null],["R0018712",null,null,"10.1111/dom.15948","39268951",null,"Hepatobiliary effects and safety of tirzepatide: A systematic review and meta-analysis.","2024","Diabetes, obesity & metabolism","Kamrul-Hasan ABM","12","4","1","none found",null],["R0018720",null,null,"10.1714/1203.13331","23258123",null,"[Incretin-based therapies and cardiovascular outcome: analyses, pooled analyses and meta-analyses].","2012","Giornale italiano di cardiologia (2006)","Mannucci E","0","0","0","none found",null],["R0018749",null,null,"10.1093/eurheartj/ehae564","39217502","PMC11458150","Semaglutide and blood pressure: an individual patient data meta-analysis.","2024","European heart journal","Kennedy C","33","11","8","none found",null],["R0018776",null,null,"10.1111/dom.13177","29193572",null,"Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.","2018","Diabetes, obesity & metabolism","Wang H","71","34","18","none found",null],["R0018795",null,null,"10.1055/s-0034-1387304","25289919",null,"[GLP-1 analogues in treatment of type 1 diabetes mellitus].","2014","Deutsche medizinische Wochenschrift (1946)","Tölle S","0","0","0","none found",null],["R0018822","CRD42019153180",null,"10.1136/bmj.m4573","33441402","PMC7804890","Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.","2021","BMJ (Clinical research ed.)","Palmer SC","108","12","9","PROSPERO","PROSPERO:CRD42019153180"],["R0018883",null,null,"10.1371/journal.pone.0153502","27078018","PMC4831684","Cardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis.","2016","PloS one","Kim JY","104","22","18","none found",null],["R0018897",null,null,"10.1002/14651858.cd006423.pub2","21975753","PMC6486297","Glucagon-like peptide analogues for type 2 diabetes mellitus.","2011","The Cochrane database of systematic reviews","Shyangdan DS","68","54","39","none found",null],["R0018914",null,null,"10.1007/s11255-020-02520-z","32524495",null,"Pleiotropic effects of antidiabetic agents on renal and cardiovascular outcomes: a meta-analysis of randomized controlled trials.","2020","International urology and nephrology","Chewcharat A","41","10","9","none found",null],["R0018947",null,null,"10.3389/fphar.2024.1290184","38633611","PMC11022205","Exenatide for obesity in children and adolescents: Systematic review and meta-analysis.","2024","Frontiers in pharmacology","Chen B","50","39","16","none found",null],["R0018949",null,null,"10.1210/clinem/dgaa337","32490533","PMC7365687","Insulin Sensitizers for Improving the Endocrine and Metabolic Profile in Overweight Women With PCOS.","2020","The Journal of clinical endocrinology and metabolism","Xing C","51","16","7","none found",null],["R0018960",null,null,"10.1016/j.ijcard.2017.01.144","28560966",null,"Incretin-based therapy for type 2 diabetes: What have we learned from the meta-analyses?","2017","International journal of cardiology","Barakat AF","5","2","0","none found",null],["R0019017",null,null,"10.7759/cureus.46091","37908927","PMC10614464","Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review and Meta-Analysis.","2023","Cureus","Karrar HR","27","18","7","none found",null],["R0019022",null,null,"10.1111/obr.13792","38923272",null,"Efficacy and safety of once-weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus-A systematic review and meta-analysis of randomized controlled trials.","2024","Obesity reviews : an official journal of the International Association for the Study of Obesity","Kommu S","43","21","12","none found",null],["R0019032",null,null,"10.1101/2022.05.28.22275730",null,null,"Hypoglycemic Events in Diabetic Patients under Non-insulin Regimens During Ramadan: A Frequentist Network Meta-Analysis","2022","medRxiv","Kacimi SEO",null,"0","0","none found",null],["R0019039",null,null,"10.1080/17446651.2023.2279533","37947481",null,"The vascular complications of diabetes: a review of their management, pathogenesis, and prevention.","2024","Expert review of endocrinology & metabolism","Meir J","99","5","1","none found",null],["R0019060","CRD42024500551",null,"10.3389/fcvm.2024.1379189","39055657","PMC11270812","Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis.","2024","Frontiers in cardiovascular medicine","Masson W","62","41","16","PROSPERO","PROSPERO:CRD42024500551"],["R0019075",null,null,"10.1007/s40262-024-01449-1","39549228",null,"Time-Efficacy Relationship of Semaglutide in the Treatment of Type 2 Diabetes Mellitus: A Model-Based Meta-Analysis.","2024","Clinical pharmacokinetics","Zhang K","27","19","16","none found",null],["R0019090","CRD42023489588",null,"10.1007/s13300-024-01540-7","38402331","PMC10951192","Comparative Efficacy and Safety of Tirzepatide in Asians and Non-Asians with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","Cui Y","43","20","9","PROSPERO","PROSPERO:CRD42023489588"],["R0019108",null,null,"10.1016/j.dsx.2024.103024","38718449",null,"Efficacy and safety of oral semaglutide in type 2 diabetes: A systematic review of real-world evidence.","2024","Diabetes & metabolic syndrome","Singh AK","30","22","13","none found",null],["R0019116","CRD42022326382",null,"10.1016/j.jdiacomp.2022.108362","36462459",null,"Effect of new glucose-lowering drugs on stroke in patients with type 2 diabetes: A systematic review and Meta-analysis.","2023","Journal of diabetes and its complications","Li J","54","15","8","PROSPERO","PROSPERO:CRD42022326382"],["R0019131",null,null,"10.1016/j.endien.2024.03.012","38555109",null,"Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis.","2024","Endocrinologia, diabetes y nutricion","Masson W","54","41","24","none found",null],["R0019132",null,null,"10.1111/obr.13727","38509775",null,"Optimized strategy among diet, exercise, and pharmacological interventions for nonalcoholic fatty liver disease: A network meta-analysis of randomized controlled trials.","2024","Obesity reviews : an official journal of the International Association for the Study of Obesity","Wang H","192","12","10","none found",null],["R0019150",null,null,"10.3390/genes16111377","41300829","PMC12652249","Genetic Assessment and Clinical Correlates in Severe Hypertriglyceridemia: A Systematic Review.","2025","Genes","De Luca C","56","7","3","none found",null],["R0019220",null,null,"10.1186/s40001-025-02368-y","39985051","PMC11843998","Effects of different hypoglycaemic drugs on beta-cell function in type 2 diabetes mellitus: a systematic review and network meta-analysis.","2025","European journal of medical research","Guo Z","44","15","0","none found",null],["R0019250",null,null,"10.62347/ryln5360","39262717","PMC11384358","Efficacy and safety of semaglutide combined with metformin in treating T2DM with overweight or obesity: a systematic review and meta-analysis.","2024","American journal of translational research","Li J","26","5","1","none found",null],["R0019253",null,null,null,null,"PMC8089576","Presentation and Management of Liraglutide-Related Pancreatitis: Systematic Review of Case Reports","2021","Journal of the Endocrine Society","Singh S","0","0","0","none found",null],["R0019260",null,null,"10.1016/j.ijcard.2016.12.113","28043676",null,"Cardiovascular safety of incretin-based therapy for type 2 diabetes: A meta-analysis of randomized trials.","2017","International journal of cardiology","Mahmoud AN","10","6","5","none found",null],["R0019286",null,null,"10.1186/s12902-023-01497-x","37974132","PMC10652559","Comparison of exenatide alone or combined with metformin versus metformin in the treatment of polycystic ovaries: a systematic review and meta-analysis.","2023","BMC endocrine disorders","Hu Y","44","20","12","none found",null],["R0019305","CRD42020201507",null,"10.1093/bjsopen/zrad077","37542473","PMC10404007","Bariatric surgery, novel glucose-lowering agents, and insulin for type 2 diabetes and obesity: Bayesian network meta-analysis of randomized controlled trials.","2023","BJS open","Wu T","63","25","7","PROSPERO","PROSPERO:CRD42020201507"],["R0019354",null,null,"10.1185/03007995.2013.852078","24106875",null,"Insulin plus incretin agent combination therapy in type 2 diabetes: a systematic review.","2014","Current medical research and opinion","Goldenberg R","92","40","16","none found",null],["R0019373",null,null,"10.7326/m18-0567","30597484","PMC6602870","Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study.","2019","Annals of internal medicine","Fralick M","32","3","0","none found",null],["R0019385",null,null,"10.1007/s40200-024-01412-8","38932909","PMC11196572","Evaluating the effectiveness and safety of various Tirzepatide dosages in the management of Type 2 diabetes mellitus: a network meta-analysis of randomized controlled trials.","2024","Journal of diabetes and metabolic disorders","Rangwala HS","46","31","14","none found",null],["R0019390",null,null,"10.1080/17512433.2022.2117152","36039827",null,"Comparison of weight loss and adverse events of obesity drugs in children and adolescents: a systematic review and meta-analysis.","2022","Expert review of clinical pharmacology","Zhao G","45","9","7","none found",null],["R0019414",null,null,"10.1097/meg.0000000000002471","36468565",null,"Side effect profile of pharmacologic therapies for liver fibrosis in nonalcoholic fatty liver disease: a systematic review and network meta-analysis.","2023","European journal of gastroenterology & hepatology","Li Y","96","27","4","none found",null],["R0019417",null,null,"10.1111/jdi.70111","40600829","PMC12400361","Effect of SGLT-2 inhibitors on COPD exacerbations in individuals with type 2 diabetes: A meta-analysis and Bayesian sensitivity analysis.","2025","Journal of diabetes investigation","Shabil M","57","11","0","none found",null],["R0019426",null,null,"10.1038/s41588-023-01462-3","37679419","PMC10484788","GWAS of random glucose in 476,326 individuals provide insights into diabetes pathophysiology, complications and treatment stratification.","2023","Nature genetics","Lagou V","96","9","0","none found",null],["R0019447","CRD42024519474",null,"10.3389/fendo.2024.1403606","38883606","PMC11176463","Long-term effects of different hypoglycemic drugs on carotid intima-media thickness progression: a systematic review and network meta-analysis.","2024","Frontiers in endocrinology","Lv Q","84","19","5","PROSPERO","PROSPERO:CRD42024519474"],["R0019464",null,null,"10.3390/jcm10184078","34575189","PMC8470178","Glycemic Variability Impacted by SGLT2 Inhibitors and GLP 1 Agonists in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis.","2021","Journal of clinical medicine","Lee H","43","13","6","none found",null],["R0019466",null,null,"10.1080/14740338.2021.1898585","33706621",null,"Effects of anti-diabetes medications on cardiovascular and kidney outcomes in Asian patients with type 2 diabetes: a rapid evidence assessment and narrative synthesis.","2021","Expert opinion on drug safety","Kadowaki T","0","0","0","none found",null],["R0019470",null,null,"10.1507/endocrj.ej24-0168","38910131",null,"Meta-analysis of the clinical efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease.","2024","Endocrine journal","Xu YY","41","22","13","none found",null],["R0019521",null,null,"10.1016/j.genhosppsych.2022.07.006","35863294",null,"A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis.","2022","General hospital psychiatry","Lee K","66","7","4","none found",null],["R0019534","CRD42018105193",null,"10.1136/bmjdrc-2019-001020","32690574","PMC7371226","Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies.","2020","BMJ open diabetes research & care","Bagepally BS","81","55","12","PROSPERO","PROSPERO:CRD42018105193"],["R0019537",null,null,"10.5114/pg.2022.112775","37007754","PMC10050979","The effects of liraglutide on liver enzymes and metabolic factors in patients with nonalcoholic steatohepatitis: a meta-analysis of randomized controlled trials.","2023","Przeglad gastroenterologiczny","Malik A","21","13","4","none found",null],["R0019566",null,null,"10.1097/mjt.0000000000001808","39297757",null,"Comparative Efficacy and Safety of Resmetirom Versus Semaglutide in Treating MASH and MASLD: A Network Meta-Analysis.","2025","American journal of therapeutics","Ayesh H","11","3","3","none found",null],["R0019574",null,null,"10.1007/s11695-024-07384-1","38987454",null,"Liraglutide for the Treatment of Weight Regain After Bariatric Surgery: A Systematic Review and Meta-analysis.","2024","Obesity surgery","de Moraes FCA","6","6","1","none found",null],["R0019583",null,null,"10.1016/j.amsu.2022.103633","35637990","PMC9142616","Effects of novel glucose-lowering drugs on the lipid parameters: A systematic review and meta-analysis.","2022","Annals of medicine and surgery (2012)","Dar S","28","8","6","none found",null],["R0019590",null,null,"10.1097/mjt.0000000000001828","40338694",null,"Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus, With or Without Cardiovascular Disease: A Systematic Review and Meta-Analysis of 10,013 Patients.","2025","American journal of therapeutics","Raja A","0","0","0","none found",null],["R0019593",null,null,"10.1111/dom.15272","37700437",null,"Effect of tirzepatide on blood pressure and lipids: A meta-analysis of randomized controlled trials.","2023","Diabetes, obesity & metabolism","Kanbay M","32","20","10","none found",null],["R0019598",null,null,"10.1007/s00592-024-02425-8","39666113","PMC12283822","The potential of precision diabetology for type 2 diabetes treatment-evidence from a meta-regression for all-cause mortality from large cardiovascular outcome trials.","2025","Acta diabetologica","Kuss O","33","14","1","none found",null],["R0019627",null,null,"10.1007/s11695-024-07445-5","39126592",null,"Comment on the Meta-analysis of Liraglutide for Weight Regain: Methodological Considerations.","2024","Obesity surgery","Conte C","3","3","0","none found",null],["R0019640",null,null,"10.1002/osp4.70188","42707648","PMC13547837","A Systematic Review and Meta-Analysis of Malnutrition and Metabolic Failure in High-Potency Incretin Therapy.","2026","Obesity science & practice","Ampofo E","32","27","23","none found",null],["R0019650",null,null,"10.1097/mjt.0000000000001814","39297747",null,"Efficacy and Safety of FGF21 Versus Semaglutide in the Management of Metabolic-Associated Steatotic Liver Disease: A Network Meta-analysis.","2024","American journal of therapeutics","Ayesh H","0","0","0","none found",null],["R0019661",null,null,"10.1016/j.ejim.2024.07.008","39069430",null,"Advances in the pathophysiology, diagnosis and management of chronic diarrhoea from bile acid malabsorption: a systematic review.","2024","European journal of internal medicine","Di Ciaula A","171","4","2","none found",null],["R0019723",null,null,"10.3390/ph15080953","36015100","PMC9412496","Continuous Subcutaneous Insulin Infusion (CSII) Combined with Oral Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomized, Controlled Trials.","2022","Pharmaceuticals (Basel, Switzerland)","Li H","20","2","1","none found",null],["R0019725","CRD42021257670",null,"10.1186/s12902-022-01031-5","35488292","PMC9055739","Impact of Cotadutide drug on patients with type 2 diabetes mellitus: a systematic review and meta-analysis.","2022","BMC endocrine disorders","Ali MM","34","16","12","PROSPERO","PROSPERO:CRD42021257670"],["R0019747","CRD42024499511",null,"10.1136/bmjopen-2024-084190","38908837","PMC11331358","Adverse effects with semaglutide: a protocol for a systematic review with meta-analysis and trial sequential analysis.","2024","BMJ open","Sillassen CDB","48","14","2","PROSPERO","PROSPERO:CRD42024499511"],["R0019748",null,null,"10.1111/dom.13924","31750601",null,"Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials.","2020","Diabetes, obesity & metabolism","Abd El Aziz M","30","19","10","none found",null],["R0019785",null,null,"10.1038/srep32714","27600499","PMC5013324","The efficacy and safety of liraglutide added to metformin in patients with diabetes: a meta-analysis of randomized controlled trials.","2016","Scientific reports","Gu J","52","31","25","none found",null],["R0019796",null,null,null,null,"PMC7234538","S90. A SYSTEMATIC REVIEW AND META-ANALYSIS OF PHARMACOLOGICAL INTERVENTIONS FOR REDUCTION OF WEIGHT GAIN IN PEOPLE WITH SCHIZOPHRENIA: 2019 UPDATE","2020","Schizophrenia bulletin","Agarwal S","0","0","0","none found",null],["R0019802",null,null,"10.1007/s12020-019-02175-6","31900793",null,"The efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes or obese adults: a systematic review and meta-analysis.","2020","Endocrine","Guo M","32","21","10","none found",null],["R0019808",null,null,"10.1055/a-2303-8558","38599612",null,"Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide in Overweight or Obese Adults: A Systematic Review with Meta-Analysis.","2024","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","Dorneles G","45","35","14","none found",null],["R0019818",null,null,"10.1016/j.cpcardiol.2024.102736","38944224",null,"A review regarding the article 'Semaglutide and heart failure: Updated meta-analysis'.","2024","Current problems in cardiology","Yuan D","5","5","1","none found",null],["R0019858",null,null,"10.1016/j.diabet.2025.101646","40220861",null,"Impact of SGLT-2i on COPD exacerbations in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.","2025","Diabetes & metabolism","Satapathy P","50","10","0","none found",null],["R0019887",null,null,"10.1111/jdi.12625","28106956","PMC5497054","Comparisons of weight changes between sodium-glucose cotransporter 2 inhibitors treatment and glucagon-like peptide-1 analogs treatment in type 2 diabetes patients: A meta-analysis.","2017","Journal of diabetes investigation","Cai X","36","10","7","none found",null],["R0019918",null,null,"10.3390/nu18030388","41683214","PMC12899271","Assessing Nutraceuticals for Hepatic Steatosis: A Standardized In Vitro Approach.","2026","Nutrients","Palasantzas VEJM","134","9","2","none found",null],["R0019924","CRD42021257670",null,"10.21203/rs.3.rs-1236048/v1",null,null,"Impact of Cotadutide Drug on Obese Individuals with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis","2022","Research Square","Ali MM",null,"0","0","PROSPERO","PROSPERO:CRD42021257670"],["R0019928",null,null,"10.1186/s13098-022-00924-8","36271423","PMC9585736","Association of the gallbladder or biliary diseases with dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes: a meta-analysis of randomized controlled trials.","2022","Diabetology & metabolic syndrome","Yu M","25","12","1","none found",null],["R0019929",null,null,"10.3389/fendo.2023.1230206","37621649","PMC10446893","The effects of subcutaneous Tirzepatide on obesity and overweight: a systematic review and meta-regression analysis of randomized controlled trials.","2023","Frontiers in endocrinology","Rohani P","52","33","10","none found",null],["R0019933","CRD42023450979",null,"10.4103/jrms.jrms_693_23","39629036","PMC11613982","Effectiveness and safety of semaglutide in overweight/obese adults with or without type 2 diabetes: A systematic review and meta-analysis.","2024","Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences","Yang L","34","33","20","PROSPERO","PROSPERO:CRD42023450979"],["R0019949","CRD42022302942",null,"10.3310/pwkq2310","41424377","PMC12746199","Cost-effectiveness of endoscopic treatments for obesity: a clinical evidence map and systematic review to inform a model-based cost-effectiveness analysis.","2025","Health technology assessment (Winchester, England)","Albon E","130","12","6","PROSPERO","PROSPERO:CRD42022302942"],["R0019952",null,null,"10.1111/jsr.70196","40974185",null,"Evaluating the Efficacy of Sodium Glucose Cotransporter-2 Inhibitors in Management of Obstructive Sleep Apnea; a Systematic Review and Meta-Analysis.","2026","Journal of sleep research","Murtaza S","34","2","1","none found",null],["R0019955",null,null,"10.21203/rs.3.rs-2737787/v1",null,null,"The effectiveness and safety of exenatide in the treatment of polycystic ovary syndrome: A systematic review and meta-analysis","2023","Research Square","Hu Y",null,"0","0","none found",null],["R0020007",null,null,null,null,"PMC9628116","ODP632 Preadmission Use Of Antidiabetic Medications And Mortality Among Patients With Covid-19 Having Type 2 Diabetes: A Meta-analysis","2022","Journal of the Endocrine Society",null,"0","0","0","none found",null],["R0020013",null,null,"10.7759/cureus.64668","39149678","PMC11326657","Semaglutide in Heart Failure: A Systematic Review of Outcomes of Semaglutide in Heart Failure Patients.","2024","Cureus","Gupta N","34","20","8","none found",null],["R0020053",null,null,"10.1111/dom.16352","40197859",null,"Meta-analysis of randomized controlled trials for the development of the International Federation for Surgery of Obesity and Metabolic Disorders-European Chapter (IFSO-EC) guidelines on multimodal strategies for the surgical treatment of obesity.","2025","Diabetes, obesity & metabolism","De Luca M","52","6","2","none found",null],["R0020069",null,null,"10.1016/j.diabres.2012.09.008","23010561",null,"A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer.","2012","Diabetes research and clinical practice","Alves C","39","17","5","none found",null],["R0020082",null,null,"10.1007/s00228-021-03261-3","34860262",null,"Updated network meta-analysis assessing the relative efficacy of 13 GLP-1 RA and SGLT2 inhibitor interventions on cardiorenal and mortality outcomes in type 2 diabetes.","2022","European journal of clinical pharmacology","Qiu M","0","0","0","none found",null],["R0020106",null,null,"10.1111/obr.13946","40437653",null,"Efficacy and Safety of Pharmacological Interventions in Managing Cardiometabolic Risk Factors in Youth Living with Overweight and Obesity: A Systematic Review and Network Meta-Analysis.","2025","Obesity reviews : an official journal of the International Association for the Study of Obesity","Faghfouri AH",null,"0","0","none found",null],["R0020126",null,null,"10.1007/s11695-023-07053-9","38183597","PMC10811090","Efficacy of High-dose Liraglutide 3.0 mg in Patients with Poor Response to Bariatric Surgery: Real-world Experience and Updated Meta-analysis.","2024","Obesity surgery","Vinciguerra F","30","9","2","none found",null],["R0020154",null,null,"10.1097/md.0000000000017081","31490412","PMC6739021","Efficacy and hypoglycemic risk of sitagliptin in obese/overweight patients with type 2 diabetes compared with GLP-1 receptor agonists: A meta-analysis.","2019","Medicine","Dai D","24","14","9","none found",null],["R0020160",null,null,"10.1210/clinem/dgaa894","33248440",null,"Microvascular Benefits of New Antidiabetic Agents: A Systematic Review and Network Meta-Analysis of Kidney Outcomes.","2021","The Journal of clinical endocrinology and metabolism","Cha AS","42","3","2","none found",null],["R0020167",null,null,"10.1097/md.0000000000037432","38489694","PMC10939689","Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials.","2024","Medicine","Xia W","41","32","14","none found",null],["R0020178",null,null,"10.1371/journal.pone.0244689","33606705","PMC7895346","Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.","2021","PloS one","Li CX","40","8","3","none found",null],["R0020200",null,null,"10.1111/dom.12293","24655583",null,"Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis.","2014","Diabetes, obesity & metabolism","Kim YG","51","35","28","none found",null],["R0020209",null,null,"10.1007/s12325-024-02941-7","39039386","PMC11349800","Clinical Efficacy and Safety of Anti-Obesity Medications Among Adult East Asian People with Obesity: A Systematic Literature Review and Indirect Treatment Comparison.","2024","Advances in therapy","Yokote K","29","11","5","none found",null],["R0020276",null,null,"10.1002/jcb.26115","28471499",null,"Efficacy and Safety of Single- or Double-Drug Antidiabetic Regimens in the Treatment of Type 2 Diabetes Mellitus: A Network Meta-Analysis.","2017","Journal of cellular biochemistry","Yang XL","48","11","10","none found",null],["R0020299",null,null,"10.2174/1573399813666170724113240","28738763",null,"An Evaluation of the Clinical Therapeutic Effect of Lixisenatide in Type 2 Diabetes Patients: A Systematic Literature Review.","2018","Current diabetes reviews","Okere AN","0","0","0","none found",null],["R0020327",null,null,"10.1186/s13098-023-01195-7","37891683","PMC10612199","Efficacy and tolerability of the Subcutaneous Semaglutide for type 2 Diabetes patients: an updated systematic review and meta-analysis.","2023","Diabetology & metabolic syndrome","Hu S","59","47","26","none found",null],["R0020376",null,null,"10.1038/s41598-022-22263-4","36316432","PMC9622886","Efficacy and safety of dulaglutide compared with the first-line hypoglycemic drugs in Asian patients with type 2 diabetes: a systematic review and meta-analysis.","2022","Scientific reports","Yu B","31","22","14","none found",null],["R0020390",null,null,"10.1007/s00431-023-05186-8","37672063",null,"Efficacy and safety of liraglutide for weight management in children and adolescents: a systematic review and meta-analysis of randomized controlled trials.","2023","European journal of pediatrics","Gou H","41","13","9","none found",null],["R0020393",null,null,"10.1007/s40200-026-02089-x","42802751","PMC13615951","Incretin-based injectable strategies versus intensified insulin for treatment intensification and simplification in type 2 diabetes: a systematic review and meta-analysis.","2026","Journal of diabetes and metabolic disorders","Mahmood T","41","27","18","none found",null],["R0020401",null,null,"10.7759/cureus.45421","37854744","PMC10581595","Safety and Efficacy of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials.","2023","Cureus","Vemulapalli HS","43","28","15","none found",null],["R0020407",null,null,"10.1016/j.clinthera.2011.04.015","21665040",null,"Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.","2011","Clinical therapeutics","Campbell RK","0","0","0","none found",null],["R0020430",null,null,"10.1155/2012/230624","23365557","PMC3540917","Impact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysis.","2012","Experimental diabetes research","Sun F","80","53","39","none found",null],["R0020440",null,null,"10.1038/s43856-024-00556-1","39025920","PMC11258280","Precision treatment of beta-cell monogenic diabetes: a systematic review.","2024","Communications medicine","Naylor RN","122","8","1","none found",null],["R0020446",null,null,"10.2337/dci20-0049","33218985","PMC7770275","Response to Comment on Gan et al. Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care 2020;43:1948-1957.","2020","Diabetes care","Gan S","5","4","0","none found",null],["R0020498",null,null,"10.7717/peerj.19221","40386230","PMC12085882","Emodin, a rising star in the treatment of glycolipid metabolism disorders: a preclinical systematic review and meta-analysis.","2025","PeerJ","Xiao Y","48","1","0","none found",null],["R0020503",null,null,"10.1016/j.ekir.2021.06.029","34514202","PMC8418973","Systematic Review of Cardiovascular Outcome Trials Using New Antidiabetic Agents in CKD Stratified by Estimated GFR.","2021","Kidney international reports","Arshad A","45","14","7","none found",null],["R0020577",null,null,"10.1111/dom.12290","24641271",null,"Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials.","2014","Diabetes, obesity & metabolism","Ahrén B","40","16","9","none found",null],["R0020590",null,null,"10.1016/j.jval.2014.08.641","27200592",null,"Assessing Consistency in a Network Meta-Analysis to Compare Once Weekly Dulaglutide Versus Other Glp-1 Receptor Agonists in Patients with Type 2 Diabetes.","2014","Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","Hawkins N","0","0","0","none found",null],["R0020618",null,null,"10.1111/dom.15386","38016699",null,"Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta-analysis including the 2-year STEP 5 trial.","2024","Diabetes, obesity & metabolism","Qin W","54","19","13","none found",null],["R0020643",null,null,"10.1111/dom.13623","30578607","PMC6590315","Comparative effectiveness of exenatide once-weekly versus liraglutide in routine clinical practice: A retrospective multicentre study and meta-analysis of observational studies.","2019","Diabetes, obesity & metabolism","Fadini GP","24","23","11","none found",null],["R0020667",null,null,"10.7759/cureus.42651","37644927","PMC10461595","Effect of Liraglutide on Cardiac Function in Individuals With Type 2 Diabetes: A Meta-Analysis.","2023","Cureus","Haroon H","26","13","8","none found",null],["R0020692",null,null,"10.1016/j.pcd.2019.01.003","30713085",null,"Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.","2019","Primary care diabetes","Alfayez OM","32","11","4","none found",null],["R0020704",null,null,"10.1016/j.ijmedinf.2024.105581","39106772",null,"A systematic review of the value of clinical decision support systems in the prescription of antidiabetic drugs.","2024","International journal of medical informatics","Tlili NE","64","2","0","none found",null],["R0020738",null,null,"10.1016/j.clinthera.2023.06.003","37400324",null,"Pharmaceutical Therapies for the Treatment of Obesity: A Network Meta-analysis.","2023","Clinical therapeutics","Morsali M","33","6","2","none found",null],["R0020743",null,null,"10.1016/j.diabres.2015.10.014","26643128",null,"Incretin-based therapies are associated with acute pancreatitis: Meta-analysis of large randomized controlled trials.","2015","Diabetes research and clinical practice","Roshanov PS","9","2","0","none found",null],["R0020753",null,null,"10.1111/dom.12386","25200423",null,"Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,324,515 patients from observational studies.","2015","Diabetes, obesity & metabolism","Wang T","49","17","0","none found",null],["R0020758",null,null,"10.1007/s00404-015-3976-7","26660657",null,"A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries.","2016","Archives of gynecology and obstetrics","Niafar M","40","16","7","none found",null],["R0020776",null,null,"10.1111/dom.14602","34766431",null,"Efficacy and safety of efpeglenatide in adults with obesity and its associated metabolic disturbance: A systematic review and meta-analysis of randomized controlled trials.","2022","Diabetes, obesity & metabolism","Abdelhaleem IA","23","15","7","none found",null],["R0020781",null,null,"10.21203/rs.3.rs-16511/v1",null,null,"Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis","2020","Research Square","Li C",null,"0","0","none found",null],["R0020809",null,null,"10.1038/srep18904","26742577","PMC4705511","Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review.","2016","Scientific reports","Zhang L","31","28","11","none found",null],["R0020844",null,null,"10.1111/dom.14291","33300282",null,"Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis.","2021","Diabetes, obesity & metabolism","Avgerinos I","43","5","1","none found",null],["R0020851",null,null,"10.1097/md.0000000000017860","31725627","PMC6867782","Cardiovascular outcomes of liraglutide in patients with type 2 diabetes: A systematic review and meta-analysis.","2019","Medicine","Duan CM","36","21","10","none found",null],["R0020877",null,null,"10.2217/pgs-2022-0192","36999540","PMC10152409","Pharmacogenetic interactions of medications administered for weight loss in adults: a systematic review and meta-analysis.","2023","Pharmacogenomics","BouSaba J","57","18","2","none found",null],["R0020960",null,null,"10.3390/ijms232314631","36498958","PMC9741068","Tirzepatide: A Systematic Update.","2022","International journal of molecular sciences","Forzano I","100","80","21","none found",null],["R0020983",null,null,"10.1016/j.diabres.2017.05.007","28552612",null,"Efficacy and safety of incretin-based drugs in patients with type 1 diabetes mellitus: A systematic review and meta-analysis.","2017","Diabetes research and clinical practice","Wang W","45","20","7","none found",null],["R0021037",null,null,"10.2174/1574886313666180601082412","29852875",null,"Risk and Benefit Profile of Dulaglutide in Established Therapeutic Indication.","2018","Current drug safety","Garg A","0","0","0","none found",null],["R0021039",null,null,"10.3275/8367","22522662",null,"Insulin vs GLP-1 analogues in poorly controlled Type 2 diabetic subjects on oral therapy: a meta-analysis.","2013","Journal of endocrinological investigation","Abdul-Ghani MA","30","15","11","none found",null],["R0021057",null,null,"10.1093/ajh/hpt196","24263424",null,"Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression.","2014","American journal of hypertension","Katout M","40","38","33","none found",null],["R0021060",null,null,"10.3390/ijms25147988","39063229","PMC11277066","Impact of Different Anti-Hyperglycaemic Treatments on Bone Turnover Markers and Bone Mineral Density in Type 2 Diabetes Mellitus Patients: A Systematic Review and Meta-Analysis.","2024","International journal of molecular sciences","Saadi MSS","71","9","4","none found",null],["R0021062",null,null,"10.1177/10600280221133577","36314281","PMC9618918","Effect of Antidiabetic Therapy on Clinical Outcomes of COVID-19 Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis.","2023","The Annals of pharmacotherapy","Zhan K","58","4","1","none found",null],["R0021076",null,null,"10.1016/j.eprac.2024.05.009","38782201",null,"Liraglutide's Effect on Weight Management in Subjects With Pre-diabetes: A Systematic Review & Meta-Analysis.","2024","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Alsanea S","52","30","20","none found",null],["R0021100",null,null,"10.1016/j.ijcard.2016.06.028","27343423",null,"Exenatide in obese or overweight patients without diabetes: A systematic review and meta-analyses of randomized controlled trials.","2016","International journal of cardiology","Su N","34","24","14","none found",null],["R0021195",null,null,"10.1016/j.phrs.2023.107031","38061595",null,"Evaluation and comparison of efficacy and safety of tirzepatide and semaglutide in patients with type 2 diabetes mellitus: A Bayesian network meta-analysis.","2024","Pharmacological research","Ding Y","63","50","39","none found",null],["R0021197",null,null,"10.5603/cj.a2020.0140","33140391","PMC9170323","Cardiovascular outcomes with glucagon-like peptide 1 agonists and sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes: A meta-analysis.","2022","Cardiology journal","Lee YM","36","13","8","none found",null],["R0021205","CRD42022337099",null,"10.3389/fendo.2023.1132004","37455913","PMC10338217","Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials.","2023","Frontiers in endocrinology","Zhang R","43","28","16","PROSPERO","PROSPERO:CRD42022337099"],["R0021211",null,null,"10.2337/dc20-1950","33218984",null,"Comment on Gan et al. Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care 2020;43:1948-1957.","2020","Diabetes care","Singh AK","0","0","0","none found",null],["R0021256",null,null,"10.3748/wjg.v29.i37.5327","37899788","PMC10600803","Efficacy and safety of semaglutide in non-alcoholic fatty liver disease.","2023","World journal of gastroenterology","Zhu K","35","15","7","none found",null],["R0021262",null,null,"10.1016/j.dsx.2023.102895","39491072",null,"Letter to the Editor regarding \"Semaglutide and cancer: A systematic review and meta-analysis\" by Nagendra L et al.","2023","Diabetes & metabolic syndrome","Xiao Y","0","0","0","none found",null],["R0021272","CRD42022319442",null,"10.3389/fphar.2022.1016639","36569320","PMC9774036","Efficacy and safety of tirzepatide in patients with type 2 diabetes: A systematic review and meta-analysis.","2022","Frontiers in pharmacology","Tang Y","39","27","12","PROSPERO","PROSPERO:CRD42022319442"],["R0021279",null,null,"10.1016/j.schres.2024.09.008","39265262",null,"Insulin-resistance as a modifiable pathway to cognitive dysfunction in schizophrenia: A systematic review.","2024","Schizophrenia research","Salvi V","80","5","3","none found",null],["R0021294",null,null,"10.1111/dom.16012","39431379",null,"Characterizing body composition modifying effects of a glucagon-like peptide 1 receptor-based agonist: A meta-analysis.","2025","Diabetes, obesity & metabolism","Jiao R","40","12","4","none found",null],["R0021339",null,null,"10.1111/dom.14908","36314246",null,"Safety and efficacy of liraglutide on reducing visceral and ectopic fat in adults with or without type 2 diabetes mellitus: A systematic review and meta-analysis.","2023","Diabetes, obesity & metabolism","He F","42","28","24","none found",null],["R0021360",null,null,"10.1111/apt.16583","34435378","PMC8711247","Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH.","2021","Alimentary pharmacology & therapeutics","Majzoub AM","47","2","2","none found",null],["R0021383",null,null,"10.1016/j.dsx.2023.102849","37717295",null,"Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis.","2023","Diabetes & metabolic syndrome","Bandyopadhyay S","60","26","9","none found",null],["R0021403",null,null,"10.1016/j.jep.2025.120960","41297722",null,"Gegen Qinlian decoction ameliorates insulin resistance in type 2 diabetes: A systematic review and meta-analysis of RCTs with mechanistic insights into SIRT1/AMPK pathway activation.","2026","Journal of ethnopharmacology","Liao Y","31","0","0","none found",null],["R0021411","CRD42023469941",null,"10.1177/20420986251335214","40290515","PMC12033536","Real-world evidence on the association of novel antidiabetic medication use with cancer risk and protective effects: a systematic review and network meta-analysis.","2025","Therapeutic advances in drug safety","Kenawy AS","138","43","2","PROSPERO","PROSPERO:CRD42023469941"],["R0021439",null,null,"10.1007/s13300-016-0207-6","27796905","PMC5118245","Lixisenatide Improves Glycemic Control in Asian Type 2 Diabetic Patients Inadequately Controlled With Oral Antidiabetic Drugs: An Individual Patient Data Meta-Analysis.","2016","Diabetes therapy : research, treatment and education of diabetes and related disorders","Shu H","26","13","8","none found",null],["R0021457",null,null,"10.1007/s10198-016-0837-7","27752788",null,"The place of DPP-4 inhibitors in the treatment algorithm of diabetes type 2: a systematic review of cost-effectiveness studies.","2017","The European journal of health economics : HEPAC : health economics in prevention and care","Baptista A","33","13","3","none found",null],["R0021460",null,null,"10.2147/dmso.s392952","36569429","PMC9769143","Semaglutide 2.4 Mg for the Management of Overweight and Obesity: Systematic Literature Review and Meta-Analysis.","2022","Diabetes, metabolic syndrome and obesity : targets and therapy","Smith I","63","22","13","none found",null],["R0021470",null,null,"10.1111/jcpt.13588","34939679",null,"Three new categories of hypoglycaemic agents and various cardiovascular diseases: A meta-analysis.","2022","Journal of clinical pharmacy and therapeutics","Liao XX","32","12","7","none found",null],["R0021475",null,null,"10.1080/13696998.2019.1681436","31613199",null,"Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin.","2020","Journal of medical economics","Gorgojo-Martínez JJ","51","19","11","none found",null],["R0021478",null,null,"10.1186/s40842-026-00272-w","41787495","PMC12964769","A bibliometric analysis of systematic reviews and meta-analyses on diabetes mellitus: global research trends from scopus database (1988-2024).","2026","Cardiovascular diabetology. Endocrinology reports","Dalvand A","75","10","0","none found",null],["R0021500",null,null,"10.1080/14740338.2016.1221402","27875915",null,"Efficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review.","2016","Expert opinion on drug safety","Cimmaruta D","48","31","25","none found",null],["R0021582",null,null,"10.15605/jafes.037.02.14","36578889","PMC9758543","Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis.","2022","Journal of the ASEAN Federation of Endocrine Societies","Tan HC","18","11","6","none found",null],["R0021633",null,null,"10.1002/oby.23760","37231621",null,"A systematic review of the economic value proposition for commercially available nonsurgical weight-loss interventions.","2023","Obesity (Silver Spring, Md.)","Finkelstein EA","65","5","1","none found",null],["R0021679","CRD42022347472",null,"10.3390/children10020208","36832337","PMC10010327","Efficacy of Liraglutide in Obesity in Children and Adolescents: Systematic Review and Meta-Analysis of Randomized Controlled Trials.","2023","Children (Basel, Switzerland)","Cornejo-Estrada A","49","22","10","PROSPERO","PROSPERO:CRD42022347472"],["R0021707",null,null,"10.1111/obr.13553","36721366",null,"The effects of weight-lowering pharmacotherapies on physical activity, function and fitness: A systematic review and meta-analysis of randomized controlled trials.","2023","Obesity reviews : an official journal of the International Association for the Study of Obesity","Jobanputra R","38","16","11","none found",null],["R0021729",null,null,"10.1016/j.ejim.2021.12.018","34953655",null,"Renal outcomes associated with glucose-lowering agents: Systematic review and meta-analysis of randomized outcome trials.","2022","European journal of internal medicine","Chalmoukou K","49","12","9","none found",null],["R0021749",null,null,"10.21203/rs.3.rs-8607418/v1",null,null,"Comparative efficacy of SGLT2 Inhibitors and Obeticholic Acid in MAFLD and Fibrosis: A Systematic Review","2026","Research Square","Ganesh T",null,"0","0","none found",null],["R0021816",null,null,"10.1159/000314690","20616619",null,"A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes.","2010","Pharmacology","Fakhoury WK","40","0","0","none found",null],["R0021908",null,null,"10.1016/j.phrs.2018.09.025","30359962",null,"Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).","2018","Pharmacological research","Bifari F","183","79","12","none found",null],["R0021925",null,null,"10.1080/17512433.2022.2130760","36180402",null,"Efficacy and safety of liraglutide for obesity and people who are overweight: a systematic review and meta-analysis of randomized controlled trials.","2022","Expert review of clinical pharmacology","Lin Q","39","17","12","none found",null],["R0021969",null,null,"10.1016/j.amjcard.2022.07.003","35977865",null,"Updated Meta-Analysis Assessing the Cardiovascular Efficacy of Tirzepatide.","2022","The American journal of cardiology","Patoulias D","5","2","1","none found",null],["R0021982",null,null,"10.1186/s12902-022-01006-6","35392872","PMC8991462","Efficacy of liraglutide in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials.","2022","BMC endocrine disorders","Mali N","21","11","5","none found",null],["R0021989",null,null,"10.21203/rs.3.rs-5522253/v1",null,null,"Effect of Obesity Pharmacotherapy on anthropometrics, metabolic parameters and blood pressure in patients with obesity or overweight: An umbrella review of systematic reviews and meta-analyses of randomized clinical trials","2024","Research Square","Abedi-yekta A",null,"0","0","none found",null],["R0022006",null,null,"10.1111/j.1463-1326.2011.01493.x","21883806",null,"Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme.","2012","Diabetes, obesity & metabolism","Zinman B","18","10","8","none found",null],["R0022047",null,null,"10.4314/ahs.v22i3.28","36910413","PMC9993257","The effect of liraglutide on renal function in type 2 diabetes: a meta-analysis of randomized controlled studies.","2022","African health sciences","Luo C","33","15","9","none found",null],["R0022094",null,null,"10.3390/cancers13205172","34680321","PMC8533943","PET with Different Radiopharmaceuticals in Neuroendocrine Neoplasms: An Umbrella Review of Published Meta-Analyses.","2021","Cancers","Treglia G","55","1","0","none found",null],["R0022126",null,null,"10.1186/s12933-020-0987-x","31969144","PMC6977298","Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis.","2020","Cardiovascular diabetology","Zhang DP","80","33","19","none found",null],["R0022144",null,null,"10.2147/dmso.s590529","42094035","PMC13142718","The Effects of Exercise Combined with Pharmacotherapy on Body Composition and Metabolic Parameters in Overweight/Obese Adults: A Meta-Analysis and Network Pharmacology Study.","2026","Diabetes, metabolic syndrome and obesity : targets and therapy","Peng T","106","24","8","none found",null],["R0022180",null,null,"10.1007/s11845-023-03337-2","37036569",null,"Liraglutide combined with metformin treatment for obese people with type 2 diabetes mellitus: a systematic review and meta-analysis.","2023","Irish journal of medical science","Long Y","30","2","2","none found",null],["R0022182",null,null,"10.1002/cpt.70211","41670332","PMC13083373","Maternal-to-Infant Transfer of Medications for Type 2 Diabetes Mellitus Via Breastmilk: A Systematic Review of Available Evidence and Clinical Guidelines.","2026","Clinical pharmacology and therapeutics","Richardson K","42","3","1","none found",null],["R0022207",null,null,"10.3389/fphar.2022.935823","36188627","PMC9515581","Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials.","2022","Frontiers in pharmacology","Gao X","62","52","22","none found",null],["R0022245",null,null,"10.1016/j.jdiacomp.2014.07.007","25130920",null,"Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis.","2014","Journal of diabetes and its complications","Charbonnel B","41","17","13","none found",null],["R0022275",null,null,"10.1007/s12020-021-02945-1","34981419",null,"Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis.","2022","Endocrine","Zhong P","3","0","0","none found",null],["R0022281",null,null,"10.1111/dom.12575","26362460","PMC5061097","Achieving the composite endpoint of glycated haemoglobin <7.0%, no weight gain and no hypoglycaemia in the once-weekly dulaglutide AWARD programme.","2016","Diabetes, obesity & metabolism","Dungan KM","22","10","7","none found",null],["R0022362",null,null,"10.1016/j.biochi.2018.06.026","30103898",null,"Glucagon-Like peptide-1: A new therapeutic target to treat abdominal aortic aneurysm?","2018","Biochimie","Raffort J","41","10","0","none found",null],["R0022364","CRD42016043823",null,"10.1371/journal.pone.0217701","31237921","PMC6592598","GLUcose COntrol Safety & Efficacy in type 2 DIabetes, a systematic review and NETwork meta-analysis.","2019","PloS one","Grenet G","56","12","5","PROSPERO","PROSPERO:CRD42016043823"],["R0022416",null,null,"10.7759/cureus.99206","41536408","PMC12799224","Systematic Review of Therapeutic Strategies for Reducing Parkinson's Disease Symptoms and Progression.","2025","Cureus","Tumu S","20","1","1","none found",null],["R0022419",null,null,"10.1111/dom.15138","37254688",null,"Clinical outcomes associated with drugs for obesity and overweight: A systematic review and network meta-analysis of randomized controlled trials.","2023","Diabetes, obesity & metabolism","Iannone A","32","8","1","none found",null],["R0022439",null,null,"10.1016/j.dld.2020.08.021","32912770",null,"Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map.","2021","Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver","Kumar J","0","0","0","none found",null],["R0022443",null,null,"10.3390/jcm11112998","35683387","PMC9181568","Efficacy of Liraglutide in Non-Diabetic Obese Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","2022","Journal of clinical medicine","Barboza JJ","33","23","15","none found",null],["R0022486","CRD42022367488",null,"10.7326/m23-3179","39496172",null,"Effect of Weight Loss Interventions on the Symptomatic Burden and Biomarkers of Polycystic Ovary Syndrome : A Systematic Review of Randomized Controlled Trials.","2024","Annals of internal medicine","Scragg J","55","11","9","PROSPERO","PROSPERO:CRD42022367488"],["R0022508",null,null,"10.21203/rs.3.rs-929327/v1",null,null,"Efficacy of Liraglutide in Patients With Diabetic Nephropathy: A Meta-Analysis of Randomized Controlled Trials","2021","Research Square","Mali N",null,"0","0","none found",null],["R0022565",null,null,"10.1007/s10557-018-6777-y","29455345",null,"The Antidiabetic Armamentarium: Reducing the Residual Cardiovascular Risk with HbA1c(v)-Lowering Medications : Editorial to: \"GLP-1 Receptor Agonists and Cardiovascular Disease: A Meta-Analysis of Recent Cardiac Outcome Trials\" by Jia X, Alam M, Ye Y et al.","2018","Cardiovascular drugs and therapy","Stryker MD","20","6","4","none found",null],["R0022566",null,null,"10.1007/s40261-018-0707-4","30255388",null,"The Effects of Novel Antidiabetic Drugs on Albuminuria in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.","2018","Clinical drug investigation","Luo Y","81","23","13","none found",null],["R0022577",null,null,"10.1016/j.jdiacomp.2020.107704","32888788",null,"Lowering of hemoglobin A1C and risk of cardiovascular outcomes and all-cause mortality, a meta-regression analysis.","2020","Journal of diabetes and its complications","Fralick M","9","2","1","none found",null],["R0022588",null,null,"10.1101/2023.05.12.23289807","37214872","PMC10197799","Systematic Review of Treatment of Beta-Cell Monogenic Diabetes.","2023","medRxiv : the preprint server for health sciences","Naylor RN",null,"0","0","none found",null],["R0022591",null,null,"10.1136/bmj.j2499","28596247","PMC5463186","Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis.","2017","BMJ (Clinical research ed.)","Liu J","49","26","12","none found",null],["R0022599",null,null,"10.1016/j.amjcard.2022.03.042","35459459",null,"Meta-Analysis Assessing the Effect of Tirzepatide on the Risk for Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus.","2022","The American journal of cardiology","Patoulias D","11","7","4","none found",null],["R0022605","CRD42025117631",null,"10.3345/cep.2025.02838","41582666","PMC12877414","Systematic review of influence of ethnicity on efficacy and safety of pharmacotherapy for childhood and adolescent obesity.","2026","Clinical and experimental pediatrics","Gupta S","50","7","5","PROSPERO","PROSPERO:CRD42025117631"],["R0022643",null,null,"10.1016/j.ahjo.2021.100063","38549742","PMC10978116","Role of glucagon-like peptide-1 agonist in patients undergoing percutaneous coronary intervention or coronary artery bypass grafting: A meta-analysis.","2021","American heart journal plus : cardiology research and practice","Ogbu IR","38","21","16","none found",null],["R0022673",null,null,"10.1016/j.ejphar.2020.173153","32360835",null,"Comparison of drug efficacy in two animal models of type 2 diabetes: A systematic review and meta-analysis.","2020","European journal of pharmacology","Ferreira GS","34","0","0","none found",null],["R0022679",null,null,"10.1016/j.diabres.2018.06.009","29935211",null,"Cardiovascular safety of GLP-1 receptor agonists for diabetes patients with high cardiovascular risk: A meta-analysis of cardiovascular outcomes trials.","2018","Diabetes research and clinical practice","Wang Q","0","0","0","none found",null],["R0022693",null,null,"10.1111/ijpo.12799","33963681","PMC8519033","Liraglutide pharmacokinetics and exposure-response in adolescents with obesity.","2021","Pediatric obesity","Carlsson Petri KC","37","14","11","none found",null],["R0022709","CRD42020212025",null,"10.3389/fendo.2021.649018","33841337","PMC8024567","Efficacy of Various Hypoglycemic Agents in the Treatment of Patients With Nonalcoholic Liver Disease With or Without Diabetes： A Network Meta-Analysis.","2021","Frontiers in endocrinology","Lian J","50","10","8","PROSPERO","PROSPERO:CRD42020212025"],["R0022714",null,null,"10.3390/biomedicines12081791","39200254","PMC11351395","Systematic Review of Left Ventricular Remodeling in Response to Hypoglycemic Medications: Assessing Changes in End-Systolic and End-Diastolic Diameters.","2024","Biomedicines","Buz BF","36","5","3","none found",null],["R0022762",null,null,"10.1016/j.metabol.2020.154265","32446679",null,"Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis.","2020","Metabolism: clinical and experimental","Zhou JB","89","11","2","none found",null],["R0022789",null,null,"10.1007/s40618-021-01666-6","34455568",null,"The effectiveness and safety of liraglutide in treating overweight/obese patients with polycystic ovary syndrome: a meta-analysis.","2022","Journal of endocrinological investigation","Ge JJ","35","17","7","none found",null],["R0022839",null,null,"10.2174/15701611113119990103","22724475",null,"Combination therapies of DPP4 inhibitors and GLP1 analogues with insulin in type 2 diabetic patients: a systematic review.","2013","Current vascular pharmacology","Rizos EC","0","0","0","none found",null],["R0022852",null,null,"10.1371/journal.pone.0236603","32706828","PMC7380634","Comparisons between dipeptidyl peptidase-4 inhibitors and other classes of hypoglycemic drugs using two distinct biomarkers of pancreatic beta-cell function: A meta-analysis.","2020","PloS one","Takahashi M","76","6","5","none found",null],["R0022868",null,null,"10.1172/jci.insight.168563","37552540","PMC10544215","Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes.","2023","JCI insight","Regan JA","38","2","1","none found",null],["R0022884",null,null,"10.7759/cureus.24829","35693370","PMC9173657","Comparing the Efficacy and Safety of Obeticholic Acid and Semaglutide in Patients With Non-Alcoholic Fatty Liver Disease: A Systematic Review.","2022","Cureus","Ahmed NR","31","9","2","none found",null],["R0022890",null,null,"10.7759/cureus.95352","41287656","PMC12640742","A Systematic Review of Treatment Approaches for Individuals With Coexisting Diabetes and Substance Use Disorder.","2025","Cureus","Husain B","37","5","2","none found",null],["R0022902",null,null,"10.1016/j.amjcard.2022.04.030","35599190",null,"Meta-Analysis Assessing the Cardiovascular Safety of Semaglutide for the Treatment of Overweight or Obesity.","2022","The American journal of cardiology","Patoulias D","11","8","6","none found",null],["R0022913",null,null,"10.1007/s13300-020-00857-3","32562244","PMC7376816","Lixisenatide for Type 2 Diabetes Mellitus Patients Inadequately Controlled on Oral Antidiabetic Drugs: A Mixed-Treatment Comparison Meta-analysis and Cost-Utility Analysis.","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","Men P","29","10","7","none found",null],["R0022923",null,null,"10.1155/2012/249827","22811735","PMC3395195","A meta-analysis of the therapeutic effects of glucagon-like Peptide-1 agonist in heart failure.","2012","International journal of peptides","Munaf M","38","6","1","none found",null],["R0022939",null,null,"10.1111/dom.12842","27935230",null,"Comment on Abd El Aziz et al., A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients.","2017","Diabetes, obesity & metabolism","Home P","9","4","2","none found",null],["R0022947",null,null,"10.1007/s40273-019-00774-9","30854589",null,"Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review.","2019","PharmacoEconomics","Hong D","110","58","15","none found",null],["R0022990",null,null,"10.1507/endocrj.ej21-0129","34024887",null,"Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials.","2021","Endocrine journal","Yin DG","23","23","22","none found",null],["R0022999",null,null,"10.1097/md.0000000000032892","36820578","PMC9907937","Liraglutide on type 2 diabetes mellitus with nonalcoholic fatty liver disease: A systematic review and meta-analysis of 16 RCTs.","2023","Medicine","Zhao Y","52","18","10","none found",null],["R0023005",null,null,"10.3389/fphar.2021.695182","34690750","PMC8526557","Efficacy and Safety of Subcutaneous and Oral Semaglutide Administration in Patients With Type 2 Diabetes: A Meta-Analysis.","2021","Frontiers in pharmacology","Zhong P","61","41","26","none found",null],["R0023023",null,null,"10.1002/ejhf.3270","38752254",null,"Intentional weight loss in overweight and obese patients with heart failure: A systematic review.","2024","European journal of heart failure","Peck KH","35","2","1","none found",null],["R0023071",null,null,null,"30334409",null,"GLP-1, a powerful physiological incretin: an update.","2018","Journal of biological regulators and homeostatic agents","Malik J","0","0","0","none found",null],["R0023112",null,null,"10.1111/dom.12462","25777247",null,"Safety and effectiveness of non-insulin glucose-lowering agents in the treatment of people with type 2 diabetes who observe Ramadan: a systematic review and meta-analysis.","2015","Diabetes, obesity & metabolism","Gray LJ","42","2","1","none found",null],["R0023113","CRD42022302648",null,"10.3389/fendo.2023.1254398","38027186","PMC10658190","Pharmacoeconomic evaluation of anti-obesity drugs for chronic weight management: a systematic review of literature.","2023","Frontiers in endocrinology","Xue Y","73","14","1","PROSPERO","PROSPERO:CRD42022302648"],["R0023166",null,null,"10.23736/s0026-4806.21.07085-3","33555153",null,"Liraglutide monotherapy and add on therapy on obese women with polycystic ovarian syndromes: a systematic review and meta-analysis.","2022","Minerva medica","Tian D","21","9","5","none found",null],["R0023176",null,null,null,"20298625",null,"[New blood glucose-lowering drugs in type 2 diabetes: a review of the literature].","2010","Nederlands tijdschrift voor geneeskunde","Kleefstra N","0","0","0","none found",null],["R0023194",null,null,"10.1111/dom.13871","31469217",null,"Comparison of lixisenatide in combination with basal insulin vs other insulin regimens for the treatment of patients with type 2 diabetes inadequately controlled by basal insulin: Systematic review, network meta-analysis and cost-effectiveness analysis.","2020","Diabetes, obesity & metabolism","Men P","59","12","4","none found",null],["R0023215",null,null,"10.3803/enm.2020.934","34139800","PMC8258332","Efficacy and Safety of the New Appetite Suppressant, Liraglutide: A Meta-Analysis of Randomized Controlled Trials.","2021","Endocrinology and metabolism (Seoul, Korea)","Moon S","54","48","37","none found",null],["R0023216",null,null,"10.1016/j.numecd.2017.09.006","29113708",null,"Efficacy and safety of glucagon-like peptide-1 agonists on macrovascular and microvascular events in type 2 diabetes mellitus: A meta-analysis.","2017","Nutrition, metabolism, and cardiovascular diseases : NMCD","Gargiulo P","26","12","5","none found",null],["R0023220",null,null,"10.3389/fnins.2021.774050","34955726","PMC8695496","An Overview of Appetite-Regulatory Peptides in Addiction Processes; From Bench to Bed Side.","2021","Frontiers in neuroscience","Shevchouk OT","185","41","2","none found",null],["R0023225",null,null,"10.1007/s11096-022-01428-1","35715543",null,"Efficacy of subcutaneous semaglutide compared to placebo for weight loss in obese, non-diabetic adults: a systematic review & meta-analysis.","2022","International journal of clinical pharmacy","Arastu N","23","15","5","none found",null],["R0023255",null,null,"10.1111/dom.14612","34866313",null,"Once-weekly  semaglutide  for obesity  or overweight: A systematic review and meta-analysis.","2022","Diabetes, obesity & metabolism","He K","20","12","8","none found",null],["R0023261",null,null,"10.14740/jocmr5007","38550552","PMC10970039","Evaluation of Alternative Treatment Strategies for Bile Acid Malabsorption in Inflammatory Bowel Disease Patients: A Network Meta-Analysis.","2024","Journal of clinical medicine research","Merza N","30","2","1","none found",null],["R0023312",null,null,"10.1016/j.dsx.2022.102539","35709586",null,"Impact of semaglutide on biochemical and radiologic measures of metabolic-dysfunction associated fatty liver disease across the spectrum of glycaemia: A meta-analysis.","2022","Diabetes & metabolic syndrome","Dutta D","22","10","7","none found",null],["R0023327",null,null,"10.1001/jama.2018.3024","29677303","PMC5933330","Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis.","2018","JAMA","Zheng SL","33","11","6","none found",null],["R0023404",null,null,"10.1016/j.farma.2023.12.004","38341366",null,"Exploring the impact of pharmacogenetics on personalized medicine: A systematic review.","2024","Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria","Amaro-Álvarez L","55","1","1","none found",null],["R0023406",null,null,"10.1016/j.clinre.2020.10.012","33309563",null,"Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials.","2021","Clinics and research in hepatology and gastroenterology","Kalogirou MS","78","22","10","none found",null],["R0023410",null,null,"10.1371/journal.pone.0090963","24614606","PMC3948731","Comparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies to sulphonylurea among diabetes patients in the Asia-Pacific region: a systematic review.","2014","PloS one","Wong MC","53","6","5","none found",null],["R0023422",null,null,"10.1111/obr.13448","35338558","PMC9287009","Prevalence, risk factors, and interventions for obesity in Saudi Arabia: A systematic review.","2022","Obesity reviews : an official journal of the International Association for the Study of Obesity","Salem V","102","6","2","none found",null],["R0023445",null,null,"10.1016/j.jchf.2018.05.021","30196071",null,"Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis.","2018","JACC. Heart failure","Kramer CK","0","0","0","none found",null],["R0023467",null,null,"10.1186/1758-5996-6-73","25006351","PMC4085736","A systematic review and mixed-treatment comparison of dapagliflozin with existing anti-diabetes treatments for those with type 2 diabetes mellitus inadequately controlled by sulfonylurea monotherapy.","2014","Diabetology & metabolic syndrome","Orme M","58","7","1","none found",null],["R0023480",null,null,"10.1177/20503121241308997","39713268","PMC11660270","Effects of SGLT-2 inhibitors on clinical and biological hyperandrogenism and menstruation irregularities in patients with polycystic ovary syndrome: A systematic review of randomized trials.","2024","SAGE open medicine","Mrabet HE","29","1","1","none found",null],["R0023483",null,null,"10.2337/dc13-1210","25504028",null,"Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.","2015","Diabetes care","Jensen TM","49","14","0","none found",null],["R0023488",null,null,"10.2174/1573399816999200821164129","32867644",null,"Systematic Review of Glucagon-Like Peptide One Receptor Agonist Liraglutide of Subjects with Heart Failure with Reduced Left Ventricular Ejection Fraction.","2021","Current diabetes reviews","Hamad F","20","15","8","none found",null],["R0023500",null,null,"10.3389/fendo.2020.541699","33424764","PMC7793753","The Body Weight Alteration and Incidence of Neoplasm in Patients With Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.","2020","Frontiers in endocrinology","Lin C","43","3","0","none found",null],["R0023530",null,null,"10.1097/meg.0000000000002463","36468574",null,"Pharmacotherapeutic efficacy on noninvasive fibrosis progression in nonalcoholic fatty liver disease: a systematic review and network meta-analysis.","2023","European journal of gastroenterology & hepatology","Kovalic AJ","33","1","0","none found",null],["R0023580",null,null,"10.3389/fendo.2020.00070","32153507","PMC7046622","Effect of Weight Loss Medications on Hepatic Steatosis and Steatohepatitis: A Systematic Review.","2020","Frontiers in endocrinology","Pan CS","82","23","18","none found",null],["R0023606",null,null,"10.1097/md.0000000000013710","30572502","PMC6320179","PRISMA-efficacy and safety of lixisenatide for type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.","2018","Medicine","Wei ZG","38","32","21","none found",null],["R0023610",null,null,"10.1016/j.psyneuen.2018.05.010","29775878",null,"Repositioning of diabetes treatments for depressive symptoms: A systematic review and meta-analysis of clinical trials.","2018","Psychoneuroendocrinology","Moulton CD","66","3","1","none found",null],["R0023651",null,null,"10.1186/1475-2840-10-22","21410975","PMC3070629","Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes.","2011","Cardiovascular diabetology","Ratner R","76","29","19","none found",null],["R0023724",null,null,"10.31083/rcm26154","40160590","PMC11951290","Effect of Hypoglycemic Drugs on Patients with Heart Failure with or without T2DM: A Bayesian Network Meta-analysis.","2025","Reviews in cardiovascular medicine","Zhang Z","134","30","16","none found",null],["R0023732",null,null,"10.1002/14651858.cd013178.pub2","37435938","PMC10355254","Interventions for people with type 2 diabetes mellitus fasting during Ramadan.","2023","The Cochrane database of systematic reviews","Lee SWH","76","8","3","none found",null],["R0023756",null,null,"10.1155/2022/1201977","35936066","PMC9325632","Efficacy and Safety of Liraglutide 3.0 mg in Patients with Overweight and Obese with or without Diabetes: A Systematic Review and Meta-Analysis.","2022","International journal of clinical practice","Konwar M","43","26","16","none found",null],["R0023785",null,null,"10.3389/fphar.2021.618208","33854433","PMC8039463","Effect of Liraglutide on Cardiometabolic Risk Profile in People with Coronary Artery Disease with or without Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","2021","Frontiers in pharmacology","Nowrouzi-Sohrabi P","35","30","14","none found",null],["R0023796",null,null,"10.1186/s13098-023-01001-4","36829204","PMC9951503","Metabolic surgery versus usual care effects on diabetes remission: a systematic review and meta-analysis.","2023","Diabetology & metabolic syndrome","Mirghani H","64","5","2","none found",null],["R0023824",null,null,"10.1001/jama.298.2.194","17622601",null,"Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.","2007","JAMA","Amori RE","0","0","0","none found",null],["R0023827",null,null,"10.1111/apt.12149","23163663",null,"Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program.","2013","Alimentary pharmacology & therapeutics","Armstrong MJ","39","18","8","none found",null],["R0023830",null,null,"10.1002/oby.24160","39725567","PMC12198421","Efficacy of antiobesity medications for weight reduction in older adults: a systematic review.","2025","Obesity (Silver Spring, Md.)","Chen AS","45","19","14","none found",null],["R0023833","CRD42016038780",null,"10.1186/s12902-022-01158-5","36261824","PMC9580135","Systematic review and meta-analysis of head-to-head trials comparing sulfonylureas and low hypoglycaemic risk antidiabetic drugs.","2022","BMC endocrine disorders","Volke V","52","10","6","PROSPERO","PROSPERO:CRD42016038780"],["R0023847",null,null,"10.36849/jdd.7325","37556513",null,"Hormonal Treatments in Hidradenitis Suppurativa: A Systematic Review.","2023","Journal of drugs in dermatology : JDD","Masson R","0","0","0","none found",null],["R0023899",null,null,"10.1111/j.2040-1124.2011.00187.x","24843578","PMC4014951","Comparative efficacy and safety of long-acting insulin analogs in patients with type 2 diabetes failing on oral therapy: Systemic review and meta-analyses.","2012","Journal of diabetes investigation","Bi Y","38","5","5","none found",null],["R0023905",null,null,"10.1186/s12995-025-00480-7","41057950","PMC12502539","Prevention and intervention against obesity and overweight in the military: a systematic review.","2025","Journal of occupational medicine and toxicology (London, England)","Scheit L","40","2","1","none found",null],["R0023915",null,null,"10.3390/ph18091276","41011147","PMC12472739","Acetyl-CoA Carboxylase Inhibitors for Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","2025","Pharmaceuticals (Basel, Switzerland)","Hasanatuludhhiyah N","50","6","1","none found",null],["R0023926",null,null,"10.31234/osf.io/y897m_v1",null,null,"Hormonal Dysregulation in Major Depressive Disorder: A Systematic Review","2025","PsyArXiv","Zehtabian K",null,"0","0","none found",null],["R0023931",null,null,"10.1016/j.phrs.2021.105765","34252552",null,"Efficacy and safety of liraglutide in type 2 diabetes mellitus patients complicated with coronary artery disease: A systematic review and meta-analysis of randomized controlled trials.","2021","Pharmacological research","Wang L","0","0","0","none found",null],["R0023947",null,null,"10.1111/ijcp.14367","33998106",null,"Withdrawal: \"Efficacy and safety of liraglutide 3.0 mg in obese diabetic and non-diabetic patients-A systematic review and meta-analysis of randomised controlled trials\" Mahanjit Konwar, Renju Ravi, Miteshkumar Maurya, Debdipta Bose, Sanjeet kumar Jaiswal.","2021","International journal of clinical practice",null,"0","0","0","none found",null],["R0023964",null,null,"10.1007/s13300-021-01072-4","34002333","PMC8179869","Effects of Liraglutide on Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","Song T","51","24","15","none found",null],["R0023975",null,null,"10.1016/j.clinthera.2024.12.013","39843265",null,"Efficacy of Oral Medication in Weight Loss Management: A Systematic Review and Network Meta-Analysis.","2025","Clinical therapeutics","Benedictus B","92","27","5","none found",null],["R0024009",null,null,"10.1002/14651858.cd011798.pub2","30246878","PMC6513625","Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.","2018","The Cochrane database of systematic reviews","Lo C","439","19","13","none found",null],["R0024071",null,null,"10.1155/2021/9993229","34221010","PMC8219465","Effects of Liraglutide on Left Ventricular Function: A Meta-Analysis of Randomized, Placebo-Controlled Trials.","2021","International journal of endocrinology","Zhong Z","45","34","22","none found",null],["R0024090","CRD42024608736",null,"10.25259/ijmr_497_2025","41296583","PMC12744563","Efficacy & safety of sodium-glucose cotransporter-2 inhibitors in polycystic ovary syndrome: A meta-analysis with trial sequential analysis.","2025","The Indian journal of medical research","Ahsan M","21","2","1","PROSPERO","PROSPERO:CRD42024608736"],["R0024111",null,null,"10.1080/10641963.2019.1676771","31610701",null,"Liraglutide reduces systolic blood pressure in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials.","2020","Clinical and experimental hypertension (New York, N.Y. : 1993)","Zhao D","53","36","26","none found",null],["R0024196",null,null,"10.2174/1573399815666190614141918","31203802",null,"Liraglutide as Adjunct to Insulin Treatment in Patients with Type 1 Diabetes: A Systematic Review and Meta-analysis.","2020","Current diabetes reviews","Dimitrios P","108","67","24","none found",null],["R0024217",null,null,null,"25997251",null,"The efficacy of placebo-adjusted taspoglutide on body weight reduction in clinical trials.","2015","Die Pharmazie","Li HQ","0","0","0","none found",null],["R0024248",null,null,"10.62347/gwmp1676","40225998","PMC11982837","Acupuncture and moxibustion as effective treatments for simple obesity in children: a meta-analysis.","2025","American journal of translational research","Cui F","36","1","0","none found",null],["R0024264",null,null,"10.4314/ahs.v19i3.35","32127832","PMC7040262","The efficacy and safety of liraglutide in the obese, non-diabetic individuals: a systematic review and meta-analysis.","2019","African health sciences","Zhang P","23","9","8","none found",null],["R0024290",null,null,"10.1016/j.jsps.2014.11.008","26106272","PMC4475818","Utilization of model-based meta-analysis to delineate the net efficacy of taspoglutide from the response of placebo in clinical trials.","2015","Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society","Li HQ","28","13","9","none found",null],["R0024354",null,null,"10.18433/j3g883","22365085",null,"The efficacy and tolerability of exenatide in comparison to placebo; a systematic review and meta-analysis of randomized clinical trials.","2012","Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques","Nikfar S","0","0","0","none found",null],["R0024386",null,null,"10.7326/m15-2650","27088241",null,"Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis.","2016","Annals of internal medicine","Maruthur NM","64","3","1","none found",null],["R0024475",null,null,"10.1016/j.jval.2014.08.010","27202544",null,"Impact of Glp-1RA on Heart Rate, Blood Pressure and Hypertension Among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.","2014","Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","Sun F","0","0","0","none found",null],["R0024483",null,null,"10.1507/endocrj.ej19-0530","31996492",null,"Analysis of the effect of liraglutide on glycemic variability in patients with type 2 diabetes.","2020","Endocrine journal","Xing Y","0","0","0","none found",null],["R0024498",null,null,"10.1185/03007995.2015.1135110","26700585",null,"Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea.","2016","Current medical research and opinion","Lozano-Ortega G","55","8","7","none found",null],["R0024512",null,null,"10.1177/09603271241290922","39378909",null,"Discovering the most impactful treatments for aluminum phosphide cardiotoxicity gleaned from systematic review of animal studies.","2024","Human & experimental toxicology","Aghebat-Bekheir S","91","1","0","none found",null],["R0024556",null,null,"10.2174/1574886315999200819150544","32819262",null,"Efficacy and Cardiovascular Safety of DPP-4 Inhibitors.","2021","Current drug safety","Subrahmanyan NA","0","0","0","none found",null],["R0024568",null,null,"10.3389/fendo.2022.1003263","36353233","PMC9637657","Comparison of efficacy and safety of three novel hypoglycemic agents in patients with severe diabetic kidney disease: A systematic review and network meta-analysis of randomized controlled trials.","2022","Frontiers in endocrinology","Li Y","44","8","3","none found",null],["R0024591",null,null,"10.3892/etm.2019.7577","31258671","PMC6566113","Meta-analysis of the efficacy of liraglutide in patients with type 2 diabetes accompanied by incipient nephropathy.","2019","Experimental and therapeutic medicine","Liu W","16","8","3","none found",null],["R0024596",null,null,"10.1532/hsf.2513","31895026",null,"The Influence of Liraglutide for Heart Failure: A Meta-Analysis of Randomized Controlled Trials.","2019","The heart surgery forum","Zhang Y","0","0","0","none found",null],["R0024621",null,null,null,null,"PMC9624984","ODP240 Routine Glucose-lowering Therapies and Risk of Adverse Outcomes in COVID-19 Patients with Diabetes: a Network Meta-analysis","2022","Journal of the Endocrine Society",null,"0","0","0","none found",null],["R0024685",null,null,"10.1002/cpt.2130","33280092",null,"Characterizing Effects of Antidiabetic Drugs on Heart Rate, Systolic and Diastolic Blood Pressure.","2021","Clinical pharmacology and therapeutics","Maringwa J","18","5","2","none found",null],["R0024692",null,null,"10.1136/bmj.g2366","24736555","PMC3987051","Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies.","2014","BMJ (Clinical research ed.)","Li L","77","47","28","none found",null],["R0024752",null,null,"10.1111/dom.13232","29369494",null,"Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network meta-analysis.","2018","Diabetes, obesity & metabolism","Tang H","76","24","19","none found",null],["R0024760",null,null,"10.1155/2019/4951379","31871617","PMC6906831","Analysis of the Relationship between Type II Diabetes Mellitus and Parkinson's Disease: A Systematic Review.","2019","Parkinson's disease","Camargo Maluf F","174","17","5","none found",null],["R0024853",null,null,"10.1136/bmj.e1369","22411919",null,"Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.","2012","BMJ (Clinical research ed.)","Karagiannis T","0","0","0","none found",null],["R0024857",null,null,"10.1002/14651858.cd012906.pub2","32501595","PMC7386876","Metformin monotherapy for adults with type 2 diabetes mellitus.","2020","The Cochrane database of systematic reviews","Gnesin F","159","15","5","none found",null],["R0024874",null,null,"10.2174/1381612825666190701155737","31267857",null,"Liraglutide for the Treatment of Obesity: Analyzing Published Reviews.","2019","Current pharmaceutical design","Pastor R","0","0","0","none found",null],["R0024881",null,null,"10.1136/bmjopen-2018-023458","31340953","PMC6661926","Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature review and network meta-analysis.","2019","BMJ open","Kanters S","54","12","5","none found",null],["R0024936",null,null,"10.1007/s13300-020-00975-y","33313996","PMC7843850","Comparative Efficacy of Dual and Single Initiation of Add-On Oral Antihyperglycemic Agents in Type 2 Diabetes Uncontrolled on Metformin Alone: A Systematic Literature Review and Network Meta-Analysis.","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","Lautsch D","43","7","2","none found",null],["R0024967",null,null,"10.1111/dme.14678","34432914",null,"Individual, healthcare professional and system-level barriers and facilitators to initiation and adherence to injectable therapies for type 2 diabetes: A systematic review and meta-ethnography.","2022","Diabetic medicine : a journal of the British Diabetic Association","Byrne J","22","0","0","none found",null],["R0025007","CRD42020221951",null,"10.1016/j.arcmed.2021.08.002","34412904","PMC8349690","Association Between Anti-diabetic Agents and Clinical Outcomes of COVID-19 in Patients with Diabetes: A Systematic Review and Meta-Analysis.","2022","Archives of medical research","Han T","68","4","0","PROSPERO","PROSPERO:CRD42020221951"],["R0025066",null,null,"10.1111/cen.14623","34713480",null,"Impact of pharmacological interventions on insulin resistance in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials.","2022","Clinical endocrinology","Abdalla MA","0","0","0","none found",null],["R0025074",null,null,"10.1159/000510677","33080602",null,"Antidiabetic Drugs in Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review.","2020","Dementia and geriatric cognitive disorders","Muñoz-Jiménez M","60","9","4","none found",null],["R0025092",null,null,"10.1371/journal.pone.0125879","25919293","PMC4412636","Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis.","2015","PloS one","Mearns ES","73","12","10","none found",null],["R0025162",null,null,"10.3390/ijerph17134805","32635358","PMC7369739","Antidiabetic Agents for Treatment of Parkinson's Disease: A Meta-Analysis.","2020","International journal of environmental research and public health","Wang SY","38","16","4","none found",null],["R0025165",null,null,"10.1002/jcp.27097","30145806",null,"Efficacy of different antidiabetic drugs based on metformin in the treatment of type 2 diabetes mellitus: A network meta-analysis involving eight eligible randomized-controlled trials.","2019","Journal of cellular physiology","Peng Y","30","5","3","none found",null],["R0025171",null,null,"10.1186/s13098-016-0151-7","27252787","PMC4888474","Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta-analysis.","2016","Diabetology & metabolic syndrome","Seino H","26","10","5","none found",null],["R0025185",null,null,"10.1007/s40273-023-01268-5","37410277","PMC10570198","A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus.","2023","PharmacoEconomics","Laursen HVB","107","51","9","none found",null],["R0025200",null,null,"10.1007/s00059-018-4748-5","30467578",null,"Efficacy of liraglutide intervention in myocardial infarction : A meta-analysis of randomized controlled trials.","2020","Herz","Yang X","33","9","6","none found",null],["R0025212",null,null,"10.1007/s40273-014-0192-4","25052903",null,"Cost effectiveness of liraglutide in type II diabetes: a systematic review.","2014","PharmacoEconomics","Zueger PM","29","21","11","none found",null],["R0025267","CRD42013005149",null,"10.1111/dom.12465","25772666",null,"Incretin-based medications for type 2 diabetes: an overview of reviews.","2015","Diabetes, obesity & metabolism","Gamble JM","30","6","0","PROSPERO","PROSPERO:CRD42013005149"],["R0025283",null,null,"10.1016/j.genhosppsych.2024.06.003","38878592",null,"Pharmacological interventions for antipsychotic-induced weight gain in schizophrenia: A network meta-analysis.","2024","General hospital psychiatry","Hegde NC","94","8","4","none found",null],["R0025290",null,null,"10.1016/j.diabres.2020.108562","33271228",null,"Efficacy and safety of the newer oral hypoglycemic agents in patients with T2DM during Ramadan: A systematic review and meta-analysis.","2021","Diabetes research and clinical practice","Gad H","51","9","3","none found",null],["R0025300",null,null,"10.1007/s40618-019-01110-w","31515744",null,"Predictors of early discontinuation of dapagliflozin versus other glucose-lowering medications: a retrospective multicenter real-world study.","2020","Journal of endocrinological investigation","Fadini GP","20","8","1","none found",null],["R0025308","CRD42017076625",null,"10.1111/obr.12720","30066361",null,"Pharmacologic therapy to induce weight loss in women who have obesity/overweight with polycystic ovary syndrome: a systematic review and network meta-analysis.","2018","Obesity reviews : an official journal of the International Association for the Study of Obesity","Wang FF","71","8","6","PROSPERO","PROSPERO:CRD42017076625"],["R0025398",null,null,"10.1097/md.0000000000008161","28953663","PMC5626306","Efficacy and safety of liraglutide versus sitagliptin both in combination with metformin in patients with type 2 diabetes: A systematic review and meta-analysis.","2017","Medicine","Li M","35","15","9","none found",null],["R0025421",null,null,"10.1186/s13643-019-1200-8","31783920","PMC6884753","Diabetes drugs for nonalcoholic fatty liver disease: a systematic review.","2019","Systematic reviews","Blazina I","23","4","2","none found",null],["R0025433",null,null,"10.1016/j.numecd.2020.12.030","33618919",null,"Efficacy and safety of glucose-lowering agents in patients with type 2 diabetes: A network meta-analysis of randomized, active comparator-controlled trials.","2021","Nutrition, metabolism, and cardiovascular diseases : NMCD","Mannucci E","31","18","6","none found",null],["R0025435",null,null,"10.5603/ep.a2021.0031","34010433",null,"Evaluation of the risk of fracture in type 2 diabetes mellitus patients with incretins: an updated meta-analysis.","2021","Endokrynologia Polska","Kong QX","0","0","0","none found",null],["R0025436",null,null,"10.1016/j.dsx.2019.02.005","31336501",null,"A systematic review on efficacy and safety of the current hypoglycemic agents in patients with diabetes during Ramadan fasting.","2019","Diabetes & metabolic syndrome","Rashid F","75","5","2","none found",null],["R0025478",null,null,"10.1016/j.numecd.2020.11.031","33549430",null,"Effect of metformin on all-cause mortality and major adverse cardiovascular events: An updated meta-analysis of randomized controlled trials.","2021","Nutrition, metabolism, and cardiovascular diseases : NMCD","Monami M","23","6","0","none found",null],["R0025525","CRD42018087336",null,"10.1016/j.diabres.2021.108688","33549676",null,"All-cause mortality and cardiovascular safety of basal insulin treatment in patients with type 2 diabetes mellitus: A systematic review with meta-analysis and trial sequential analysis.","2021","Diabetes research and clinical practice","Rados DV","0","0","0","PROSPERO","PROSPERO:CRD42018087336"],["R0025534",null,null,"10.1097/mjt.0000000000001088","31567175",null,"Insulin Therapy in Type 2 Diabetes.","2020","American journal of therapeutics","Aschner P","88","10","0","none found",null],["R0025593",null,null,"10.1093/bjd/ljae228","38819233",null,"The Dermatology Life Quality Index as the primary outcome in randomized clinical trials: a systematic review.","2024","The British journal of dermatology","Johns JR","78","1","1","none found",null],["R0025616",null,null,"10.1186/s13098-021-00733-5","34663429","PMC8522222","The best drug supplement for obesity treatment: a systematic review and network meta-analysis.","2021","Diabetology & metabolic syndrome","Salari N","60","11","6","none found",null],["R0025617",null,null,"10.1080/03007995.2018.1476332","29764222",null,"Comparative efficacy of once-weekly semaglutide and SGLT-2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic literature review and network meta-analysis.","2018","Current medical research and opinion","Sharma R","42","9","2","none found",null],["R0025665",null,null,"10.1007/s13300-016-0217-4","27995594","PMC5306116","Liraglutide Versus SGLT-2 Inhibitors in People with Type 2 Diabetes: A Network Meta-Analysis.","2017","Diabetes therapy : research, treatment and education of diabetes and related disorders","Lorenzi M","32","8","2","none found",null],["R0025696",null,null,"10.1111/dom.12617","26662611","PMC5067695","Improvement in glycated haemoglobin evaluated by baseline body mass index: a meta-analysis of the liraglutide phase III clinical trial programme.","2016","Diabetes, obesity & metabolism","Montanya E","13","12","9","none found",null],["R0025734",null,null,"10.2174/1871529x18666180206160838","29412124",null,"Sodium-glucose Cotransporter 2 Inhibitors: Glucose Lowering Against other Hypoglycemic Agents.","2018","Cardiovascular & hematological disorders drug targets","Avranas K","0","0","0","none found",null],["R0025744",null,null,"10.33588/rn.5911.2014023","25418147",null,"[Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimer's disease?].","2014","Revista de neurologia","García-Casares N","0","0","0","none found",null],["R0025760",null,null,"10.1111/ijpo.13113","38454737",null,"Pharmacological interventions for the management of children and adolescents living with obesity-An update of a Cochrane systematic review with meta-analyses.","2024","Pediatric obesity","Torbahn G","107","12","6","none found",null],["R0025772",null,null,"10.1016/j.diabres.2022.109824","35271879",null,"The cardiovascular benefits of GLP1-RAs are related to their positive effect on glycemic control: A meta-regression analysis.","2022","Diabetes research and clinical practice","Ghosal S",null,"0","0","none found",null],["R0025809",null,null,"10.1016/j.dsx.2015.08.008","26341928",null,"Evaluation of unmet medical need among Japanese patients with type 2 diabetes mellitus and efficacy of Lixisenatide treatment among Asian type 2 diabetes mellitus patients.","2016","Diabetes & metabolic syndrome","Terauchi Y","21","7","3","none found",null],["R0025816",null,null,"10.1080/07853890.2017.1306653","28286967",null,"Protective effect of glucagon-like peptide-1 agents on reperfusion injury for acute myocardial infarction: a meta-analysis of randomized controlled trials.","2017","Annals of medicine","Huang M","31","11","7","none found",null],["R0025843",null,null,null,"37323046",null,"[Prevention and treatment of antipsychotic induced weight gain].","2023","Tijdschrift voor psychiatrie","Veerman SRT","0","0","0","none found",null],["R0025849",null,null,"10.3310/hta14360","20646668",null,"Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.","2010","Health technology assessment (Winchester, England)","Waugh N","0","0","0","none found",null],["R0025876",null,null,"10.4158/ep.17.6.906","22193143",null,"Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program.","2011","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Henry RR","19","10","9","none found",null],["R0025877",null,null,"10.1111/dom.12623","26679282","PMC5324626","Impact of diabetes duration on achieved reductions in glycated haemoglobin, fasting plasma glucose and body weight with liraglutide treatment for up to 28 weeks: a meta-analysis of seven phase III trials.","2016","Diabetes, obesity & metabolism","Seufert J","12","11","9","none found",null],["R0025880",null,null,"10.1111/j.1463-1326.2011.01512.x","21958121",null,"Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients.","2012","Diabetes, obesity & metabolism","Esposito K","16","2","0","none found",null],["R0025922",null,null,"10.1111/j.1463-1326.2012.01606.x","22486990",null,"Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis.","2012","Diabetes, obesity & metabolism","Liu SC","53","10","8","none found",null],["R0025932",null,null,"10.1111/ijcp.13274","30295381",null,"The role of glucagon in the possible mechanism of cardiovascular mortality reduction in type 2 diabetes patients.","2018","International journal of clinical practice","Skelin M","82","12","9","none found",null],["R0025934","CRD42022341966",null,"10.3389/fcvm.2022.990182","36119737","PMC9472131","Optimal dose of tirzepatide for type 2 diabetes mellitus: A meta-analysis and trial sequential analysis.","2022","Frontiers in cardiovascular medicine","Yu Y","51","27","11","PROSPERO","PROSPERO:CRD42022341966"],["R0026006",null,null,"10.3389/fgene.2021.675053","34194474","PMC8236944","The Genetics of Adverse Drug Outcomes in Type 2 Diabetes: A Systematic Review.","2021","Frontiers in genetics","Baye AM","55","2","0","none found",null],["R0026012",null,null,"10.1186/s12911-021-01516-8","34016120","PMC8139150","Surrogate endpoint evaluation using data from one large global randomized controlled trial.","2021","BMC medical informatics and decision making","Geybels M","22","3","1","none found",null],["R0026030",null,null,"10.1185/03007995.2014.921608","24805140",null,"The effect of a dual combination of noninsulin antidiabetic drugs on lipids: a systematic review and network meta-analysis.","2014","Current medical research and opinion","Dai X","46","5","3","none found",null],["R0026103",null,null,"10.1177/2050312116659090","27516879","PMC4968114","An updated systematic review and meta-analysis on the efficacy and tolerability of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes with moderate to severe chronic kidney disease.","2016","SAGE open medicine","Singh-Franco D","48","2","2","none found",null],["R0026156",null,null,"10.3389/fendo.2019.00455","31354627","PMC6639788","Effects of Lifestyle Modification and Anti-diabetic Medicine on Prediabetes Progress: A Systematic Review and Meta-Analysis.","2019","Frontiers in endocrinology","Sheng Z","48","1","1","none found",null],["R0026177",null,null,"10.1080/03007995.2017.1345730","28635331",null,"Network meta-analysis of liraglutide versus dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes in Japanese patients.","2017","Current medical research and opinion","Ayers D","70","17","6","none found",null],["R0026179",null,null,"10.1177/1060028019898912","31958967",null,"Pharmacological Treatment for Obesity in Adults: An Umbrella Review.","2020","The Annals of pharmacotherapy","Khalil H","36","11","1","none found",null],["R0026242",null,null,"10.1007/s12325-014-0164-2","25388240",null,"Liraglutide for the treatment of type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials.","2014","Advances in therapy","Du Q","37","18","12","none found",null],["R0026357",null,null,"10.1136/bmjopen-2020-040644","32928868","PMC7490921","Currently prescribed drugs in the UK that could upregulate or downregulate ACE2 in COVID-19 disease: a systematic review.","2020","BMJ open","Dambha-Miller H","102","2","0","none found",null],["R0026369",null,null,"10.1101/2020.05.19.20106856",null,null,"Currently prescribed drugs in the UK that could up or downregulate ACE2 in COVID-19 disease: A systematic review","2020","medRxiv","Dambha-Miller H",null,"0","0","none found",null],["R0026427",null,null,"10.1016/j.jphs.2014.12.004","25727954",null,"Target-mediated pharmacokinetic/pharmacodynamic model based meta-analysis and dosing regimen optimization of a long-acting release formulation of exenatide in patients with type 2 diabetes mellitus.","2015","Journal of pharmacological sciences","Li H","37","20","9","none found",null],["R0026460","CRD42020183541",null,"10.1186/s12958-023-01075-9","36869381","PMC9983155","The effects of first-line pharmacological treatments for reproductive outcomes in infertile women with PCOS: a systematic review and network meta-analysis.","2023","Reproductive biology and endocrinology : RB&E","Peng G","44","4","1","PROSPERO","PROSPERO:CRD42020183541"],["R0026524",null,null,"10.1111/fcp.12263","28036112",null,"Protocol of GLUcose COntrol Safety and Efficacy in type 2 DIabetes, a NETwork meta-analysis: GLUCOSE DINET protocol-Rational and design.","2017","Fundamental & clinical pharmacology","Grenet G","29","6","2","none found",null],["R0026614",null,null,"10.1111/dom.12239","24237939",null,"Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis.","2014","Diabetes, obesity & metabolism","Goring S","58","7","2","none found",null],["R0026671",null,null,"10.1016/j.jad.2019.05.044","31153593",null,"A systematic review of the antidepressant effects of glucagon-like peptide 1 (GLP-1) functional agonists: Further link between metabolism and psychopathology: Special Section on \"Translational and Neuroscience Studies in Affective Disorders\". Section Editor, Maria Nobile MD, PhD. This Section of JAD focuses on the relevance of translational and neuroscience studies in providing a better understanding of the neural basis of affective disorders. The main aim is to briefly summaries relevant research findings in clinical neuroscience with particular regards to specific innovative topics in mood and anxiety disorders.","2019","Journal of affective disorders","Pozzi M","26","10","5","none found",null],["R0026679",null,null,"10.3390/pharmacy6030057","29954090","PMC6164486","Systematic Review of Efficacy and Safety of Newer Antidiabetic Drugs Approved from 2013 to 2017 in Controlling HbA1c in Diabetes Patients.","2018","Pharmacy (Basel, Switzerland)","Palanisamy S","86","39","33","none found",null],["R0026681",null,null,"10.1007/s13300-018-0443-z","29808360","PMC6064594","Meta-Analysis of Sulfonylurea Therapy on Long-Term Risk of Mortality and Cardiovascular Events Compared to Other Oral Glucose-Lowering Treatments.","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","Powell WR","13","1","0","none found",null],["R0026683",null,null,"10.1111/cob.12294","30677252",null,"Incremental cost-effectiveness of evidence-based non-surgical weight loss strategies.","2019","Clinical obesity","Finkelstein EA","51","2","2","none found",null],["R0026693",null,null,"10.1111/obr.13326","34423889","PMC9285776","Clinical outcomes associated with anti-obesity medications in real-world practice: A systematic literature review.","2021","Obesity reviews : an official journal of the International Association for the Study of Obesity","Ahmad NN","52","7","1","none found",null],["R0026728",null,null,"10.2174/1381612823666170519144841","28741456",null,"Effects of Oral and Non-Insulin Injectable Antidiabetic Treatment in Hypertension: A Systematic Review.","2017","Current pharmaceutical design","Katsi V","0","0","0","none found",null],["R0026741",null,null,"10.1080/14656566.2016.1202921","27322963",null,"Efficacy of hypoglycemic treatment in type 2 diabetes stratified by age or diagnosed age: a meta-analysis.","2016","Expert opinion on pharmacotherapy","Cai X","29","3","2","none found",null],["R0026757",null,null,"10.1001/jama.2016.7602","27299618","PMC5617638","Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.","2016","JAMA","Khera R","48","3","3","none found",null],["R0026810","CRD42021287205",null,"10.1016/j.numecd.2022.07.001","35970684",null,"Effect of pharmacological interventions and placebo on liver Histology in nonalcoholic steatohepatitis: A network meta-analysis.","2022","Nutrition, metabolism, and cardiovascular diseases : NMCD","Pennisi G","63","4","0","PROSPERO","PROSPERO:CRD42021287205"],["R0026883",null,null,"10.1016/s2213-8587(20)30038-3","32333878",null,"Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials.","2020","The lancet. Diabetes & endocrinology","Ghosh-Swaby OR","48","12","12","none found",null],["R0026944",null,null,null,"22046219","PMC3205809","Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis.","2011","Open medicine : a peer-reviewed, independent, open-access journal","McIntosh B","87","11","7","none found",null],["R0026965",null,null,"10.1111/j.1463-1326.2011.01533.x","22074017",null,"The effects of exenatide bid on metabolic control, medication use and hospitalization in patients with type 2 diabetes mellitus in clinical practice: a systematic review.","2012","Diabetes, obesity & metabolism","Best JH","32","29","16","none found",null],["R0026978",null,null,"10.5664/jcsm.9326","34743790","PMC8636345","Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment.","2021","Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine","Maski K","111","1","0","none found",null],["R0027002",null,null,"10.1016/j.biopha.2017.05.002","28586742",null,"A network meta-analysis for efficacy and safety of seven regimens in the treatment of type II diabetes.","2017","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","Wang LG","50","6","3","none found",null],["R0027019",null,null,"10.1210/jc.2014-3421","25590213","PMC5393509","Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis.","2015","The Journal of clinical endocrinology and metabolism","Domecq JP","44","3","1","none found",null],["R0027035",null,null,"10.1111/dom.12297","24702687",null,"A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position.","2014","Diabetes, obesity & metabolism","Giorda CB","68","21","0","none found",null],["R0027063",null,null,"10.1097/md.0000000000002457","26765440","PMC4718266","Strategies to Make Ramadan Fasting Safer in Type 2 Diabetics: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials and Observational Studies.","2016","Medicine","Lee SWH","41","4","1","none found",null],["R0027080",null,null,"10.1002/jcph.781","27277818",null,"Exploratory Literature Meta-Analysis to Characterize the Relationship Between Early and Longer Term Body Weight Loss for Antiobesity Compounds.","2017","Journal of clinical pharmacology","Plock N","116","18","16","none found",null],["R0027132",null,null,"10.1371/journal.pone.0197321","29787616","PMC5963790","Efficacy and safety of saxagliptin in patients with type 2 diabetes: A systematic review and meta-analysis.","2018","PloS one","Men P","114","6","2","none found",null],["R0027134",null,null,"10.4158/ep10215.ra","21700561",null,"Mild renal impairment and the efficacy and safety of liraglutide.","2011","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","Davidson JA","35","10","8","none found",null],["R0027182",null,null,"10.3310/hta15380","22059955","PMC4781160","Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.","2011","Health technology assessment (Winchester, England)","Shyangdan D","0","0","0","none found",null],["R0027195",null,null,"10.1111/j.1464-5491.2009.02790.x","19719703",null,"Exenatide efficacy and safety: a systematic review.","2009","Diabetic medicine : a journal of the British Diabetic Association","Norris SL","45","26","16","none found",null],["R0027218",null,null,"10.1186/s12933-017-0512-z","28249585","PMC5333444","Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.","2017","Cardiovascular diabetology","Zhang Z","68","23","8","none found",null],["R0027270",null,null,"10.21037/jtd-22-550","35693625","PMC9186250","The effectiveness of SGLT2 inhibitor in the incidence of atrial fibrillation/atrial flutter in patients with type 2 diabetes mellitus/heart failure: a systematic review and meta-analysis.","2022","Journal of thoracic disease","Wang M","19","1","1","none found",null],["R0027330",null,null,"10.1080/17512433.2020.1698291","31770497",null,"Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs.","2020","Expert review of clinical pharmacology","Singh AK","57","7","7","none found",null],["R0027359",null,null,"10.1111/dme.12837","26104021",null,"Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in Type 2 diabetes: a network meta-analysis.","2015","Diabetic medicine : a journal of the British Diabetic Association","Mearns ES","45","5","3","none found",null],["R0027373",null,null,"10.1111/dme.12301","24073725",null,"The potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential (cardiovascular) benefits.","2013","Diabetic medicine : a journal of the British Diabetic Association","Ryder RE","56","19","4","none found",null],["R0027374",null,null,null,"23696771","PMC3659216","Choice of therapy in patients with type 2 diabetes inadequately controlled with metformin and a sulphonylurea: a systematic review and mixed-treatment comparison meta-analysis.","2012","Open medicine : a peer-reviewed, independent, open-access journal","McIntosh B","70","13","7","none found",null],["R0027378",null,null,"10.1345/aph.1l198","18957626",null,"Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.","2008","The Annals of pharmacotherapy","Pinelli NR","43","7","6","none found",null],["R0027438",null,null,"10.1111/dom.14304","33368954",null,"Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: A hierarchical network meta-analysis.","2021","Diabetes, obesity & metabolism","Panunzi S","36","1","1","none found",null],["R0027473",null,null,"10.2174/157339908786241133","18991602",null,"The effects of medications used for the management of diabetes and obesity on postprandial lipid metabolism.","2008","Current diabetes reviews","Eleftheriadou I","0","0","0","none found",null],["R0027477",null,null,"10.1001/jama.2016.9400","27434443",null,"Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis.","2016","JAMA","Palmer SC","0","0","0","none found",null],["R0027481","CRD42018085967",null,"10.1111/dom.13373","29790638",null,"Comparative efficacy and acceptability of antidiabetic agents for Alzheimer's disease and mild cognitive impairment: A systematic review and network meta-analysis.","2018","Diabetes, obesity & metabolism","Cao B","15","1","0","PROSPERO","PROSPERO:CRD42018085967"],["R0027505",null,null,"10.1007/s00592-012-0370-9","24809070",null,"A nomogram to estimate the proportion of patients at hemoglobin A1c target <7% with noninsulin antidiabetic drugs in type 2 diabetes: a systematic review of 137 randomized controlled trials with 39,845 patients.","2014","Acta diabetologica","Esposito K","22","4","0","none found",null],["R0027524",null,null,"10.1016/j.clinthera.2014.06.035","25109773",null,"Assessment of the relative effectiveness and tolerability of treatments of type 2 diabetes mellitus: a network meta-analysis.","2014","Clinical therapeutics","Zintzaras E","28","3","0","none found",null],["R0027525","CRD42018086446",null,"10.1016/j.smrv.2019.04.009","31075665",null,"Efficacy of pharmacotherapy for OSA in adults: A systematic review and network meta-analysis.","2019","Sleep medicine reviews","Gaisl T","96","1","1","PROSPERO","PROSPERO:CRD42018086446"],["R0027595","CRD42016039486",null,"10.1053/j.gastro.2017.12.024","29305933","PMC5880739","Effects of Weight-Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-analysis.","2018","Gastroenterology","Khera R","54","5","4","PROSPERO","PROSPERO:CRD42016039486"],["R0027650",null,null,"10.1001/jama.2010.405","20388897",null,"Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes.","2010","JAMA","Phung OJ","0","0","0","none found",null],["R0027729",null,null,null,"23862772","PMC3462437","Diabetes: glycaemic control in type 2 (drug treatments).","2012","BMJ clinical evidence","Gorter KJ","201","19","15","none found",null],["R0027755",null,null,"10.1016/s1499-2671(09)33072-5","25998594",null,"Reductions in lipids and CV risk markers in patients with type 2 diabetes treated with liraglutide: a meta-analysis.","2009","Canadian journal of diabetes","Plutzky J","0","0","0","none found",null],["R0027769",null,null,"10.1016/j.soard.2019.04.029","31201113",null,"Meta-analysis of metabolic surgery versus medical treatment for macrovascular complications and mortality in patients with type 2 diabetes.","2019","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","Billeter AT","39","1","1","none found",null],["R0027771",null,null,"10.1002/14651858.cd007654.pub4","26934640",null,"Long-term effects of weight-reducing drugs in people with hypertension.","2016","The Cochrane database of systematic reviews","Siebenhofer A","196","4","1","none found",null],["R0027808",null,null,"10.1111/j.1742-1241.2012.03006.x","22925173","PMC3506736","Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations.","2012","International journal of clinical practice","Pencek R","11","10","9","none found",null],["R0027866",null,null,"10.1002/14651858.cd012650.pub2","33765343","PMC8094444","Pharmacological and non-pharmacological strategies for obese women with subfertility.","2021","The Cochrane database of systematic reviews","Taghavi SA","122","2","2","none found",null],["R0027875",null,null,"10.1002/14651858.cd009966.pub3","32803882","PMC8477618","Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.","2020","The Cochrane database of systematic reviews","Lo C","112","8","5","none found",null],["R0027933",null,null,"10.18553/jmcp.2012.18.s1-a.1","22313233","PMC10437459","AHRQ's comparative effectiveness research on oral medications for type 2 diabetes: a summary of the key findings.","2012","Journal of managed care pharmacy : JMCP","Bennett WL","0","0","0","none found",null],["R0027951",null,null,"10.1002/14651858.cd012368.pub2","30998259","PMC6472662","Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus.","2019","The Cochrane database of systematic reviews","Madsen KS","259","41","22","none found",null],["R0028010",null,null,"10.1002/14651858.cd010211.pub3","28836274","PMC6483533","Interconception care for women with a history of gestational diabetes for improving maternal and infant outcomes.","2017","The Cochrane database of systematic reviews","Tieu J","48","0","0","none found",null],["R0028050",null,null,"10.1002/14651858.cd007654.pub5","33454957","PMC8094237","Long-term effects of weight-reducing drugs in people with hypertension.","2021","The Cochrane database of systematic reviews","Siebenhofer A","134","17","9","none found",null],["R0028116",null,null,"10.1002/14651858.cd012436","27899001","PMC6472619","Drug interventions for the treatment of obesity in children and adolescents.","2016","The Cochrane database of systematic reviews","Mead E","245","6","3","none found",null],["R0028119",null,null,null,"30354042",null,"Behavioral and Pharmacotherapy Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: An Updated Systematic Review for the U.S. Preventive Services Task Force","2018","Agency for Healthcare Research and Quality (US), Rockville (MD)","LeBlanc EL","0","0","0","none found",null],["R0028385",null,null,"10.1016/j.beem.2007.08.002","18054741",null,"Pharmaco-economic issues for diabetes therapy.","2007","Best practice & research. Clinical endocrinology & metabolism","Bottomley JM",null,"0","0","none found",null],["R0028489",null,null,"10.1111/eci.13377","32914429",null,"Effects of antidiabetic drugs on psoriasis: A meta-analysis.","2021","European journal of clinical investigation","Chi CC",null,"0","0","none found",null],["R0028498",null,null,"10.1016/j.phrs.2020.105052","32650058",null,"Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists.","2020","Pharmacological research","Berra C",null,"0","0","none found",null],["R0028598",null,null,"10.1016/j.diabres.2019.02.014","30794833",null,"Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure.","2019","Diabetes research and clinical practice","Sinha B",null,"0","0","none found",null],["R0028658",null,null,"10.1111/cpf.12526","29808958",null,"Cardiometabolic effects of antidiabetic drugs in non-alcoholic fatty liver disease.","2019","Clinical physiology and functional imaging","Rix I",null,"0","0","none found",null],["R0028700",null,null,"10.1016/j.burns.2017.09.013","29029859",null,"Intensive insulin therapy, insulin sensitisers and insulin secretagogues for burns: A systematic review of effectiveness and safety.","2018","Burns : journal of the International Society for Burn Injuries","Campbell JM",null,"0","0","none found",null],["R0028804",null,null,"10.1136/ebmed-2015-110374","26912572",null,"Importance and methods of searching for E-publications ahead of print in systematic reviews.","2016","Evidence-based medicine","Thompson JC",null,"0","0","none found",null],["R0028873",null,null,"10.1210/clinem/dgad356","37329216","PMC10735305","Adipose Tissue Dysfunction in Polycystic Ovary Syndrome.","2023","The Journal of clinical endocrinology and metabolism","Bril F",null,"0","0","none found",null],["R0028884",null,null,"10.3390/ijms24076192","37047163","PMC10094585","Systematic Review and Meta-Analysis of the Impact of Bariatric Surgery on Future Cancer Risk.","2023","International journal of molecular sciences","Wilson RB",null,"0","0","none found",null],["R0028890",null,null,"10.1111/eci.13997","37002856",null,"Meta-analysis of factors associated with antidiabetic drug prescribing for type 2 diabetes mellitus.","2023","European journal of clinical investigation","Mahmoud F",null,"0","0","none found",null],["R0028936",null,null,"10.1016/j.diabres.2022.110082","36122867",null,"Risk of fracture caused by anti-diabetic drugs in individuals with type 2 diabetes: A network meta-analysis.","2022","Diabetes research and clinical practice","Tsai WH",null,"0","0","none found",null],["R0028960","CRD42020213127",null,"10.3389/fcvm.2022.876795","35571207","PMC9098935","Glucose-Lowering and the Risk of Cardiovascular Events With Antidiabetic Therapies: A Systematic Review and Additive-Effects Network Meta-Analysis.","2022","Frontiers in cardiovascular medicine","de Carvalho LSF",null,"0","0","PROSPERO","PROSPERO:CRD42020213127"],["R0028976",null,null,"10.3389/fendo.2021.825100","35082762","PMC8785330","Commentary: Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis.","2021","Frontiers in endocrinology","Zhao LM",null,"0","0","none found",null],["R0028989",null,null,"10.1111/dom.14603","34779107","PMC9299643","Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: A systematic literature review.","2022","Diabetes, obesity & metabolism","Evans M",null,"0","0","none found",null],["R0029002",null,null,"10.1016/j.phrs.2021.105862","34481073",null,"Comment on \"SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies\".","2021","Pharmacological research","Qiu M",null,"0","0","none found",null],["R0029009","CRD42020223435",null,"10.1371/journal.pone.0255726","34383800","PMC8360366","GLP-1 and GIP receptor agonists in the treatment of Parkinson's disease: Translational systematic review and meta-analysis protocol of clinical and preclinical studies.","2021","PloS one","Vaccari C",null,"0","0","PROSPERO","PROSPERO:CRD42020223435"],["R0029051",null,null,"10.1371/journal.pmed.1004553","40193407","PMC12052138","Frailty in randomized controlled trials of glucose-lowering therapies for type 2 diabetes: An individual participant data meta-analysis of frailty prevalence, treatment efficacy, and adverse events.","2025","PLoS medicine","Wightman H",null,"0","0","none found",null],["R0029062",null,null,"10.1080/02813432.2025.2477141","40071612","PMC12090293","Patients' experiences with GLP1-RAs - a systematic review.","2025","Scandinavian journal of primary health care","Ibsen CK",null,"0","0","none found",null],["R0029071",null,null,"10.1186/s11671-025-04215-9","39961878","PMC11832960","Systematic review of peptide nanoparticles for improved diabetes outcomes: insights and opportunities.","2025","Discover nano","Dangana RS",null,"0","0","none found",null],["R0029113",null,null,"10.1111/dom.16076","39563616","PMC11701179","Glucagon-like peptide 1 (GLP1) receptor agonists and risk for ischemic optic neuropathy: A meta-analysis of randomised controlled trials.","2025","Diabetes, obesity & metabolism","Silverii GA",null,"0","0","none found",null],["R0029173",null,null,"10.1097/mjt.0000000000001689","38976535",null,"Cardiovascular Safety of Glucagon-Like Receptor 1 Agonists in Patients With Type 2 Diabetes and Peripheral Arterial Disease: A Meta-Analysis of Randomized Controlled Trials.","2024","American journal of therapeutics","Ashraf MT",null,"0","0","none found",null],["R0029251",null,null,"10.4103/aca.aca_307_25","42862661",null,"GLP-1 Receptor Agonists and Insulin Versus Insulin for Perioperative Glycemic Control in Patients with Type 2 Diabetes Undergoing Cardiac Surgery: A Systematic Review.","2026","Annals of cardiac anaesthesia","Hassan D",null,"0","0","none found",null],["R0029274",null,null,"10.1016/j.disamonth.2026.102231","42855378",null,"Status Of GLP-1 drugs and their application in treating substance use disorders: A systematic review.","2026","Disease-a-month : DM","Inban P",null,"0","0","none found",null],["R0029295","CRD420251183082",null,"10.1111/dom.71418","42850058",null,"GLP-1 Receptor Agonist Therapy for Glucocorticoid-Induced Dysglycaemia: A Systematic Review.","2026","Diabetes, obesity & metabolism","Jędrasek A",null,"0","0","PROSPERO","PROSPERO:CRD420251183082"],["R0029326",null,null,"10.1007/s11886-026-02431-y","42842171",null,"Disparities in GLP-1RA and SGLT2i Uptake: a Systematic Review and an Equity-First Framework for Cardiovascular-Kidney-Metabolic Care.","2026","Current cardiology reports","Chu AH",null,"0","0","none found",null],["R0029343","CRD42024564018",null,"10.1007/s11325-026-03826-5","42837024",null,"GLP-1 receptor agonists for obstructive sleep apnea: a meta-analysis of randomized controlled trials.","2026","Sleep & breathing = Schlaf & Atmung","Carvalhal G",null,"0","0","PROSPERO","PROSPERO:CRD42024564018"],["R0029447",null,null,"10.1177/10815589261460894","42257390",null,"Effects of the glucagon-like peptide-1 and glucagon receptor dual agonists on glycemic markers: A systematic review and meta-analysis of randomized controlled trials.","2026","Journal of investigative medicine : the official publication of the American Federation for Clinical Research","Simental-Mendía LE","0","0","0","none found",null],["R0029555",null,null,"10.1111/jdv.70247","41416383","PMC13206337","Impact of weight-loss interventions on psoriasis severity: A systematic review and meta-analysis.","2026","Journal of the European Academy of Dermatology and Venereology : JEADV","Morrow S",null,"0","0","none found",null],["R0029572","CRD420251177348",null,"10.1016/j.jcot.2025.103256","41245346","PMC12617777","Meta-analysis of GLP1R, GIPR, ADCY3, and CREB1 expression in osteoarthritis identifies CREB1 as a potential biomarker and therapeutic target.","2025","Journal of clinical orthopaedics and trauma","Alizargar J",null,"0","0","PROSPERO","PROSPERO:CRD420251177348"],["R0029598",null,null,"10.3390/ani15172561","40941356","PMC12427183","Efficacy and Safety of Non-Insulin Antidiabetic Drugs in Cats: A Systematic Review.","2025","Animals : an open access journal from MDPI","Romero-Vélez F",null,"0","0","none found",null],["R0029681",null,null,"10.1093/sleep/zsaf004","39758029",null,"A meta-analysis of glucagon-like peptide 1 receptor and dual agonists for the treatment of obstructive sleep apnea: end of the story or just the beginning?","2025","Sleep","Drager LF","15","4","2","none found",null]]}